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ABSTRACT 
 
Streptococcus pyogenes, the Group A Streptococcus (GAS), is the most common cause of bacterial 
pharyngitis in children and adults. Host innate and adaptive immune responses mediate defence 
against streptococcal pharyngitis and are also central to the clinical manifestation of the disease. The 
ability of GAS to invade the host and establish infection likely involves subversion of host immune 
defences, however the signalling pathways and immune responses elicited during streptococcal 
pharyngitis, particularly by epithelial cells, are currently not well understood.  
 
This thesis focuses on characterising the inflammatory responses of primary human tonsil epithelial 
(TEpi) cells during intracellular infection with two distinct GAS strains; the laboratory-adapted M6 
strain JRS4 and the M1T1 clinical isolate 5448. M1T1 is a globally-disseminated GAS clone that is 
the most commonly isolated serotype (approximately 20% of all isolates) in high income countries 
(1). This thesis aims to investigate innate immune responses triggered and/or subverted by these 
different GAS strains in order to uncover why the M1T1 strain is such a successful pathogen.  
 
The pharyngeal and tonsil epithelia are important components of innate immune defence against GAS 
infection. They primarily act as a physical barrier, but also secrete antimicrobial peptides and 
cytokines/chemokines that have direct antimicrobial effects and/or signal to immune cells. Previous 
studies have investigated epithelial immune responses to GAS infection by utilising a number of 
different cell types, largely immortalised and nonpharyngeal-derived cell lines such as HEp-2 and 
HaCaT cells, which may not respond in the same manner as pharyngeal cells to GAS infection. 
Nonetheless, several studies that have used tonsil explant tissue or pharyngeal-derived cell lines 
appear to be congruent with studies that have used nonpharyngeal cell lines to examine a number of 
immune mediators secreted in response to GAS infection.  
 
Next generation Illumina RNA sequencing was employed to characterise the inflammatory gene 
expression profile of JRS4- and 5448-infected TEpi cells during early intracellular infection, as 
reported in Chapter 4. I found that, whilst infection with either GAS strain induced the mRNA 
expression of a similar array of host inflammatory genes, the transcriptional response to 5448-
infection was of a much higher magnitude compared to JRS4-infection. Sequential window 
acquisition of all theoretical fragment ion mass spectra (SWATH-MS) was also employed to 
characterise changes in the host proteome during early GAS infection, and proteins that significantly 
changed in abundance during 5448-infection consisted mainly of those involved in metabolic and 
trafficking pathways, as well as transcriptional regulation.   
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Work in Chapter 5 investigates the role of Streptococcus pyogenes Cell Envelope Protease (SpyCEP; 
also known as ScpC and PrtS) and its ability to dampen levels of secreted IL-8 during intracellular 
5448-infection of TEpi cells. RNA sequencing detected a significant increase in IL-8 mRNA 
expression during JRS4- and 5448-infection, and pathway analysis revealed differentially expressed 
genes between mock and JRS4- or 5448-infected TEpi cells were enriched in transcription factor 
networks that regulate IL-8 expression, such as AP-1, ATF-2 and NFAT. Whilst JRS4-infection 
resulted in high levels of secreted IL-8, 5448-infection did not, suggesting that 5448 may post-
transcriptionally dampen IL-8 production or accumulation. Infection with 5448ΔcepA, an isogenic 
mutant lacking the IL-8 protease SpyCEP, resulted in levels of secreted IL-8 that were comparable to 
JRS4 infection, whilst complementation of 5448ΔcepA significantly reduced IL-8 secretion by TEpi 
cells. These results suggest that intracellular infection with the pathogenic M1T1 strain 5448 induces 
a strong pro-inflammatory response in primary tonsil epithelial cells but is able to modulate this host 
response by the expression of SpyCEP, which selectively degrades IL-8. As IL-8 is a neutrophil-
recruiting chemokine implicated in the host response to GAS, reducing IL-8 secretion may ultimately 
benefit GAS infection.  
 
Finally, in Chapter 6 the level of IL-6 production during GAS infection of TEpi cells was investigated. 
Both JRS4- and 5448-infection were found to induce IL-6 mRNA expression, however JRS4-infected 
TEpi cells secreted high levels of IL-6 in comparison to 5448-infected cells. By screening a collection 
of 5448-isogenic mutants I identified streptolysin O (SLO) as the GAS protein responsible for 
suppressing IL-6 secretion. Infection with 5448Δslo, an isogenic mutant lacking SLO, resulted in IL-
6 secretion at levels similar to that of JRS4-infected cells, whilst complementation of 5448Δslo 
significantly reduced IL-6 secretion during infection. 5448 was also found to induce significantly 
higher levels of haemolysis than JRS4, suggesting that the SLO-dependent effect on IL-6 may be due 
to a difference in SLO expression or activity during infection.  
 
Overall, this thesis characterises the transcriptome and proteome of TEpi cells during intracellular 
GAS infection and provides new insight into the roles of SpyCEP and SLO in host immune 
modulation during infection. I found that IL-8 secretion during 5448-infection was dampened by 
expression of the serine protease SpyCEP, an IL-8 protease whose production during intracellular 
infection of primary epithelial cells was previously not well defined. I also found that 5448 post-
transcriptionally dampens host IL-6, and this effect was dependent on the expression of SLO; 
however, the mechanism by which SLO achieves this effect is as yet unknown. My fndings reinforce 
the hypothesis that the success of the M1T1 clone is due to its ability to modulate host inflammatory 
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responses to benefit infection. Better understanding of the host responses that mediate immunity to 
GAS infection should ultimately help facilitate the development of effective strategies to combat 
GAS pharyngitis.  
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EDTA  Ethylenediaminetetraacetic acid 
ELISA  Enzyme-linked immunosorbent assay 
EMMPRIN Extracellular matrix metalloproteinase inducer 
ERK  Extracellular-signal-regulated kinase 
F2RL1  Proteinase-activated receptor 2 
FBS  Foetal bovine serum 
FOSB  FBJ murine osteosarcoma viral oncogene homolog B 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GAS  Group A Streptococcus 
GM-CSF Ganulocyte-macrophage colony-stimulating factor 
GP  Guttate psoriasis 
GRO  Growth-regulated oncogene  
GuHCl  Guanidine hydrochloride 
HAS2  Hyaluronan synthase 2 
HBD  Human β defensin 
HBEGF Heparin-binding epidermal growth factor-like growth factor 
HCl  Hydrochloric acid 
HaCaT  Human skin keratinocyte cell line 
 19 
HeLa  Human cervix carcinoma epithelial cells 
HEp-2  HeLa contaminated human epithelial type 2 
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HPRT  Hypoxanthine-guanine phosphoribosyltransferase 
HSP70B Heat shock protein 70B 
IF  Immunofluorescence microscopy 
IFIT  IFN-induced protein with tetratricopeptide repeats 
IFN  Interferon 
IFNAR IFN-α/β receptor 
IGF-II  Insulin-like growth factor II 
IgG  Immunoglobulin G 
I𝜅B𝛼 Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha 
IL Human interleukin 
IL-1F9 IL-1 family member 9 
IL-1ra  IL-1 receptor antagonist 
IL-1RL1 IL-1 receptor-like 1 
IP-10  IFN-γ-inducible protein 10 
IRAK-4 Interleukin-1 receptor-associated kinase 4 
ISG  IFN-stimulated gene 
I-TAC  IFN-inducible T-cell α chemoattactant 
JNK  c-Jun N-terminal kinase 
JUN  V-Jun sarcoma virus 17 oncogene homolog 
LDH  Lactate dehydrogenase 
LIF  Leukaemia inhibitory factor 
LL-37  Cathelicidin antimicrobial peptide 
LPS  Lipopolysaccharide 
LTB4  Leukotriene B4 
M  Molar 
M-CSF Macrophage colony-stimulating factor 
MIG  Monokine induced by IFN-γ 
mAb  Monoclonal antibody 
MAC  Membrane attack complex 
MALDI-ToF Matrix-assisted laser desorption/ionization time-of-flight mass spectrometer 
MAPK  Mitogen-activated protein kinases 
MCET  Mast cell extracellular trap 
MeOH  Methanol 
MgCl2  Magnesium chloride 
MHC-I Major histocompatibility complex class I molecule 
MHC-II Major histocompatibility complex class II molecule 
MIF  Macrophage migration inhibitory factor 
MIG  Monokine induced by gamma interferon 
Min  Minute 
ml  Millilitre 
mm  Millimeter 
mM  Millimolar 
MOI  Multiplicity of infection 
mRNA  Messenger ribonucleic acid 
MS  Mass Spectrometry 
MTT  3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
MyD88 Myeloid differentiation primary response 88 
NALT  Nasal-associated lymphoid tissue 
NET  Neutrophil extracellular trap 
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ng  Nanogram 
NH4Ac Ammonium acetate 
NK  Natural killer cells 
Nlrp3 Nucleotide-binding domain leucine-rich repeat containing family pyrin domain 
containing 3 
nm  Nanometers 
O2  Oxygen 
OD  Optical density 
OPD  O-phenylenediamine dihydrochloride 
OSAS  Obstructive sleep apnoea syndrome 
pAb  Polyclonal antibody 
PAMP  Pathogen-associated molecular pattern 
PBMC  Peripheral blood mononuclear cell 
PBS  Phosphate-buffered saline 
PerR  Peroxide regulator 
PFA  Paraformaldehyde 
PGE2  Prostaglandin E2 
PI3K  Phosphoinositide 3-kinase 
PKA  Protein kinase A 
PRR  Pattern recognition receptor 
PSGN  Post-streptococcal glomerulonephritis 
PTGS2 Prostaglandin-endoperoxide synthase 2 
RANTES Regulated on activation, normal T cell expressed and secreted 
RHD  Rheumatic heart disease 
RNA  Ribonucleic acid 
RNase  Ribonuclease 
RPL32  60S ribosomal protein L32 
rpm  Revolutions per minute 
RT  Reverse transcriptase 
S10A8  Calgranulin A 
S10A9  Calgranulin B 
SCPA  Group A streptococcal C5a peptidase 
Sda1  Streptodornase D 
SDS  Sodium dodecyl sulfate 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis  
SEM  Standard error of the mean 
SIC  Streptococcal inhibitor of complement 
Ska  Streptokinase 
SlaA  Streptococcal phospholipase A2 
SLO  Streptolysin O 
SLS  Streptolysin S 
Spe  Streptococcal pyrogenic exotoxin 
SpyA  S. pyogenes ADP-ribosyltransferase 
SpyCEP Streptococcus pyogenes cell envelope protease 
SWATH-MS Sequential window acquisition of all theoretical fragment ion mass spectra 
TEBP  Prostaglandin E synthase 3 
TEpi  Tonsil epithelial 
TGF  Transforming growth factor 
Th  T helper cell 
THP-1  Leukemic monocyte cell line 
THY  Todd Hewitt broth supplemented with 0.2% yeast extract 
TNF-α  Tumour necrosis factor alpha 
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TNF-β  Tumour necrosis factor-beta/ Lymphotoxin-alpha 
TNFAIP3 TNF-α induced protein 3 
TNS  Trypsin neutralisation solution 
TLR  Toll-like receptor 
Treg  Regulatory T cell 
Tris  Tris(hydroxymethyl) aminomethane 
VEGFA Vascular endothelial growth factor A 
WB  Western blot 
WHO  World Health Organisation 
WT  Wild type 
µg  Microgram 
µl  Micro litre 
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1.0 LITERATURE REVIEW 
 
1.1 INTRODUCTION  
Streptococcus pyogenes (also designated Group A Streptococcus; GAS) is a bacterial pathogen that 
causes a wide spectrum of disease in humans and has developed a myriad of virulence mechanisms 
to avoid host defences (2). It is commonly carried asymptomatically, as well as causing superficial 
infections such as impetigo and pharyngitis (3, 4). In rare cases, GAS breaches epithelial tissues and 
invades the bloodstream and deeper tissues, resulting in invasive infections such as bacteraemia, 
necrotising fasciitis and streptococcal toxic shock syndrome (5). Upon repeated infection, post-
infection sequelae can develop, such as acute rheumatic fever (ARF) and acute post-streptococcal 
glomerulonephritis (PSGN) (6). GAS has a significant impact on human health and is estimated to 
infect over 600 million people per year and cause over half a million deaths annually (7). Therefore, 
the development of improved treatment and prevention strategies are needed to combat GAS disease 
and GAS disease-associated complications. 
 
GAS is strictly a human pathogen with no known environmental reservoir and is capable of colonising 
different human tissue types, primarily the pharyngeal mucosal epithelium and epidermal layer of the 
skin (8). The first stage of infection requires colonisation of epithelial tissues lining the skin or 
oropharynx, and mechanisms of adhesion and intracellular uptake have been well studied (9-11). 
However, the outcome of intracellular GAS infection and the interaction with innate immune 
defences and signalling pathways is still under investigation. The aim of this PhD project is to 
investigate the intracellular innate immune signalling pathways that are engaged during GAS 
infection of primary human tonsil epithelial cells.  
 
1.2 GAS 
GAS is a species of Gram-positive bacteria, which exists as a circular-shaped coccus and divides to 
form pairs or chains of cocci. Other defining characteristics of GAS include being non-motile, non-
spore forming, facultative anaerobic, catalase negative, β-haemolytic, pyogenic (pus-forming) and 
homofermentative (12, 13).  
 
1.2.1 Classification methods 
Multiple methods have been developed to accurately classify GAS, which are essential for laboratory 
research and epidemiological studies. Lancefield developed the first serotyping method of the genus 
Streptococcus, which identified streptococci based on group-specific antigens present in cell wall 
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polysaccharides (14). This method classified S. pyogenes as Group A Streptococcus, by the presence 
of an N-acetyl-β-D-glucosamine linked to a polymeric rhamnose backbone. Therefore, the names of 
S. pyogenes and Group A Streptococcus are used interchangeably. It should be noted that some non-
S. pyogenes streptococcal species also carry the Lancefield group A antigen (15), therefore A antigen 
tests are not definitive for the presence of GAS. The M-protein is a highly variable surface antigen 
and virulence determinant present on the cell wall of GAS, and is used to identify different GAS 
serotypes (16). Serological typing using antiserum directed to M-proteins of different isolates 
identified more than 80 distinct M types, and protective immunity was found to be M type-specific 
(8, 17). The T antigen is another cell wall protein used to identify GAS strain diversity (18). emm 
sequence typing is a more recently developed molecular approach for GAS serotyping, based on the 
hyper-variable 5’ region of the emm gene that encodes the M protein (19). Currently over 200 emm 
types have been recorded using this method (20).      
 
1.2.2 Epidemiology 
GAS is capable of causing a wide spectrum of disease in humans from mild, superficial infections to 
invasive and life-threatening infections. The outcome of infection is dependent on a variety of factors: 
host immunogenetics such as human leukocyte antigen class II haplotypes (21), the expression of 
protective levels of anti-streptococcal antibodies due to a previous exposure event (22), the serotype 
of GAS encountered (23), the virulence factors expressed by GAS (24), the route of entry into the 
host (25), and whether the disease is treated in its early stages (26).  
 
GAS is a globally disseminated pathogen that places substantial burden on health systems around the 
world. GAS causes over 600 million infections annually; disease most commonly occurs in children 
and young adults living in low income countries, where there is inadequate health care to treat 
infections, and where poor living conditions promote transmission (7, 27). The 2004 World Health 
Report by WHO ranked GAS as the ninth leading infectious cause of human mortality (7, 28). The 
2005 World Health Organisation report on Group A streptococcal diseases estimates 18.1 million 
people have a severe case of GAS disease (rheumatic fever, rheumatic heart disease (RHD), post-
streptococcal glomerulonephritis (PSGN), and invasive infections), with 1.78 million new cases per 
year (29). However, this is a conservative estimate based on a limited number of epidemiological 
studies, and the true disease burden of GAS is likely higher. The majority of these cases are people 
suffering from chronic RHD, which comprises 15.6 million people. GAS is responsible for at least 
517,000 deaths yearly, with the majority of these deaths attributed to severe invasive infections and 
autoimmune diseases, particularly RHD, in developing countries (7). 
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1.2.3 Superficial, severe and post-streptococcal diseases 
The primary ecological niche of GAS, and the site for transmission and acquisition, is the throat and 
skin (8). GAS infection of the skin or throat typically results in mild disease manifestations including 
pharyngitis, impetigo, cellulitis and scarlet fever (2). It is estimated >616 million cases of throat 
(tonsillitis, pharyngitis) infections occur annually (29, 30). Severe disease occurs rarely, and 
manifests as a wide array of diseases, including bacteraemia, puerperal sepsis, streptococcal toxic 
shock syndrome, necrotising fasciitis, pneumonia and endocarditis (31). Severe invasive infections 
have a mortality rate of approximately 15-30% and are more difficult to treat, often requiring surgical 
intervention (7, 32). GAS infection can also lead to post-infectious pathologies with features of 
autoimmunity, such as acute post-streptococcal glomerulonephritis, acute rheumatic fever and 
rheumatic heart disease (33).  
 
1.2.4 Global emm type distribution  
Epidemiological studies have shown that GAS emm types from different geographic and 
socioeconomic regions of the world are remarkably diverse (1). There is a particular difference in the 
molecular epidemiology of GAS strains from Africa and the Pacific region when compared to high-
income countries. In industrialised countries, 40% of GAS isolates belong to a small number of emm 
types: 1, 3, 12, and 28 (1, 2, 34). However, in Africa and the Pacific these emm types are significantly 
less common, and there is a lack of dominant emm types (1, 35).  
 
1.2.5 Tissue tropism and emm pattern  
Many GAS serotypes have a strong tendency to cause particular disease manifestations, suggesting a 
degree of specialisation exists among GAS emm types (36, 37). The chromosomal arrangement of 
emm and emm-like genes, termed the emm pattern, is used as a genetic marker for the preferred 
infection site of GAS emm types, and GAS strains are divided into 5 emm pattern groups; patterns A-
E (37). Emm patterns A-C are considered throat specialists, emm pattern D are skin specialists and 
pattern E are generalists, tropic for both skin and throat infections (8).  
 
The cause of tissue tropism is likely due to tissue-specific colonisation factors, which are expressed 
by specific emm patterns (38). For example, GAS possesses a large collection of adhesins, which are 
used to mediate attachment and internalisation into host cells by targeting cell membrane proteins or 
extracellular matrix proteins of the host (9). Most adhesins show a large degree of functional 
redundancy, and the majority of adhesins are not present in all GAS serotypes, which usually possess 
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a selection of adhesins that allow colonisation of specific tissue environments (39, 40). For example, 
prtF1, a gene encoding a fibronectin binding protein, is present in most emm pattern A-C strains and 
absent from most pattern D strains (41).  
 
1.2.6 GAS infection of pharyngeal epithelial tissues 
GAS is the leading cause of bacterial pharyngitis and tonsillitis in humans (13, 42). The pathogenesis 
of GAS pharyngitis is poorly understood, however it has been postulated that GAS penetrates the 
mucosal layer covering the pharyngeal epithelium, before adhering to and invading the epithelial 
tissues that line the pharynx (43-45). In particular, GAS is known to infect the palatine tonsil during 
pharyngitis, and the tonsil is often responsible for disease presentations characteristic of pharyngitis, 
such as erythema and exuding pus (46). The palatine tonsil contains areas of invaginations called 
crypts (47). During infection, GAS has been shown to form biofilms within these crypts, as well as 
invading the epithelial cells and lymphocytes lining the crypt walls (48-50). The palatine tonsils of 
patients with recurrent cases of GAS pharyngitis have been shown to act as a sanctuary for GAS, and 
antibiotic treatment is often not effective in treating GAS pharyngitis in these patients (48, 51), 
possibly because antibiotics cannot penetrate bacterial biofilms or kill intracellular bacteria 
effectively. In addition, the palatine tonsils can act as a reservoir for GAS during asymptomatic 
infection (52, 53). This suggests the palatine tonsil and its epithelial surfaces are highly relevant in 
studying GAS infection and would provide one of the more robust models for investigating host 
innate immune responses that are elicited during GAS infection of epithelial tissues. 
 
1.3 MUCOSA-ASSOCIATED LYMPHOID TISSUE (MALT) 
Mucosal-associated lymphoid tissues (MALT) are located on internal surfaces of the body, and play 
an important immunological role as part of the front-line defence against invading pathogens (54). 
Examples of MALT include the bronchus-associated lymphoid tissue, the gut-associated lymphoid 
tissue, and the lymphoepithelial tonsils (55, 56). Each MALT is located at sites continuously exposed 
to inhaled or ingested materials, and MALT are usually the first lymphoid organs to encounter 
infectious microorganisms (57). The main function of MALT is to sample antigens, allow them to be 
investigated locally by immune cells that target and kill harmful microorganisms, and generate 
effector and memory lymphocytes that migrate to other mucosal sites (58). However, MALTs are 
also vulnerable to infection and are often targeted by pathogens, which either colonise the mucosal 
epithelium or use the lymphoid tissue as an entry portal to other sites in the body (59). 
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1.3.1 Tonsil anatomy and physiology 
The tonsils are a collection of lymphoidal tissue on the surface of the pharyngeal wall, encompassing 
both the naso- and oro-pharyngeal regions. In 1884 the German anatomist Waldeyer first described 
the human tonsils as a ring of lymphoid tissue structures on the pharynx, and these tissues are now 
collectively known as Waldeyer’s ring (60). This ring is comprised of four distinct regions of MALT 
tissue: the adenoid (nasopharyngeal) tonsil joined to the roof of the pharynx, the paired tubal tonsils 
on the openings of the Eustachian tube connecting the nasopharynx to the middle ear, the paired 
palatine tonsils positioned either side of the oropharynx, and the lingual tonsil located on the posterior 
of the tongue (Figure 1) (57, 61). The pharyngeal mucosae also contain collections of lymphoid 
tissue between these regions that completes the circular ring of tissue. The adenoid, palatine and tubal 
tonsils are sites of colonisation during GAS pharyngitis (62, 63).  
 
 
 
 
Figure 1. Anatomy of the human tonsil. 
The pharyngeal lymphoidal tissue collectively known as Waldeyer’s ring is comprised of four distinct 
regions: the adenoid, tubal tonsil, palatine tonsil and lingual tonsil. These regions together form a 
circular arrangement located where the mouth transitions to the pharynx. Adapted from Perry and 
Whyte (1998).  
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Tonsils are secondary lymphoid organs and possess subepithelial lymphoid compartments containing 
secondary lymphoid follicles (B-cell areas) that are surrounded by interfollicular regions (T-cell 
areas) (64, 65). Tonsils possess several unique features from other lymphoid organs which highlight 
their specialised function: they are not fully encapsulated; they do not possess afferent lymphatics; 
they are lymphoepithelial organs, and they possess an epithelium lining the surface of the tonsil which 
also lines the tonsillar crypts (61, 66, 67). In contrast to other lymphoid organs such as the spleen and 
lymph nodes, which depend on the delivery of antigens by afferent lymphatics, the localisation and 
organisation of the tonsils allow the capture of foreign material directly from the epithelial surface 
and deliver it directly to underlying lymphocytes (68). This localisation also means the tonsils are the 
first lymphoid organ to provide an immunological response to inhaled or ingested antigens. 
 
1.3.2 Experimental models of the human tonsil  
Whilst MALT is present in mammals, most have a different pharyngeal anatomy to humans, and 
therefore may be unsuitable models for functional studies.  Mice and rats lack palatine and adenoid 
tonsils, and only primates and omnivorous pigs have been shown to possess the four discrete 
lymphoid structures of Waldeyer’s ring (69, 70). Most studies investigating the human tonsil function 
and immunological response to infectious microorganisms have been performed in vitro using ex vivo 
tonsil explants from tonsillectomies, or immortalised human cell lines (71-73). Due to the anatomical 
position and large size of the palatine tonsils, they are easily removed and are the most studied 
component of Waldeyer’s ring.  
 
1.3.3 Palatine tonsil epithelial cell types 
The lymphoepithelial palatine tonsil consists of multiple cell types across several defined regions. A 
uniform layer of stratified, squamous, non-keratinised epithelial cells protects its surface, and the 
function of this epithelium is mainly as a protective barrier (61). In regions of the palatine tonsil, this 
uniform epithelium is disrupted by 10-30 invaginations (crypts), which are narrow channels that 
extend through the entire thickness of the tonsil into the lymphoid tissue (74, 75). The surface of an 
adult palatine tonsil is covered by 45cm2 of epithelium, whilst tonsil crypts have a surface area of 
approximately 295cm2 (61, 74). This creates a greater surface area available for direct antigenic 
stimulation, and an important function of crypts is to entrap foreign material that can be sampled by 
local lymphocytes. The crypts are also the site where the immune response of the palatine tonsil is 
initiated (57). 
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Crypts provide a dynamic environment that is different from the pharyngeal surface of the palatine 
tonsil, providing a space for interactions between epithelial and nonepithelial cells, and allowing 
trans-epithelial access to antigens (76). Crypts are lined with epithelial cells that are a modified form 
of the epithelium covering the tonsil surface. Crypt epithelial cells are non-uniform, reticulated, 
elongated, and star, sickle or irregular in shape (59). This modified morphology allows the infiltration 
of non-epithelial cells such as lymphocytes, plasma cells, macrophages and dendritic cells (68). In 
crypts, antigens are taken up by specialised cells that resemble intestinal membranous (M) cells (57, 
77). These cells function to endocytose antigens and exocytose these into sub-epithelial spaces, where 
they will come into contact with lymphoid cells (78). Multiple micro-compartments of 
immunocompetent cells also exist within and beneath the crypt epithelium (79). Beneath the crypts 
lie a number of spherical B cell aggregates called follicular germinal centres, and T cell areas are 
located between these follicles (59). Macrophages and dendritic cells are also distributed amongst the 
extrafollicular region. The palatine tonsils are thought to be most active in children, as in adults an 
involution of lymphoid elements is observed, in addition to the proliferation of fibrous tissue and 
decrease in tonsil size (80).  
    
1.3.4 Immunological function of tonsil epithelial cells 
The immunological function of the epithelial cell types comprising the surface epithelium and crypts 
of the palatine tonsil are not well defined, as most studies have focused on the non-epithelial immune 
cells present in this region (81). Toll-like receptors TLR1 and TLR2, which ligate bacterial 
lipopeptides and peptidoglycan, are reported to be expressed by the crypt epithelium (82). Tonsillar 
epithelial cell lines UT-SCC-60A and UT-SCC-60B express TLR2 and TLR3, an intracellular ligand 
for dsRNA which induces the secretion of pro-inflammatory cytokines such as IL-6 and CXCL10 
(68). In response to enterovirus 71 infection, UT-SCC-60A and UT-SCC-60B display innate antiviral 
immunity by activating PI3K/AKT, p38, ERK1/2 and JNK1/2 signalling pathways and secrete IFNα, 
IL-8, IL-1β, IL-6 and IL-12β (83). IL-33, a potent inflammatory cytokine that activates T helper 2 
lymphocytes, is reported to be constitutively expressed by the tonsil crypt epithelium (84), whilst 
GAS infection of the tonsil epithelium induces the expression of the antimicrobial peptide human β-
defensin 1 (71). Together, these results suggest that tonsillar epithelial cells can directly recognise 
and respond to the presence of microbial antigens and can have direct antimicrobial functions.  
 
1.3.5 Pathogens that infect tonsils 
Due to its accessible location, human tonsils are the primary site of infection for a number of different 
viral and bacterial pathogens. Viral pathogens of the tonsil include rhinoviruses (85) and Epstein Barr 
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virus (86, 87), which may increase the susceptibility of the tonsils to secondary bacterial infections 
by downregulating pro-inflammatory responses such as the production of TNF-α (88). Many species 
of bacteria are able to infect and persist in human tonsils, including Group A (89-91), B, F and G 
Streptococcus (91), Staphylococcus aureus (89, 90), Moraxella catarrhalis (89), Haemophilus 
influenzae (89, 91), Streptococcus pneumoniae (89) and Pseudomonas aeruginosa (90).  
 
1.4 GAS PHARYNGITIS 
GAS is the most common bacterial cause of acute pharyngitis (92). Over 616 million incident cases 
of GAS pharyngitis are estimated to occur globally each year, making this one of the most prevalent 
bacterial diseases in humans (93). Transmission primarily occurs through direct human-to-human 
contact, via respiratory droplets or nasal secretions from infected individuals (2). Illness 
predominantly occurs in children between 5 and 15 years of age but can also occur in adults (94). 
Disease severity of GAS pharyngitis is variable, but in most cases, it is a mild, self-limiting disease 
that resolves within 7 days. Characteristic symptoms include sudden onset of sore throat, fever, 
headache, abdominal pain, nausea and vomiting (92). GAS can also asymptomatically infect the 
oropharynx for weeks to months at a time, during which time little or no immune response to 
streptococcal antigens is elicited (53, 95). Approximately 10-20% of school-age children are 
asymptomatic carriers of GAS (48, 96). 
 
Upon etiologic diagnosis of an active infection, usually by rapid antigen detection tests and/or throat 
culture, antibiotic treatment is employed to reduce the severity and duration of pharyngitis symptoms, 
as well as to limit disease spread, suppurative complications (peritonsillar or retropharyngeal abscess, 
cervical lymphadenitis, sinusitis, otitis media and mastoiditis), and development of acute rheumatic 
fever (46). Penicillin is the treatment of choice for GAS pharyngitis due to its efficacy and low-cost 
(97). There is no preventative vaccine against GAS currently available, although multiple vaccine 
candidates are in clinical and pre-clinical development (98). A better understanding of immunological 
responses that are effective against GAS could lead to host-directed preventative or therapeutic 
regimes.  
 
Previous studies on GAS-related immune responses have largely focused on those elicited during 
invasive GAS infections, where severe morbidity and mortality may result from failure to control 
bacterial infection (99). The findings from such studies are not necessarily reflective of immune 
responses elicited during superficial GAS infections such as pharyngitis and impetigo, and indeed, 
the molecular and cellular bases of host immune responses to superficial GAS infections are 
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comparatively less well understood. Although GAS is exclusively a human pathogen, several animal 
models that at least partly mimic human GAS pharyngitis have been established (100-102). Murine 
nasopharyngeal infection models are most commonly used, with mice being inoculated with GAS 
under each nostril. In this model, GAS colonise the nasal-associated lymphoid tissue (NALT), which 
is functionally equivalent to the human palatine tonsil (101). Such models have allowed the analysis 
of immune responses that are associated with either host protection or susceptibility. For example, 
transgenic expression of the human MHC-II molecules HLA-DR4 and HLA-DQ8 in mice promoted 
acute nasopharyngeal GAS infection, suggesting that MHC-II molecules contribute to the human-
specific tropism of a GAS serotype M18 strain (103). This was mediated, at least in part, by the GAS 
superantigen SpeA, suggesting a possible role for GAS superantigens during human colonisation. 
 
In addition to mouse models, several (usually immortalised) cell lines have been employed to 
examine GAS-induced inflammatory responses. In vitro studies have been useful in investigating the 
immune response of individual cell types following GAS infection, however the variety of cellular 
models used, as well as the dearth of studies in primary cells, makes the interpretation of such findings 
complex. Much of this work has also been done with non-pharyngeal derived cell lines such as HEp-
2 (HeLa derivative epithelial cells from cervix) and HaCaT (skin keratinocytes), which may not 
respond in the same way as pharyngeal cells to GAS infection. Fortunately, follow-up studies that 
have utilised primary tonsil or pharyngeal-derived cells appear to be largely in agreement with studies 
that employed non-pharyngeal cell lines for a wide number of immune mediators secreted in response 
to GAS infection, such as IL-6, TNF-α and IL-8 (Table 1). In addition, work using both human and 
murine cell lines have shown that the level of inflammatory mediators produced in response to GAS 
is often genotype (emm type)-dependent (104-106), making results difficult to extrapolate for other 
emm types. Here, I present the current state of knowledge on innate and adaptive immune responses 
elicited during GAS pharyngitis and discuss how these might influence the outcome of infection.  
 
1.5 INNATE IMMUNE RESPONSE TO GAS PHARYNGITIS 
As with other infections, the innate immune system plays an essential role in the early detection of 
GAS, and subsequent initiation of pro-inflammatory responses. GAS pharyngitis is characterised by 
bacterial colonisation of the palatine tonsil, a specialised lymphoid tissue that contains a number of 
cell types with innate immune defence roles, including epithelial cells, neutrophils, macrophages and 
dendritic cells. In response to GAS infection, these cell types secrete a number of inflammatory 
mediators (Table 1) including cytokines, chemokines, antimicrobial peptides (AMPs) and 
prostaglandins, as part of a highly coordinated host process. These mediators orchestrate the ensuing 
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inflammatory response to GAS, and also instruct the resulting adaptive immune response. Below I 
discuss some of the key innate cell types and soluble mediators that have been examined in the context 
of GAS pharyngitis, as well as specific mechanisms by which GAS counteracts their actions. 
 
Table 1. Host factors implicated in GAS pharyngitis. 
Host factors are grouped and colour-coded into different classes as follows: aqua: antimicrobial 
factors; pink: chemokines; blue: cytokines; purple: eicosanoids; yellow: growth factors; green: 
receptors; orange: single stranded RNA binding proteins; grey: other host factors.  
Inflammatory 
mediator 
Class Function 
(Uniprot.org) 
Source Evidence References 
Azurocidin AMP Chemotactic for 
monocytes, 
antimicrobial activity 
Macaque 
throat swab 
mRNA (107) 
HBD1 AMP Antimicrobial HaCaT, 
primary 
human tonsil 
tissue 
mRNA (71) 
HBD2 AMP Antimicrobial HaCaT, 
primary 
human tonsil 
tissue, 
human 
foreskin 
keratinocytes 
mRNA (71, 108) 
LL-37/Cathelicidin AMP Antimicrobial, 
functions in cell 
chemotaxis, immune 
mediator induction, 
and inflammatory 
response regulation 
HaCaT, 
primary 
human tonsil 
tissue 
mRNA (71) 
RNASE7 AMP Broad-spectrum 
antimicrobial 
HaCaT mRNA (106) 
CCL19/MIP-3β Chemokine Chemotactic for T 
cells and B cells 
PBMC mRNA (109) 
CCL2/MCP-1 Chemokine Chemotactic for 
monocytes and 
basophils 
murine nasal 
turbinate, 
PBMC 
mRNA, 
protein 
(103, 109) 
CCL20/MIP-3α Chemokine Chemotactic for 
lymphocytes and 
dendritic cells, and can 
repress proliferation of 
myeloid progenitors 
HaCaT, 
PBMC 
mRNA, 
protein 
(106, 109) 
CCL3/MIP-1α Chemokine Plays role in 
inflammatory 
responses 
murine nasal 
turbinate, 
PBMC 
mRNA, 
protein 
(103, 109) 
CCL4/MIP-1β Chemokine Chemotactic and 
inflammatory 
functions 
Murine nasal 
turbinate 
protein (103) 
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CCL5/RANTES Chemokine Chemotactic for blood 
monocytes, memory T 
helper cells and 
eosinophils. Causes 
histamine release from 
basophils and activates 
eosinophils 
HEp-2, 
PBMC, 
murine nasal 
turbinate 
mRNA, 
protein 
(103, 109, 
110) 
CCL7/MCP-3 Chemokine Chemotactic for 
macrophages 
PBMC mRNA, 
protein 
(109) 
CXCL1/GROα Chemokine Plays a role in 
inflammation, 
chemotactic for 
neutrophils 
murine nasal 
turbinate, 
HaCaT 
mRNA, 
protein 
(103, 106) 
CXCL10/IP-10 Chemokine Stimulation of 
monocytes, NK and T-
cell migration, 
modulation of 
adhesion molecule 
expression 
Detroit 562, 
murine nasal 
turbinate, 
PBMC, 
tonsil fluid 
from GAS 
pharyngitis 
patients 
mRNA, 
protein 
(103, 109, 
111) 
CXCL11/I-TAC Chemokine Chemotactic for 
activated T cells 
Detroit 562 protein (111) 
CXCL2/GROβ Chemokine Suppresses 
hematopoietic 
progenitor cell 
proliferation 
HEp-2 mRNA (112) 
CXCL3/GROγ Chemokine Plays a role in 
inflammation and 
chemotactic for 
neutrophils 
HEp-2, 
HaCaT 
mRNA (106, 112) 
CXCL9/MIG Chemokine/cytokine Chemotactic for 
lymphocytes, 
antimicrobial against 
GAS 
Detroit 562, 
THP-1, 
murine nasal 
turbinate, 
tonsil fluid 
from GAS 
pharyngitis 
patients, 
PBMC 
mRNA, 
protein 
(103, 109, 
111, 113) 
IL-8/CXCL8 Chemokine Major mediators of the 
inflammatory 
response, functions as 
chemoattractant, and is 
also a potent 
angiogenesis factor 
HEp-2, 
HaCaT, 
THP-1, 
PBMC, 
tonsil 
explant 
tissue 
mRNA, 
protein 
(105, 106, 
109, 110, 
112, 114-
116) 
GM-CSF/CSF-2 Cytokine Controls the 
production, 
differentiation and 
function of 
granulocytes and 
macrophages 
HaCaT mRNA (106, 117) 
IFN-α Cytokine Anti-viral activity PBMC protein (118) 
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IFN-β Cytokine Anti-viral factor that 
also induces 
transcription of 
inflammatory 
cytokines and 
chemokines, controls 
IL-1β levels 
BMDM, 
murine DCs 
and 
neutrophils 
protein (104, 119-
121) 
IFN-γ Cytokine Triggers cellular 
response to viral and 
microbial infections 
HEp-2, 
murine CD4+ 
T cells, 
PBMC, 
human 
tonsillar T 
cells, tonsil 
explant 
tissue 
protein (105, 112, 
116, 122-
126) 
IL-1 family, 
member 9 (IL1F9)/ 
IL-36γ 
Cytokine Keratinocyte 
inflammatory response 
HaCaT mRNA (106) 
IL-10 Cytokine Has pleiotropic effects 
in immunoregulation 
and inflammation, 
enhances B cell 
survival, proliferation 
and antibody 
production, 
downregulates 
expression of Th1 
cytokines, MHC class 
II antigens and 
costimulatory 
molecules in 
macrophages 
tonsil 
explant 
tissue 
Protein (116) 
IL-11 Cytokine Stimulates 
hematopoietic stem 
cell proliferation, 
stimulates T-cell-
dependent 
development of 
immunoglobulin-
producing B cells 
HaCaT mRNA (106) 
IL-12a (p35) Cytokine Growth factor for 
activated T cells and 
NK cells, stimulates 
the production of IFN-
γ by PBMC. Forms 
heterodimer with p40 
to generate IL-12p70, 
which drives Th1 
development 
HEp-2 mRNA (117) 
IL-12b (p40) Cytokine Growth factor for 
activated T cells and 
NK cells, stimulates 
the production of IFN-
γ by PBMC.  Forms 
heterodimer with p35 
HEp-2, 
murine nasal 
turbinate, 
mRNA, 
protein 
(103, 117) 
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to generate IL-12p70, 
which drives Th1 
development 
IL-13 Cytokine Involved in B cell 
maturation and 
differentiation, 
downregulates 
macrophage activity 
and inflammatory 
cytokine/chemokine 
production 
PBMC protein (125) 
IL-17A Cytokine Positively regulates 
pro-inflammatory 
cytokine production 
murine nasal 
turbinate, 
HEp-2, 
A549, 
primary 
human 
tonsillar T 
cells, murine 
CD4+ T 
cells, PBMC 
Protein, 
mRNA 
(103, 122-
125, 127, 
128) 
IL-1Ra Cytokine Inhibits activities of 
IL-1α and IL-1β and 
modulates IL-1 related 
immune and 
inflammatory 
responses 
HaCaT protein (106) 
IL-1α Cytokine Pleiotropic cytokine 
involved in 
inflammatory 
processes and 
haematopoiesis 
HaCaT, 
HEp-2, 
tonsil 
explant 
tissue 
mRNA, 
protein 
(106, 110, 
114, 116) 
IL-1β Cytokine Important mediator of 
the inflammatory 
response, involved in 
cell proliferation, 
differentiation and 
apoptosis, induces 
cyclooxygenase-2, 
promotes Th17 
differentiation of T 
cells 
murine nasal 
turbinate, 
HaCaT, 
HEp-2, 
PBMC, 
BMDM, 
tonsil 
explant 
tissue 
mRNA, 
protein 
(103, 106, 
110, 114, 
116-118) 
IL-2 Cytokine Induces proliferation 
of T and B cells 
murine nasal 
turbinate, 
HEp-2, 
human 
tonsillar 
CD4+ T 
cells, tonsil 
explant 
tissue 
protein, 
mRNA 
(103, 116, 
117, 126) 
IL-20 Cytokine Regulates proliferation 
and differentiation of 
epithelial cells during 
inflammation 
HaCaT mRNA (106) 
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IL-23 Cytokine Forms a heterodimer 
with IL-12b, stimulates 
the production of IFN-
γ 
HEp-2, 
A549 
mRNA (127) 
IL-24 Cytokine May contribute to 
terminal cell 
differentiation 
HaCaT mRNA (106) 
IL-4 Cytokine Activates B cells human 
tonsillar 
CD4+ T cells 
protein (126) 
IL-5 Cytokine Acts as a growth and 
differentiation factor 
for B cells and 
eosinophils 
PBMCs, 
human 
tonsillar 
CD4+ T cells 
protein (125, 126) 
IL-6 Cytokine Functions in 
inflammation and 
maturation of B cells, 
endogenous pyrogen 
capable of inducing 
fever 
 
 
murine nasal 
turbinate, 
HEp-2, 
HaCaT, 
BMDM, 
PBMC, 
THP-1, 
human 
tonsillar 
CD4+ T 
cells, tonsil 
explant 
tissue 
mRNA, 
protein 
(103-105, 
110, 112, 
114-116, 
118, 126, 
129) 
LIF (leukaemia 
inhibitory factor) 
Cytokine Involved in the 
induction of 
hematopoietic 
differentiation 
murine nasal 
turbinate 
protein (103) 
MIF Cytokine Lymphokine involved 
in cell-mediated 
immunity, 
immunoregulation and 
inflammation, 
regulates macrophage 
function 
HaCaT protein (106) 
TNF-α Cytokine Multifunctional pro-
inflammatory cytokine, 
involved in a wide 
spectrum of 
inflammatory 
processes including 
cell proliferation, 
apoptosis and 
differentiation 
murine nasal 
turbinate, 
PBMC, 
BMDM, 
HEp-2, 
tonsil 
explant 
tissue 
protein (103-105, 
112, 116, 
118, 125) 
TNF-
β/lymphotoxin-α 
Cytokine Mediates 
inflammatory, 
immunostimulatory 
and antiviral responses 
HEp-2, 
tonsil 
explant 
tissue 
mRNA, 
protein 
(116, 117) 
CysLT Eicosanoid Pro-inflammatory and 
immunoregulatory 
roles 
Human 
tonsil 
mononuclear 
cells 
protein (130) 
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PGE2 Eicosanoid Pro-inflammatory and 
immunoregulatory 
HaCaT, 
BMDM 
protein (114, 131) 
PTGS2 
(prostaglandin-
endoperoxide 
synthase 2) 
Eicosanoid pathway Key enzyme in 
prostaglandin 
biosynthesis 
HEp-2 mRNA (112) 
Connective tissue 
growth factor 
(CTGF) 
Growth factor Important for wound 
healing, plays a role in 
chondrocyte 
proliferation and 
differentiation and cell 
adhesion 
HaCaT mRNA (106) 
Heparin-binding 
epidermal growth 
factor-like growth 
factor (HBEGF) 
Growth factor May be involved in 
macrophage-mediated 
cellular proliferation 
HaCaT mRNA (106) 
IGF-II Growth factor Potent mitogen for 
cultured cells 
HEp-2 mRNA (117) 
Transforming 
growth factor α 
(TGFα) 
Growth factor Activates cell 
proliferation, 
differentiation and 
development 
HaCaT mRNA (106) 
Transforming 
growth factor β1 
(TGFβ1) 
Growth factor Required for Th17 
differentiation, 
regulates cell 
proliferation, 
differentiation and 
growth 
Primary 
human tonsil 
cells, NALT 
protein (128) 
Vascular 
endothelial growth 
factor A (VEGFA) 
Growth factor Induces permeability 
of blood vessels 
HaCaT mRNA (106) 
CD147/EMMPRIN Receptor Regulatory of 
leukocyte migration 
HaCaT protein (106) 
IL1RL1/ST2 Receptor Receptor induced by 
pro-inflammatory 
stimuli, involved in 
helper T cell function 
HaCaT mRNA (106) 
Protease-activated 
receptor 2 (F2RL1) 
Receptor Modulates 
inflammatory 
responses, activation 
dilates blood vessels 
and lowers blood 
pressure 
HaCaT mRNA (106) 
IFIT1 Single stranded 
RNA binding 
protein 
Type I interferon 
signalling pathway, 
antiviral activity 
HEp-2 mRNA (112) 
IFIT2 Single stranded 
RNA binding 
protein 
Type I interferon 
signalling pathway, 
antiviral activity, can 
promote apoptosis 
HEp-2 mRNA (112) 
IFIT4 Single stranded 
RNA binding 
protein 
Type I interferon 
signalling pathway, 
antiviral activity 
HEp-2 mRNA (112) 
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1.5.1 Epithelial cells  
The pharyngeal and tonsil epithelia are an important component of innate immune defence against 
GAS infection, primarily by acting as a physical barrier, but also by secreting AMPs and 
cytokines/chemokines to signal to other immune cell mediators. GAS not only forms biofilms on the 
surface of the tonsillar epithelium but can also invade the epithelium to survive intracellularly (49, 
50). Primary human tonsil fibroblasts, and single-cell suspensions of NALT or human tonsil cells 
secrete TGF-β1 following exposure to GAS, which, in concert with IL-6 secreted by GAS-infected 
epithelial cells and macrophages, drives CD4+ T helper 17 (Th17) cell differentiation (72, 128).  TGF-
β1 also regulates the expression of extracellular matrix proteins including fibronectin and αβ-integrins 
IgG1/IgG2/IgG3 Antibody Opsonises microbes to 
enhance phagocytosis, 
activates the 
complement system 
PBMC, 
blood 
plasma 
protein (125) 
HSP70B Chaperone Implicated in a wide 
variety of cellular 
processes, such as 
protection of the 
proteome from stress 
HEp-2 mRNA (112) 
TNFAIP3 DNA binding 
protein 
Induced by TNF, 
involved in cytokine-
mediated immune and 
inflammatory 
responses 
HaCaT, 
HEp-2 
mRNA (106, 112) 
Interferon 
stimulated 
exonuclease gene 
20 (ISG20) 
Exonuclease Antiviral defence HEp-2 mRNA (112) 
HAS2 (hyaluronan 
synthase 2) 
Glycosyltransferase Essential for 
hyaluronic acid 
synthesis, which is 
produced during 
wound healing and 
tissue repair. 
Hyaluronic acid 
interacts with the 
leukocyte receptor 
CD44 and is important 
in tissue-specific 
homing by leukocytes 
HaCaT mRNA (106) 
HLA-DPB1 MHC class II 
molecule 
Plays a central role in 
the immune system by 
presenting peptides 
derived from 
extracellular proteins 
HEp-2 mRNA (112) 
ISG15 Ubiquitin-like 
protein 
Chemotactic factor for 
neutrophils, antiviral 
activity 
HEp-2 mRNA (112) 
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(132, 133), and TGF-β1 signalling has been shown to enhance GAS invasion of epithelial cells (72), 
suggesting it may play a role in promoting bacterial colonisation. In response to GAS infection, 
epithelial cells also secrete neutrophil chemoattractants such as IL-8 (110), with this process likely to 
be an important protective mechanism elicited by epithelial cells during GAS pharyngitis (106).    
 
1.5.2 Neutrophils  
Neutrophils, the most abundant type of leukocyte in the blood, rapidly infiltrate the NALT in a murine 
GAS nasopharyngeal infection model (103). Neutrophils kill GAS by the release of AMPs through 
degranulation, phagocytosis and phagolysosomal destruction of GAS by reactive oxygen species, and 
the formation of neutrophil extracellular traps (NETs) (134). Repeated GAS infection or intranasal 
vaccination stimulates an IgA/IgG antibody and Th17 cellular response in mice, which dramatically 
enhances neutrophil recruitment and myeloperixodase antimicrobial activity during early infection 
(135). This is thought to be mediated by Th17 cell secretion of IL-17A, which stimulates the 
production of chemokines and cytokines, promoting the recruitment and activation of 
polymorphonuclear leukocytes such as neutrophils, as well as macrophages (136, 137). Indeed, a 
neutralising antibody against IL-17A prevented GAS clearance from the NALT (138), likely because 
of impaired leukocyte infiltration.  
 
Several GAS virulence factors have been characterised to impair neutrophil recruitment and activity 
during infection. The bacteriophage-encoded GAS DNase (Sda1) protects GAS from neutrophil 
killing by degrading NETs, which are released by neutrophils to entrap and kill invading bacteria 
(139). M1T1 is a globally disseminated clone of GAS that is frequently recovered from cases of 
streptococcal pharyngitis (140), and an M1T1 Sda1-mutant showed reduced survival compared to 
wild-type strains in human neutrophil killing assays (141). A DNase inhibitor also increased GAS 
sensitivity to neutrophil killing in vitro and in a murine model of necrotising fasciitis (139), indicating 
that Sda1 is essential for GAS resistance to neutrophils. Group A streptococcal C5a peptidase (SCPA) 
cleaves murine and human polymorphonuclear leukocyte chemotactic factor C5a, and intranasal 
vaccination against SCPA generated serum IgG/IgA responses and prevented GAS nasopharyngeal 
colonisation of mice (142). In a murine air sac model, SCPA-mutant GAS were cleared more 
efficiently than wild-type GAS, and induced the infiltration of significantly higher numbers of 
polymorphonuclear leukocytes (143), suggesting that subversion of leukocyte recruitment is critical 
for GAS to establish an infection. Immunisation with Streptococcus pyogenes cell envelope protease 
(SpyCEP/ScpC), which cleaves chemokines that attract phagocytes including neutrophils, protected 
mice against nasopharyngeal infection (144). A GAS knockout mutant lacking SpyCEP had 
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significantly reduced survival compared to wildtype GAS in human neutrophil killing assays (145), 
and SpyCEP expression also enhanced bacterial dissemination from the NALT to the lungs in mice 
(146). SpyCEP expression by the commensal Lactococcus lactis enabled its survival in the 
nasopharynx, and whilst GAS expression of SpyCEP also contributed to its survival in the NALT, it 
was not essential, suggesting that other virulence factors expressed by GAS are able to compensate 
for SpyCEP (146). In a murine soft tissue model of GAS infection, the infiltration of 
polymorphonuclear leukocytes to the infection site was impaired (147), with this effect being 
attributed to SpyCEP-mediated degradation of the polymorphonuclear leukocyte-attracting 
chemokine IL-8. In mice infected with SpyCEP-deficient GAS, polymorphonuclear infiltration was 
increased and the infection was controlled. However, this strain caused a lethal infection in 
polymorphonuclear leukocyte-depleted mice, thus underscoring the importance of neutrophils in the 
innate immune response to GAS infection. 
 
The hemolysins streptolysin S (SLS) and streptolysin O (SLO) are pore-forming toxins which induce 
osmotic lysis of a broad spectrum of host cells, including neutrophils (148). GAS production of SLO 
is associated with human neutrophil lysis in vitro, with a reduction in neutrophil lysis observed 
following incubation with SLO-mutant GAS (149). SLS has also been shown to induce apoptosis of 
human neutrophils, with SLS-mutant GAS inducing significantly lower levels of neutrophil apoptosis 
(150). Elimination of neutrophils that encounter GAS, by the expression of cytotoxic virulence factors 
such as SLO and SLS, is a mechanism the bacterium may employ during pharyngeal infection in 
order to evade host innate immune responses.  
 
1.5.3 Mast cells 
Mast cells participate in the early recognition and clearance of pathogens and contribute to pathology 
in allergic diseases, rapidly degranulating upon activation to release pre-formed mediators including 
histamine and TNF-α (151). Mast cells appear to play an important role in GAS skin infection models 
(152, 153), however studies have yet to investigate the role of mast cells during streptococcal 
pharyngitis. Mast cells have been reported to kill GAS by extracellular structures similar to NETs 
(mast cell extracellular traps, MCETs), and disruption of MCETs reduced the antimicrobial activity 
of mast cells against GAS in vitro, suggesting that MCETs are important for the inhibition of bacterial 
growth (154). Mast cell-deficient mice were also more susceptible to GAS dissemination in a skin 
infection model, which was attributed to a loss of the mast cell-derived AMP cathelicidin (LL-37), a 
key component of MCETs (152). SLO activates primary murine bone marrow-derived mast cells to 
produce a number of cytokines and chemokines including TNF-α (155), which is critical for the early 
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recruitment of neutrophils in mouse models of bacterial infection. One study reported that the cysteine 
protease SpeB stimulates histamine release by human mast cells in vitro, although its role in GAS 
infection of mucosal membranes is not yet known (156).  
 
1.5.4 Macrophages  
Tissue resident macrophages contribute to control of GAS infection by phagocytosis and the 
production of reactive oxygen species, whilst stimulating the recruitment of inflammatory monocytes 
and their differentiation to inflammatory macrophages at the site of infection. Macrophages express 
a number of cytokines in response to GAS, including IL-6, TNF-α, IFN-β and IL-8 (104, 157). IL-6 
contributes to the differentiation of Th17 cells from naive T cells during GAS infection, whilst TNF-
α recruits and activates many cell types, including neutrophils and monocytes. In a murine soft tissue 
model of GAS infection, TNF-α secretion by macrophages was required for monocyte recruitment to 
the site of infection (158). TNF-α-deficient mice were impaired in monocyte infiltration, whilst 
systemic depletion of monocytes using clodronate-containing liposomes rendered mice sensitive to 
GAS infection, thus suggesting that monocytes and/or macrophages play an important role in 
resistance to GAS infection. The function of type I IFN signalling during GAS infection has currently 
only been investigated in invasive infection, where it plays an immunomodulatory role. Mice 
deficient for the interferon-α/β receptor (Ifnar1-/-) had decreased survival following subcutaneous 
GAS infection, which was accompanied by increased neutrophil recruitment, as well as exaggerated 
destruction of infected tissues (119). Another study showed that subcutaneous infection of Ifnar1-/- 
mice with GAS was accompanied by elevated systemic levels of the pro-inflammatory cytokine IL-
1β that exceeded the protective range (120). Exogenous IFN-β suppressed IL-1β gene expression and 
secretion from wild type but not Ifnar1-/- BMDMs, suggesting that type I IFN signalling is required 
to control macrophage-expressed IL-1β to enable protective effects, rather than pathological ones, 
during GAS infection. Supernatants from GAS-infected macrophages (containing CXCL9 and 
CXCL10) stimulated the migration of T helper cell type 1 (Th1) cells in vitro (109), suggesting that 
macrophages are important for Th1 cell recruitment during infection. GAS infection of human 
macrophages also activated the Nlrp3 inflammasome (see below), leading to the secretion of the pro-
inflammatory cytokine IL-1β (159). This cytokine has a well-characterised role in promoting 
neutrophil recruitment, however its function in the context of pharyngitis infection is not yet known.  
 
Eicosanoids, such as prostaglandin E2 (PGE2) and leukotrienes, are lipid mediators that play both 
pro-inflammatory and immunoregulatory roles in the innate immune response (160), and are known 
to regulate the capacity of macrophages to respond to GAS during infection. PGE2 was produced by 
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macrophages following GAS infection and suppressed the bactericidal activity of bone marrow-
derived macrophages (BMDMs) in vitro by preventing the generation of reactive oxygen species 
(131). This was attributed to PGE2-mediated accumulation of intracellular cAMP and activation of 
protein kinase A (PKA), an endogenous suppressor of phagocytosis and reactive oxygen intermediate 
generation (161). Treatment of BMDMs with PGE2 or the PKA activator (S)-p-8-(-4-
chloropheynlthio) adenosine-3’,5’-cAMP enhanced bacterial survival, whilst treatment with the 
PGE2 receptor EP2 inhibitor AH6809 or the PKA inhibitor PKI12-22 restored BMDM-mediated killing 
of GAS (131). In contrast, leukotriene B4 (LTB4) is a potent stimulator of macrophage phagocytosis 
of GAS, and treatment of human macrophages with LTB4 prior to GAS infection, reduced 
intracellular cAMP levels and significantly increased macrophage phagocytic activity and 
intracellular bacterial killing (162).  
 
Several mechanisms of GAS resistance to macrophage killing have been described in the literature. 
SLS and SLO induced oncotic cell death of BMDMs, with strains deficient in both SLS and SLO 
activity significantly more attenuated for cytotoxicity than single-mutant strains (163). The peroxide 
response regulator PerR, which is thought to enhance GAS virulence by modulating bacterial 
responses in oxidative environments, appears to play a critical role in GAS resistance to macrophage 
phagocytosis, as well as virulence during pharyngeal infection (164). Deletion of PerR was associated 
with reduced resistance to phagocytic killing by murine macrophages and to human blood leukocytes 
in vitro, and attenuated GAS colonisation in a baboon model of GAS pharyngitis (164). The 
streptococcal AgI/II family adhesin AspA, which is required for GAS colonisation of the nasopharynx 
by mediating adhesion to pharyngeal epithelial cells, is also an anti-phagocytic factor required for 
resistance to murine macrophage phagocytosis and neutrophil killing in vitro. Deletion of AspA 
results in increased susceptibility to macrophage phagocytic killing and failure of GAS (serotypes 
M2 and M28) to establish infection following intranasal challenge in mice (165), suggesting that 
AspA plays an important role in GAS colonisation and persistence in the pharynx. SpeB is known to 
facilitate evasion of autophagy and enhance GAS replication intracellularly by degrading host 
autophagy adaptor proteins (166), and has been shown to contribute to GAS survival within human 
macrophages from soft tissue infection biopsies (167). SpeB-deficient GAS show decreased viability 
following infection of human macrophages in vitro (167), suggesting that SpeB could contribute to 
immune evasion and bacterial persistence during GAS pharyngitis. 
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1.5.5 Dendritic cells  
Dendritic cells (DCs) are abundant in the pharynx, and these cells have key functions in priming T 
cell responses during GAS infection. The interaction of GAS with murine and human DCs in vitro 
induced DC maturation and the production of Th1-polarising cytokines, such as IL-12 (168, 169). 
Selective depletion of CD11c+ DCs in mice abolished GAS-induced IL-12 production, and enhanced 
dissemination of GAS into the lymph nodes and liver from a localised subcutaneous infection (168). 
IL-12 is known to stimulate natural killer (NK) cells to generate IFN-γ (170), which is a classic 
macrophage-activating cytokine (171). Whilst NK cells are implicated in the pathogenesis of GAS 
invasive infections, where they are major sources of IFN-γ, IL-6 and IL-12 (172), the role of NK cells 
during GAS pharyngitis and superficial infections is currently not known. In a nasopharyngeal 
infection model, a significant decrease in CD11c+ leukocytes were observed, which the authors 
hypothesised to be mediated by superantigen-mediated cytokine responses that induced 
immunosuppression, allowing GAS to escape myeloid cell-mediated killing (103). As with findings 
in macrophages (see above), type I IFN signalling also appears to negatively regulate inducible IL-
1β expression in DCs, thus limiting IL-1β-associated immunopathology (119, 120).  
 
1.5.6 PRRs and signalling pathways linked to GAS-initiated inflammatory 
responses 
The host employs families of pattern recognition receptors (PRRs), such as the toll-like receptors 
(TLRs), to recognise and respond to highly conserved pathogen-associated molecular patterns that 
are displayed by invading microorganisms. Early studies demonstrated that the TLR adaptor protein 
MyD88 is required for GAS-mediated production of key cytokines (173), however the identification 
of the TLRs engaged upstream of MyD88 has presented a significant challenge to the field (174, 175). 
Innate immune cells from mice deficient in TLR1, TLR2, TLR4 or TLR9, TLR2/6 double-deficient 
mice and TLR2/4/9 triple deficient mice were still able to produce inflammatory cytokines following 
GAS infection (121, 176). More recently, however, TLR2 and TLR13 were identified as GAS 
sensors, with knock-out of both receptors being required for abrogation of macrophage-mediated 
inflammatory responses to GAS in vitro (157). TLR13, which is not present in humans, recognises 
bacterial ribosomal RNA (177), thus raising questions about possible species differences in innate 
immune recognition of GAS. However, another study showed that in human monocyte-derived 
macrophages, GAS RNA is recognised by TLR8 (178), a functional equivalent of TLR13 (179). 
TLR8 is located in endosomes of myeloid cells such as monocytes, macrophages and myeloid 
dendritic cells, and its activation triggers the release of IL-6, TNF-α, IFN-β and LL-37 (178, 180). 
Interestingly, TLR8 signalling has also been shown to induce autophagy (180), a conserved cellular 
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pathway that targets intracellular bacteria for lysosomal degradation. Of interest in this regard, 
autophagy plays a role in the defence of nonphagocytic cells against GAS in vitro (181), and the 
suppression of the autophagy pathway has been implicated in the success of the globally disseminated 
GAS M1T1 clone (166). Mice deficient in either TLR2 or Unc93b1 (a trafficking protein required 
for endosomal TLR function) showed an increased susceptibility to GAS infection upon subcutaneous 
challenge, suggesting that both TLR2 and TLR13 are required for protective defence against GAS in 
mice (157). 
 
GAS has also been shown to trigger non-TLR PRRs during infection, by activating the Nod-like 
receptor family pyrin domain-containing 3 (Nlrp3) inflammasome. In response to endogenous and 
microbial stimuli, this signalling complex initiates caspase-1 activation, which drives the proteolytic 
processing of inflammatory cytokines such as IL-1β and IL-18 (182). In response to live GAS 
expressing the virulence factor SLO, murine macrophages activate caspase-1 and secrete the pro-
inflammatory cytokine IL-1β (183). In contrast to these findings, extracellular NAD+-glycohydrolase, 
a SLO co-expressed toxin, is reported to decrease inflammasome-dependent IL-1β release from 
infected macrophages (184), suggesting that GAS is able to manipulate host cell secretion of IL-1β 
by multiple mechanisms. Using macrophages deficient in inflammasome components, it was shown 
that both Nlrp3 and Asc were crucial for caspase-1 activation and IL-1β secretion during GAS 
infection. The membrane-bound GAS virulence factor SpyA, an ADP-ribosyltransferase, has also 
been shown to stimulate caspase-1-dependent inflammatory responses and IL-1β production in 
murine macrophages (185), whilst the GAS virulence factor SpeB has been proposed to function as 
an inflammatory caspase mimic to cleave pro-IL-1β to generate mature IL-1β (186). This suggests 
that GAS can generate active IL-1β via multiple mechanisms. Another study using human 
macrophages showed that, following stimulation with live or inactivated M1 GAS, inflammasome 
activation mediates the maturation of pro-IL-1β into mature-IL-1β (159). Consistent with the 
inflammasome playing a protective role during GAS infection, BMDMs from Caspase-1-/- mice 
showed decreased survival and impaired killing of GAS (185). 
 
Downstream of PRRs, particularly the TLRs, activation of the MAPK signalling pathways (ERK, 
JNK and p38), as well as the pro-inflammatory transcription factors NF-κB and AP-1, mediate pro-
inflammatory gene expression during GAS pharyngitis (106, 110, 187-189). For example, mRNA 
expression of the AMP human β-defensin-2 by primary human keratinocytes requires the activity of 
the MAPKs p38 and JNK, as well as NF-κB; inhibitors of these components blocked GAS-inducible 
expression of this AMP (108). A transcriptome study of GAS-infected HEp-2 epithelial cells detected 
differential expression of the AP-1 transcription factor family members c-JUN and FOSB, as well as 
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ATF3 (112), which interacts with AP-1 (190). This further implicates the MAPK-AP-1 signalling 
axis as a key mediator of GAS-regulated inflammatory gene expression. These signalling pathways 
lead to the production of numerous inflammatory mediators, the roles of which in GAS pharyngitis 
are discussed below.  
 
1.5.7 PGE2 and leukotrienes 
Several studies have suggested a role for the eicosanoid PGE2 during GAS pharyngitis (112, 114, 
131). This lipid mediator is secreted by many cell types in response to cytokines such as TNF-α, IL-
1 and IL-6 or bacterial pathogen-associated molecular patterns such as lipopolysaccharide (LPS). 
PGE2 has both pro-inflammatory and immunosuppressive effects on innate immune cells, including 
macrophages, neutrophils, NK cells and dendritic cells (191). PGE2 is synthesised from arachidonic 
acid via the actions of the cyclooxygenase enzymes (COX-1/2) and downstream enzymes, and signals 
through four known G protein-coupled receptors (EP1, EP2, EP3 and EP4). Several bacterial 
pathogens including Salmonella spp., Escherichia coli, mycobacteria and GAS are known to induce 
PGE2 production, which has inhibitory effects on immune cells, aiding in bacterial colonisation of 
mucosal surfaces (192). In response to GAS infection, HaCaT epithelial cells promote the secretion 
of PGE2 (114). BMDMs also secrete PGE2 in response to GAS infection (131), which is associated 
with decreased macrophage bactericidal activity, likely facilitating GAS colonisation and survival 
during the early stages of infection.  
 
Leukotrienes, another family of eicosanoid inflammatory mediators derived from arachidonic acid, 
have also been associated with GAS pharyngitis. LTB4 has been reported to enhance pro-
inflammatory responses to several pathogens including GAS by suppressing intracellular cyclic AMP 
production in differentiated THP-1 macrophages, thus stimulating macrophage phagocytosis and 
intracellular killing (162). A transcriptome analysis of pharyngeal infection in cynomolgus macaques 
detected a positive correlation between expression of the uncharacterised GAS transaldolase mipB 
and two genes encoding host leukotriene receptors, LTB4 receptor (LTB4R) and cysteinyl leukotriene 
receptor 2 (CYSLTR2) (107). Transaldolase is a key enzyme involved in carbohydrate metabolism, 
which is a cue for virulence gene expression in GAS (193), suggesting that leukotriene signalling 
may enhance the pro-inflammatory responses to GAS virulence factors during infection. The role of 
leukotrienes during GAS pharyngitis now requires functional studies to investigate the cellular 
meditators and pro-inflammatory phenotypes that leukotrienes orchestrate during infection. 
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1.5.8 Chemokines 
GAS has been reported to induce a plethora of chemokines from the pharyngeal-derived epithelial 
cell line Detroit 562 (111, 113), non-pharyngeal-derived epithelial cell lines HEp-2 (105, 110, 112) 
and HaCaT (106, 110, 114), primary human macrophages (109) and the monocyte-like cell line THP-
1 (113, 115). GAS-induced secretion of IL-8 from HEp-2 cells promoted monocyte (U937) 
transmigration, suggesting that epithelial cell-secreted IL-8 is an important mediator for 
chemoattraction of monocytes during GAS infection (110). Supernatants from GAS-stimulated 
human macrophages induces the migration of Th1 cells, suggesting that macrophages may be 
involved in the recruitment of Th1 cells to the infection site (109).  In HLA-DR4 and HLA-DQ8 mice 
(a murine nasopharyngeal infection model), profiling of nasal turbinates showed that a robust 
chemokine response was induced by the NALT (103). The secretion of inflammatory chemokines 
was accompanied by the marked infiltration of neutrophils, and appeared to be largely dependent on 
GAS superantigens, as a GAS deletion strain for all six superantigen genes (encoding SpeA, SpeC, 
SpeG, SpeL, SpeM and SmeZ) induced much lower levels of inflammatory chemokine secretion and 
only mild neutrophil infiltration.  
 
Given the key role of chemokines in orchestrating leukocyte recruitment and host-protective immune 
responses, it is not surprising that GAS can combat their activities. GAS secretes several proteases 
that specifically cleave and inactivate various chemokines. SpyCEP cleaves and abrogates the 
activities of CXCL1, CXCL2, CXCL6 and IL-8 (146), thus impairing neutrophil recruitment and 
function (194). During GAS lower respiratory tract infection in mice, an inverse relationship between 
the bacterial load and CXCL1 levels was observed, which was attributed to the protease activity of 
SpyCEP (146). SpeB also cleaves a number of chemokines including CXCL1, CXCL2, CXCL3, 
CXCL10, CXCL11 and abolishes the chemotactic, but not antimicrobial, activity of CXCL9 (195). 
The activity of SpeB is required for GAS proliferation in human saliva (196), as well as the 
dampening of the early host immune responses to establish skin infections (197). Due to SpeB 
cleavage of host chemokines that attract macrophages and neutrophils to the infection site, SpeB 
activity may potentially reduce the recruitment of specific cell types to the infection site and thus 
enhance GAS survival and immune evasion during GAS pharyngitis.  
 
1.5.9 Pro-inflammatory cytokines 
Cytokines secreted during GAS pharyngitis signal in an autocrine and/or paracrine manner to instruct 
specific inflammatory responses during infection, with multiple studies investigating those cytokines 
released from different cell types. GAS infection of HEp-2 epithelial cells induced the secretion of 
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IL-6 and TNF-α (105, 112, 129), and increased mRNA expression of RANTES, IL-1α and IL-
1b (110). One study showed that M49 GAS infection of HEp-2 epithelial cells induced a significant 
pro-inflammatory response, with the authors speculating that this would lead to tissue destruction in 
vivo, thus allowing GAS to disseminate deeper into host tissues (112). In response to GAS, HaCaT 
keratinocytes increased expression of mRNA for the cytokines IL-1α, IL-1b and IL-6 (114),  and 
HaCaT cells incubated with M1 protein released MIF, IL-1α and IL-1 receptor antagonist (IL-1Ra) 
(106). BMDMs are reported to secrete IL-6, TNF-α and IFN-β in response to GAS (104), and PBMCs 
secrete IL-1β, IL-6, TNF-α and IFN-α (118). Blood samples from patients with acute GAS 
pharyngitis showed high levels of the pro-inflammatory cytokines TNF-α and IL-6, and reduced 
levels of the T helper 2 (Th2) signature cytokines IL-4 and IL-10, suggesting that immune responses 
are skewed away from a Th2 phenotype (198). In a murine nasopharyngeal GAS infection model, 
analysis of nasal turbinates revealed an early Th17-skewed response, with enhanced secretion of 
TNF-α, IL-6 and IL-17A (103). Other cytokines secreted included IL-1α, IL-1β, IL-2, leukaemia 
inhibitory factor (LIF) and macrophage colony stimulating factor (M-CSF). Despite these findings 
on individual cytokines produced during GAS infection, in many cases, their specific functions in 
host protection versus susceptibility during GAS pharyngitis are still not well understood, as their 
roles have mainly been investigated using GAS invasive disease models. 
 
Multiple studies have identified IL-1b as a GAS-inducible cytokine (183, 199, 200). Pro-IL-1b must 
be proteolytically processed to generate biologically active IL-1b that is secreted from cells, and IL-
1b is critical in host defence against GAS invasive infection (2), which may be mediated by the ability 
of IL-1b to enhance the production of neutrophil chemoattractants (201). In this respect, a recent 
study by LaRock et al. found that the cysteine protease SpeB, which is secreted by the majority of 
disease-causing GAS strains including the M1T1 strain 5448 (202, 203), is able to generate mature 
and active IL-1β by proteolytic cleavage (186). This effect was not observed for another M1 GAS 
strain, which may reflect strain variation differences (184). During invasive infection, GAS isolates 
often acquire mutations that down-regulate SpeB expression, and therefore reduce the capacity of 
such strains to cleave IL-1β. This presumably decreases IL-1b-mediated host responses. LaRock et 
al. also hypothesised that the increased rate of invasive GAS disease observed in patients who receive 
the IL-1β inhibitor drug anakinra is therefore due to a loss of host immunity in response to IL-1β, 
which would normally protect against the development of invasive GAS infection.  
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1.5.10 Antimicrobial peptides (AMPs) 
AMPs are an important component of host innate defence against GAS infection, through both direct 
antimicrobial action at mucosal surfaces and chemokine-like immunomodulatory activities (204). 
The bactericidal activity of AMPs against GAS has been extensively investigated. Primary human 
epithelia produce the human beta defensins (HBD), HBD2 and HBD3, which show bactericidal 
activity against GAS (205). Human and mouse cathelicidins (LL-37 and CRAMP, respectively) are 
expressed in the skin and potently inhibit GAS bacterial growth (206). The immunomodulatory 
activity of LL-37 has been widely studied in vitro, where it has been shown to stimulate IL-8 
production by monocytes, as well as activate the AKT, CREB and NF-κB signalling pathways leading 
to the expression of a number of cytokines and chemokines (207).  
 
AMPs are often downregulated by pathogenic bacteria in order to establish an infection (208). Indeed, 
GAS infection of HaCaT keratinocytes reduced mRNA expression of genes encoding the AMPs 
HBD1 and HBD2 (71). Primary epidermal keratinocytes did not express HBD2 in response to GAS, 
however HBD2 mRNA expression was restored in response to a CS101 GAS mutant lacking 
hyaluronic acid capsule expression (has mutant) (108). GAS also circumvents the antimicrobial 
activity of host AMPs by secreting the proteins streptococcal inhibitor of complement (SIC) and 
through the action of the cell-wall-anchored M1 protein, which binds AMPs (including LL-37, human 
α-defensin-1, HBD2, HBD3, lysozyme and secretory leukocyte protease inhibitor) and prevents them 
from accessing the bacterial membrane (209-212). Inactivation of SIC resulted in decreased GAS 
proliferation in human saliva, and significantly impaired colonisation of the mouse oropharynx (196, 
213). GAS also secretes the plasminogen activator streptokinase (Ska), which activates host plasmin 
that can bind to the GAS surface, resulting in degradation of host LL-37 (214). Mutagenesis of the 
ska gene, or proteolytic inhibition of plasmin, reduced the virulence of GAS in a murine skin lesion 
infection model, implying that the activity of LL-37 is important for controlling GAS infection at the 
epithelial surface (214). Mechanisms of GAS resistance to LL-37 have also been reported, where sub-
inhibitory concentrations of LL-37 induced the GAS CsrRS (also designated CovRS) two-component 
regulatory system, which upregulates the expression of virulence factors streptolysin O and 
hyaluronic acid capsule, significantly reducing GAS killing by human oropharyngeal keratinocytes, 
neutrophils and macrophages (73). Μ1 protein has also been demonstrated to promote resistance to 
LL-37 that is present in the extracellular traps of human neutrophils and the human mast cell line 
HMC-1; loss of M1 protein increased GAS killing by neutrophil NETs and mast cell MCETs (215). 
M1 protein appears to act by enabling GAS to evade LL-37 killing by sequestering and neutralising 
LL-37 antimicrobial activity, as well as binding to the LL-37 precursor hCAP-18 and preventing its 
maturation (216).  
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1.5.11 The complement system 
The complement system contributes to the opsonisation of GAS for subsequent phagocytic killing, 
and a number of GAS virulence factors are reported to target components of the complement system 
during infection as an immune evasion strategy. SCPA cleaves the complement component C5a, a 
potent polymorphonuclear leukocyte chemotactic factor, and intranasal vaccination against SCPA 
prevented GAS nasopharyngeal colonisation in mice (142). SIC inhibits complement-mediated 
formation of the membrane attack complex (MAC) by blocking the membrane-insertion site on C5b-
7 (217), and inactivation of SIC impaired M1 GAS colonisation of the mouse oropharynx (213). GAS, 
like all Gram-positive bacteria, is also resistant to MAC-dependent lysis (218). The mechanism is 
thought to involve the thick peptidoglycan layer present in the cell wall of Gram-positive bacteria, 
that prevents incorporation of the complex into the membrane and subsequent lysis. Whilst MAC 
ring structures are reported to form on the cell wall of GAS, the role of MAC in immune defence 
against GAS is unclear (203). GAS M protein also plays a role in resistance to complement-mediated 
opsonophagocytosis by binding to complement-inhibitory proteins present in human serum such as 
C4b binding protein (219), factor H (220) and factor H-like protein 1 (221). M protein also binds to 
other host proteins such as fibrinogen, which inhibits complement C3 convertase deposition and 
provides resistance to phagocytosis by human blood leukocytes (222), and plasmin, which prevents 
deposition of the opsonin C3b and inhibits neutrophil phagocytosis of GAS (223).  
 
1.6 ADAPTIVE IMMUNITY DURING GAS INFECTION 
A number of studies have investigated the role of acquired immunity in the clearance or protection 
against GAS pharyngitis. Patients lacking the innate signalling components MyD88 (a TLR adaptor) 
or the serine/threonine kinase IRAK-4 are susceptible to invasive and non-invasive pyogenic 
infections as children but become less susceptible with age (224, 225). This suggests that the adaptive 
immune response, which develops throughout life, can compensate for innate immune deficiencies, 
and its role in protection against GAS infection is likely underestimated. Indeed, the majority of GAS 
pharyngitis cases occur in children, whilst infection in adults is less common (92). A recent study 
comparing the humoral and cellular adaptive immune responses of children and adults to conserved 
GAS antigens, revealed that strong Th1 and Th17 cellular memory responses, IFN-γ release and an 
IgG1/IgG3-dominated humoral immune response develops in children following exposure to GAS 
(125). Children showed significantly lower levels of IFN-γ and IgG3 than in adults, which may 
contribute to the higher GAS infection rates that are observed in children. Thus, Th1- and/or Th17-
biased responses are likely to play an important role in the development and preservation of GAS 
 50 
immunity over time (Figure 2). Tonsil explants from tonsillar hypertrophy and recurrent tonsillitis 
patients stimulated with heat-killed GAS also developed a Th1 cytokine response, with IL-1β, IFN-γ 
and TNF-β being the dominate cytokines secreted (116). IFN-γ has been suggested to prevent the 
local dissemination of GAS in a murine NALT model (226), and is critical for protection against 
lethal skin infections in mice (227). A study by Fan et al. suggested that the role of B cells may be 
less important for clearance of, or protection against, GAS infection. In this study, immunised B cell-
deficient mice cleared GAS intranasal challenges as efficiently as wild type mice, and B cell adoptive 
transfer from immunised to naïve mice did not provide protection against infection (138). 
 
 
Figure 2. Interplay between immune cells in the clearance of GAS within the tonsil, as well as 
GAS subversion mechanisms. 
Upon infection, GAS (red) colonises and invades the tonsillar epithelium. Epithelial cells secrete 
bactericidal AMPs and neutrophil chemotactic factors such as IL-8, while tissue resident 
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macrophages phagocytose colonising bacteria and produce TNF-α, which in turn activates 
neutrophils and monocytes. Upon GAS recognition, dendritic cells promote Th1 maturation by the 
secretion of Th1 polarising cytokines such as IL-12, whilst epithelial cells and macrophages 
contribute to Th17 maturation by the secretion of the Th17 polarising cytokines IL-6, TGFβ-1 and 
IL-1β. Th17 cells secrete IL-17A, which promotes epithelial cell-mediated recruitment and activation 
of neutrophils and macrophages. Th1 cells produce IFN-γ, which activates neutrophils and regulates 
neutrophil recruitment to the infection site, but also contributes to bacterial carriage in the NALT. A 
number of GAS virulence factors have been characterised using in vivo models of GAS pharyngitis, 
which target soluble and cellular immune mediators in order to subvert infection (Red text). SpyCEP 
cleaves IL-8 abrogating its chemotactic activity, whilst PerR is a peroxide response regulator that 
provides resistance to macrophage phagocytosis. The adhesin AspA is an anti-phagocytic factor that 
inhibits macrophage and neutrophil phagocytosis, and SpeB cleaves pro-IL-1β to produce mature IL-
1β during infection, which enhances neutrophil recruitment. SIC binds to and inhibits secreted AMPs. 
 
Antigen presentation to CD4+ T cells in the presence of the cytokines IL-6 and TGF-β1 promotes 
Th17 differentiation (72, 228), with the IL-12 family member, IL-23, also contributing to this 
phenotype (72). Not surprisingly, several studies have implicated IL-17A-producing Th17 cells, 
which are particularly important in conferring host protection against extracellular pathogens at 
epithelial surfaces (229), as playing a dominant role in the clearance of GAS in a murine infection 
model of pharyngitis (123, 124, 128). In a murine pharyngitis model, Th17 cells had a protective role 
against GAS infection. For example, transfer of wild type CD4+ T cells from immunised IL-17A+/+ 
mice enabled naïve mice to clear a GAS infection, whereas this protective effect was not apparent 
when IL-17A-/- CD4+ T cells from immunised mice were used (128). During GAS infections, TGF-
β1 produced by monocytes and dendritic cells was shown to be an essential driver of Th17 cell 
differentiation (123). In addition, IL-6 secreted by a specialised CD301b+ dendritic cell subset from 
cervical lymph nodes (124), as well as epithelial-derived IL-6 and IL-23, also contributed to the 
development of this T cell response (127). Although the precise mechanisms by which Th17 cells 
control GAS infections are yet to be fully elucidated, IL-17A is well known to mediate the recruitment 
and expansion of neutrophils and macrophages (123), key cell types that contribute to the detection 
and clearance of GAS. 
 
Interestingly, Th17-skewed CD4 T cell responses to GAS are dependent upon intranasal inoculation, 
whereas intravenous or subcutaneous inoculation generated a Th1 response, with a characteristic IFN-
γ signature (124). In IL-6-/- mice, IFN-γ+ CD4 T cells were expanded during GAS infection, and these 
mice were unable to clear the infection from the NALT and became long-term carriers (124). This is 
likely because the IFN-γ+ CD4 T cells are unable to attract host-protective neutrophils to the infection 
site. This raises the intriguing possibility that an imbalance between IL-17A- and IFN-γ-producing 
CD4 T cells could contribute to GAS carriage in humans. Th17 cells and IL-17A have been implicated 
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in murine models of various GAS aetiologies, such as chronic arthritis, acute sepsis and puerperal 
sepsis. In a murine puerperal sepsis model, neutrophil recruitment and clearance of GAS was 
significantly attenuated in IL-17A-/- mice (230), suggesting that IL-17A contributes to the control of 
GAS mucosal colonisation. During acute sepsis, enhanced levels of IL-17A were detected in the 
serum of both sham-infected and GAS-infected mice within a short time of inoculation, indicating 
the speed and potency of the IL-17A response, which can be stimulated by trauma alone (231). In a 
murine model of chronic arthritis, IL-17 receptor-deficient mice showed reduced joint destruction 
(232). Mice deficient for IL-1β, which is required for the differentiation of Th17 cells, were fully 
protected against joint destruction during late stages of disease, implicating Th17 cells in host-
destructive inflammatory responses during GAS infection. It is important to note that gamma-delta 
(γδ) T cells are also a major source of IL-17A, and are present in large numbers in the surface 
epithelium of tonsils from patients with recurrent tonsillitis (81). As γδ T cells differentiate quickly 
upon stimulation and can respond to different antigens independently of classical MHC class II-
mediated presentation of peptide epitopes, these cells are likely to play an important role in bridging 
the innate and adaptive immune responses during GAS infection (233).  
 
Several studies have shown that regulatory T cells (Tregs) and Th2 responses are not typically 
generated during murine intranasal GAS infection (128, 234). In contrast, Tregs, which dampen 
immune responses to self-antigens and to foreign antigens, are induced by superantigens during 
systemic GAS infection (235), and in vitro, GAS M proteins (M5 and M22) have been shown to 
induce the differentiation of human CD4+ lymphocytes into Tregs (236). During systemic infection, 
Tregs can be induced by superantigens or M protein triggering the cross-linking of the T cell receptor 
and CD46 on naïve T cells (236). GAS may exploit the Treg signalling pathway as a strategy to 
induce an immunosuppressive/immunomodulatory T cell phenotype, which may facilitate GAS 
immune evasion as well as contribute to pathogenesis. Mucosa-associated invariant T cells, a subclass 
of innate-like T cells, have recently been identified as a major source of IFN-γ and pro-inflammatory 
cytokines (TNF-α, IL-2 but not IL-17A) after exposure to superantigen staphylococcal enterotoxin B 
(237), and therefore may contribute to the cytokine storm and subsequent immunosuppression 
observed during systemic superantigen-mediated GAS infections.  
 
1.7 PROTECTIVE ROLES OF PHARYNGEAL MICROBIOTA AGAINST GAS 
INFECTION 
The normal microbiota that colonises mucosal layers is an important component of first-line defence 
against invading pathogens, with commensal and probiotic bacteria competing with foreign microbes 
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for niche and nutrients. Furthermore, initial studies showed that normal throat flora contains bacterial 
species (nonhaemolytic streptococci, viridans streptococci and Neisseria spp.) that are both inhibitory 
and bactericidal to GAS and can protect against GAS colonisation in children (238, 239). The 
microbiota can also regulate host immunity and contribute to host defence by modulating the 
cytokines and antimicrobial peptides that host cells secrete (240). For example, probiotic 
Lactobacillus species commonly colonise mucosal membranes of the oral tract, and certain strains 
can skew immune responses into a regulatory or tolerant mode by suppressing pro-inflammatory 
responses (IL-6, IL-12, TNF-α, IL-17A/IL-23, and T helper 2 cytokines) (127, 241, 242), modulating 
expression and/or function of PRRs that detect GAS components (127), and inducing the production 
of regulatory cytokines such as IL-10 (241). Strains of Lactobacillus (L. rhamosus Kx151A1 and L. 
reuteri PTA-5289) have also been reported to attenuate the expression of SLS at the transcriptional 
level and inhibit the haemolytic activity of GAS in vitro (243), which may help protect the pharyngeal 
mucosa from GAS colonisation during early infection.  
 
In light of the evidence above, microbiota-mediated suppression of inflammation could potentially 
inhibit GAS growth and colonisation of the tonsils. Pro-inflammatory cytokine production is often 
accompanied by increased epithelial permeability due to perturbation of tight junctions, which GAS 
can exploit to gain access to host metabolites, adhesive factors and underlying tissues (244). 
Therefore, the ability of microbiota to dampen host pro-inflammatory responses is predicted to be 
beneficial in the control of GAS infections. Conversely, the anti-inflammatory effects of microbiota 
could also contribute to asymptomatic and/or chronic bacterial carriage in children, where immune 
tolerance prevents the clearance of GAS. In addition, the ability of Lactobacilli to reduce SLS 
production suggests that microbiota may also play a role in regulating GAS virulence factor 
production in order to control bacterial colonisation.  
 
The oral microbiota can also protect against pathogenic bacterial infection by the secretion of 
bactericidal compounds, and BLIS K12 (BLIS being an acronym for bacteriocin-like inhibitor 
substances) is a commercially available oral cavity probiotic that protects against GAS pharyngitis 
(245). BLIS K12 is developed from Streptococcus salivarius K12, which is a bacterial species found 
in the oral microbiota of healthy humans. BLIS K12 antagonises GAS growth by secreting the 
bacteriocins salivaricin A2 and B, and has been shown to reduce GAS pharyngitis and/or tonsillitis 
episodes in children (246-248) and adults (249) who experience recurrent GAS infections. Given the 
widespread interest in microbiota-mediated immune regulation and control of disease outcomes, this 
will undoubtedly be an area of burgeoning interest in the future.  
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1.8 COMPLICATIONS ARISING FROM GAS PHARYNGITIS 
GAS pharyngitis has been associated with the development of several disease pathologies, including 
autoimmune diseases. The pharynx is the primary site of infection of GAS, and from there local 
complications can occur, such as peritonsillar or retropharyngeal abscess formation, as well as 
tonsillar hypertrophy. Autoinflammatory complications that may accompany pharyngitis infection 
can include scarlet fever, whilst post-infectious sequelae include acute rheumatic fever and guttate 
psoriasis (250).  
 
1.8.1 Acute rheumatic fever and rheumatic heart disease  
Acute rheumatic fever (ARF) and rheumatic heart disease (RHD are serious autoimmune diseases 
that can develop following GAS pharyngitis. These GAS-associated conditions have been reviewed 
extensively (7, 251, 252). The pathogenesis of GAS infection-induced non-suppurative pathologies 
remain elusive, however they appear to be the result of an exaggerated immune response to specific 
GAS epitopes in susceptible individuals (30). Clinical features of ARF include arthritis, carditis and 
fever, and ARF episodes can occur recurrently (253). RHD develops as a result of ARF, and refers to 
the long-term damage of heart valves (251). Prevention of these autoimmune conditions is best 
achieved through timely identification and antibiotic treatment of GAS pharyngitis (254).  
 
1.8.2 Scarlet fever 
Scarlet fever is a skin rash that can be present during GAS pharyngitis. The rash typically appears 
within the first few days of GAS infection, spreading from the trunk to the extremities of the body 
(250). The pathogenesis of scarlet fever is not well characterised; however, GAS secreted pyrogenic 
exotoxins have been implicated in evoking a rash in naïve subjects. No single toxin has been 
consistently associated with scarlet fever, but combinations of the exotoxins SpeA, SpeC and 
streptococcal superantigen A (SSA) are often seen in GAS strains causing scarlet fever outbreaks 
(255-258). The mechanisms by which these exotoxins may contribute to the symptoms of scarlet 
fever are not well studied, but they have been found to alter IgG production and reticuloendothelial 
clearance function, induce T-cell proliferation and enhance skin reactivity (259).   
 
1.8.3 Adenotonsillar hypertrophy and paediatric sleep apnoea 
GAS pharyngitis is associated with paediatric adenotonsillar hypertrophy (abnormal enlargement of 
the tonsil) and has recently been implicated in paediatric obstructive sleep apnoea syndrome (OSAS), 
which is primarily characterised by enlarged tonsils (130). Tonsillar hypertrophy is caused by the 
proliferation of immune cells in the follicles and interfollicular areas of the tonsils in response to 
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infection, and GAS was present in the tonsillar reticulated crypt epithelium of 37 % of children who 
had tonsillectomy for adenotonsillar hypertrophy (48). The composition of immune cells in tonsils 
from recurrent GAS tonsillitis patients and from tonsillar hypertrophy patients are similar, and upon 
stimulation with GAS both produce a Th1 cytokine response (81, 116). A study by Viciani et al. 
reported an association between OSAS and GAS tonsil colonisation. These authors showed that the 
GAS toxin SLO induced production of CysLTs, by a TLR4-mediated pathway, that involved the TLR 
adaptors MyD88 and TRIF and the p38 MAP kinase (130). CysLTs activated primary T and B cell 
proliferation in vitro, which might mediate the development of tonsil hypertrophy, and thus paediatric 
OSAS. A second study by the same authors identified the GAS virulence factor SlaA, which is 
reported to target the CysLTs production pathway, to also be associated with OSAS (260). The slaA 
gene was found in 45.5% of GAS strains isolated from OSAS patients. SlaA cleaves the fatty acids 
palmitic and oleic acids to release arachidonic acid, which is then converted to leukotrienes and 
CysLTs by the 5-lipoxygenase pathway, and may contribute to tonsil hypertrophy and thus OSAS 
(261). 
 
1.8.4 Guttate psoriasis 
Guttate psoriasis (GP) is an abnormal immune reaction characterised by the sudden onset of small, 
rounded skin lesions, caused by abnormal reactivity of specific T lymphocytes in the skin, leading to 
the infiltration of inflammatory cells and proliferation of keratinocytes (262). GAS pharyngitis is 
often considered as a trigger of GP, and in 56% to 97% of GP cases, GAS pharyngitis precedes lesion 
formation (263). The immunological mechanisms that cause lesion formation are not well understood, 
however Th17 responses are thought to play an important role (264). Superantigens from GAS have 
been demonstrated to enhance T-cell expression of cutaneous lymphocyte antigen (CLA+), which is 
a carbohydrate moiety expressed by 80% of T cells in the skin, and the abundance of CLA+ CD8+ T 
cells in the blood of patients with psoriasis correlates with disease severity (265). CLA+ T cells in the 
tonsils and GP lesions of the same patient show identical T-cell receptor beta rearrangement (Vβ2+), 
suggesting that migration of these cells occurs from the tonsils to the skin (266). Once in the skin, the 
CLA+ T cells interact with lesional epidermal cells and induce a dominant Th17 response (267). Some 
studies have reported that tonsillectomy results in improvement of psoriasis in the majority of cases, 
and is associated with a reduction in the frequency of skin-homing T cells in the blood that were 
reactive to peptides derived from human epidermal keratins and streptococcal M proteins (267, 268). 
The actual events that drive T cells to migrate from the tonsil to the skin and cause GP is not known. 
As GAS has been detected in the skin but not tonsils of patients with GP, it has been proposed that a 
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transient presence of intracutaneous GAS during GAS pharyngitis could trigger autoimmunity against 
local skin proteins by molecular mimicry (269). 
 
1.9 CONCLUSIONS 
GAS pharyngitis and resulting post-immune sequelae continue to cause a significant burden on 
human health globally, and an improved understanding of how the host immune system responds to 
GAS is important in developing better strategies to combat infection and disease. An abundance of 
in vitro data and murine infection studies demonstrate that both the innate and adaptive immune 
systems play a key role in protection against GAS infection. However, our knowledge of the specific 
signalling pathways activated during human infection and how innate and adaptive immunity cross-
communicate with each other is still quite limited. Key aspects of innate immunity that are 
particularly important in defence against GAS include the secretion of pro-inflammatory mediators 
by epithelial cells, and the roles of neutrophils and macrophages in the control and clearance of GAS. 
Current evidence suggests that Th17 cells are central players during GAS pharyngitis, contributing 
to both protection against infection, as well as immune-related pathologies. Areas that require more 
extensive exploration in the context of GAS pharyngitis include the roles of mast cells and innate 
lymphoid cells, as well as the contribution of the inflammasome pathway to inflammation and 
bacterial clearance in the pharynx. The role of microbiota in immunity is an emerging area of 
research, and the initial studies describing microbiota-mediated regulation of inflammation during 
GAS infection will likely gain increasing interest into the future. An improved understanding of the 
cellular and humoral responses that mediate immunity to GAS should enable the development of 
better therapeutic and preventative strategies to combat GAS infection and related 
immunopathologies.  
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2.0 Project aims 
 
The aim of this project is to investigate the inflammatory responses of primary human tonsil epithelial 
cells during intracellular infection with two different GAS strains; the laboratory-adapted M6 strain 
JRS4 and the M1T1 clinical isolate 5448. This thesis aims to investigate innate immune responses 
triggered and/or subverted by these different GAS strains in order to further understand why the 
M1T1 strain is so successful at causing disease in humans. 
 
2.1 Research Objectives 
• To determine whether primary human tonsil epithelial cells elicit different pro-inflammatory 
responses during intracellular infection with different GAS M types. 
• Investigate the role of specific immune signalling pathways and signalling components during 
GAS infection. 
• Identify potential GAS virulence factors that play a role in GAS-host innate immune 
interactions. 
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3.0 General Materials and Methods 
 
Methods utilised in results chapters 4, 5 and 6.  
 
3.1 Bacterial strains and growth conditions 
GAS M1T1 strain 5448 was originally isolated from a patient with necrotising fasciitis and toxic 
shock syndrome (270). JRS4 is a streptomycin-resistant derivative of D471, a rheumatic fever-
associated isolate (271). GAS strains were grown in Todd-Hewitt broth supplemented with 0.2 % 
yeast extract (THY) at 37°C. To measure the growth kinetics of the bacterial strains, overnight 
cultures grown in THY broth were diluted to an optical density of 600nm (OD600) = 0.05 in fresh 
THY broth. The bacteria were then grown in a 96-well microplate, and OD600 was measured every 15 
min over 12 h using the FLUOstar Optima (BMG Labtech) plate reader at 37°C (see Supplementary 
Figure 1). Prior to each reading the 96-well plate was orbital shaken for 20 seconds at 300 rpm. 
 
3.2 Cell lines 
Human primary tonsil epithelial (TEpi) cells were purchased from Sciencell Research Laboratories, 
California (Cat. #2560). TEpi cells consist of a heterogeneous population of actively differentiating 
stratified squamous epithelial cells and reticulated epithelial cells isolated from the tonsil explants of 
an individual donor (Lot. No. 10474, 10 y.o. male, Caucasian). TEpi cells were cultured at 37°C 
under a 5% CO2/ 20 % O2 atmosphere in Tonsil Epithelial Cell Medium (Sciencell, Cat. #2561) 
supplemented with 1 % Tonsil Epithelial Cell Growth Supplement (Sciencell, Cat. #2562). TEpi cells 
were cultured on poly-L-lysine coated tissue culture vessels (Greiner Bio-one). At 95 % confluency, 
cells were trypsinised and handled according to instructions provided by the manufacturer. TEpi cells 
were cultured for several weeks with media changed every 2-3 days and utilised for experiments at 
passage 4.  
 
3.2.1 Sub-culturing techniques of TEpi cells 
At 95 % confluency, TEpi cells were sub-cultured by trypsinisation. Briefly, culture media was 
aspirated and cells were washed 2x with PBS. Cells were incubated in 2 ml of a trypsin solution 
containing 75 % PBS, 25 % of 0.25 % Trypsin-EDTA (Gibco, Cat # 25200-056), 2 mM of 1 M 
HEPES Buffer Solution (Gibco, Cat# 15630-106) and 0.2 mM of 100 mM sodium pyruvate (Gibco, 
Cat# 11360-070), for 2 min at 37 ºC. The solution was then aspirated into 5 ml of trypsin 
neutralisation solution (TNS) containing 90 % PBS, 10 % FBS and 2 mM HEPES. This process was 
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repeated until most cells had detached from the flask. After the last trypsin incubation, 5 ml of TNS 
was added to the flask to collect the remaining cells. The TEpi cells were pelleted by centrifugation 
at 600 x g for 5 min. The supernatant was discarded and cells were re-suspended in fresh culture 
media.  
 
3.2.2 Storage of TEpi cells 
Cryo-vials of TEpi cells were cultured to passage number two before being stored in liquid nitrogen. 
Cells at 95 % confluence were harvested (as described above), pelleted by centrifugation at 600 x g 
for 5 min, and re-suspended in ice-cold freezing media consisting of Tonsil Epithelial Cell Medium 
supplemented with 1 % Tonsil Epithelial Cell Growth Supplement, 10 % DMSO and 10 % FBS. 
Cells were aliquoted into cryo-vials, before being frozen to -80 ºC in cryo-freezing containers 
containing 300 ml isopropanol, and then transferred to liquid nitrogen. Cryo-vials of cells were 
defrosted at room temperature and re-suspended in Tonsil Epithelial Medium as described above. The 
next day the medium was replaced with fresh cell culture medium. 
 
3.3 Intracellular infection assays  
TEpi cells were seeded at a density of approximately 2 x 104 viable cells per well in 24-well tissue 
culture plates or 12 x 104 viable cells per well in 6 well plates coated with poly-L-lysine. Cells were 
grown at 37°C under a 5 % CO2/20 % O2 until they formed a confluent monolayer. Immediately prior 
to infection, the TEpi medium was removed, and replaced with fresh TEpi medium. GAS strains were 
grown to early stationary phase (OD600 = 1.2 for 5448 and OD600 = 1.6 for JRS4), re-suspended in 
cell culture medium, and then added to cell monolayers at the required multiplicity of infection 
(MOI). Controls included for each experiment were cells not exposed to bacteria (mock). At 2 h post-
infection, the media was aspirated and cells were washed twice with fresh media, before TEpi media 
containing 100 µg/ml of gentamicin was added to each well for the duration of the experiment to kill 
extracellular GAS (166). For each strain, colony forming unit (CFU) assays were performed 
following infection to retrospectively determine MOI. Bacterial cultures were serially diluted in PBS, 
before being spotted in triplicate onto THY agar plates and left to incubate for 24 h at 37°C. Bacterial 
colony numbers were then counted and the average CFU/ml calculated. 
 
3.4 E. coli transformation protocol 
Competent MC1061 cells were thawed on ice for 30 min. 2 µl plasmid DNA was added to 50 µl 
competent cells, and in a separate tube 2 µl sterile H2O was added to 50 µl competent cells as a 
negative control. Samples were mixed by flicking 4-5 times, before being placed on ice for 30 min. 
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The cells were then heat shocked at 42 °C for 1.5 min, before placed on ice for 5 min. 950 µl LB was 
added to each tube, and incubated at 28 °C for 30 min. Several dilutions (1:10 – 1:100) of transformed 
cells were plated onto LB agar containing 100 µg/ml spectinomycin, and incubated overnight at 28 
°C. Several colonies were picked for PCR and sequencing analysis to confirm the presence of plasmid 
DNA. 
 
3.5 Lactate dehydrogenase cytotoxicity assay 
Cell death following GAS infection was quantified by measuring lactate dehydrogenase (LDH) 
release from cell supernatants, using CytoTox96® Non-Radioactive Cytotoxicity Assay (Promega, 
G1781), as per the manufacturer’s instructions. Cells lysed in 0.2 % Triton-X 100/1 x PBS were 
included as a positive control for 100 % cell death, for each condition at each time point. Sample 
absorbance was measured by spectrophotometer (SpectraMax Plus 384, Softmax Pro 5.4 software) 
at an absorbance of 490 nm. Sample readings were analysed by Prism 7 software and divided by the 
positive control for cell lysis to give a percentage of total cell death for each sample.  
 
3.6 Sandwich ELISA  
TEpi cells were infected with GAS as described above. At each time point post-infection, the media 
was removed from each well and centrifuged at 13,000 x g for 5 min at 4°C. The pellet was then 
discarded and the supernatant stored at -80°C. IL-6 (BD Biosciences OptEIA™, Cat. # 550799) or 
IL-8 (BD Biosciences OptEIA™, Cat. #555244) protein levels were measured by ELISA according 
to manufacturer’s directions using 96 well microplates (Greiner Bio-One, Cat. # 655001). O-
phenylenediamine dihydrochloride (Thermo Scientific Pierce, Cat. # 34006) was used as a substrate 
for horseradish peroxidase. Sample absorbance was measured by spectrophotometer (SpectraMax 
Plus 384, Softmax Pro 5.4 software) at 450 nm, with 𝜆	correction at 570 nm. Sample readings were 
analysed using Prism 7 software, and protein concentrations were interpolated by linear regression of 
samples against a known standard curve of human recombinant IL-6 or IL-8.  
 
3.7 SDS-PAGE and western immunoblotting 
Protein concentrations were determined using bicinchoninic acid (BCA) assay (Thermo Scientific, 
Cat. #23225) following the manufacturer’s instructions. Equivalent protein concentrations of samples 
were diluted in SDS-PAGE loading buffer/ 0.1 M DTT, boiled for 5 min at 100°C, before being 
loaded and resolved on an SDS-PAGE gel prepared as described by previous studies (272). Proteins 
were resolved at 80 V for 10 min, then 150 V for 75 min. Proteins were transferred to a methanol-
activated PVDF membrane (Immobilon-FL, Millipore) using a wet transfer apparatus (Bio-Rad) at 
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100 V for 1-2 h at 4 °C. Membranes were then blocked in OdysseyÒ blocking buffer (Li-Cor, Cat. 
#927) for 1 h at room temperature. Primary antibody diluted 1:1000 in blocking buffer containing 
0.01 % Tween-20 was then incubated with the membrane overnight at 4°C, with slow rotation. The 
membrane was washed for 5 min in PBS/ 0.1 % Tween-20 with gentle shaking (repeated 3 times). A 
fluorescently labelled secondary antibody diluted 1:10 000 in blocking buffer containing 0.2 % 
Tween-20 and 0.02 % SDS was then incubated on the membrane for 60 min at room temperature 
protected from light, with gentle rotation. The washing step was then repeated as described above. 
The membrane was rinsed in PBS and allowed to dry. Bound secondary antibody was detected using 
near-infrared (NIR) western blot detection system Odyssey CLx (Li-Cor).    
 
Table 2. Antibodies used in this study 
Type Animal 
raised in 
Target 
protein 
Working 
dilution 
Application Supplier Catalogue # 
Primary 
(polyclonal) 
Mouse  SpyCEP 1:1000 Western blot In house Not 
applicable 
Primary 
(polyclonal) 
Mouse  SLO 1:1000 Western blot In house Not 
applicable 
Primary 
(polyclonal) 
Rabbit GAPDH 
(GAS) 
1:1000 Western blot In house Not 
applicable 
Secondary Goat  anti-mouse 1:10 000 Western blot Li-Cor 926-32210 
Secondary 
IgG Dylight 
580 
conjugate 
 anti-rabbit 1:10 000 Western blot Cell 
Signaling 
5366 
Secondary 
IgG Fab2 
Alexa Fluor 
488 
 anti-mouse 1:10 000 IF-IC Cell 
Signaling 
4408 
Primary 
(monoclonal) 
Mouse Keratin 8/18 1:200 IF-IC Cell 
Signaling 
4546 
Primary 
(monoclonal) 
Rabbit phospho- 
NF-κB p65 
1:1000 Western blot Cell 
Signaling 
3033 
Primary 
(monoclonal) 
Rabbit NF-κB p65 1:1000 Western blot Cell 
Signaling 
8242 
Primary 
(monoclonal) 
Rabbit IκBα 
 
1:1000 Western blot Cell 
Signaling 
4812 
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Primary 
(monoclonal) 
Rabbit GAPDH 
(human) 
1:1000 Western blot Cell 
Signaling 
2118 
Primary 
(monoclonal) 
Rabbit β-tubulin 1:1000 Western blot Cell 
Signaling 
2146 
Primary 
(monoclonal) 
Rabbit Phospho Akt 1:1000 Western blot Cell 
Signaling 
4060 
Primary 
(monoclonal) 
Rabbit p105/p50 1:1000 Western blot Cell 
Signaling 
3035 
 
3.8 RNA extraction  
Tissue culture medium was aspirated from TEpi cell monolayers and RNA lysis buffer (Buffer RLT 
(Qiagen) plus 0.1 M β-mercaptoethanol) added to each well. Cells were scraped into the buffer using 
a cell-scraper, and passed through a QIAshredder homogenizer column (Qiagen, Cat. #79654) by 
centrifugation. RNA was then isolated using the RNeasy Mini Kit (Qiagen, Cat. #74104), according 
to the manufacturer’s instructions. Absorbance of RNA samples was measured at 260 nm using a 
ND1000 Nanodrop (Biolab), and RNA concentration (µg/ml) was determined by the A260 reading: 
A260 = 1.0 is equivalent to 40 µg/ml RNA. RNA integrity of each RNA sample was confirmed by 
Agilent 2100 BioAnalyzer analysis (RIN score of >7.0).  
 
3.9 RNA sequencing and bioinformatics analyses 
Confluent 6-well plates of TEpi cells were infected with JRS4 or 5448, as described above, at an MOI 
of 5 for 6 h. Mock-treated cells were included as a control. RNA from four biological replicates was 
extracted, as described above. RNA-Seq libraries were generated using the Illumina TruSeq Stranded 
mRNA LT Sample Prep Kit (Illumina, RS-122-2101/RS-122-2102), according to the standard 
manufacturer’s protocol (Illumina, 15031047 Rev. E October 2013). Total RNA was enriched for 
mRNA using an oligo-dT bead isolation method. The enriched mRNA was then subjected to a heat 
fragmentation step aimed at producing fragments between 120-210 bp (average 155 bp). cDNA was 
synthesised from the fragmented RNA using SuperScript II Reverse Transcriptase (Invitrogen, 
Catalog no. 18064014) and random primers. The resulting cDNA was converted into dsDNA in the 
presence of dUTP to prevent subsequent amplification of the second strand and thus maintaining the 
‘strandedness’ of the library. Following 3’ adenylation and adaptor ligation, libraries were subjected 
to 15 cycles of PCR to produce libraries ready for sequencing. The libraries were quantified on the 
Agilent BioAnalyzer 2100 using the High Sensitivity DNA Kit (Agilent, 5067-4626). Libraries were 
pooled in equimolar ratios, and the pool was quantified by qPCR using the KAPA Library 
Quantification Kit - Illumina/Universal (KAPA Biosystems, Part no. KK4824) in combination with 
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the Life Technologies Viia 7 real time PCR instrument. Library preparation was performed at the 
Institute for Molecular Bioscience Sequencing Facility (University of Queensland). 
 
Sequencing was performed using the Illumina NextSeq500 (NextSeq control software v2.0.2.1 / Real 
Time Analysis v2.4.11). The library pool was diluted and denatured according to the standard 
NextSeq protocol (Illumina, Document # 15048776 v02), and sequenced to generate single-end 76 
bp reads using a 75 cycle NextSeq500/550 High Output Reagent Kit v2 (Illumina, FC-404-2005). 
After sequencing, fastq files were generated using bcl2fastq2 (v2.17.1.14). Sequencing was 
performed at the Institute for Molecular Bioscience Sequencing Facility (University of Queensland). 
 
Quality-checked RNAseq FASTQ libraries were aligned to the reference Human genome (hg19) 
using the Subread (273) library version 1.18 for the R package for statistical computing version 3.2.1, 
with default mapping parameters. Reads were summarised and annotated to Ensembl version 69 
transcripts and genes using the featureCounts function of Subread. A known batch effect in the post-
normalised log2 expression data was successfully corrected for using the removeBatchEffect function 
of limma (274) version 3.26.8. Batch-corrected RPKM (Reads Per Kilobase of transcripts per Million 
mapped reads) and TMM normalised, log2 transformed expression data is available in Stemformatics 
(275) at http://www.stemformatics.org/datasets/view/6991. Raw data and count tables have been 
deposited to NCBI’s Gene Expression Omnibus (GEO) (276) under accession GSE107001. 
 
Differential expression analysis was separately performed using R version 3.2.2 using the limma 
library version 3.26.8. The known batch effect was specified as part of the linear model and factored 
into the analysis. Genes were tested for differential expression if they displayed one count per million 
in all replicates of at least one phenotypic group. We used limma’s Voom function to modify linear 
model fitting parameters based on the mean variance trend of counts observed. Input counts were 
TMM (277, 278) normalised and median-centered in addition to the log2 and count-per-million 
transforms applied by Voom. For downstream analyses, genes were considered differentially 
expressed with a Benjamini–Hochberg adjusted p-value < 0.05 and a Log2FC > 1 or < -1. 
 
3.10 RNAseq interaction networks and pathway analysis  
Protein-protein interaction networks from the top 100 differentially expressed genes (at an adjusted 
P value <0.05) from each group comparison (5448-infected TEpi cells vs mock cells, JRS4-infected 
TEPi cells vs mock cells, and 5448-infected vs JRS4 infected TEPi cells) were constructed using 
STRINGdb.com. Network edges show the confidence of interactions, where the line thickness 
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indicates the strength of data support. Active interaction sources include textmining, experiments, 
databases, co-expression, neighborhood, gene fusion and co-occurrence. Minimum required 
interaction score of medium confidence (0.400). Pathway over-representation analysis of all 
differentially expressed genes (adjusted P value < 0.05, Log2FC > 1 or < -1) for 5448-infected TEpi 
cells in comparison to mock cells and JRS4-infected TEpi cells in comparison to mock cells was 
performed using InnateDB.com. Hypergeometric analysis algorithm was used, with Benjamini 
Hochberg correction method. HOMER motif analysis software was used to identify enriched 
transcription factor recognition motifs within the regulatory regions of the top 400 differentially 
expressed genes for 5448-infected tonsil epithelial cells and JRS4-infected TEpi cells (279). Motif 
finding parameters: motifs of a length of 8,10 or 12 bases from -300 to +50 bases relative to the 
transcription start site, with 2 mismatches allowed in global optimisation phase. The background gene 
list used comprised of all gene IDs detected by RNAseq. Heat maps were drawn using R (version 
3.3.2) gplots package, using RNAseq data available at NCBI’s Gene Expression Omnibus (GEO) 
(276), under accession GSE107001. 
 
3.11 Quantitative Real-Time (qRT) PCR  
cDNAs were synthesised from extracted RNA using the Superscript® First-Strand Synthesis System 
(Thermofisher scientific, Cat. #18080051), as per the manufacturer’s instructions. cDNA was diluted 
to 1 ng/µl in RNase-free water and used for qPCR. The relative expression of target genes was 
determined using the Applied Biosystems (ABI) ViiATM 7 Real-Time PCR System. A 15 µl reaction 
mixture was prepared with 2 x SYBR Green PCR Master Mix (Qiagen) (7.5 µl), 200 nm of forward 
and reverse primers, and 3 µl of diluted cDNA. cDNA and reagent master mixes (primer pair and 
SYBR Green) were automatically loaded into the 384-well plate using the Eppendorf epMotion 5075 
robot and Eppendorf epBlue software. All cDNA samples were run in triplicate in a 384-well plate. 
Standard qPCR cycles were used (10 min at 95°C step for polymerase activation, followed by 40 
cycles of two-step thermal cyclic PCR at 95°C for 15 sec and 60°C for 1 min). mRNA levels for 
specific genes were quantified relative to expression of the house-keeping gene hypoxanthine-
guanine phosphoribosyltransferase (HPRT). qPCR data was analysed using QuantStudioTM Software 
V1.2 and GraphPad Prism 6. The following equation was used to calculate relative gene expression: 
Gene/house-keeping gene = 2-∆Ct; where ∆Ct = geneCt – house-keeping geneCt (the difference in cycle 
thresholds).  
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3.12 Primers  
Primers used for quantitative PCR (qRT-PCR) analysis were either designed using NCBI primer 
design public software (http://www.ncbi.nlm.nih.gov/tools/primer-blast), sourced from Harvard 
Medical School PrimerBank (https://pga.mgh.harvard.edu/primerbank/), or were from Prof. Matthew 
Sweet (Institute for Molecular Biosciences, University of Queensland, Australia). At least one primer 
per primer pair was designed to span exon-exon junctions to avoid amplification of any contaminating 
genomic DNA. Primer pairs were designed to amplify a product of 70-190 bp, and to have melting 
temperatures of 59-61°C. Absence of predicted hairpins, self-dimers and hetero-dimers were 
confirmed using the Integrated DNA technologies OligoAnalyzer 3.1 
(https://sg.idtdna.com/calc/analyzer). Primer concentrations of 2 µm were used for quantitative 
analyses. The amplification of a single product was confirmed by the melt curve of each qRT-PCR. 
Primer pairs used for qRT-PCR are listed in Table 3.  
 
Table 3. List of primers used for qPCR 
Primer Primer Sequences Produce 
size 
Exons 
targeted 
IL-6 Forward (5’ – 3’): CTCAGCCCTGAGAAAGGAGACAT  
Reverse (5’ – 3’): TCAGCCATCTTTGGAAGGTTCA 
99 2-3 
IL-8 Forward (5’ – 3’): GGAGAAGTTTTTGAAGAGGGCTGA 
Reverse (5’ – 3’): TGCTTGAAGTTTCACTGGCATCTT 
93 3-4 
TEBP  Forward (5’ – 3’): GACCGGAGAGAAAAAGCGGA 
Reverse (5’ – 3’): AGGCTGCTTTTCCAAAGACATA 
144 1-2 
CYTA Forward (5’ – 3’): ACATTAAGGTACGAGCAGGTGA 
Reverse (5’ – 3’): CATGCTGCTAAAAGCCCGTC 
144 2-3 
CYTB Forward (5’ – 3’): GTGAGGTCCCAGCTTGAAGA 
Reverse (5’ – 3’): CGTGCACCTTGATGAAGTAGTTTG 
109 2-3 
S10A8 Forward (5’ – 3’): GTTTTTCAGGTGGGGCAAGTC 
Reverse (5’ – 3’): CGTCTGCACCCTTTTTCCTGA 
188 2-3 
S10A9 Forward (5’ – 3’): CGGCTTTGACAGAGTGCAAG 
Reverse (5’ – 3’): GCCCCAGCTTCACAGAGTAT 
105 1-2 
HPRT Forward (5’ – 3’): TCAGGCAGTATAATCCAAAGATGGT 
Reverse (5’ – 3’): AGTCTGGCTTATATCCACACTTCG 
84 6-7 
RPL32 Forward (5’ – 3’): ATCTCCTTCTCGGCATCATGG 
Reverse (5’ – 3’): GGCATCAAGATCTGGCCCTT 
184 1-3 
GAPDH Forward (5’ – 3’): CTCCTGTTCGACAGTCAGCC 
Reverse (5’ – 3’): ACCAAATCCGTTGACTCCGAC 
101 1-3 
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4.0 Investigating the activation of host immune pathways 
during intracellular Group A Streptococcus infection 
 
4.1 INTRODUCTION 
 
Group A Streptococcus (GAS) causes a wide spectrum of disease in humans, from self-limiting 
infection of the skin or throat to life-threatening invasive diseases. Whilst molecular mechanisms 
underlying the pathogenesis of GAS infections are still being defined, it is evident that the interactions 
of GAS with host cells play a critical role in determining the outcome of infection. GAS is the most 
common bacterial cause of pharyngitis, and the epithelial cells lining the pharyngeal mucosa have 
been shown to have an important immunological function in signalling the presence of GAS. Studies 
have shown that following GAS infection of epithelial cells, many of the activated genes, including 
cytokines, chemokines and other signalling proteins, are target genes of NF-κB (110, 187). These 
include the expression and/or secretion of pro-inflammatory cytokines and chemokines IL-6, IL-8, 
TNF-α, IL-1α and IL-1β (110, 114). NF-κB is a multigene family of transcription factors that form 
homo- or heterodimers and have a conserved DNA binding domain (see Figure 3) (280, 281). 
Numerous studies have implicated NF-κB activation during GAS infection of epithelial cells, as well 
as other immune cell types, indicating it is an important driver of host immune responses during GAS 
infection. Other studies have also reported the AP-1 transcription factor family and MAPK (JNK, 
p38) signalling as other important pathways which driving changes in gene expression during 
infection of epithelial cells (108, 110).  
 
Host defence mechanisms and pathways engaged during GAS infection have traditionally been 
identified by genetic approaches and hypothesis driven research. Whilst this approach has been 
successful, the immune responses and pathways that mediate the control and resolution of GAS 
infection are yet to be completely defined. Much less is known about the global transcriptional and 
proteome responses of infected host cells during GAS infection, as few studies so far have 
investigated this. In this chapter immunoblotting, RNA sequencing and sequential window 
acquisition of all theoretical fragment ion mass spectra (SWATH-MS) was used to investigate the 
signalling pathways and immune mediators engaged by primary human tonsil epithelial (TEpi) cells 
during M1T1 GAS infection, in order to better understand the innate immune responses engaged 
during GAS pharyngitis. This approach revealed that during early infection with either JRS4 or 5448 
GAS strains, a large number of cytokines, chemokines and inflammatory signalling molecules are 
differentially expressed at the RNA level, whilst changes detected at the protein level consisted of 
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proteins involved in metabolism, RNA transcription and intracellular trafficking pathways. These 
findings provide insight into the global changes in host responses during GAS infection, and sheds 
light on the functional mechanisms employed by epithelial cells to overcome infection.   
 
 
Figure 3. NF-κB signal transduction pathways. 
(A) The classical or canonical pathway of NF-κB signalling is rapidly activated upon stimulation and 
is one of the most common pathways by which NF-κB signalling is stimulated during bacterial 
infection (282, 283). Key downstream steps in this pathway involve the phosphorylation, 
ubiquitination and subsequent degradation of the NF-κB inhibitory protein IκBα. In addition, the p65 
subunit of the NF-κB complex is phosphorylated prior to translocating to the nucleus. Therefore, the 
loss of total IκBα protein and production of the phosphorylated form of p65 are typically detected 
when investigating the activation of the classical signalling pathway. TNF-α is a well-characterised 
agonist of this pathway. (B) During non-canonical pathway signalling, receptor binding induces 
activation of the NIK kinase, which phosphorylates and activates the IKKα complex. IKK then 
phosphorylates two serine residues of p100, leading to its partial proteolysis and release of the 
RelB/p52 complex. The non-canonical pathway activates p100/RelB complexes, which enter the 
nucleus and activate gene transcription. In the p105 pathway, upon degradation of p105, p50 
homodimers enter the nucleus and activate transcription by interaction with the IκB-like co-activator 
Bcl-3. The upstream regulation and activation of this pathway is not known. Figure adapted from 
Gilmore (2006) Bienke and Ley (2004) (280, 284). 
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4.2 MATERIALS AND METHODS 
 
4.2.1 Western blot for quantification of NF-κB activation 
TEpi cells were grown to confluency before an infection assay was performed (as described in general 
methods) using the GAS strains JRS4 and 5448. At each time point post-infection the cells were lysed 
in chilled lysis buffer containing 1 x PBS, 10 % Triton X-100, 1 % SDS, protease inhibitor (Roche) 
and phosphatase inhibitor (1 mM sodium molybdate, 1 mM sodium pyrophosphate, 10 mM sodium 
fluoride) on ice. The lysate was then passed through a 23-gauge needle (0.6 mm diameter) several 
times, before being centrifuged at 13 000 rpm for 10 min at 4°C. The resulting pellet was discarded, 
and protein concentrations were determined using a bicinchoninic acid assay (Thermo Scientific), 
following the manufacturer’s instructions. The absorbance of samples was measured by 
spectrophotometer (SpectraMax Plus 384, Softmax Pro 5.4 software) at 562 nm. 
 
A 10 % SDS-PAGE gel was prepared as described by previous studies (272). Equivalent protein 
concentrations of cell lysates were diluted in SDS-PAGE loading buffer/ 0.1 M DTT, boiled for 5 
min at 100°C, before being loaded and resolved on the gel. The gel was run at 80 V for 10 min, and 
then 150 V for 75 min. Proteins were transferred to a methanol activated PVDF membrane 
(Immobilon-FL, Millipore) using a wet transfer apparatus (Bio-Rad) at 100 V for 60 min. Membranes 
were then blocked in Odyssey blocking buffer diluted 1:1 in 1 x PBS for 1 h at room temperature, 
and incubated with diluted primary antibodies in Odyssey blocking buffer containing 0.2 % Tween-
20 (BioChemica) at 4°C overnight. Membranes were washed 4 x 5 min in 0.1 % Tween-20/ 1 x PBS, 
and then incubated for 1 h with the fluorescent dye conjugated secondary antibody (anti-rabbit 548), 
diluted 1: 10 000 in 1:1 PBS/Odyssey blocking buffer containing 0.2 % Tween-20 and 0.02 % SDS, 
protected from light. Membranes were then washed again in 1x PBS containing 0.1 % Tween-20 
several times, before being washed once in 1x PBS and left to dry completely. The Li-Cor Odyssey 
Infrared Imaging System (Li-Cor Biosciences) was used to detect the fluorescent intensities, utilising 
antibodies listed in Table 4.  
 
4.2.2 MTT assay 
Immediately prior to assay, media on TEpi cells was replaced with fresh culture media. 10 µl of 12 
mM MTT was added to each well, with 10 µl MTT added to medium alone as a negative control. 
TEpi cells were incubated with MTT at 37°C for 4 h. The media was then mixed and all but 25 µl of 
medium was removed from each well. 50 µl DMSO was then added to each well and mixed 
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thoroughly. TEpi cells were incubated at 37°C for 10 min. Each well was mixed again, and 
absorbance read at 540 nm. 
 
Table 4. Antibodies and stains used in Chapter 4. 
Type Animal 
raised in 
Target 
protein 
Working 
dilution 
Application Supplier Catalogue # 
Secondary 
IgG Dylight 
580 
conjugate 
 anti-rabbit 1:10 000 Western blot Cell 
Signaling 
5366 
Primary 
(monoclonal) 
Rabbit phospho- 
NF-κB p65 
1:1000 Western blot Cell 
Signaling 
3033 
Primary 
(monoclonal) 
Rabbit NF-κB p65 1:1000 Western blot Cell 
Signaling 
8242 
Primary 
(monoclonal) 
Rabbit IκBα 
 
1:1000 Western blot Cell 
Signaling 
4812 
Primary 
(monoclonal) 
Rabbit GAPDH 
(human) 
1:1000 Western blot Cell 
Signaling 
2118 
Primary 
(monoclonal) 
Rabbit β-tubulin 1:1000 Western blot Cell 
Signaling 
2146 
Primary 
(monoclonal) 
Rabbit Phospho-Akt 1:1000 Western blot Cell 
Signaling 
4060 
Primary 
(monoclonal) 
Rabbit p105/p50 1:1000 Western blot Cell 
Signaling 
3035 
Primary 
(monoclonal) 
Mouse Cytokeratin 
8/18 
1:200 IF-IC Cell 
Signaling 
4546 
Secondary 
IgG Fab2 
Alexa Fluor 
488 
 anti-mouse 1:10 000 IF-IC Cell 
Signaling 
4408 
 
4.2.3 DEAD® staining of GAS infected TEpi cells  
TEpi cells were seeded onto poly-L lysine coated coverslips and grown to confluent monolayers, 
before being infected with GAS at an MOI of 1 or 10. At 6 h and 24 h post-infection the cells were 
stained with DEAD® fixable green dead cell stain for 488 nm excitation (Life Technologies, L34969), 
before being fixed with 4 % PFA. TEpi cell nuclei were stained with DAPI (Roche, 10236276001). 
Imaging was performed using an Olympus BX51 fluorescent microscope under 10 x magnification. 
At least 5 images were captured per coverslip. Images shown are representative of three independent 
experiments.  Macros created using NIH ImageJ (version 2.0.0) were used to automatically count the 
number of nuclei and dead cells per image (5 images per condition). Stained nuclei were used to count 
the total number of cells per image, and cell death was measured by calculating the percentage of 
dead stained cells per image.  
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4.2.4 Immunofluorescence of cultured cell lines 
TEpi cells were cultured on poly-L-lysine coated 10 mm glass coverslips to 80 % confluency. For 
staining of cytokeratins 8/18, coverslips were fixed in 100 % methanol for 20 min at -20°C. 
Coverslips were then washed 2 x 5 min in PBS before the addition of the primary antibody (anti- 
cytokeratin 8/18, Cell Signaling #4546) diluted 1:200 in antibody dilution buffer (1 x PBS/ 1 % 
BSA/0.3% Triton X-100) for 2 h at room temperature. The coverslips were washed 3 x 5 min in 1 x 
PBS before the secondary (antibody Alexa Fluor 488 anti-mouse, diluted 1:400 in antibody dilution 
buffer) and DAPI (5 mg/ml, diluted 1:1000) for 1 h at room temperature, protected from light. 
Coverslips were then washed 3 x 5 min in PBS, before being fixed in 4 % PFA/ PBS for 15 min. 
Coverslips were dipped in water and air dried for 15 min, before being mounted on glass slides using 
fluorescent mounting media (DAKO). The medium was left to harden overnight at room temperature.  
Imaging was performed at the Institute for Molecular Biosciences Cancer Biology Imaging Facility 
(UQ, St Lucia, QLD), using the Deltavision inverted wide field deconvolution microscope (Olympus 
IX71). 40 x magnification was used, and images were captured using Softworx software, processed 
using ImageJ (Version 2.0.0), and assembled using Adobe Photoshop CC 2018.  
 
4.2.5 Protein harvesting for SWATH-MS 
TEpi cells were grown to confluency in 6 well plates. TEpi cells were infected with GAS strains 5448 
or JRS4 at an MOI of 5 as described in the General Methods Section, with untreated (mock) and 
human TNF-α (30 ng/ml) treated cells included as positive and negative controls respectively. At 6 h 
post-treatment, the TEpi cells were washed twice with chilled PBS. TEpi cells were resuspended in 
300 µl of lysis buffer (6 M GuHCl, 50 mM Tris, 10 mM DTT) using a cell scraper, and pipetted into 
Eppendorf® LoBind microcentrifuge tubes (Product #Z666505). Samples were shaken for 30 min at 
30°C on an orbital shaker. 30 mM acrylamide was added to each sample, before being incubated for 
30 min at 30°C on an orbital shaker. 20 mM DTT was then added to each sample. 1/5 of each sample 
was pipetted into a new LoBind microcentrifuge tube. For tubes containing 1/5 and 4/5 of each 
sample, protein was precipitated by adding 600 µl MeOH and 600 µl acetone. Samples were then 
frozen overnight at -20°C. Samples were centrifuged at room temperature for 10 min at 16 000 rpm, 
before supernatants were removed and discarded. This step was repeated 2 x to completely remove 
supernatants. The protein pellet was resuspended in 100 µl of 100 mM ammonium acetate. 0.5 µg of 
trypsin from porcine pancreas (Sigma, T6567) was added per sample and digested overnight at 30°C 
on an orbital shaker, to completely resuspend the protein pellet in ammonium acetate. Samples were 
stored at -20°C until use.            
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4.2.6 Zip Tip procedure for SWATH-MS sample preparation 
A C18 Zip Tip (Millipore, ZTC18S096) was washed 3 x in a solution containing 90 % acetonitrile, 
0.1 % formic acid in H2O. 10 µl of prepared protein sample was loaded onto the Zip Tip by pipetting 
up and down 3 x. The Zip Tip was gently dried with a kimwipe, before being washed with 10 µl of 
0.1 % formic acid in H2O by pipetting up and down 3 x, with the last wash keeping 10 µl in the tip. 
Using another pipette, 5 µl of a solution containing 70 % acetonitrile and 0.1 % formic acid in H2O 
was pipetted into a glass SWATH-MS tube. The 10 µl of solution in the Zip Tip was released into a 
kimwipe, and the tip was then used to pipette the 5 µl in the SWATH-MS tube up and down 5 x. The 
empty Zip Tip was then used to pipette 10 µl of 90 % acetonitrile and 0.1 % formic acid to wash, 
keeping the 10 µl in the tip. With a new pipette, 95 µl of 5 % acetonitrile and 0.1 % formic acid was 
pipetted into the SWATH-MS tube.  
 
 
4.2.7 SWATH-MS data analysis 
SWATH-MS data was analysed using R 3.2.2 and the R MSstats package 2.4.0. For each comparison, 
the threshold for significance was a log2 fold-change (FC) of ≥	0.5 or ≤ -0.05, and an adjusted p-
value of < 0.01. Comparisons shown are 5448 infected TEpi cells compared to uninfected mock TEpi 
cells, JRS4 infected TEpi cells compared to mock TEpi cells, and 5448 infected TEpi cells compared 
to JRS4 infected cells. R commands used were as follows:  
library(MSstats) 
 
MS<-read.csv("/Users/ameliasoderholm/Google Drive/UQ/ 
SWATH/20160226_5448vJRS4.csv", sep=",") 
 
head(MS) 
 
QuantData <- dataProcess(MS) 
 
levels(QuantData$GROUP_ORIGINAL) 
comparison <- matrix(c(-1,1), nrow=1) 
row.names(comparison) <- c("JRS4-5448") 
comparison 
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InfJRS4VInf5448Comparison <- groupComparison(contrast.matrix=comparison, 
data=QuantData, labeled=FALSE, interference=FALSE, featureVar=TRUE) 
 
InfJRS4VInf5448Comparison$ComparisonResult 
 
4.3 RESULTS 
 
4.3.1 Activation of classical NF-κB pathway signalling was not detected in TEpi 
cells in response to GAS infection.  
Previous studies utilising immortalised epithelial cell lines have shown classical NF-κB signalling is 
induced following GAS challenge (110, 187), however the inflammatory signalling pathways 
activated in primary tonsil epithelial cells during GAS infection have not been characterised. To 
investigate whether the classical NF-κB pathway is activated in TEpi cells, confluent monolayers of 
TEpi cells were infected with GAS strains JRS4 or 5448 at a multiplicity of infection (MOI) of 1 
(Figure 4A) or 10 (Figure 4B). Cell lysates were collected at 15 min, 30 min, 1 h, 2 h, 4 h, and 6 h 
post infection, and activation of the classical NF-κB pathway was monitored by the degradation of 
IκBα and the accumulation of phospho-p65 by SDS-PAGE/immune blotting. In comparison to mock, 
TNF-α treatment resulted in a loss of IκBα and an increase in phospho-p65 from 15 min to 1 h post 
treatment, indicating the classical NF-κB pathway is functional in these cells. Both JRS4- and 5448-
infection of TEpi cells induced no detectable change in phospho-p65 or total IκBα levels across the 
infection time course (15 min – 2 h) at an MOI of 1 (Figure 4A). Lengthening the infection time 
course (30 min – 6 h) and increasing the MOI to 10 also did not induce a detectable change in 
phospho-p65 or IκBα (Figure 4B), suggesting that this pathway is not activated by GAS during 
infection. Akt phosphorylation was also monitored following infection (Figure 4B), and no change 
in Akt phosphorylation was observed, suggesting the Akt-PI3K pathway is not activated during GAS 
infection of TEpi cells. Activation of the p105 NF-κB pathway was also investigated by monitoring 
the levels of p105 and p50 in total cell lysates following GAS infection as described above 
(Supplementary Figure 2). TNF-α treatment resulted in a reduction in total p105 levels, suggesting 
this pathway may be functional in TEpi cells. No change in p105/p50 levels was observed following 
JRS4- and 5448-infection, indicating that this pathway is not active during GAS infection of this cell 
type.  
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4.3.2 RNA sequencing of GAS-infected TEpi cells reveals both JRS4 and 5448 
strains induce an inflammatory response  
As immunoblotting was unable to detect the immune pathways activated during GAS infection of 
TEpi cells, RNA sequencing was performed to identify inflammatory mediators and pathways 
involved in the host inflammatory response to GAS intracellular infection. Prior to RNA sequencing, 
the level of TEpi cell death induced during infection with either GAS strain was investigated, in order 
to determine if both strains induce similar levels of cell death during infection. Initially an MTT assay 
was performed on confluent TEpi cells infected with JRS4 or 5448 at an MOI of 1, 3, 5 or 10 for 6 
or 24 h (Supplementary Figure 3). 
 
Figure 4. Expression of classical NF-κB and Akt pathway components during GAS infection. 
TEpi cells were infected with GAS strains at a multiplicity of infection (MOI) of 1 (A) or an MOI of 
10 (B). Human TNF-α was included as a positive control, and untreated cells (mock) as a negative 
control. At each time point post infection, total cell lysates were assayed for the levels of NF-κB-
phospho p65, total NF-κB p65, IκBα and phospho Akt. GAPDH or β-tubulin were included as loading 
controls. Western blots are representative of the results from 3 independent experiments.  
 
 
No significant difference in cell death compared to mock cells was detected following infection by 
either strain. A more sensitive method utilising a dead cell stain was also tested (Supplementary 
Figure 4). By this method at an MOI of 10, 5448 infection was detected to induce a significantly 
higher level of TEpi cell death than JRS4 from 6 h post infection, whilst at an MOI of 5 5448 did not 
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induce a significantly higher level of cell death until 24 h post infection. Dead cell staining also 
detected a similar trend in cell death by fluorescence microscopy (Supplementary Figure 5). In order 
to minimise the level of cell death occurring during infection, an MOI of 5 was selected for 
subsequent experiments.   
 
Samples for RNA sequencing were prepared by infecting TEpi cells with JRS4 and 5448 at an MOI 
of 5 for 6 h, before cell lysates were collected and RNA purified. Mock cells were included as a 
negative control. Next generation Illumina sequencing and bioinformatics analyses were performed 
on 4 biological replicates per treatment condition. In order to determine whether the sequencing 
results for each sample can be can be clustered according to treatment condition, a principle 
component analysis (PCA) was performed on the raw read counts of the top 500 genes that display 
the most variance across all samples, transforming the data into linearly uncorrelated variables 
(Figure 5A). The PCA plot showed that the samples for each treatment condition can be clustered 
together. No overlap in the variance between each treatment condition was observed, indicating the 
variation that exists between treatments is larger than within treatments. The first 2 PCA plots account 
for 86% of total variance (Figure 5B), whilst a further 10 PCA plots account for the remaining 14% 
in variance.  This indicates that the majority of sample variation is captured by this graph. Box and 
whisker plots of read counts per gene from both raw sequencing data (Supplementary Figure 6A) 
and normalised data (Supplementary Figure 6B) showed that all samples had a similar range in read 
counts per gene. Quality-checked RNAseq FASTQ libraries were aligned to the reference Human 
genome (hg19), as described in General Materials and Methods.  
 
In order to determine what genes are differentially expressed following GAS infection, group 
comparisons were performed between the RNA sequencing result of 5448-infected TEpi cells and 
mock TEpi cells (5448 vs Mock), between JRS4-infected cells and mock cells (JRS4 vs Mock), and 
between 5448-infected cells and JRS4-infected cells (5448 vs Mock). Genes were considered 
differentially expressed with Log2 fold change of > 1 or < -1 and a Benjamini–Hochberg adjusted P-
value of < 0.05. Volcano plots of each group comparison were used to visualise the magnitude and 
number of differentially expressed genes for each group comparison (Figure 6A-C). At this 
threshold, the number of differentially expressed genes detected for each comparison were as follows: 
5448 vs Mock = 1108 genes (Figure 6A), JRS4 vs Mock = 153 genes (Figure 6B) and 5448 vs JRS4 
= 533 genes (Figure 6C). When comparing the differentially expressed genes between each group 
comparison, the majority of differentially expressed genes during 5448-infection were also found to 
be differentially expressed following JRS4-infection (Figure 6D). The top 100 differentially 
 75 
expressed genes following 5448 and JRS4 infection are listed in Supplementary Table 1 and 
Supplementary Table 2. 
  
 
 
Figure 5. Principle component analysis of RNA sequencing samples. 
(A) PCA plot was constructed using the top 500 genes that display the most variance across all 
samples. Each data point on the scatter plot represents one sample. (B) Ellipses indicate clustering of 
samples to treatment conditions. Total principle component plots for data set, and the percentage of 
variance they account for. 
 
Previous studies have reported a number of inflammatory mediators that are differentially expressed 
by epithelial cells or by other immune cell types during GAS infection (102, 103, 105, 110). 
Therefore, the expression level of these genes was examined from the RNAseq dataset. 
Stemformatics was utilised to construct multigene expression graphs of normalised read counts for 
mock, JRS4 and 5448-infected TEpi cells. A number of these inflammatory mediators were found to 
be unchanged in gene expression in comparison to uninfected TEpi cells following GAS infection. 
These included the antimicrobial peptides LL-37, RANTES and HBD1, and the chemokines CXCL5, 
CXCL10 and CXCL11 (Figure 7A). Genes significantly upregulated in expression by both GAS 
strains, included the chemokines CXCL1 and CXCL3, the cytokines IL-1β, IL-24, and IL-36γ, and 
the immunoregulatory prostaglandin synthase 2 (PTGS2) (Figure 7B). A number of GAS-infection 
associated genes were significantly upregulated by 5448 in comparison to JRS4 infected TEpi cells. 
These included CCL20, CXCL2 and TNF-α (Figure 7C), as well as the AP-1 transcription factors 
FOS and ATF3, and NF-κB transcription factors including REL (Figure 7D). No GAS-infection 
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associated genes were significantly higher in JRS4-infected TEpi cells in comparison to 5448-
infected TEpi cells. Overall the RNAseq results showed that 5448 infection induces a much stronger 
inflammatory response than JRS4 at the transcriptional level. Further analyses of RNAseq data were 
performed in chapters 5 and 6. 
  
 
Figure 6. TEpi cell differential gene expression during intracellular GAS infection.  
Volcano plots of group comparisons performed between the normalised gene read counts for each 
condition, to detect differentially expressed genes between (A) 5448 infected cells and mock cells, 
(B) JRS4 infected cells and mock cells, and (C) between 5448 infected cells and JRS4 infected cells. 
For each group comparison, each gene is plotted by its Log2 fold change in expression against its 
adjusted P value. Genes with a significant Log2 fold change of ≥ 1 or ≤	-1 and Benjamini–Hochberg 
adjusted P value of < 0.05 are plotted in dark blue. Genes with a Benjamini–Hochberg p value < 0.05 
but a fold change of < 1 or > -1 are plotted in light blue, and genes with a Benjamini–Hochberg p 
value > 0.05 and a fold change < 1 or > -1 are plotted in grey. (D) Venn diagram of differentially 
expressed genes for each group comparison. 
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Figure 7. Differential gene expression of GAS-associated inflammatory mediators. 
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Gene expression graphs for mock, JRS4 and 5448-infected TEpi cells was constructed using 
Stemformatics (https://www.stemformatics.org/datasets/search?ds_id=6991&filter=6991#). Gene 
expression is shown as Log2 Reads Per Kilobase per Million mapped reads (RPKM) with Trimmed 
Mean of M-values (TMM) normalisation. An unpaired, two-way T-test was performed to detect 
significant differences in gene expression. (A) GAS-infection associated inflammatory mediator-
encoding genes not differentially expressed following infection with either GAS strain. (B) GAS-
infection associated genes significantly upregulated following JRS4 and 5448 infection. (C) 
Cytokines and chemokines and (D) transcription factors significantly upregulated by 5448 in 
comparison to JRS4 infected TEpi cells. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. 
Data represents mean ±SDM from 4 independent experiments.  
 
4.3.3 SWATH-MS proteomics analysis of GAS-infected TEpi cells  
SWATH-MS was performed on protein harvested from TEpi cells infected with GAS strains JRS4 
or 5448 at the same MOI and time point used for RNA sequencing (MOI of 5, 6 h post-infection), to 
capture changes in host protein expression during early GAS infection. A PCA plot of SWATH-MS 
data showed that whilst samples for each treatment can be clustered together, the variance for each 
treatment condition overlap (Figure 8A), indicating that changes in protein levels between each 
condition may not be vastly different to each other. The first 2 PCA plots account for 72% of total 
variance, whilst a further 7 PCA plots account for the remaining 28% in variance (Figure 8B), 
indicating the majority of sample variation is captured by this graph.   
 
 
Figure 8. Principle component analysis of SWATH-MS samples. 
PCA plot was constructed using the total list of proteins detected across all samples. Each data point 
on scatter plot represents one sample (A). Total principle component plots for data set, and the 
percentage of variance they account for (B). Ellipses indicate clustering of samples to treatment 
conditions.  
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Across all samples, 416 human proteins were detected, with the presence of bacterial proteins unable 
to be detected. In order to determine what host proteins are differentially expressed following GAS 
infection, group comparisons were performed between the RNA sequencing result of 5448-infected 
TEpi cells and mock TEpi cells (5448 vs Mock), between JRS4-infected cells and mock cells (JRS4 
vs Mock), and between 5448-infected cells and JRS4-infected cells (5448 vs Mock). Proteins were 
considered differentially expressed with Log2 fold change of > 0.5 or < -0.5 and a Benjamini–
Hochberg adjusted P-value of < 0.01. Volcano plots of each group comparison were used to visualise 
the magnitude and number of differentially expressed genes for each group comparison (Figure 9A-
C). At this threshold, 71 proteins were differentially expressed between the different treatment 
conditions: 5448 vs Mock = 47 proteins (Figure 9A), JRS4 vs Mock = 29 (Figure 9B), and 5448 vs 
JRS4 = 43 (Figure 9C). When comparing differentially expressed proteins the majority of proteins 
overlapped between each group comparison, indicating that only a small number of differentially 
expressed proteins were unique for each group comparison (Figure 9D). The gene names of all 
differentially expressed proteins detected by SWATH-MS were compared to the differentially 
expressed genes identified by RNAseq, and surprisingly, no overlap was identified (Figure 9E).  
 
The 71 differentially expressed proteins following 5448 and JRS4 infection are listed in 
Supplementary Table 3. The molecular function and biological process of each gene was 
investigated using uniprot.org, and genes are grouped according to their function. Differentially 
expressed proteins were found to possess functions in immunity such as NF-κB and MAPK pathways, 
and included proteins that were significantly increased in abundance following infection with either 
5448 and/or JRS4 strains ((proteasome subunits (PSMB4, PSMD2, PSMD5, PSMD6), MAPK kinase 
MAP2K1)), as well as proteins involved in these pathways that were significantly decreased in 
abundance (phospholipase annexin A1 (ANXA1), calgranulin A subunits (S100A8, S100A9), 
antioxidant SODC). Proteins associated with autoimmune skin diseases such as bullous dermatosis 
(collagen alpha-1(XVII) chain (COL17A1)) and atopic dermatitis (cystatin A (CSTA)) were also 
differentially expressed.  A number of proteins involved in protein trafficking and transport pathways 
were also detected, including ARFIP1, COPE (intracellular protein transport), KPNA4 (nuclear 
protein import),  SCYL2 (transgolgi/endosomal trafficking), RANBP1 (nucleocytoplasmic 
transport), and in metabolism and metabolic pathways such as tricarboxylic acid cycle (CS), 
glycolysis (HK1, OGDH), pyruvate metabolism (GLO1, BSG), creatine metabolism (CKB), fatty 
acid metabolism (ECI1, FABP5, ACSL3) and carbohydrate metabolism (ALDH1B1, ALDH2). 
Finally, a large number of differentially expressed proteins involved in mRNA binding and protein 
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translation (NUDT21, EPRS, LRPPRC, SERBP1, RPL9, RS18, DHX15, SNRNP200, EIF3I, RPL29, 
RPL23, RPN2, EIF2S2, AIMP2, HARS) were detected.  
 
 
Figure 9. TEpi cell differential protein expression during intracellular GAS infection. 
Group comparisons were performed between the normalised peptide intensities for each condition, 
to detect differentially expressed genes between (A) 5448 infected cells and uninfected (mock) cells, 
(B) JRS4 infected cells and mock cells, and (C) between 5448 infected cells and JRS4 infected cells. 
For each group comparison, each gene is plotted by its Log2 fold change in expression against its 
adjusted P value. Genes with a significant Log2 fold change of ≥ 0.5 or ≤	-0.5 and adjusted P value 
of < 0.01 are plotted in dark blue. Genes with a significant P value but nonsignificant fold change are 
 81 
plotted in light blue, and genes with a nonsignificant fold change and P value are plotted in grey. 
Uniprot IDs of the most differentially expressed proteins are shown. (D) Venn diagram of 
differentially expressed genes for each group comparison. (E) Venn diagram of differentially 
expressed proteins detected by SWATH-MS and differentially expressed genes detected by RNA 
sequencing. 
 
Whilst 17 of the total differentially expressed proteins were annotated with immune-related functions 
on Uniprot (www.uniprot.org), the pathway tool on DAVID Bioinformatics Resources 6.8 did not 
detect enrichment of an immune pathway for these genes. This was likely due to the small number of 
differentially expressed proteins detected. Enriched terms for the differentially expressed proteins 
from each group comparison, included acetylation, phosphoproteins and cell-cell adhesion 
(Supplementary Table 3).  
 
4.3.4 Differentiation of surface and crypt TEpi cells using keratin immunostaining  
The tonsil crypt epithelial cells are thought to play an important immune function during infection 
and disease of the palatine tonsil, due to their direct contact with infiltrating effector cells and 
proximity to lymphoid follicles (74). As the TEpi cells used in this study are a heterogeneous 
population of crypt and surface epithelial cell types, being able to differentiate between each cell type 
may be useful for microscopy analysis of GAS infection. Previous studies have shown that crypt cells 
can be distinguished from surface epithelial cells by keratin 8 and keratin 18 immunostaining, the 
expression of which is limited to the crypt epithelial cells (86, 285). Therefore, TEpi cells were 
immunostained for cytokeratin 8/18 (Cell Signaling, #4546) and examined by wide field 
deconvolution microscopy for differences in expression across the TEpi cell population. Strong 
cytokeratin 8/18 staining was observed by all cell examined, and no difference in expression for these 
keratins in the TEpi cell population could be detected (Supplementary Figure 7).  
 
4.3.5 RT/qPCR of differentially expressed host immune proteins during GAS 
infection 
SWATH-MS detected 71 differentially expressed proteins with immune functions following GAS 
infection of TEpi cells. Several of these proteins were further investigated by RT/qPCR to determine 
if changes in expression could also be detected at the transcriptional level. Cystatin A (CYTA) and 
Cystatin B (CYTB) were significantly decreased in protein abundance following 5448-infection but 
not following JRS4 infection, suggesting that 5448 may be targeting these proteins during infection. 
CYTA and CYTB are cysteine cathepsin inhibitors involved in antigen processing and presentation, 
inflammation and cancer (286). 
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Table 5. Enriched terms associated with differentially expressed proteins detected by group 
comparison analysis. 
Gene lists from group comparisons of SWATH-MS data (R 3.2.2, MSstats package 2.4.0) with 
significant Log2 fold changes in gene expression (> 0.5 Log2FC, Benjamini adjusted p-value < 0.01) 
entered into the DAVID Bioinformatics Resources 6.8 (http://david.ncifcrf.gov/summary.jsp). The 
Functional Annotations Chart was used to detect keywords, gene ontology (GO) terms, and pathways 
enriched from the list of differentially expressed proteins. Thresholds: Count = 2, EASE = 0.1. A 
Benjamini-adjusted P value < 0.05 was considered significant. Legend: Count = number of 
differentially expressed proteins associated with functional category, % = percentage of proteins from 
total protein list.  
 
Comparison Category Term Count % Benjamini-
adjusted P 
value 
 UP_KEYWORDS Acetylation 37 78.7 7.1E-18 
5448 vs 
Mock 
GOTERM_CC_DIRECT Extracellular exosome 31 66 4.1E-12 
 GOTERM_CC_DIRECT Cytosol 25 53.2 1.3E-5 
 GOTERM_CC_DIRECT Focal Adhesion 9 19.1 2.4E-4 
 GOTERM_MF_DIRECT Cadherin binding 
involved in cell-cell 
adhesion 
8 17 1.3E-3 
 UP_KEYWORDS Phosphoprotein 34 72.3 9.0E-4 
 GOTERM_CC_DIRECT Cell-cell adherens 
junction 
8 17 5.2E-4 
 GOTERM_BP_DIRECT Translation initiation  6 12.8 1.2E-2 
 UP_KEYWORDS Cytoplasm 24 51.1 3.4E-3 
 UP_KEYWORDS Acetylation 21 72.4 2.1E-8 
JRS4 vs 
Mock 
GOTERM_CC_DIRECT Extracellular exosome 15 51.7 1.8E-3 
 UP_KEYWORDS Phosphoprotein 23 79.3 2.0E-2 
 GOTERM_CC_DIRECT Focal adhesion 6 20.7 1.3E-2 
 GOTERM_CC_DIRECT Cytosol 14 48.3 1.7E-2 
 UP_KEYWORDS Acetylation 31 72.1 7.7E-13 
5448 vs 
JRS4 
GOTERM_CC_DIRECT Extracellular exosome 28 65.1 1.2E-10 
 GOTERM_CC_DIRECT Cytosol 26 60.5 1.7E-7 
 UP_KEYWORDS Phosphoprotein 34 79.1 2.9E-5 
 GOTERM_BP_DIRECT Keratinocyte 
differentiation 
6 14.0 5.0E-4 
 UP_KEYWORDS Cytoplasm 24 55.8 5.4E-4 
 GOTERM_CC_DIRECT Focal adhesion 8 18.6 1.1E-3 
 GOTERM_BP_DIRECT Embryo implantation 4 9.3 3.1E-2 
 GOTERM_MF_DIRECT Poly(A) RNA binding 11 25.6 4.4E-2 
 GOTERM_CC_DIRECT mitochondrion 11 25.6 2.1E-2 
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Dysregulated CYTA expression is associated with inflammatory skin diseases such as psoriasis and 
atopic dermatitis (287), and CYTA has been shown to protect the skin by blocking the up-regulation 
of IL-8 and GM-CSF in keratinocytes stimulated with antigens (288). In comparison to mock TEpi 
cells, no difference in the expression of these genes was observed at the transcriptional level (Figure 
10A-B). This is in agreement with the RNAseq result for these genes, which also did not detect a 
difference in expression during GAS infection. Calprotectin subunits S10A8 and S10A9, which is a 
calcium- and zinc-binding protein that plays a prominent role in host immune responses, including 
pro-inflammatory, antimicrobial, oxidant-scavenging and apoptosis-inducing activities (289). 
Calprotectin is also a TLR4 agonist, and binding to TLR4 activates MAPK and NF-κB signalling 
pathways (290). Calprotectin was significantly decreased in protein abundance following 5448 GAS 
infection, however RT/qPCR did not detect any difference in expression at the mRNA level for these 
genes (Figure 10C-D), supporting the RNAseq findings for these genes.  
 
 
Figure 10. Immune signalling proteins detected by SWATH-MS to be differentially expressed 
during GAS infection are not differentially transcribed at the mRNA level. 
TEpi cells were grown to confluency and infected with GAS strains JRS4 and 5448 at an MOI of 5. 
mock and human TNF-α (30 ng/ml) treated TEpi cells were used as positive and negative controls, 
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respectively. After 2 h infection with GAS the media was replaced with TEpi medium containing 100 
µg/ml gentamicin. At 6 h post-infection total RNA was collected and mRNA expression relative to 
HPRT (Hypoxanthine-guanine phosphoribosyltransferase), was quantified by qRT-PCR for CYTA 
(Cystatin A) (A), CYTB (Cystatin B) (B), S10A8 (Calgranulin A) (C) and S10A9 (Calgranulin B) (D). 
Data represents mean ±SEM from 3 independent experiments. One-way ANOVA followed by 
Bonferroni’s test was performed to detect statistical significance.  
 
4.4 DISCUSSION 
 
In this chapter I demonstrate that classical p65-p50 NF-κB signalling is not activated in TEpi cells 
during GAS infection. This is in conflict with previous studies, which showed GAS infection induces 
classical NF-κB activation in immortalised HEp-2 epithelial cells (110, 187, 188). This suggests that 
a difference exists in the inflammatory pathways engaged during GAS infection of immortalised and 
primary epithelial cell lines. However, some studies have reported the activation of alternative 
pathways of NF-κB signalling during infection. Non-classical p65-p52 NF-κB signalling was 
detected in GAS infected murine macrophages (291), and a transcriptional study of GAS infected 
murine macrophages also detected an increase in the expression of alternative NF-κB signalling 
components RelB, NF-κB/p105 and Rel/c-Rel (292). This indicates that classical NF-κB signalling 
may not be activated by the presence of GAS in all host cell types. Further immunoblot analysis of 
different NF-κB components is required to determine which NF-κB signalling pathway is activated 
during GAS infection of TEpi cells.  
 
RNAseq of GAS infected TEpi cells enabled characterisation of the host transcriptional responses in 
response to JRS4 and 5448 GAS strains. An increase in gene transcriptional levels is likely the driving 
force behind the RNAseq results observed, however it should be noted that the expression of some 
innate immune genes can also be upregulated by an increase in mRNA stability (293). Therefore, 
changes in mRNA stability may also contribute to TEpi transcriptional responses observed during 
GAS infection. Upon differential gene expression analysis, both GAS strains were found to induce 
the expression of a similar array of genes (Figure 6D), however 5448 infection was found to induce 
differential gene expression of a much higher magnitude than JRS4 infection. Previous studies have 
also shown that the magnitude of inflammatory mediators produced by host cells in response to GAS 
infection is often M type-dependent (104, 106, 112). In one study, M1 GAS isolates were shown to 
induce stronger inflammatory responses than other M types (M28, M89) during infection of murine 
macrophages (104). The factors driving the strong transcriptional inflammatory response during 
M1/5448 infection are unclear, however it may be due to a difference in surface proteins and virulence 
factors expressed by different GAS M types. The strong inflammatory transcriptional response 
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induced by TEpi cells during 5448 infection may also contribute to the success of M1T1 in causing 
disease.  
 
Antimicrobial peptides including LL-37, RANTES and HBD1 which are reported to be expressed by 
epithelial cells during GAS infection (71, 73, 110) were not differentially expressed by TEpi cells 
during infection with either JRS4 or 5448 GAS strains (Figure 7A). This discrepancy may be due to 
a difference in cell types or GAS strains utilised by previous studies. The neutrophil-recruiting 
chemokine CXCL5 was constitutively expressed at high levels. CXCL5 expression is an important 
protective host response against GAS infection and is targeted for degradation by the GAS virulence 
factors SpeB and SpyCEP (195, 294). A number of cytokines and chemokines were significantly 
upregulated by both JRS4 and 5448 GAS strains. These include the cytokine IL-36γ/IL1F9, which is 
expressed by keratinocytes in response to GAS M protein (106), and by GAS-induced skin lesions of 
patients with guttate psoriasis (266). IL-36γ is an important component of mucosal immunity in 
response to gram-positive bacterial infections (295),  and contributes to the generation of Th1 and 
Th17 responses by stimulating the production of an array of inflammatory mediators (296). As Th1 
and Th17 are reported to provide protective immunity following GAS pharyngitis infections in 
humans (125) and nasopharyngeal infection in mice (128), this indicates that IL-36γ secretion by 
TEpi cells likely plays an important role in orchestrating host immune responses during GAS 
pharyngitis.  Prostaglandin-endoperoxide synthase 2 (PTSG2) was also highly upregulated following 
infection with either GAS strain, which is an enzyme in the prostaglandin E2 (PGE2) biosynthesis 
synthesis pathway. PGE2 is an eicosanoid implicated in GAS infection by several studies (112, 114, 
131). Due to its inhibitory effects on immune cells (191), PGE2 expression is thought to aid GAS 
colonisation of mucosal surfaces (192), and is associated with decreased macrophage bactericidal 
activity (131). Therefore, the upregulation of PTSG2 expression by JRS4 and 5448 suggests that 
PGE2 production by TEpi cells may be subverted by GAS during infection to aid in bacterial 
colonisation and survival. As 5448 induced a stronger inflammatory response, there were a number 
of inflammatory mediators significantly upregulated by 5448 in comparison to JRS4. These include 
CCL20, a lymphocyte-attracting chemokine expressed by epithelial cells in response to GAS M 
protein (106), and which is partly degraded by SpeB activity (195). TNF-α was also highly expressed, 
which is a multi-functional pro-inflammatory cytokine secreted by most host cell types including 
epithelial cells in response to GAS infection and plays important roles in the activation of leukocytes 
and the development of a Th17 response. Overall, many of the differentially expressed genes by TEpi 
cells in response to 5448 or JRS4 infection are inflammatory mediators that play important roles in 
the host immune response to GAS infection, such as leukocyte activation and recruitment and the 
development of Th1 and Th17 responses. In addition, a number of these inflammatory mediators are 
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targeted by GAS virulence factors, indicating that GAS is able to modulate the protective responses 
of the tonsillar epithelium in order to survive and establish infection.  
 
SWATH-MS analysis of the TEpi cell proteome during GAS infection with either GAS strain, a 
similar array of proteins was significantly altered in their abundance. In agreement with the RNAseq 
result, 5448 infection induced changes in protein abundance that were of a higher magnitude than the 
JRS4 strain. In total I identified 416 proteins and 71 proteins significantly altered in abundance 
following infection. As the human genome encodes ~30 000 proteins, this method yielded limited 
proteome coverage. Due to the low-sensitivity of SWATH-MS, which detected changes in only the 
most abundant proteins, no overlap was observed between the proteome and transcriptome data. As 
the SWATH-MS and RNAseq were both performed at the same time-point (6 h) post infection, this 
also suggests that there is a delay between RNA transcriptional responses and downstream changes 
in protein levels. Another possible explanation is that GAS proteases could be altering protein 
abundance with no effect on inflammatory gene transcription. 5448 expresses the streptococcal 
cysteine protease SpeB (166) which degrades an array of GAS and host proteins during infection 
(297), whilst JRS4 is defective in the expression of SpeB (298), therefore SpeB expression may be 
driving the decrease in abundance of a number of proteins in 5448 infected TEpi cells compared to 
JRS4 infected TEpi cells. A number of proteins which are implicated in NF-κB and MAPK pathways 
were detected, the majority of which were downregulated during 5448 infection. For example, the 
MAPK kinase MAP2K was increased in protein abundance following JRS4 infection but decreased 
during 5448 infection, and the Calgranulin A subunits (S10A8, S10A9), which are multifunctional 
pro-inflammatory proteins which activate MAPK/ NF-κB signalling by binding to and activating 
TLR4 (299), were also downregulated by 5448 infection. This is in contrast with what is observed by 
RNAseq, with 5448 infection resulting in the significant upregulation in expression of an array of 
pro-inflammatory genes. This suggests that 5448 is able to post-transcriptionally dampen host 
inflammatory responses during infection, which I further investigate this hypothesis in Chapters 5 
and 6. Few studies have investigated the host proteome responses during GAS infection, therefore it 
is difficult to draw comparisons with findings from previous studies. Characterising the host proteome 
during infection remains a challenge for future studies to overcome and will undoubtedly provide 
new insight into the host responses engaged during GAS infection.  
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5.0 Group A Streptococcus M1T1 intracellular infection of 
primary tonsil epithelial cells dampens levels of secreted IL-8 
through the action of SpyCEP  
 
5.1 INTRODUCTION 
 
Streptococcus pyogenes (Group A Streptococcus; GAS) is the most common bacterial cause of acute 
pharyngitis (92), with over 616 million incident cases of GAS pharyngitis predicted to occur 
worldwide each year (93). GAS pharyngitis has also been associated with inflammatory 
complications such as scarlet fever (250), chronic diseases including tonsillar hypertrophy and sleep 
apnoea (130), and the post-infectious sequelae including acute rheumatic fever (254), 
poststreptococcal glomerulonephritis (300) and guttate psoriasis (301). During pharyngitis, GAS 
colonises the mucosal layers of the pharynx including the palatine tonsil epithelium, forming biofilms 
on the tonsillar surface and inside tonsillar crypts, as well as invading the epithelium to survive 
intracellularly (48, 50). The ability of GAS to colonise the host and establish infection likely involves 
subversion of host immune defences (2). 
 
Epithelial cells are among the first cell types encountered by GAS during pharyngeal infection. 
During the early stages of infection, epithelial cells play important roles in barrier defence, secretion 
of antimicrobial peptides and innate immune signalling (4). In response to GAS infection, 
immortalised epithelial cell lines derived from epithelial cell cancers, such as Detroit 562 (cancer of 
the pharynx), HEp-2 (HeLa derivative epithelial cells derived from the cervix), HaCaT (skin 
keratinocytes) and A549 (lung tissue derivative) cells have been shown to express and/or secrete a 
wide array of pro-inflammatory mediators, including chemokines (IL-8, CXCL2, CXCL3, 
CCL5/RANTES), cytokines (IL-1α, IL-1β, IL-2, IL-6, TNF-α, TNF-β, IFN-γ, CSF2, IL-17A, IL-23), 
growth factors (IGF-II) and the eicosanoid prostaglandin E2 (105, 110, 112, 114, 117, 127, 129). In 
addition, GAS-infected Detroit 562 cells have been shown to secrete the chemokines CXCL9, 
CXCL10 and CXCL11 (111, 113). However, a potential limitation of these studies is that 
immortalised cell lines may not respond in the same way as primary tonsil epithelial cells to GAS 
infection. While the limited studies utilising human tonsil explants have been fairly consistent with 
these cell line results (71, 116, 128), as these studies did not isolate epithelial cells from the tonsil 
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explant tissue, it is difficult to elucidate the contribution of tonsil epithelial cells to these immune 
responses during GAS infection. 
 
Pro-inflammatory gene expression during GAS infection of nonpharyngeal-derived immortalised 
epithelial cell lines has been shown to be driven by the activation of mitogen-activated protein kinases 
(MAPK) signalling pathways (extracellular signal-regulated kinase, ERK; Jun N-terminal protein 
kinase, JNK; and p38), as well as the transcription factors NF-κB and AP-1 (105, 106, 110, 187, 188). 
For example, exposure of HEp-2 cells to GAS strain A40 resulted in activation of the classical NF-
κB pathway (187). Another study showed that inducible IL-6 and IL-8 production from HEp-2 cells 
upon infection with GAS strain M29588 was blocked by NF-κB and MAPK inhibitors (110). Studies 
using the HEp-2 cell line and primary mouse bone marrow-derived macrophages have also shown 
that the magnitude of cytokine responses to GAS infection is often genotype (emm-type)-dependent, 
making these findings difficult to generalise for other emm types (104, 105). A possible explanation 
for this observation is that certain GAS strains may be able to subvert host inflammatory responses 
during infection. However, the underlying GAS virulence factors and host-pathogen interactions 
leading to these differing cytokine responses are currently not well defined.  
 
The aim of this study was to identify, through the use of RNAseq and pathway analysis, key innate 
immune signalling responses and downstream biological effects that are initiated by primary human 
tonsil epithelial (TEpi) cells upon M1T1 GAS infection. This approach revealed transcription factor 
networks, including activator protein-1 (AP-1), activating transcription factor 2 (ATF-2) and nuclear 
factor of activated T cells (NFAT) pathways, as signalling hubs that control GAS-regulated IL-8 
expression. Subsequent validation studies revealed that, whilst infection of TEpi cells with the 
laboratory-adapted GAS strain JRS4 induced strong IL-8 secretion, infection with the clinical M1T1 
clone (strain 5448) did not, which I demonstrate to be dependent on the activity of the IL-8 protease 
SpyCEP. This study provides insight into the modulation of the tonsillar immune response during 
infection with M1T1 GAS strains, which may contribute to the success of this globally-disseminated 
human pathogen. 
 
5.2 MATERIALS AND METHODS 
 
5.2.1 Bacterial strains and growth conditions  
GAS M1T1 strain 5448 was originally isolated from a patient with necrotising fasciitis and toxic 
shock syndrome (270). JRS4 is a streptomycin-resistant derivative of D471, a rheumatic fever-
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associated isolate (271). 5448ΔcepA and 5448ΔcepA complemented with pDCermcepA are described 
by Zinkernagel and colleagues (145). JRS4 (pDCermcepA) was generated by isolating total DNA 
from 5448ΔcepA (pDCermcepA), using Wizard® Plus SV miniprep DNA Purification System 
(Promega, A1460). Plasmid DNA was then purified using the Qiagen DNeasy blood and tissue kit 
(Cat. # 69504). The pDCermcepA plasmid was then transformed into E. coli MC1061 and purified 
by Qiagen Plasmid PlusMidi Kit (Cat. #12943). JRS4 was electroporated with 2 µg of pDCermcepA, 
before being plated onto Todd-Hewitt agar supplemented with 0.2% yeast extract (THY) and 
erythromycin (4 µg/ml) for 48 h at 37°C. GAS strains were grown in Todd-Hewitt broth 
supplemented with 0.2 % yeast extract (THY) at 37°C. Where appropriate, erythromycin was 
supplemented at 4 µg/ml. 
   
5.2.4 Cytotoxicity assay  
Cell death following GAS infection was quantified by measuring lactate dehydrogenase (LDH) 
release from cell supernatants, using CytoTox96® Non-Radioactive Cytotoxicity Assay (Promega, 
G1781), as per the manufacturer’s instructions. Cells lysed in 0.2% Triton-X 100/1 x PBS were 
included as a positive control for 100% cell death, for each condition at each time point. Sample 
absorbance was measured by spectrophotometer (SpectraMax Plus 384, Softmax Pro 5.4 software) 
at an absorbance of 490 nm. Sample readings were analysed by Prism 7 software and divided by the 
positive control for cell lysis to give a percentage of total cell death for each sample. 
 
5.2.7 RNAseq interaction networks and pathway analysis  
Protein-protein interaction networks from the top 100 differentially expressed genes (at an adjusted 
P value <0.05) from each group comparison (5448-infected TEpi cells vs mock cells, JRS4-infected 
TEPi cells vs mock cells, and 5448-infected vs JRS4 infected TEPi cells) were constructed using 
STRINGdb.com (302). Network edges show the confidence of interactions, where the line thickness 
indicates the strength of data support. Active interaction sources include textmining, experiments, 
databases, co-expression, neighbourhood, gene fusion and co-occurrence. Minimum required 
interaction score of medium confidence (0.400). Pathway over-representation analysis of all 
differentially expressed genes (adjusted P value <0.05, Log2FC >1 or <-1) for 5448-infected TEpi 
cells in comparison to mock cells and JRS4-infected TEpi cells in comparison to mock cells was 
performed using InnateDB.com. Hypergeometric analysis algorithm was used, with Benjamini 
Hochberg correction method. HOMER motif analysis software was used to identify enriched 
transcription factor recognition motifs within the regulatory regions of the top 400 differentially 
expressed genes for 5448-infected tonsil epithelial cells and JRS4-infected TEpi cells (279). Motif 
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finding parameters: motifs of a length of 8,10 or 12 bases from -300 to +50 bases relative to the 
transcription start site, with 2 mismatches allowed in global optimisation phase. The background gene 
list used comprised of all gene IDs detected by RNAseq. Heat maps were drawn using R (version 
3.3.2) gplots package, using RNAseq data available at NCBI’s Gene Expression Omnibus (GEO) 
(276), under accession GSE107001. 
 
5.2.10 GAS cell wall fractionation and western blot analysis 
The fractionation protocol was adapted from Sumby and colleagues, 2008 (194). GAS strains were 
grown to mid-exponential phase (OD600 = 0.45) in THY containing 28 µm E-64 (Sigma-Aldrich, 
E3132), before being pelleted by centrifugation at 8000 x g for 20 min at 4°C. The bacterial pellet 
was washed twice with TE buffer (50 mM Tris-HCl, 1 mM EDTA; pH 8.0), supplemented with 1 
mM PMSF (Sigma-Aldrich, P7626). The bacterial pellet was then resuspended in cold TE-sucrose 
buffer (50 mM Tris-HCl, 1 mM EDTA, 20 % w/v sucrose; pH 8.0), supplemented with 5 mg 
lysozyme (Amresco, Cat. #0663), 200 U mutanolysin (Sigma-Aldrich, M9901) and protease inhibitor 
cocktail (Roche, Cat. #1187358). Samples were incubated for 2 h at 37°C with shaking (200 rpm). 
Samples were centrifuged at 16,000 x g for 5 min at room temperature, and supernatants containing 
the cell wall fraction were retained. Protein concentrations were determined using bicinchoninic acid 
assay (Thermo Scientific, Cat. #23225) following the manufacturer’s instructions. Equivalent protein 
concentrations of samples were diluted in SDS-PAGE loading buffer/0.1 M DTT, boiled for 5 min at 
100°C, before being loaded and resolved on a SDS-PAGE gel prepared as described by previous 
studies (272). Proteins were transferred to a methanol-activated PVDF membrane (Immobilon-FL, 
Millipore) using a wet transfer apparatus (Bio-Rad) at 100 V for 2 h. Membranes were then blocked 
in Odyssey blocking buffer for 1 h at room temperature. For detection of SpyCEP protein produced 
by GAS strains, anti-SpyCEP sera was generated by immunising 4-6-week-old BALB/c mice using 
purified recombinant SpyCEP (amino acids 40 to 683) in its inactive form (D151A S617A) and used 
at 1:1000 dilution. This polyclonal antibody was cross-absorbed twice against cell-wall extract from 
5448ΔcepA (pDCermcepA) that had been impregnated onto methanol-activated PVDF membranes. 
Secondary antibody conjugated with a fluorescent dye (Anti-mouse IgG, Alexa Fluor® 488 
Conjugate #4408, Cell Signaling Technology®) was utilised, and bound secondary antibody was 
detected using near-infrared (NIR) western blot detection system Odyssey CLx (Li-Cor Biosciences). 
 
5.2.11 IL-8 degradation assays  
GAS strains grown to early stationary phase in THY broth were pelleted and washed twice in PBS 
before dilution to an OD600 of 0.40. GAS was then added to DMEM/10 % FCS containing 400 pg/ml 
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of recombinant human IL-8 (BD Biosciences Pharmingen™, Cat. # 554609), and incubated at 37°C.  
IL-8 alone and 5448ΔcepA were included as negative controls. 
 
5.2.12 Ethics approvals  
All procedures involving animals were conducted according to Australian Code for the Care and Use 
of Animals for Scientific Purposes (303) and were approved by the University of Queensland Animal 
Ethics Committee (SCMB/140/16/NHMRC). 
 
5.3 RESULTS 
 
5.3.1 Intracellular infection of TEpi cells with 5448 or JRS4 GAS strains induces                    
the transcriptional upregulation of multiple pro-inflammatory pathways  
Previous studies utilising immortalised epithelial cell lines have shown an array of pro-inflammatory 
mediators are induced following GAS challenge (105, 110-114, 129), however, the response of 
primary tonsil epithelial cells to GAS infection has not been characterised. In addition, different GAS 
serotypes have previously been shown to induce epithelial inflammatory responses of differing 
magnitudes (105, 106). To investigate whether this variation exists in primary cells and to identify 
potential mechanisms, we performed RNAseq on TEpi cells infected with GAS strains JRS4 or 5448, 
for 6 h at a multiplicity of infection (MOI) of 5, an MOI where no significant difference in cell death 
was observed between the two strains and mock-treated cells (Supplementary Figure 4). No 
difference in intracellular bacteria numbers or intracellular survival was observed between JRS4 and 
5448 GAS strains (Supplementary Figure 9). After 6 h infection of TEpi cells with 5448, 1109 
genes were significantly up or down regulated in comparison to uninfected (mock) TEpi cells 
(adjusted P value < 0.05, Log2 fold change > 1 or < -1), and 153 genes were differentially expressed 
following infection with the JRS4 strain in comparison to mock cells. Due to the large difference in 
the number of differentially expressed genes induced between the two strains at this threshold, the 
top 100 most differentially expressed genes in JRS4-infected and 5448-infected TEpi cells in 
comparison to mock cells (Supplementary Table 1 and Supplementary Table 2) were used to 
construct predicted protein-protein interaction networks.  Both strains resulted in the expression of 
an abundance of inflammatory mediators by the TEpi cells, and amongst these was a highly connected 
network of interacting proteins, with inflammatory mediators such as IL-8 and IL-6 at the core of the 
network (Figure 11A and B). Within these networks, interacting genes encoding proteins from 
several inflammatory pathways were identified. For 5448-infected TEpi cells, these genes included 
transcription factors and signalling proteins from the AP-1, ATF-2 and NFAT transcription factor 
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networks (FOSB, FOSL1, ATF3, EGR1, EGR2, EGR3, EGR4, DUSP5). Cytokines (TNF, IL6, CSF2, 
LIF), chemokines (IL8, CXCL2, CCL20, CXCL3) and peptide hormones (EDN1) regulated by these 
pathways were also detected. Other interacting genes detected including those encoding components 
of the NF-kB pathway (NFKBIE, TRAF1, BIRC3, TNFAIP3), apoptosis (BBC3, PMAIP1, BCL2A1, 
IRF1) and MAPK pathway (GADD45B, PIM1) (Figure 11A). For JRS4-infected TEpi cells, 
interacting genes were also detected for AP-1, ATF-2 and NFAT transcription factor networks, for 
transcription factors/signalling proteins (JUN, FOSB, FOSL1, ATF3, DUSP1, DUSP5, EGR2, 
EGR3), and inflammatory transcriptional targets of these pathways (TNF, IL8, IL6, IL1B, MMP1, 
CXCL1, CXCL2, CXCL3, CCL20). Interacting genes were also detected for tight junctions and 
epithelial barrier integrity (OCLN, CLDN4, CLDN1, GRHL1, GRHL3) (Figure 11B).  
 
Pathway enrichment tests identified a role for the AP-1, ATF-2 and NFAT transcription factor 
networks and GPCR signalling in TEpi cell responses to 5448-infection (Figure 11C). These 
pathways are known to drive the transcription of inflammatory cytokines such as IL6, TNF and IL8 
following activation (304-306). Fewer genes were significantly differentially expressed following 
JRS4 infection, but many of the induced pathways were common to 5448-infected TEpi cells (Figure 
11D). This indicated that 5448 induces a stronger TEpi cell inflammatory response, at the 
transcriptional level, compared to JRS4 infection. No pathways were enriched and significantly 
downregulated following either 5448 or JRS4 infection. Metadata from group comparisons is shown 
in Supplementary Table 4 and Supplementary Table 5. 
 
5.3.2 5448 GAS infection activates inflammatory pathways which lead to inducible   
IL8 expression 
The expression of genes contributing to each pathway was visualised using a heat map. The 
differences in amplitude of response between 5448- and JRS4-infected TEpi cells was consistently 
observed across each up-regulated network, and was apparent for the AP-1, ATF-2 and NFAT 
transcription factor networks (Figure 12A, B and C). Euclidean distance of samples showed highest 
similarity between replicates from each infection condition, with AP-1 and ATF-2 networks 
separating 5448-infected TEpi cells from mock-treated or JRS4-infected cells. (Figure 12A and B). 
For JRS4-infected TEpi cells, most differentially expressed genes are at a lower expression level than 
following 5448-infection. A protein-protein interaction network derived from the top 100 most 
differentially expressed genes in 5448-infected TEpi cells compared to JRS4-infected cells, revealed 
gene clusters of transcription factors and cytokines/chemokines from the AP-1 and NFAT 
transcription factor networks (FOSB, EGR1, EGR2, EGR3, EGR4, TNF, LIF, CXCL2, CCL20). 
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Pathway analysis also detected an enrichment of differentially expressed genes in the NFAT and AP-
1 networks (Supplementary Figure 10, metadata shown in Supplementary Table 6).  
 
 
Figure 11. RNAseq transcriptome network and pathway enrichment of 5448 and JRS4 GAS-
infected TEpi cells in comparison to mock cells. 
RNAseq transcriptome network and pathway enrichment of 5448 and JRS4 GAS-infected TEpi cells 
in comparison to mock cells. Protein-protein interaction network of the top 100 differentially 
expressed genes (at an adjusted P value < 0.05) for (A) 5448-infected TEpi cells in comparison to 
mock TEpi cells and (B) JRS4-infected TEpi cells in comparison to mock TEpi cells, generated using 
STRINGdb (http://string-db.org/). IL-8 is highlighted (red box). Network edges show the confidence 
of interactions, where the line thickness indicates the strength of data support. Active interaction 
sources include textmining, experiments, databases, co-expression, neighbourhood, gene fusion and 
co-occurrence. Minimum required interaction score of medium confidence (0.400). Non-protein 
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coding genes and disconnected nodes are not shown. Node colour is arbitrary. (C) Pathway over-
representation analysis of all differentially expressed genes (adjusted P value <0.05, Log2FC > 1 or 
< -1) for 5448 infected TEpi cells in comparison to mock cells and (D) JRS4-infected TEpi cells in 
comparison to mock cells was performed using Innatedb.com. Fold-change cut-off (+/-) 1.0 and P-
value cut-off 0.05. Hypergeometric analysis algorithm was used, with Benjamini Hochberg 
correction method. Top 15 up-regulated pathways shown. Green line indicates threshold for 
significance. Metadata from analysis results shown in (Supplementary Table 4 and Supplementary 
Table 5). 
 
Transcription factor motif enrichment using HOMER motif analysis software was performed on the 
top 400 differentially expressed genes for 5448-infected and JRS4-infected TEpi cells (279). 
Enrichment of known motifs in differentially expressed genes identified enrichment of motifs for NF-
κB (307) and serum response factor (SRF) (308) transcription factors in both JRS4- and 5448-infected 
TEpi cells (Figure 12D). Forty-two 5448-induced genes contained the NF-κB motif (enrichment P-
value < 0.001), and this motif was also highly represented in genes responding to JRS4 infection (38 
differentially expressed genes contained the motif, enrichment P-value < 0.01). Similarly, 21 
differentially expressed genes contained the SRF motif following 5448-infection (enrichment P-value 
< 0.001), and 19 differentially expressed genes (P-value < 0.01) contained the SRF motif following 
JRS4 infection. The basic Leucine Zipper Domain (bZIP) motif (309) was also enriched after 
infection with either GAS strains (21 differentially expressed genes following 5448 infection 
(enrichment P-value < 0.001); 58 differentially expressed genes following JRS4 infection 
(enrichment P-value < 0.001)). The bZIP recognition motif is bound by multiple transcription factors 
including ATF-1 and Fosl2/Fra-2, which are members of the AP-1 and ATF-2 transcription factor 
networks (190). This analysis indicates that the same signalling pathways are engaged by both strains, 
but the amplitude of signalling is reduced in JRS4-infected TEpi cells, perhaps by abrogated 
feedforward amplification via cytokine signalling. 
 
5.3.3 5448 suppresses levels of secreted IL-8 in primary human tonsil epithelial 
cells  
RNAseq highlighted increased IL8 mRNA expression following both JRS4 and 5448 infection, with 
5448-infected TEpi cells inducing IL8 mRNA to levels that were 23-fold higher than mock cells, and 
2.9-fold higher than JRS4-infected cells (Figure 12E). These strain differences in inducing IL8 were 
confirmed by qRT-PCR analysis of gene expression at 6 h post-infection; in these experiments, IL8 
mRNA levels were 21-fold higher in 5448-infected TEpi cells than in mock cells, and 2.2-fold higher 
than JRS4-infected cells (Figure 12F). IL8 mRNA levels relative to additional housekeeping genes 
GAPDH and RPL32 also showed a similar trend (Supplementary Figure 11).  
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Figure 12. IL-8 mRNA expression analysis of 5448 and JRS4 GAS-infected TEpi cells in 
comparison to mock cells. 
Regulated IL-8 expression in 5448 and JRS4 GAS-infected TEpi cells in comparison to mock cells. 
Heat maps of differentially expressed genes from top pathways enriched by Innatedb.com that induce 
IL-8 gene mRNA expression. (A) AP1 transcription factor network, (B) ATF-2 transcription factor 
network, and (C) Calcineurin-regulated NFAT-dependent transcription. (D) Known transcription 
factor motifs enriched from top 400 differentially expressed genes for 5448-infected TEpi cells and 
JRS4-infected TEpi cells using HOMER motif analysis. 5448vsMock: NF-κB-p65 Rel homology 
domain (RHD) target sequences with motif = 42. CArG(MADS-domain)/Serum response factor 
(SRF) target sequences with motif = 21. Fosl2/basic Leucine Zipper (bZIP) target sequences with 
motif = 21. JRS4vsMock: NF-κB-p65(RHD) target sequences with motif = 38. Atf1/(bZIP) target 
sequences with motif = 58. CArG (MADS) target sequences with motif = 19. (E) RNAseq IL8 read 
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counts. (F) qPCR of IL-8 mRNA levels, normalised to HPRΤ.   Data in E and F (mean ± s.e.m.) are 
combined from at least three independent experiments performed in triplicate and analysed by one-
way ANOVA with Tukey’s post-test. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.  
 
To determine whether the increased IL8 mRNA expression following GAS infection resulted in 
increased IL-8 production by these cells, I next quantified IL-8 secretion by TEpi cells. TEpi cells 
were cultured to confluent monolayers, infected with GAS strains JRS4 and 5448 at multiple MOIs 
(1, 5 and 10), and IL-8 levels quantified by ELISA at 6, 12 and 24 h post-infection (Figure 13). 
Surprisingly, while the IL-8 response to JRS4 infection increased in a time- and MOI-dependent 
manner, the IL-8 response to 5448-infection did not increase above that of mock cells and decreased 
with increasing MOI. In order to ensure the differences in cytokine secretion were not due to 
differences in cell death induced by the two GAS strains, tonsil cell death was measured by 
quantifying the lactate dehydrogenase levels released by TEpi cells following with each strain 
(Supplementary Figure 4). Both strains induced TEpi cell death at 24 h, however the level of cell 
death induced by JRS4 and 5448 was not significantly different between the two strains.  
 
The TEpi cells utilised in the experiments above were sourced from the tonsil explant of one human 
donor. In order to determine whether the IL-8 response to GAS infection is similar across different 
human donors, and is not a donor-specific response, the IL-8 response of TEpi cells from a second 
donor were tested (ScienCell, Cat. #2560, Lot no. 7658). The donor 2 TEpi cells were cultured to 
confluency and infected with JRS4 and 5448 strains at an MOI of 1 and 10, and IL-8 secretion was 
measured by ELISA at 12 h and 24 h post-infection. The response by the donor 2 TEpi cells to GAS 
infection showed a similar trend to the original donor, in that JRS4-infection resulted in IL-8 secretion 
at 24 h, whilst 5448-infection resulted in IL-8 secretion that was significantly reduced in comparison 
to mock cells (Supplementary Figure 8A, B). Due to a high level of IL-8 secretion by mock cells 
was observed by the donor 2 TEpi cells, which could obscure the IL-8 response induced during GAS 
infection, TEpi cells from this donor were not used for further experiments.  
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Figure 13. 5448-infected TEpi cells show reduced levels of IL-8 production. 
IL-8 produced by TEpi cells intracellularly infected with GAS strains 5448 and JRS4, as measured 
by ELISA. Data are plotted as the mean ± s.e.m. and are combined from three independent 
experiments performed in triplicate and analysed by two-way ANOVA with Tukey’s post-test. 
Significance is shown relative to mock at each time point. ** P < 0.01; *** P < 0.001; **** P < 
0.0001. 
 
5.3.4 SpyCEP degrades IL-8 during infection of TEpi cells  
I considered the possibility that the decrease in levels of secreted IL-8 in 5448-infected TEpi cells 
may relate to proteolytic degradation of this key neutrophil-recruiting chemokine. SpyCEP is a 170 
kDa serine protease expressed on the surface of GAS, which proteolytically cleaves and abrogates 
the activities of the human chemokines CXCL1, CXCL2, CXCL6 and CXCL8/IL-8, impairing 
neutrophil recruitment to the site of infection (145, 147, 194, 310, 311). In order to investigate the 
impact of SpyCEP expression on IL-8 secretion during intracellular GAS infection of TEpi cells, the 
GAS strains 5448, JRS4 and 5448 SpyCEP knockout (5448ΔcepA) were utilised. A plasmid 
expressing 5448-derived SpyCEP (pDCermcepA) was introduced into both JRS4 and 5448ΔcepA 
strains to confirm SpyCEP specificity for the observed phenotype. Comparison of the genome 
sequences of JRS4 (312) and 5448 (313) revealed that both GAS strains contained the SpyCEP 
encoding gene cepA, that would encode proteins with 99% amino acid sequence identity, and 
conserve the catalytic triad residues required for serine-protease activity. However, several amino 
acid differences between 5448 and JRS4 were observed in the N-terminal region of SpyCEP 
(Supplementary Figure 12), suggesting that there might be differences in secretion and/or cell 
surface localisation of this protein between 5448 and JRS4. To determine whether both GAS strains 
produce surface-anchored SpyCEP, western blot analysis was employed to detect SpyCEP expression 
in the cell wall fraction of GAS strains (Figure 14A). Equivalent protein concentrations were loaded 
for 5448, JRS4 and 5448ΔcepA strains. A protein band at the predicted molecular weight of the 
surface-bound cleaved form of SpyCEP (150 kDa) was detected for both the 5448 and JRS4 strains. 
This protein band was not detected for 5448ΔcepA. Detectable levels of the 170 kDa protein, 
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corresponding to the uncleaved form of SpyCEP, were observed following introduction of cepA on a 
plasmid in strains 5448ΔcepA (pDCermcepA) and JRS4 (pDCermcepA). 
 
The levels of IL-8 secreted by TEpi cells following intracellular infection with GAS strains (MOI of 
5) at 6 h and 24 h post-infection was measured by ELISA. At 6 h post-infection, IL-8 secretion was 
not significantly elevated for all infections compared to mock cells (Figure 14B). At 24 h post-
infection, JSR4 induced a significant increase in levels of secreted IL-8 compared to mock TEpi cells, 
whilst 5448 did not induce an IL-8 response. 5448ΔcepA induced an IL-8 response similar to JRS4 
levels, and the complemented 5448ΔcepA (pDCermcepA) IL-8 response was similar to 5448 levels. 
Infection with JRS4 expressing cepA (pDCermcepA) significantly reduced the IL-8 response of TEpi 
cells in comparison to JRS4-infected cells at 24 h post-infection (P value< 0.05) (Figure 14B). To 
determine whether the presence or absence of SpyCEP expression impacts the level of TEpi cell 
death, lactate dehydrogenase release was used to quantify cell death following GAS intracellular 
infection. No significant difference in cell death was observed between cells infected with 5448, 
5448ΔcepA, 5448ΔcepA (pDCermcepA), JRS4, or JRS4 (pDCermcepA). (Figure 14C). To confirm 
that the effect of SpyCEP on IL-8 production was due to its ability to proteolytically degrade IL-8, I 
next quantified IL-8 levels by ELISA following incubation of recombinant IL-8 with each GAS strain 
over a time course. Both JRS4 and 5448 strains degraded IL-8, however 5448 degraded IL-8 more 
efficiently than JRS4 after 4 h incubation (p < 0.001). IL-8 degradation was not observed following 
incubation with 5448ΔcepA, whilst the complemented strains 5448ΔcepA (pDCermcepA) and JRS4 
(pDCermcepA) exhibited enhanced IL-8 degradation (Figure 14D).   
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Figure 14. SpyCEP expression by 5448 reduces levels of secreted IL-8 by TEpi cells during 
GAS intracellular infection. 
(A) Western blot analysis of cell wall extracts for detection of SpyCEP. Equivalent protein 
concentrations were loaded for 5448, JRS4 and 5448ΔcepA (100 µg), whilst 5 µg was loaded for 
5448ΔcepA (pDCermcepA) and JRS4 (pDCermcepA). (B) IL-8 present in supernatants due to 
secretion by TEpi cells following GAS intracellular infection at 6 and 24 h post-infection, measured 
by ELISA. (C) Cell death measured by percentage of LDH released from TEpi cells at 6 and 24 h 
post-infection. (D) GAS strains were incubated with recombinant IL-8 at 37 oC. SpyCEP activity 
correlates with IL-8 degradation as assessed by ELISA. For B-D, data are plotted as the mean ± 
s.e.m. and represent three independent experiments performed in triplicate and analysed by two-way 
ANOVA with Tukey’s post-test. Significance shown is relative to mock at each time point, unless 
otherwise indicated. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. 
 
 
5.4 DISCUSSION 
 
Whilst GAS is the most common cause of bacterial pharyngitis, my understanding of the host innate 
immune responses during GAS colonisation of the tonsil is surprisingly limited. Given that the M1T1 
strain disproportionately causes GAS pharyngitis in high income countries, a better understanding of 
the host responses that mediate immunity to M1T1 GAS infection could lead to the development of 
better therapeutic and preventative strategies to combat GAS pharyngitis. Moreover, understanding 
the fundamental aspects of host innate immunity is likely to provide additional insights into the 
pathology of other bacterial pathogens that colonise the human pharynx.  
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Here I demonstrate that the highly successful and globally-disseminated M1T1 GAS clone (strain 
5448) induces a strong pro-inflammatory transcriptional response yet degrades IL-8 post-
transcriptionally through expression of the protease SpyCEP. IL-8 plays an important role in the 
recruitment of neutrophils during infection (110), which is likely an important protective mechanism 
elicited by epithelial cells during GAS pharyngitis (106). IL-8 was one of the most differentially 
expressed chemokines at the level of mRNA expression following intracellular infection with both 
5448 and a laboratory-adapted strain (JRS4). In contrast, whilst JRS4 infection resulted in the 
secretion of IL-8 at levels significantly higher than mock TEpi cells, 5448 infection did not result in 
increased levels of secreted IL-8 beyond that observed for mock TEpi cells. This lack of response in 
5448-infected cells was found to be dependent on the expression of the GAS virulence factor 
SpyCEP. The function of SpyCEP has been defined by previous studies as a serine protease that 
cleaves the human chemokines CXCL1, CXCL2, CXCL6 and CXCL8/IL-8, abrogating their 
biological activity, and enabling resistance of GAS to phagocytic clearance (145, 194, 310, 311). 
SpyCEP expression by the 5448 strain has also been reported to decrease the adherence and invasion 
of GAS into epithelial cells, as well as impair biofilm formation, suggesting that SpyCEP expression 
may modulate colonisation and GAS-host cell interactions (294). This study highlights the important 
role played by SpyCEP during infection, by demonstrating that different GAS strains (5448 and 
JRS4) exhibit varying levels of IL-8 degradative activity, resulting in varying levels of IL-8 secretion 
during intracellular infection of primary epithelial cells. 
 
SpyCEP is a highly conserved virulence factor across GAS M types (194); however different GAS 
strains have been shown to exhibit varying levels of SpyCEP activity as a result of covRS mutation 
(310). My results show that whilst both JRS4 and 5448 GAS strains express SpyCEP at similar levels 
(Figure 14A), JRS4 showed reduced efficiency in cleaving human recombinant IL-8 (Figure 14D). 
This reduced SpyCEP activity could explain the IL-8 secretion detected during JRS4 intracellular 
infection of TEpi cells (Figure 14B). In contrast, 5448 efficiently cleaved human recombinant IL-8, 
supporting the hypothesis that 5448 SpyCEP degrades IL-8 during TEpi cell infection. The cause of 
this difference in SpyCEP activity or protein levels is unknown. Amino acid sequence alignment 
shows the 3 amino acids encoding the catalytic triad responsible for serine protease activity and the 
residues around this region are conserved, while the N-terminal region of cepA shows some 
variability in amino acids for JRS4, as compared to 5448. It is not known what role these specific 
residues play in the protease activity of SpyCEP. However, the N-terminal region is an important 
component of the protease, as it encodes the 20 kDa fragment that is cleaved from the 170 kDa full 
length SpyCEP resulting in protease activity (314). This 20 kDa fragment then associates with the 
150 kDa cell-wall anchored portion of SpyCEP, with both fragments required for protease activity 
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(314). Previous studies have also shown that different GAS M types induce differing levels of 
secreted IL-8 by immortalised epithelial cells (105, 106); differences between GAS M types in the 
capacity of SpyCEP to cleave IL-8 could explain this observation.  
 
Whilst this study has shown that 5448-derived SpyCEP induces IL-8 degradation during GAS 
infection, the cellular location where SpyCEP encounters IL-8 is not known. IL-8 secretory pathways 
are not well characterised in epithelial cells; however, the current understanding is that intracellular 
IL-8 is trafficked in secretory vesicles (315). Some studies have reported cytoplasmic IL-8 present in 
the epithelial cells from human tissue biopsies (316, 317) and in Chlamydia trachomatis infected 
HeLa cells (318), suggesting that there may be another uncharacterised mechanism by which 
epithelial cells secrete IL-8. Cytoplasmic IL-8 would enable SpyCEP direct access to cleave IL-8 
during intracellular infection. It is also plausible that SpyCEP degradation of IL-8 does not occur 
intracellularly. SpyCEP is cell wall anchored in the strains utilised in this study, however SpyCEP 
secretion and extracellular release of SpyCEP during infection could also contribute to the IL-8 
degradation observed.  
 
Previous studies have demonstrated that, during infection of immortalised epithelial cells, GAS 
activates the AP-1, NF-κB and MAPK pathways, leading to increased expression and secretion of 
key cytokines and chemokines, particularly IL-8 and IL-6 (105, 106, 110, 187, 188). These 
inflammatory responses serve as an early signalling system to activate and recruit immune cells to 
the site of infection, thereby helping combat bacterial infection. The findings from this study show 
that both 5448 and JRS4 GAS strains induce the expression of inflammatory mediators enriched in 
the AP-1, ATF-2 and NFAT pathways, all of which are linked to the production of IL-8 (304-306). 
Both NFAT and ATF-2 are able to bind cooperatively with transcription factors of the AP-1 (Fos/Jun) 
family to composite NFAT:AP-1 or ATF-2:AP-1 sites. These sites are found in the regulatory regions 
of genes that are inducibly transcribed during immune responses, including cytokines and other genes 
critical to immune signalling and activation (319). HOMER analysis detected the enrichment of 
motifs in the promoters of differentially expressed genes for NF-κB and the MAPK-activated 
transcription factor SRF, indicating that these pathways are likely upstream of AP-1/ATF-2/NFAT-
mediated gene expression, as detected by RNAseq at 6 h post-infection. 5448 and JRS4 GAS 
infection also activated G protein-coupled receptor (GPCR) signalling (Figure 11C and Figure 11D), 
which is another pathway that may regulate inflammatory responses during GAS infection (320). 
GPCRs play a critical role in modulating the expression or activity of transcription factors through 
complex signalling networks, which includes NF-κB, AP-1 MAPK, NFAT, SRF and ATF-2 (321, 
322). Inflammatory mediators such as chemokines and complement proteins can stimulate the 
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activation of specific GPCRs, leading to the expression of cytokines such as IL-6, IL-8, TNF-α and 
IL-1β (323, 324). It should also be noted that 5448-infection was found to induce an inflammatory 
transcriptional response in TEpi cells of a much higher magnitude than during JRS4-infection. 
Previous studies have also shown that the magnitude of host inflammatory mediators in response to 
GAS is emm-type dependent (104-106). As 5448 is an M1T1 clinical GAS isolate and JRS4 an M6 
laboratory adapted isolate, there is likely a difference in the virulence factor expression profiles of 
these strains during intracellular infection, which may be driving the large difference in TEpi cell 
transcriptional responses detected. The virulence factors responsible for this, however, remain to be 
defined.  
 
In summary, I have shown the pathogenic M1T1 strain 5448 induces robust changes in pro-
inflammatory gene expression following intracellular infection of primary human tonsil epithelial 
cells and degrades host-protective neutrophil-recruiting IL-8, which is driven by the activity of the 
GAS serine protease SpyCEP. This is an exciting and potentially novel mechanism by which a 
bacterial pathogen modulates the host inflammatory response and supports the hypothesis that the 
high burden of pharyngitis caused by M1T1 GAS is due to its ability to modulate host inflammatory 
responses that are triggered by infection. 
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6.0 Group A Streptococcus M1T1 expression of SLO blocks the 
host IL-6 response during intracellular infection of primary 
tonsil epithelial cells 
 
6.1 INTRODUCTION 
 
The ability of GAS to colonise the mucosal layers of the pharynx during pharyngitis is due to the 
expression of virulence factors which subvert host immune defences (2). The majority of studies have 
focused on the function of these virulence factors in non-epithelial cell types, however some studies 
have also investigated their function using epithelial cells or nasopharyngeal models of infection. For 
example, the AgI/II family adhesin AspA is required for GAS colonisation of the nasopharynx, by 
mediating adhesion to pharyngeal epithelial cells (165). Streptococcal inhibitor of complement (SIC) 
also contributes to GAS colonisation of the mouse oropharynx by inhibiting MAC-dependent lysis 
of GAS (213) and by binding to and circumventing the activity of antimicrobial peptides (211, 212). 
GAS also secretes the cholesterol-dependent cytolysin (CDC) streptolysin O (SLO), which is well 
characterised to promote immune evasion by inducing osmotic lysis of a broad spectrum of host cells, 
including epithelial cells (149). M6 (JRS4) GAS mutants defective in SLO production resulted in 
reduced IL-1β, IL-6 and IL-8 expression by infected keratinocytes, indicating SLO expression is also 
required manipulate pro-inflammatory signalling pathways (114, 325). 
 
CDCs are pore-forming toxins that act by binding to cholesterol and glycans in the target cell 
membrane, before forming a large homo-oligomeric complex (326, 327). The resulting 
transmembrane pore is up to 30 nm in diameter and provides the toxin with its cytolytic and 
haemolytic properties (327-329). SLO is closely associated with a second virulence factor, SPN (S. 
pyogenes NAD+-glycohydrolase), and when GAS binds to epithelial cells, SLO mediates the 
translocation of SPN from the bacterial cytoplasm into the host cytosol (330). SPN NAD+-
glycohydrolase activity results in the depletion of intracellular NAD+ and ATP (331), enhancing GAS 
survival and cytotoxicity of host cells (332).  
 
During SLO pore formation in cell membranes, intrinsic membrane repair is activated to maintain 
cell viability and protect cells from pore-forming toxins by microvesicle shedding (333, 334). This 
also leads to the shedding of membrane receptors which localise to cholesterol rich microdomains, 
such as IL-6R, CD14 (LPS receptor), TLR4 and IFNγR (333, 335, 336). Shedding of IL-6R and CD14 
is reported to broaden the spectrum of host cells for IL-6 and LPS by trans-signalling of these soluble 
receptors, enhancing systemic inflammatory effects (336, 337). However, loss of surface receptors 
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by microvesicle shedding in response to SLO is also reported to attenuate the immune response of 
host cells during GAS infection without inducing cell death (333). SLO membrane disruption is 
detected by cytoplasmic NLRP3, which leads to Casp1 and inflammasome activation, resulting in the 
secretion of the pro-inflammatory cytokine IL-1β (183, 338). A recent study has reported extracellular 
NADase can inactivate IL-1β (184), suggesting that GAS is able to manipulate host cell secretion of 
IL-1β by multiple mechanisms. Therefore, whilst the cytotoxic properties of SLO and NADase are 
well characterised, these virulence factors also play a role in evading host immune responses during 
infection.  
 
During GAS pharyngitis, cytokines secreted by different tonsillar cell types act in an autocrine and/or 
paracrine manner to instruct inflammatory responses during infection. Epithelial cells strongly secrete 
IL-6 and TNF-α in response to GAS infection (105, 112), with one study speculating that significant 
pro-inflammatory responses by epithelial cells would lead to tissue destruction in vivo, allowing GAS 
to disseminate deeper into host tissues (112). Blood samples from patients with acute GAS 
pharyngitis also showed high levels of IL-6 and TNF-α (198), further indicating that these cytokines 
are important in the pathology of this disease. Despite GAS employing a vast array of virulence 
factors to dampen host responses during infection, the ability of GAS to target the production of IL-
6 and TNF-α during infection is relatively unknown.  
 
The aim of this chapter was to investigate the role of IL-6 during M1T1 GAS infection of TEpi cells. 
RNAseq analysis performed in Chapter 5 identified a number of transcription factors (AP-1, ATF-2 
and NFAT), which control GAS-regulated IL-6 expression. Subsequent validation studies revealed 
that, whilst infection of TEpi cells with the laboratory-adapted GAS strain JRS4 induced strong IL-6 
secretion, infection with the clinical M1T1 clone (strain 5448) did not. An isogenic mutant screen 
identified IL-6 secretion was dependent on SLO expression by 5448. This was further demonstrated 
by SLO chromosomal complementation of 5448Δslo, which restored IL-6 secretion to 5448 WT 
levels. I demonstrated that 5448 has significantly greater SLO haemolytic activity than JRS4, which 
is likely due to a difference in SLO production between the two strains. This study provides insight 
into the ability of M1T1 GAS to modulate tonsillar cytokine responses during infection, which may 
contribute to immune evasion and survival of this successful human pathogen.   
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6.2 METHODS 
 
6.2.1 Bacterial strains  
GAS M1T1 strain 5448 was originally isolated from a patient with necrotising fasciitis and toxic 
shock syndrome (270). JRS4 is a streptomycin-resistant derivative of D471, a rheumatic fever-
associated isolate (271). 5448 isogenic knockouts utilised in this study are described in Table 6.  
 
Table 6. 5448 isogenic knockout library. 
Strain Protein Role in immunity 
5448ΔcepA Streptococcus pyogenes cell envelope 
protease (SpyCEP), serine protease 
Cleaves human CXCL1, 2, 6 and 8 (146), 
dampening host inflammatory responses. 
5448Δslo Streptolysin O (SLO), haemolytic toxin  Induces apoptosis (339), promotes GAS 
resistance to phagocytic clearance by 
neutrophils (340), dampens macrophage 
cytokine responses (341) 
5448ΔdltA D-alanylation of lipotechoic acids on the 
surface of GAS 
D-alanylation of lipotechoic acids increases 
the positive surface charge of GAS, 
resulting in increased resistance to host anti-
microbial peptides, lysozyme, neutrophil 
killing, and enhances adherence to and 
invasion of pharyngeal epithelial cells (342). 
LTA is a ligand of TLR2, which is 
implicated in the detection of GAS during 
infection (157).  
5448ΔhasB Hyaluronic acid capsule, homologue to 
human hyaluronic acid 
Required for GAS capsule production (343), 
inhibits phagocytosis (344) and promotes 
resistance to opsonisation of GAS (345). 
5448ΔspeB Cysteine protease, degrades GAS and 
human proteins  
Activates IL-1β (199), determinant of 
tissue-specific GAS infection at the skin 
(346), degrades human extracellular matrix, 
immunoglobulins and complement 
components (347). 
5448Δemm1 M1 protein Antiphagocytic (220), inhibits complement 
(348), protects GAS by being a dominant 
surface protein that is immunologically 
distinct between different GAS serotypes, so 
antibodies raised against one serotype are 
not effective against other GAS serotypes 
(349).   
5448Δsda1 Extracellular nuclease, homologue of 
human SdaD 
Degrades DNA component of NETs and 
extruded by macrophages (139), may 
provide protection by suppressing TLR9-
mediated immune response (350).  
5448Δnga Nicotinamide adenine dinucleotide 
(NAD)- glycohydrolase 
Translocated by SLO into host cell. NADase 
depletes cellular energy stores and enhances 
GAS intracellular survival. Intracellular 
bacteria are protected from many host 
antimicrobial agents and host immune 
effectors (351). 
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5448Δmac mac-1-like protein, homologue of human 
integrin CD11b 
Mac blocks immunoglobulin recognition by 
Fc receptors and degrades immunoglobulin 
by endopeptidase activity, thereby inhibiting 
phagocytosis, endocytosis of IgG-opsonised 
antigens and antibody-dependent cell-
mediated cytotoxicity (352).  
5448ΔspyA ADP ribosyltransferase Triggers caspase-1 dependent inflammatory 
responses in macrophages, leading to 
pyroptosis (185). 
5448ΔsagA Streptolysin S (SLS), haemolytic toxin  Induces cell death (150), inhibits neutrophil 
recruitment (353), activates p38 MAPK and 
NF-κB signalling (354). 
 
6.2.2 Chromosomal complementation of 5448Δslo  
Construction of complemented 5448Δslo was performed using the NEBuilder system 
(https://nebuilder.neb.com), following a modified method designed by Dr. T.C. Barnett (under 
publication).  Primers were designed to amplify 550 bp upstream and 550 bp downstream of the slo 
gene in the 5448 GAS strain (slo locus tag = “SP5448_00880”, NCBI Reference Sequence: 
NC_002737.2), with a 5’ region overlapping the linearised vector pLZts (temperature sensitive, 
containing spectinomycin resistance). Primers designed to amplify slo were as follows: Forward (5’ 
– 3’) primer: ttggtcgtcagactgatgggcccCTTAGCAGAGATTGATGC, Reverse (5’ – 3’) primer: 
cataacctgaaggaagatctATTATAACCATCTCTGTACCC (uppercase = gene-specific, lowercase = 
vector-specific). The linearised vector pLZts was pretreated with Dpnl to digest and destroy plasmid 
DNA, before being amplified using the following primers: Forward (5’ – 3’) primer: 
GGGCCCATCAGTCTGACG, Reverse (5’ – 3’) primer: AGATCTTCCTTCAGGTTATG. 
Amplification of vector and insert was performed using KAPA HiFi PCR kit (cat. #KR0368). The 
two PCR products were then mixed using 120 ng vector and a 2-fold molar excess of insert fragments, 
in a 20 µl reaction containing 10 µl NEBuilder HiFi DNA Assembly Master Mix reagent (cat. 
#E2621S). The vector-insert mix was incubated at 50°C for 60 min. MC1061 competent E. coli was 
transformed with 2 µl of the mix. Transformed E. coli was then plated on Luria-Bertani agar 
containing 100 µg/ml spectinomycin at 28°C. Plasmid DNA was purified using Wizard® Plus SV 
Minipreps DNA Purification Systems (cat. #A1330) and tested for correct insertion of slo using the 
primers listed above. The plasmid was transformed into GAS by electroporation (2500 V, 25 µF, 600 
Ω) and incubated at 28°C on THY agar containing 100 µg/ml spectinomycin for 2 days. Isolated 
colonies were streak purified at 28°C on THY agar containing 100 µg/ml spectinomycin for 1 day. 
GAS was then grown overnight at 28°C in THY containing 100 µg/ml spectinomycin. To select for 
plasmid integration, GAS was diluted 1:100 in THY containing 100 µg/ml spectinomycin and 
cultured for 2 h at 28°C, before being shifted to 37°C and cultured for 3 h. Dilutions (10-2 – 10-4) 
were then plated on THY agar containing 100 µg/ml spectinomycin at 37°C overnight to select for 
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integrants. 3-4 colonies were picked onto a single loop and streak purified on THY agar containing 
100 µg/ml spectinomycin at 37°C overnight. Several colonies were then inoculated into THY 
containing 100 µg/ml spectinomycin and grown overnight at 37°C. GAS was then diluted 1:10 000 
into THY (without spectinomycin) and cultured at 28°C for > 30 h. Serial dilutions (10-5 and 10-6) 
were plated onto THY agar (without spectinomycin) at 37°C. Individual colonies were then patched 
on THY agar and THY agar containing 100 µg/ml spectinomycin, with excised plasmids being 
spectinomycin-sensitive. slo insertions were screened by PCR and DNA sequencing (AEGRC 
Genotyping and Sequencing Facility, University of Queensland).     
 
6.2.3 SLO Haemolytic assay  
Haemolysis activation assay was performed utilising a previous method (355) modified by Dr. S. 
Brouwer. Chemically defined media recipe from a previous study (258) was optimised by Dr. T.C. 
Barnett. GAS strains 5448, JRS4, 5448Δslo, 5448Δslo complemented and 5448ΔsagA (involved in 
streptolysin S production) were streaked on horse blood agar plates and grown overnight at 37°C (5 
% CO2). A single loopful of growth was then used to inoculate modified RPMI to an OD600 of 0.1 
(supplemented with 50 mM HEPES (Sigma H0877), 0.5 % w/v glucose, 1X BME Vitamins (Sigma 
B6891), RPMI containing L-glutamine and without glucose (ThermoFisher 11879), 25 µg/mL 
guanine, 25 µg/mL uracil and 5 µg/mL adenine), before grown at 37°C (5 % CO2) to an OD600 of 0.5. 
Culture supernatants were then filtered through a 0.22 µm Millipore filter. Human blood was 
centrifuged at 500 x g for 10 min, and the levels of haematocrit (red, lower layer), buffy coat (white 
blood cells and platelets, thin clear mid-layer), and plasma (yellowish, upper layer) were marked on 
tube. The plasma and buffy coat was gently aspirated using a micropipette and discarded. The tube 
was filled to the marked line to the original level of plasma with Hank’s Balanced Salt Solution 
(HBSS), inverted a few times to gently mix, and centrifuged at 500 x g for 10 min. The washing step 
was repeated (in total 2 washes). The supernatant was aspirated and replaced with HBSS, inverted to 
mix, and considered 100 % red blood cells (RBC). A 2 % RBC solution was prepared in HBSS, and 
200 µl of 2 % RBC was aliquoted in a 96 well plate. 40 µl of filtered bacterial supernatants were 
added to each well. Triton X-100 (final concentration of 1 %) was included as a positive control for 
100 % RBC lysis. Samples were incubated for 30 min at 37°C (5 % CO2). The plate was centrifuged 
at 1000 x g for 10 min at room temperature to pellet intact red blood cells. 100 µl was transferred into 
a new plate and the amount of haemoglobin released into the medium was measured 
spectrophotometrically at 405 nm.  
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6.3 RESULTS 
 
6.3.1 5448 GAS infection activates inflammatory pathways which lead to inducible   
IL6 expression 
In Chapter 5, RNAseq analysis of TEpi cells infected with GAS strains JRS4 and 5448 revealed that 
IL-6 is differentially expressed during GAS infection. Protein-protein interaction networks 
constructed from the top 100 most differentially expressed genes in JRS4-infected and 5448-infected 
TEpi cells in comparison to mock cells, showed IL-6 to be at the core of these networks (Figure 11A 
and B). Within these networks, transcription factors and signalling proteins from the AP-1, ATF-2 
and NFAT transcription factor networks were identified, which in addition to inducing IL-8 
expression are also known to activate IL-6 expression. For example, in response to cAMP treatment 
of intestinal epithelial cells AP-1 binds to the promoter of the IL-6 gene and activates IL-6 expression 
(356). Ectopic expression of AP-1 (c-Jun), CCAAT/enhancer-binding protein delta (C/EBPδ) and 
NF-κB (p65) subunits, synergistically activates an IL-6 promoter construct in HeLa epithelial cells 
(357). The ATF-2 transcription factor is also reported to be an activator of IL-6 expression in 
bronchial epithelial cells (358) and osteoblasts (359), and in ATF2-knockout mice the IL-6 response 
was suppressed (360). NFAT is also involved in IL-6 gene induction in epithelial cells (361) and 
macrophages (362), and ectopic expression of NFAT strongly enhances IL-6 mRNA induction in 
smooth muscle cells (363).  
 
Pathway enrichment also identified AP-1, ATF-2 and NFAT transcription factor networks as the 
signalling pathways engaged by both strains during infection (Figure 11C). Transcription factor 
motif enrichment, which identifies the main transcription factors responsible for driving changes in 
gene expression, identified motifs for NF-κB and serum response factor (SRF), in addition to ATF-1 
and Fosl2/Fra-2 (Figure 12D), which are members of the AP-1 and ATF-2 transcription factor 
networks (190). NF-κB is also an important mediator for the activation of IL-6 expression in epithelial 
cells (364, 365), and can act in co-operation with AP-1 and NFAT (357, 363, 366, 367). SRF is 
reported to regulate IL-6 expression and in SRF-knockout muscle myofibers IL-6 is overexpressed 
(368). SRF is also activated by the IL-6 signalling cascade and regulates the expression of genes that 
respond to IL-6 production (369).  
 
6.3.2 5448 infection reduces levels of secreted IL-6 in TEpi cells  
The mRNA expression level of IL-6 during GAS infection of TEpi cells was first investigated by 
RNAseq and qRT-PCR. RNAseq detected an increase in IL6 mRNA expression following JRS4 and 
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5448 infection, with 5448-infected TEpi cells inducing IL6 mRNA to levels that were 11 fold higher 
than mock cells, and JRS4-infected TEpi cells induced IL6 mRNA 6 fold higher than mock cells 
(Figure 15A). The IL6 mRNA response to 5448- and JRS4- infected TEpi cells were not significantly 
different to each other. The ability of these strains to induce IL6 mRNA expression were confirmed 
by qRT-PCR analysis of gene expression at 6 h post-infection; in these experiments, IL6 mRNA 
levels were 7-fold higher in 5448-infected TEpi cells than in mock cells, and 5-fold higher in JRS4-
infected TEpi cells than mock cells (Figure 15B). IL6 mRNA levels relative to additional 
housekeeping genes GAPDH and RPL32 also showed a similar trend (Supplementary Figure 11). 
To investigate whether the increase in IL6 mRNA expression following GAS infection resulted in 
increased IL-6 production by TEpi cells, IL-6 secretion by TEpi cells was quantified. TEpi cells 
cultured to confluent monolayers were infected with GAS strains JRS4 and 5448 at multiple MOIs 
(1, 5 and 10), and IL-6 levels quantified by ELISA at 6, 12 and 24 h post-infection. Similar to what 
was observed for IL-8 in Chapter 5, I found the IL-6 response to JRS4 infection resulted in an increase 
in IL-6 secretion in a time- and MOI- dependent manner, whilst the IL-6 response to 5448 infection 
did not increase above that of mock cells and decreased with increasing MOI (Figure 16). As 
described in Chapter 5, to ensure the difference in cytokine secretion was not due to a difference in 
cell death induced by the two GAS strains, an LDH assay was performed and showed that the level 
of cell death induced by JRS4 and 5448 was not significantly different between the two strains 
(Supplementary Figure 4). GAS infection of TEpi cells from a second human donor also showed 
that 5448-infection dampens IL-6 secretion, whilst JRS4-infection does not (Supplementary Figure 
8C, D).    
 
Figure 15. IL6 mRNA expression by 5448 and JRS4 GAS-infected TEpi cells in comparison to 
mock cells. 
(A) RNAseq IL6 read counts per million reads, TMM normalised. (B) qRT-PCR of IL6 mRNA levels, 
normalised to HPRT. Data in A and B (mean ± s.e.m.) are combined from at least three independent 
experiments performed in triplicate and analysed by unpaired, two-way t-test. * P < 0.05. 
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Figure 16. 5448-infected TEpi cells show reduced IL-6 secretion compared to JRS4-infected 
cells. 
IL-6 produced by TEpi cells intracellularly infected with GAS strains 5448 and JRS4, as measured 
by ELISA. Human TNF-α treatment (30 ng/ml) was included as a positive control, and untreated cells 
(mock) as a negative control. Data are plotted as the mean ± s.e.m. from three independent 
experiments performed in triplicate and analysed by two-way ANOVA with Tukey’s post-test. 
Significance is shown relative to mock (stars directly above each bar), and between JRS4 and 5448 
(indicated by bars). ** P < 0.01; *** P < 0.001; **** P < 0.0001. 
 
 
6.3.3 5448 isogenic mutant screen reveals infection with 5448Δslo increases IL-6 
secretion by TEpi cells  
In order to determine whether a particular virulence factor expressed by 5448 dampens the IL-6 
response of TEpi cells during intracellular infection, a screen was performed utilising 5448 isogenic 
mutants for individual virulence factors that have been reported to impact the host immune response 
during infection (Table 6). Confluent monolayers of TEpi cells were infected with each mutant, and 
IL-6 and IL-8 secretion was measured at 24 h post infection by ELISA. JRS4-infected and mock TEpi 
cells were included as positive and negative controls. Due to the large number of isogenic mutants to 
test, the mutants were spread across 2 experiments, as shown in Figure 17.  At 24 h post-infection, 
infection with 5448Δslo significantly increased the IL-6 response of TEpi cells similar to JRS4-
infecton levels, whilst no other isogenic mutant was detected to have an effect on IL-6 secretion 
(Figure 17A, B). 5448Δslo did not impact TEpi cell IL-8 secretion, indicating SLO expression may 
specifically affect IL-6 secretion during infection (Figure 17C, D). With the exception of 
5448ΔcepA, which was characterised in Chapter 5, no 5448-isogenic mutant had an effect on TEpi 
cell IL-8 secretion during infection. Cell death during GAS infection was also characterised by LDH 
release at 24 h post-infection. Infection with 5448Δslo and 5448Δsda1 both resulted in a significant 
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decrease in LDH release in comparison to 5448 WT (Figure 17E, F), whilst other isogenic mutants 
induced a similar level of LDH release as 5448 WT. 
 
Figure 17. IL-6 and IL-8 ELISA screen of 5448 isogenic mutants. 
Two screens of 5448 isogenic mutants were performed to measure the IL-6 (A and D) and IL-8 (B 
and E) response by TEpi cells intracellularly infected with GAS strains at 24 h post-infection. Cell 
death was measured as a percentage of LDH released from TEpi cells after 24 h following GAS 
infection (C and F). Data are plotted as the mean ± s.e.m. from three independent experiments and 
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analysed by one-way ANOVA with Tukey’s post-test. Significance is shown relative to mock (stars 
directly above each bar), and between other treatment conditions (indicated by bars). * P < 0.05; ** 
P < 0.01; *** P < 0.001; **** P < 0.0001. 
 
6.3.3 Complementation of 5448Δslo diminishes TEpi IL-6 secretion during 
intracellular infection  
Following the discovery that 5448Δslo restores the IL-6 response of TEpi cells during intracellular 
infection, I hypothesised that SLO activity may be driving the decrease in levels of secreted IL-6 by 
5448-infected TEpi cells. The mechanism by which SLO may achieve this is not yet defined. In order 
to further investigate the impact of SLO expression on IL-6 secretion during intracellular GAS 
infection of TEpi cells, chromosomal complementation of 5448Δslo was performed as described in 
Materials and Methods. Immunoblotting equivalent protein concentrations with anti-SLO sera 
detected JRS4, 5448 and 5448Δslo complemented strains express a strong protein band at 69 kDa, 
which corresponds to the molecular weight of SLO (Figure 18A). Degradation products below 69 
kDa were also observed. SLO expression was not detected for 5448Δslo. Comparison of the genomic 
sequences of JRS4 (312) and 5448 (313) revealed that the slo gene encodes proteins with 99% amino 
acid sequence identity (Supplementary Figure 13).  
 
The levels of IL-6 secreted by TEpi cells following intracellular infection with GAS strains (MOI of 
5) at 6 h and 24 h post-infection was measured by ELISA. At 6 h post-infection, IL-6 secretion was 
not significantly elevated for all infection conditions compared to mock cells (Figure 18B). At 24 h 
post-infection, JRS4 induced a significant increase in levels of secreted IL-6 compared to mock TEpi 
cells, whilst 5448 did not induce an IL-6 response. 5448Δslo induced an IL-6 response similar to 
JRS4 levels, and the complemented 5448Δslo IL-6 response was similar to 5448 WT levels. 5448Δslo 
and complemented 5448Δslo strains had no effect on IL-8 secretion at 6 h and 24 h post-infection 
(Figure 18C). To determine whether the presence or absence of SLO expression impacts the level of 
TEpi cell death, lactate dehydrogenase release was used to quantify cell death following GAS 
intracellular infection. 5448Δslo resulted in a significant decrease in cell death compared to 5448, 
whilst complemented 5448Δslo restored cell death to 5448 levels (Figure 18D).  
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Figure 18. SLO expression is required for dampening IL-6 secretion by TEpi cells during 
intracellular 5448 infection. 
(A) Immunoblotting of GAS supernatants for detection of SLO. Equivalent protein concentrations 
were loaded for 5448, JRS4, 5448Δslo and 5448Δslo complemented (40 µg). GAPDH was included 
as a loading control. (B) IL-6 secretion by TEpi cells following GAS intracellular infection for 6 h 
and 24 h, measured by ELISA. (C) IL-8 secretion by TEpi cells following GAS intracellular infection 
for 6 h and 24 h post-infection, measured by ELISA. (D) Cell death measured by percentage of LDH 
released from TEpi cells at 6 h and 24 h post-infection. For B-D, data are plotted as the mean ± s.e.m. 
and represent three independent experiments performed in triplicate and analysed by two-way 
ANOVA with Tukey’s post-test. Significance between different treatment conditions is indicated by 
bars. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. 
 
This indicates that SLO expression contributes to TEpi cell death induced by 5448 during infection. 
I next quantified SLO activity by measuring red blood cell (RBC) haemolysis by 5448, JRS4, 
5448Δslo and complemented 5448Δslo. 5448ΔsagA, an isogenic mutant for streptolysin S, the second 
haemolysin expressed by GAS was also included as a control for SLS activity, to ensure that the 
haemolysis activity observed was due to SLO activity. 5448, 5448ΔsagA and 5448Δslo 
complemented induced similar levels of RBC haemolysis (60%), whilst JRS4 induced a significantly 
reduced level of haemolysis (<10%) (Figure 19). No haemolysis was observed for 5448Δslo.      
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Figure 19. JRS4 and 5448 GAS strains induce different levels of RBC haemolysis. 
GAS strains 5448, JRS4, 5448Δslo, 5448Δslo complemented and 5448ΔsagA were grown in 
modified RPMI to an OD600 of 0.5, before being incubated with human RBCs for 30 min at 37°C (5 
% CO2). Triton X-100 (final concentration of 1 %) was included as a positive control for 100 % RBC 
lysis. The amount of haemoglobin released into the medium was measured spectrophotometrically at 
405 nm. Data are plotted as the mean ± s.e.m. and represent three independent experiments performed 
in triplicate and analysed by one-way ANOVA with Tukey’s post-test. **** P < 0.0001. 
 
 
6.4 DISCUSSION 
 
Group A streptococcal pharyngitis places a significant burden on global health, with no protective 
vaccine currently available for human use. Despite more than 200 different identified GAS M types, 
GAS pharyngitis is disproportionately caused by the M1T1 strain in high income countries. By 
utilising a primary tonsil epithelial cell model, this study seeks to further understand the innate 
immune responses elicited during intracellular infection with the M1T1 strain at both the gene 
expression and protein level. An improved understanding of the host responses that mediate immunity 
to GAS infection will help facilitate the development of better strategies to combat GAS pharyngitis.  
 
In this chapter I demonstrate that the M1T1 GAS clone (strain 5448) induces a strong IL-6 pro-
inflammatory transcriptional response, yet IL-6 is dampened post-transcriptionally. This lack of IL-
6 response in 5448-infected cells was found to be dependent on the expression of the GAS virulence 
factor and cholesterol-dependent cytolysin (CDC) SLO. Whilst SLO is well characterised to form 
 115 
pores in host cell membranes and induce cell death as a mechanism of immune evasion (163, 339, 
341), CDCs have also been reported to utilise non-lethal mechanisms to dampen the host immune 
response during infection. These include reducing phagocytosis and promoting phagolysosomal 
escape (73, 370), as well as impairing oxidative burst and activation of neutrophils (340). A recent 
study reported that sub-lytic doses of SLO suppresses TNF-α responses of macrophages, which the 
authors hypothesised is due to cell membrane shedding of the TNF-α activation receptors TLR4 and 
IFNγR following SLO challenge (333). Cell death did not account for the attenuation of TNF-α, as 
increased macrophage cytotoxicity did not impair TNF-α production. This suggests that CDCs may 
have the ability to impair pro-inflammatory cytokine production during GAS infection. TNF-α is also 
an agonist of IL-6 production (371), so dampening of TNF-α could also lead to a decrease in the IL-
6 response. TLR4 signalling also leads to IL-6 mRNA expression, thus shedding of TLR4 from the 
cell membrane in response to SLO could also play a role in reducing the IL-6 response during 
infection. A previous study also showed that low concentrations of SLO augments IL-6 responses 
elicited by human vaginal epithelial cells (HVECs) in response to superantigen SPEA (372), 
indicating that SLO may regulate host inflammatory responses to GAS by preventing the recognition 
of highly immunogenic GAS antigens. However, several studies have also reported SLO induces IL-
6 production in HaCaT keratinocytes (325, 373), which suggests this response may be cell type- or 
dose-dependent.   
 
SLO is a highly conserved and ubiquitous virulence factor among GAS strains (374, 375), however 
differing SLO production varies according to GAS M types (376). Amino acid sequence alignment 
of the SLO gene between JRS4 and 5448 strains revealed 99% sequence identity, with one non-
conservative amino acid substitution at the N-terminus, indicating that SLO is highly conserved 
between the two strains. My results show that both JRS4 and 5448 GAS strains express SLO at similar 
levels when grown to mid-log phase in THY and immunoblotted for SLO expression. However, when 
grown in THY the RBC haemolytic ability of 5448 was found to be dependent on SLS activity 
(Supplementary Figure 14). Dr. S. Brouwer previously showed the haemolytic activity of GAS 
grown in chemically defined media is due to SLO expression (unpublished data), therefore this media 
was subsequently utilised. When grown in chemically defined media to mid-log phase, the SLO 
haemolytic ability of JRS4 was significantly lower than the 5448 strain. This suggests that difference 
in haemolytic activity may be due to a difference in SLO protein expression levels between the two 
strains in this media. Reduced SLO production may explain the IL-6 secretion detected during JRS4 
intracellular infection of TEpi cells (Figure 18B). In contrast, 5448 induced a high level of haemolytic 
activity, supporting the hypothesis that 5448 SLO activity is driving the loss of IL-6 secretion during 
TEpi cell infection. The mechanism by which SLO is dampening IL-6 secretion remains to be 
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investigated. Sub-lytic doses of SLO have been shown to dampen levels of the IL-6 agonist TNF- α 
(333), therefore this is one mechanism by which the IL-6 response could be suppressed during GAS 
infection.  
 
Construction of protein-protein interaction networks from the most differentially expressed genes 
during JRS4 and 5448 GAS infection revealed IL-6 to be at the core of these networks. This indicates 
that IL-6 has a large number of interactions with other differentially expressed genes, and likely plays 
a central role in the immune response to GAS infection.  Previous studies have shown GAS infection 
of epithelial cells activates AP-1, NF-κB and MAPK pathways (108, 110), which induce IL-6 gene 
expression. The findings from this study show that both 5448 and JRS4 strains increase the expression 
of inflammatory mediators enriched in the AP-1, ATF-2 and NFAT transcription factor pathways, 
which also induce IL-6 expression (356). In addition, transcription factor motif enrichment identified 
NF-κB and SRF as the drivers of large changes in differential gene expression, with SRF being 
another regulator of IL-6 gene expression. It is likely that IL-6 mRNA expression requires the 
cooperative binding of multiple transcription factors to its promoter in order to inducibly transcribe 
IL-6 during GAS infection, as this has been observed for other bacterial pathogens. During 
Helicobacter pylori infection of gastric epithelial cells, full IL-6 transcription required binding sites 
for NF-κB, cAMP response element (CRE), CCAAT/enhancer binding protein (C/EBP), and AP-1 
(377). In addition, Mycobacterium tuberculosis activation of IL-6 gene transcription in human 
monocytes is mediated by transcription factors NF-IL6 and NF-κB (378). 
 
The impact of these findings has implications in understanding the role of IL-6 during GAS 
pharyngitis. IL-6 is a marker of acute pharyngitis (198) and plays an important role, in combination 
with TGF-β, in promoting Th17 differentiation in murine nasopharyngeal models of pharyngitis (72). 
Current evidence suggests that Th17 cells are central players during GAS pharyngitis and in immune-
related pathologies (123, 124, 264). IL-6 also signals to other immune cell types implicated in GAS 
pharyngitis. For example, IL-6 is a potent growth and maturation factor for B cells that are 
differentiating into antibody-producing plasma cells (379), and aids keratinocyte proliferation and 
cytoskeleton reorganisation (380). IL-6 also inhibits TGF-β-induced Treg differentiation (381), with 
Tregs not typically generated during murine intranasal GAS infection (128, 234). IL-6 therefore has 
both pro-inflammatory and immune regulatory functions, the dysregulation of which can lead to the 
development of various diseases. In light of previous studies, my results suggest that IL-6 secretion 
by epithelial cells likely plays an important role in orchestrating the host immune response during 
GAS pharyngitis and dampening of host IL-6 responses by SLO likely has a widespread impact on 
host immune responses during GAS infection. 
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In summary, I have shown that during intracellular infection of primary human tonsil epithelial cells 
with the M1T1 strain 5448, a number of different signalling pathways which induce IL-6 gene mRNA 
expression are activated. The subsequent dampening of IL-6 secretion is driven by the activity of the 
GAS cholesterol-dependent cytolysin SLO. Dysregulation of this pleiotropic cytokine which plays a 
key role in orchestrating host inflammatory responses during infection likely has a significant impact 
on the outcome of infection. This is a novel mechanism by which a CDC modulates the host 
inflammatory response and supports the hypothesis that the success of the M1T1 GAS strain in 
causing pharyngitis is due to the numerous mechanisms it employs to evade host inflammatory 
responses during infection.  
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7.0 Conclusions and Future Directions 
 
7.1 Preface  
 
The overarching aim of this thesis was to examine the innate immune responses engaged by M1T1 
during infection of primary human tonsil epithelial cells, in order to further understand the host 
responses elicited during GAS pharyngitis. In pursuing this objective, I gained insights into the ability 
of M1T1 to post-transcriptionally modulate host immune responses. My findings reinforce the idea 
that the success of the M1T1 clone is due to its ability to subvert host inflammatory mediators to 
benefit infection. Using innovative approaches and a combination of microbiology, immunology and 
bioinformatics techniques, I focused on the ability of M1T1 to modulate host IL-6 and IL-8 responses 
during infection. 
 
My findings show the pathogenic M1T1 strain 5448 induces robust changes in pro-inflammatory 
gene expression following intracellular infection of TEpi cells. 5448 was found to degrade host-
protective neutrophil-recruiting IL-8 by the activity of the GAS serine protease SpyCEP, and the 
secretion of IL-6 by TEpi cells was found to be dampened in response to 5448 SLO activity. These 
findings are potentially novel mechanisms by which GAS modulates host responses during infection. 
The significance of these findings is discussed below, along with questions that now arise for further 
detailed investigation.  
 
7.2 Host proteome and transcriptome during GAS infection 
In chapter 4, immunoblotting was unable to detect activation of classical and alternate NF-κB 
pathways during GAS infection. Therefore, I utilised RNAseq to identify the inflammatory mediators 
and pathways activated by primary tonsil epithelial cells during intracellular infection with the 
laboratory-adapted M6 strain JRS4 and the M1T1 clinical isolate 5448. Differential gene expression 
identified a number of key inflammatory mediators that were significantly increased in expression 
following JRS4 and 5448 infection, including IL-36γ, Prostaglandin-endoperoxide synthase 2, 
CCL20 and TNF-α, and transcription factors from NF-κB (Rel) and AP-1 (FosB), which have 
previously been implicated in the host inflammatory response during GAS infection (105, 110). 
Differential gene expression also revealed a greater number of genes were upregulated than 
downregulated for both GAS strains, and upregulated genes had a higher fold-change in expression 
than downregulated genes.  SWATH-MS was utilised to characterise the host proteome during GAS 
infection. A number of proteins implicated in NF-κB and MAPK pathways were detected, the 
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majority of which were downregulated during 5448 infection. This is in contrast to what was observed 
by RNAseq and suggests that 5448 is able to post-transcriptionally dampen host inflammatory 
responses during infection. Some of the key inflammatory cytokines and transcription factors 
identified by RNAseq are further characterised in chapters 5 and 6.  
 
Experiments to perform in the future which would further clarify the findings from this chapter 
include:  
 
1.) Perform RNA sequencing at multiple MOIs and time-points during infection (ie 2 h, 4 h, 6 h, 12 
h post-infection), to characterise the host transcriptional response at different stages of infection and 
during exposure to different bacterial loads.  
 
2.) Use a more powerful method to quantify host proteome responses during GAS infection, such as 
LC-MS2/MS3 mass spectrometry, which tags peptides with stable isotope labelled reagents (382).  
 
3.) Utilise primary tonsil epithelial cells from multiple donors to perform RNA sequencing during 
infection, to determine the differences and similarities between the inflammatory transcriptional 
responses of different individuals.  
 
4.) In these experiments, a monolayer of TEpi cells cultured on plastic were utilised to study the 
responses of these cells to GAS infection. However, as the epithelial cells that comprise the tonsil 
surface and crypts are multilayered, a better in vitro model would be to grow these cells in a collagen 
gel or semi-solid growth medium and allow them to form a multi-layered epithelium, as described by 
Gursoy et al. (383). Other epithelium-associated cell types could also be added to the model, to study 
the responses of multiple cell types during infection. As cross-talk occurs between different cell types 
during infection, the presence of other immune cell types may enhance the way the epithelium 
responds to bacterial infection.  
 
5.) Perform a multiplex ELISA to measure all differentially expressed cytokines and chemokines at 
the protein level. 
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7.2 M1T1 expression of SpyCEP dampens IL-8 secretion during 
intracellular infection  
 
From the RNAseq data in Chapter 4, I discovered IL-8 was one of the most differentially expressed 
inflammatory mediators in response to either JRS4 or 5448 infection. To investigate this phenotype, 
I performed further analyses of the RNAseq data from chapter 4. Pathway analysis revealed 
differentially expressed genes by both JRS4- or 5448-infected TEpi cells, were enriched in 
transcription factor networks that regulate IL-8 expression, such as AP-1, ATF-2 and NFAT. Whilst 
JRS4 infection resulted in high levels of secreted IL-8, 5448 infection did not, suggesting that 5448 
may post-transcriptionally dampen IL-8 production. Infection with 5448ΔcepA, an isogenic mutant 
lacking the IL-8 protease SpyCEP, resulted in IL-8 secretion levels comparable to JRS4 infection. 
Complementation of 5448ΔcepA and JRS4 with a plasmid encoding 5448-derived SpyCEP 
significantly reduced IL-8 secretion by TEpi cells. My results suggest that intracellular infection with 
the pathogenic GAS M1T1 clone induces a strong pro-inflammatory response in primary tonsil 
epithelial cells but modulates this host response by selectively degrading the neutrophil-recruiting 
chemokine IL-8 to benefit infection. 
 
This is the first study to characterise the transcriptome of primary human tonsil epithelial cells in 
response to intracellular GAS infection. The GAS strains I utilised are well described in current 
literature: 5448 is an M1T1 clinical isolate from a case of necrotising fasciitis (270), and JRS4 a 
model laboratory strain (271). My hypothesis was that the host response elicited by a clinical GAS 
isolate would be different to the response induced by a standard laboratory strain. The magnitude of 
transcriptional responses induced by 5448 were found to be much higher than in response to the JRS4 
strain, that at an arbitrary cut-off for differential gene expression (>1 log2 fold change), more than 10 
times more genes were differentially expressed in response to 5448 infection than in response JRS4 
infection. The driving force behind the robust transcriptional responses during 5448 infection, or the 
weak transcriptional response to JRS4, is unclear. Intracellular survival and invasion rates of both 
strains were subsequently investigated; however, no difference was detected between the two strains.  
 
Protein-protein interaction networks and pathway analysis were used to understand the pathways, 
transcription factors and clusters of interacting genes that drive TEpi cell inflammatory responses 
during infection. The protein-protein interaction network constructed from the top 100 differentially 
expressed genes by 5448-infected TEpi cells had fewer nodes and interactions than the network for 
JRS4-infected TEpi cells. This was due to a number of non-coding RNAs that were differentially 
expressed in response to 5448-infection, and therefore were excluded from the network. The role of 
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these non-coding RNAs was not investigated, and the role of non-coding RNAs in regulating gene 
expression during GAS infection is not known. Non-coding RNAs have been reported to play an 
important role in regulating host defence mechanisms of the gastric epithelium during H. pylori 
infection (384), therefore this could be an interesting avenue of research to investigate in the future.  
 
RNAseq detected the activation of inflammatory pathways leading to inducible IL8 expression during 
infection with either 5448 or JRS4 strains, with IL8 expression confirmed by qPCR. However, when 
IL-8 secretion was measured by ELISA, 5448 infection was found to suppress the levels of secreted 
IL-8, whilst JRS4 infection did not. SpyCEP, the IL-8 degrading cysteine protease, was shown to 
dampen IL-8 secretion during 5448 infection, by utilising 5448ΔcepA knockout and 5448ΔcepA 
(pDCermcepA) complemented strains. 5448-derived SpyCEP was also introduced into JRS4, and 
significantly reduced the IL-8 response of TEpi cells. However, the driving factor behind why 5448-
derived SpyCEP results in IL-8 cleavage but JRS4-derived SpyCEP does not, has not been defined. 
Possible explanations include a difference in SpyCEP activities levels, or a difference in SpyCEP 
expression during infection. SpyCEP amino acid sequence alignment revealed a number of non-
conservative changes exist in the N-terminus region of JRS4-derived SpyCEP, which may interfere 
with SpyCEP activation (by auto-catalytic cleavage), or by interfering with IL-8 cleavage ability. The 
crystal structure of SpyCEP has not been solved, therefore I cannot determine where in the protein 
structure these non-conservative changes map to. SpyCEP expression levels in THY broth were found 
to be similar between strains, however whether the expression levels remain similar during 
intracellular infection of TEpi cells remains to be investigated. To further support the hypothesis that 
SpyCEP expressed by JRS4 and 5448 contain different activity levels, GAS strains grown to OD600 
of 0.5 in THY broth were incubated with recombinant IL-8, and IL-8 degradation measured over a 
time course revealed that 5448 was able to degrade IL-8 more efficiently than JRS4. No IL-8 
degradation was observed following incubation with 5448ΔcepA, and enhanced IL-8 degradation was 
observed for the complemented strains 5448ΔcepA (pDCermcepA) and JRS4 (pDCermcepA) which 
expressed high levels of SpyCEP, indicating that SpyCEP expression is responsible for the IL-8 
degradation observed.  
 
This study has shown that 5448 intracellular infection dampens IL-8 secretion of TEpi cells, however 
the cellular location where SpyCEP encounters IL-8 is unknown. IL-8 secretory pathways are not 
well characterised in epithelial cells; however, the current understanding is that intracellular IL-8 is 
trafficked in secretory vesicles (315). Therefore, whether GAS dysregulates these vesicles to gain 
access to IL-8 intracellularly remains to investigated. It is also plausible that SpyCEP, which is cell 
wall-anchored in JRS4 and 5448 strains, is secreted from the cell wall during infection. Extracellular 
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release of SpyCEP during infection into the culture media could also contribute to the IL-8 
degradation observed.  
 
Whilst this study has identified a potentially novel role of SpyCEP in dampening IL-8 secretion 
during intracellular infection, there are a number of experiments which would aid in clarifying this 
phenotype: 
 
1.) Perform RNAseq and proteomics analysis of 5448 and JRS4 GAS strains grown in chemically 
defined media. This would determine the differences in expression profiles between the two strains 
that may be driving the difference in the magnitude of TEpi cell transcriptional responses observed.  
 
2.) Perform RNAseq of 5448 and JRS4 GAS strains during intracellular infection of TEpi cells. This 
would elucidate the entire repertoire of GAS genes and virulence factors which are differentially 
expressed during infection.   
 
4.) Purify SpyCEP from 5448 and JRS4 strains, and compare IL-8 proteolytic activity, to determine 
if SpyCEP expressed by these strains has a difference in activity levels. 
 
5.) Perform qPCR of SpyCEP from JRS4 and 5448 infected TEpi cells, to determine if there is a 
difference in SpyCEP expression levels between the two strains during intracellular infection.  
 
6.) Clone cepA gene of JRS4 and introduce intra-chromosomally into 5448ΔcepA, and measure IL-8 
secretion during TEpi cell infection. If 5448ΔcepA expressing JRS4-derived SpyCEP induces the 
same IL-8 response as JRS4, this would confirm the difference in IL-8 secretion induced by the two 
strains is dependent on a difference in the SpyCEP expressed.  
 
7.) Clone SpyCEP with a fluorescent tag (ie GFP, RFP) and introduce into 5448ΔcepA, then perform 
microscopy to determine the intracellular location of SpyCEP during infection of TEpi cells.  
 
8.) Immunofluorescently stain for endogenous IL-8 levels and perform co-localisation analysis 
between fluorescently tagged SpyCEP and IL-8.  
 
9.) Immunofluorescently stain for intracellular compartments including endosomes and trans-golgi 
network and perform co-localisation between these compartments and fluorescently labelled 
SpyCEP. 
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7.3 IL-6 secretion downregulated in response to M1T1 SLO activity  
From the RNAseq data in Chapter 4, I discovered IL-6 was one of the most differentially expressed 
cytokines during JRS4 and 5448 infection compared with mock cells. The transcription factors 
identified in Chapter 5 as regulators of IL-8 expression (AP-1, ATF-2 and NFAT), are also well 
characterised regulators of IL-6 expression (356). Whilst JRS4 infection resulted in the secretion of 
IL-6, 5448 infection did not, suggesting that 5448 may post-transcriptionally dampen IL-6 
production. An isogenic mutant screen discovered infection with 5448Δslo, an isogenic mutant 
lacking the expression of SLO, resulted in IL-6 secretion levels comparable to JRS4 infection. This 
suggested that IL-6 secretion was dependent on SLO expression by 5448, which was further 
demonstrated by chromosomal complementation of 5448Δslo, which restored IL-6 secretion to 5448 
wild type levels. By performing a red blood cell haemolytic activity assay, I demonstrated that 5448 
has significantly greater SLO activity than JRS4, which may be due to a difference in SLO expression 
or secretion between the two strains.  
 
RNAseq detected the activation of inflammatory pathways leading to inducible IL6 expression during 
infection with either 5448 or JRS4 strains, with IL6 expression confirmed by qPCR. However, when 
IL-6 secretion was measured by ELISA, 5448 infection suppressed the levels of secreted IL-6, whilst 
JRS4 infection did not. A mutant screen of 5448 isogenic mutants identified 5448Δslo, an isogenic 
mutant for the the pore forming toxin SLO, resulted in a significant increase in IL-6 secretion during 
infection. The role of SLO in dampening IL-6 responses was confirmed by complementing 5448Δslo. 
However, the driving factor behind why 5448-derived SLO results in a reduced IL-6 response but 
JRS4-derived SLO does not, has not been defined. Possible explanations include a difference in SLO 
activity levels, or a difference in SLO expression during infection. By horizontal gene transfer, M1T1 
GAS has acquired a different promoter that increases SLO and NADase production (385), therefore 
this is likely driving increased SLO production during infection. SLO amino acid sequence alignment 
revealed sequence similarity between the two strains was 99%, with only one non-conservative amino 
acid residue in the N-terminus region of JRS4-derived SLO. This suggests that SLO is highly 
conserved between the two strains and should possess similar activity levels. When both strains were 
grown to mid-log phase in THY broth, western blot detected similar SLO expression levels between 
the two strains. To measure SLO activity, a red blood cell haemolytic activity assay was performed 
on GAS strains grown to mid-log phase in chemically defined media. This assay detected the 
haemolytic ability of JRS4 was significantly lower than the 5448 strain. This result suggests there 
may be a difference in SLO expression levels between the two strains when grown in this media. 
Alternatively, the single amino acid difference is critical for SLO activity. 
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This is the first study to describe M1T1 SLO expression dampening host IL-6 secretion during 
intracellular infection of primary human tonsil epithelial cells. The mechanism by which SLO may 
achieve this has yet to be defined. A recent study by Bhattercharjee and Keyel (333) found sub-lytic 
doses of SLO attenuated TNF-α production in murine macrophages, the suppression of which was 
associated with  SLO-induced membrane shedding of the TNF-α activation receptors TLR4 and 
IFNγR. Attenuated TNF-α production was not accounted for by cell death. This suggests that SLO 
may be capable of utilising mechanisms apart from cell death to dampen host cytokine responses 
during infection. As TNF-α is an agonist for IL-6 production (386), this could also play a role in 
reducing the IL-6 response during GAS infection.  
 
Experiments which would aid in clarifying the role of SLO in dampening the IL-6 response of TEpi 
cells include:   
 
1.) Western blot of SLO protein levels during growth in chemically defined media, to determine if a 
difference in SLO expression levels between JRS4 and 5448 is responsible for the difference in SLO 
activity observed. 
 
2.) Determine what surface proteins/receptors are being shed from TEpi cell membranes in the 
presence of SLO. This could be performed by isolating shed microvesicles and SDS-
PAGE/immunoblotting for different proteins (334).  
 
3.) Fluorescently tag SLO and perform microscopy to determine where SLO localises during 
intracellular infection. The localisation of SLO primarily to the cell membrane would indicate that its 
primary role is altering the abundance of surface receptors that activate inflammatory responses.  
 
4.) Investigate IL6 mRNA expression following 5448 and 5448Δslo infection of TEpi cells, to 
determine whether IL-6 mRNA expression is the same or is enhanced by the 5448Δslo strain. 
 
5.) Investigate the impact of the single non-conservative amino acid substitution present in the JRS4 
slo gene and its impact on SLO activity by integrating it into 5448 slo.  
 
6.) An alternative hypothesis is that SLO is interfering with IL-6 trafficking during infection, resulting 
in a decrease in IL-6 secretion. This could be investigated by:  
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i. Treat cells with brefeldin A to trigger accumulation of IL-6, immunostain for IL-6, then 
quantify total protein levels by flow cytometry. Determine whether there is any difference in 
total protein levels in cells for IL-6 during 5448, JRS4 and 5448Δslo infection. This would 
confirm that the difference in IL-6 secretion is not due to IL-6 degradation, but a dysregulation 
of trafficking. 
ii. Western blot for IL-6 present in cells (if not being secreted, might be abundant in cell lysate). 
iii. Perform immunofluorescence microscopy of IL-6 during GAS infection and determine its 
intracellular location during 5448 vs JRS4 infection, by co-localisation with intracellular 
compartments. If 5448 is dysregulating the trafficking of IL-6, then it may be accumulating 
in the endoplasmic reticulum or trans-golgi network. 
   
7.4 Final remarks 
GAS is the most common cause of bacterial pharyngitis, disproportionately caused by the M1T1 
strain in high income countries. An improved understanding of the host responses that mediate 
immunity to M1T1 infection will help facilitate the development of better strategies to combat GAS 
pharyngitis and prevent the immune complications that can result from infection. Research has 
identified virulence factors and host defence mechanisms involved in GAS infection, however there 
still remains a challenge in identifying the immune responses required to effectively kill and clear 
GAS from the tonsils and pharynx. With the advent of RNA sequencing and mass spectrometry 
techniques which can simultaneously capture the host transcriptome and proteome during infection, 
future work should be aimed at harnessing these technologies to better understand the immune 
responses that occur during infection. The findings presented in this thesis highlight the complexity 
of host-pathogen interactions during GAS pharyngitis. My findings, which are summarised in  Figure 
20, reinforce the idea that the success of the M1T1 clone is due to its ability to modulate host 
inflammatory responses to benefit infection and provides evidence to target SpyCEP and SLO in the 
development of a GAS vaccine.  
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Figure 20. Model of TEpi inflammatory responses during intracellular infection with GAS 
strains JRS4 and 5448. 
During intracellular infection of TEpi cells, the JRS4 GAS strain induces an inflammatory 
transcriptional response which results in the expression and secretion of inflammatory mediators such 
as IL-6 and IL-8. This is hypothesised to induce host-protective responses such as inflammation and 
neutrophil recruitment to the site of infection, which may ultimately result in JRS4 being killed and 
cleared from the tonsils. In contrast, 5448 infection results in an inflammatory transcriptional 
response of a much higher magnitude than JRS4 infection, resulting in the expression of IL-6 and IL-
8. However, 5448 is then able to post-transcriptionally dampen these host responses: the IL-8 
response is dampened by expression of the IL-8 protease SpyCEP, and reduction in the IL-6 response 
was shown to be dependent on SLO expression, by an as yet uncharacterised mechanism. This results 
in reduced IL-6 and IL-8 secretion by TEpi cells in response to 5448 infection. I hypothesise that a 
reduction in inflammatory mediator production may impair host-protective responses during 
infection, ultimately enabling 5448 to survive and establish its niche in the tonsil. The findings of this 
study may help in further elucidating the ability of the globally disseminated M1T1 GAS clone in 
causing GAS pharyngitis.  
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8.0 Supplementary figures 
 
 
Supplementary Figure 1. Growth kinetics of GAS strains used in this study. 
GAS strains JRS4 and 5448 were cultured overnight in THY broth at 37°C, and then diluted to an 
OD600 of 0.05. The bacteria were then grown in a 96-well microplate, and OD600 was measured every 
15 min for 12 h using the FLUOstar Optima (BMG Labtech) plate reader at 37°C. Data represents 
mean ± SEM from 3 independent experiments.  
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Supplementary Figure 2. Expression of the p105/atypical NF-κB pathway components during 
GAS infection. 
(A) TEpi cells were grown to confluent monolayers and infected with GAS strains at an MOI of 1. 
Human TNF-α treatment (30 ng/ml) was included as a positive control, and untreated cells (mock) as 
a negative control. At each time point post-infection, cells were lysed and total protein collected. 
Equivalent protein concentrations of each sample were resolved by SDS-PAGE. GAPDH was 
included as a loading control. (B) Relative fold-change in protein expression was calculated by 
dividing p105 and p50 expression values by GAPDH, before normalising to mock at each time-point.  
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Supplementary Figure 3. MTT assay of GAS infected TEpi cells. 
TEpi cells were grown to confluent monolayers and infected with GAS strains at different 
multiplicities of infection (MOI). Untreated (mock) cells were included as a positive control. At 6 h 
and 24 h post-infection TEpi cell metabolism was quantified by the conversion of MTT to an 
insoluble purple formazan, which was quantified by absorbance measured by spectrophotometer. 
TEpi metabolic activity was calculated by normalising the absorbance values of each condition to 
mock values at each time point. A two-way ANOVA was performed with Tukey’s post-test. Data 
represents mean ±	SEM from 3 independent experiments.  
 
 
 
Supplementary Figure 4. TEpi cell death during intracellular infection with JRS4 or 5448 
GAS strains. 
TEpi cell death during intracellular infection with JRS4 or 5448 GAS strains. Cell death measured as 
percentage of LDH released from TEpi cells after 6 or 24 h following GAS infection. Data are plotted 
as the mean ± s.e.m. and represent three independent experiments performed in triplicate and 
analysed by two-way ANOVA with Tukey’s post-test. Significance shown is relative to mock, unless 
otherwise indicated. * P < 0.05; *** P < 0.001.  
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Supplementary Figure 5. DEAD® staining of GAS infected human tonsil epithelial cells. 
(A) Tonsil epithelial cells were infected with GAS at multiple MOIs. At 6 h and 24 h post-infection 
the TEpi cells were stained with DEAD® fixable green dead cell stain, and TEpi cell nuclei were 
stained with DAPI. Images shown are representative of three independent experiments. Scale bar 
represents 100 µm. (B) Stained nuclei were used to count the total number of cells per image, and 
cell death was measured by calculating the percentage of dead stained cells per image. A two-way 
ANOVA with Tukey’s post-hoc test was performed to detect significance in comparison to mock 
(stars directly above each bar), and between JRS4 and 5448 infected cells (indicated by bars). * 
p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. Data represents mean ±SEM from 3 independent 
experiments. 
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Supplementary Figure 6. Box and whisker plots of RNA sequencing read counts. 
Spread of read counts per gene for each sample from total raw read counts (A), and Log2 normalised 
read counts (B).   
 
 
 
Supplementary Figure 7. Cytokeratin 8/18 immunostaining of TEpi cells. 
TEpi cells were immunofluorescently stained for cytokeratin 8/18 (Cell Signaling, #4546). Imaging 
was performed using an epifluorescent-inverted wide field deconvolution microscope (Australian 
Cancer Research Facility, Institute for Molecular Biosciences, University of Queensland). Images 
were captured at 40x magnification using softWoRx software. Scale bar represents 28 µm.  
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Supplementary Figure 8. The IL-6 and IL-8 responses of TEpi cells from a second human 
donor to GAS infection. 
Tonsil cells (Cat. #2560, Lot no. 7658) were grown to confluent monolayers and infected with GAS 
strains at multiple multiplicities of infection (MOI) as indicated. Human TNF-α treatment (30 ng/ml) 
was included as a positive control, and untreated cells (mock) as a negative control. At 12 and 24 h 
post infection the IL-8 (A, B) and IL-6 (C, D) concentrations were measured by ELISA. Error bars 
are SEM. A two-way ANOVA was performed with Dunnett’s post-hoc test to detect significance in 
comparison to mock. * = P≤0.05, **= P≤0.01. Data presented is the average of 2 independent 
experiments. 
 
 
 
 
Supplementary Figure 9. Invasion rate and intracellular survival of JRS4 and 5448 GAS 
strains during TEpi cell infection. 
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Confluent TEpi cells were infected with either GAS strain at an MOI of 5. (A) Invasion rate was 
measured at each time post-infection by lysing TEpi cells with 0.2 % Triton X-100, before performing 
a colony forming unit (CFU) assay. TEpi cells infected in parallel were washed and treated with 
gentamicin for 2 h, before being lysed and CFU assay performed. The invasion rate was measured by 
dividing the CFU counts of gentamicin treated TEpi cells by non-gentamicin treated wells at each 
time point. (B) Intracellular survival of GAS was measured by infecting confluent TEpi cells with 
either GAS strain for 2 h, before replacing the media with gentamicin-containing media for the 
duration of the experiment. At each time point post-infection, TEpi cells were lysed with 0.2 % Triton 
X-100 and CFU assay performed. Results are representative of three independent experiments.  
 
 
Supplementary Figure 10. RNAseq transcriptome network and pathway enrichment of 5448 
GAS-intracellularly infected primary tonsil epithelial cells in comparison to JRS4-infected 
cells. 
RNAseq transcriptome network and pathway enrichment of 5448 GAS-intracellularly infected 
primary tonsil epithelial cells in comparison to JRS4-infected cells. (A) Protein-protein interaction 
network from the top 100 differentially expressed genes (at an adjusted P value <0.05) for 5448-
intracellularly infected TEpi cells in comparison to JRS4-infected TEpi cells, generated using 
STRINGdb (http://string-db.org/). Network edges show the confidence of interactions, where the line 
thickness indicates the strength of data support. Active interaction sources include textmining, 
experiments, databases, co-expression, neighbourhood, gene fusion and co-occurrence. Minimum 
required interaction score of medium confidence (0.400). Non-protein coding genes and disconnected 
nodes are not shown. Node colour is arbitrary. (B) Pathway over-representation analysis of all 
differentially expressed genes (adjusted P value <0.05, Log2FC >1 or <-1) was performed using 
innatedb.com, for 5448-infected TEpi cells in comparison to JRS4-infected cells. Top 15 up-regulated 
pathways are shown. Green line indicates threshold for significance. Metadata from analysis results 
shown in Supplementary Table 6. 
 
 
 
 
 
 
 
 134 
 
 
 
Supplementary Figure 11. IL6 and IL8 mRNA expression by 5448 and JRS4 GAS-infected 
TEpi cells in comparison to mock cells. 
qRT-PCR of IL6 and IL8 mRNA levels, normalised to housekeeping genes GAPDH (A, B) and 
RPL32 (C, D). Data (mean ± s.e.m.) are combined from four independent experiments performed in 
triplicate and analysed by unpaired, two-way t-test. * P < 0.05, ** P < 0.01, **** P < 0.0001. 
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Supplementary Figure 12. Amino acid sequence alignment between the cepA genes of 5448 
and JRS4. 
The amino acid residues required for serine protease activity are highlighted (red boxes). An asterisk 
(*) indicates positions which have a conserved residue, a colon (:) and green lettering indicates 
conservative amino acid changes, and a period (.) and blue lettering indicates semi-conservative 
changes. Non-conservative changes are indicated by red lettering. 5448 GenBank accession number: 
CP008776, SpyCEP protein ID: AKK70939; JRS4 GenBank accession number: CP011414, SpyCEP 
protein ID: AKI75695. 
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Supplementary Figure 13. Amino acid sequence alignment between the slo genes of 5448 and 
JRS4. 
An asterisk (*) indicates positions which have a conserved residue, a colon (:) and green lettering 
indicates conservative amino acid changes, and a period (.) and blue lettering indicates semi-
conservative changes. Non-conservative changes are indicated by red lettering. 5448 GenBank 
accession number: CP008776, SLO protein ID: AKK69649; JRS4 GenBank accession number: 
CP011414, SLO protein ID: BAR43648. 
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Supplementary Figure 14. RBC haemolysis by GAS grown in THY is dependent on SLS 
expression. 
GAS strains 5448, 5448Δslo, 5448Δslo complemented and 5448ΔsagA were grown in THY to an 
OD600 of 0.5, before being incubated with human RBCs for 30 min at 37°C (5 % CO2). Triton X-100 
(final concentration of 1 %) was included as a positive control for 100 % RBC lysis. The amount of 
haemoglobin released into the medium was measured spectrophotometrically at 405 nm. Data are 
plotted as the mean ± s.e.m. and represent three independent experiments performed in triplicate and 
analysed by one-way ANOVA with Tukey’s post-test. **** P < 0.0001. 
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9.0 Supplementary tables 
 
Supplementary Table 1. Top 100 differentially expressed genes by TEpi cells following 6 h 
intracellular infection with GAS strain 5448. 
Following a group comparison to mock TEpi cells, genes with a significant Log2 fold change (FC) 
of ≥	1 or ≤	-1 and Benjamini–Hochberg adjusted P value (pval) of < 0.05 were considered 
differentially expressed. For each differentially expressed gene, the Log2 fold change for JRS4 
infected TEpi cells is also shown.  
 
Gene symbol Aliases Description Log2 fold 
change 5448 vs 
Mock 
Log2 fold 
change JRS4 
vs Mock 
C11orf96 AG2 chromosome 11 open reading 
frame 96  
6.51 3.32 
RP11-
613D13.8 
    6.15 3.21 
NEURL3 LINCR neuralised homolog 3 
(Drosophila) pseudogene  
5.77   
FOSB AP-1 G0S3 GOS3 GOSB FBJ murine osteosarcoma viral 
oncogene homolog B  
5.41 1.93 
RNA5-8SP2   RNA, 5.8S ribosomal pseudogene 
2  
5.36   
TNF DIF TNF-alpha TNFA 
TNFSF2 
tumor necrosis factor  5.23 2.61 
MIR3687   microRNA 3687  5.03   
MIR3648   microRNA 3648  5.00   
RNA5-8SP6   RNA, 5.8S ribosomal pseudogene 
6  
4.74   
CXCL2 CINC-2a GRO2 GROb 
MGSA-b MIP-2a MIP2 
MIP2A SCYB2 
chemokine (C-X-C motif) ligand 2  4.72 2.90 
IL8 CXCL8 GCP-1 GCP1 LECT 
LUCT LYNAP MDNCF 
MONAP NAF NAP-1 
NAP1 
interleukin 8  4.66 3.06 
ANKRD30BL   ankyrin repeat domain 30B-like  4.57   
ATF3   activating transcription factor 3  4.38 3.30 
GEM KIR GTP binding protein 
overexpressed in skeletal muscle  
4.37 2.42 
RP3-410C9.1     4.36   
EGR2 AT591 CMT1D CMT4E 
KROX20 
early growth response 2  4.34 1.93 
TRPV3 OLMS VRL3 transient receptor potential 
cation channel, subfamily V, 
member 3  
4.29 1.89 
AC058791.1     4.27 1.62 
IL36G IL-1F9 IL-1H1 IL-1RP2 
IL1E IL1F9 IL1H1 IL1RP2 
interleukin 36, gamma  4.09 3.03 
PPP1R15A GADD34 protein phosphatase 1, 
regulatory subunit 15A  
4.06 1.92 
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EGR4 NGFI-C NGFIC PAT133 early growth response 4  3.97   
TNFAIP3 A20 OTUD7C TNFA1P2 tumor necrosis factor, alpha-
induced protein 3  
3.97 2.27 
AC073072.5     3.94 3.14 
TRAF1 EBI6 MGC:10353 TNF receptor-associated factor 1  3.93   
CCL20 CKb4 LARC MIP-3-alpha 
MIP-3a MIP3A SCYA20 
ST38 
chemokine (C-C motif) ligand 20  3.90 1.59 
LIF CDF DIA HILDA MLPLI leukemia inhibitory factor  3.87   
HBEGF DTR DTS DTSF HEGFL heparin-binding EGF-like growth 
factor  
3.87 1.82 
IRF1 IRF-1 MAR interferon regulatory factor 1  3.81   
EGR1 AT225 G0S30 KROX-24 
NGFI-A TIS8 ZIF-268 
ZNF225 
early growth response 1  3.81   
IL6 BSF2 HGF HSF IFNB2 IL-6 interleukin 6 (interferon, beta 2)  3.74 2.85 
PTX3 TNFAIP5 TSG-14 pentraxin 3, long  3.72   
BIRC3 AIP1 API2 CIAP2 HAIP1 
HIAP1 MALT2 MIHC 
RNF49 c-IAP2 
baculoviral IAP repeat containing 
3  
3.69   
OVOL1 HOVO1 ovo-like 1(Drosophila)  3.68 2.93 
NR4A1 GFRP1 HMR N10 NAK-1 
NGFIB NP10 NUR77 TR3 
nuclear receptor subfamily 4, 
group A, member 1  
3.67   
CD83 BL11 HB15 CD83 molecule  3.66   
TM4SF19-AS1   TM4SF19 antisense RNA 1  3.64   
MAFF U-MAF hMafF v-maf musculoaponeurotic 
fibrosarcoma oncogene homolog 
F (avian)  
3.61 1.40 
AC003092.1     3.56 1.11 
RNASE7   ribonuclease, RNase A family, 7  3.52 1.21 
RNF223   ring finger protein 223  3.51   
PTGS2 COX-2 COX2 GRIPGHS 
PGG/HS PGHS-2 PHS-2 
hCox-2 
prostaglandin-endoperoxide 
synthase 2 (prostaglandin G/H 
synthase and cyclooxygenase)  
3.47 3.21 
CLDN4   claudin 4  3.42 2.74 
NR4A3 CHN CSMF MINOR NOR1 
TEC 
nuclear receptor subfamily 4, 
group A, member 3  
3.40   
IL1RL1 DER4 FIT-1 IL33R ST2 
ST2L ST2V T1 
interleukin 1 receptor-like 1  3.40 2.28 
GS1-600G8.5     3.33   
CSRNP1 AXUD1 CSRNP-1 
FAM130B TAIP-3 URAX1 
cysteine-serine-rich nuclear 
protein 1  
3.31 1.43 
STX11 FHL4 HLH4 HPLH4 syntaxin 11  3.30   
EGR3 EGR-3 PILOT early growth response 3  3.28 1.50 
GADD45B GADD45BETA MYD118 growth arrest and DNA-damage-
inducible, beta  
3.28 1.45 
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SOCS3 ATOD4 CIS3 Cish3 SOCS-
3 SSI-3 SSI3 
suppressor of cytokine signaling 3  3.28 1.83 
ZNF460 HZF8 ZNF272 zinc finger protein 460  3.26   
RP11-770G2.5     3.25 2.87 
RP11-
525A16.4 
    3.23 1.71 
INSIG1 CL-6 CL6 insulin induced gene 1  3.22 1.70 
DUSP8 C11orf81 HB5 HVH-5 
HVH8 
dual specificity phosphatase 8  3.17   
CLCF1 BSF-3 BSF3 CISS2 CLC 
NNT-1 NNT1 NR6 
cardiotrophin-like cytokine factor 
1  
3.15 2.32 
DUSP5 DUSP HVH3 dual specificity phosphatase 5  3.14 1.91 
SEMA7A CD108 CDw108 H-
SEMA-K1 H-Sema-L JMH 
SEMAK1 SEMAL 
semaphorin 7A, GPI membrane 
anchor (John Milton Hagen blood 
group)  
3.10 1.67 
CCRN4L CCR4L NOC CCR4 carbon catabolite 
repression 4-like (S. cerevisiae)  
3.03 1.16 
DLX2 TES-1 TES1 distal-less homeobox 2  3.03 2.14 
AL161668.12     2.99 1.20 
CSF2 GMCSF colony stimulating factor 2 
(granulocyte-macrophage)  
2.97   
NFKBIE IKBE nuclear factor of kappa light 
polypeptide gene enhancer in B-
cells inhibitor, epsilon  
2.95   
ARID3B BDP DRIL2 AT rich interactive domain 3B 
(BRIGHT-like)  
2.91 1.43 
RND1 ARHS RHO6 RHOS Rho family GTPase 1  2.91 1.69 
RASGEF1B GPIG4 RasGEF domain family, member 
1B  
2.89   
FOSL1 FRA FRA1 fra-1 FOS-like antigen 1  2.89 1.52 
PMAIP1 APR NOXA phorbol-12-myristate-13-acetate-
induced protein 1  
2.87 1.70 
EDN1 ET1 HDLCQ7 PPET1 endothelin 1  2.83 1.35 
BCL2A1 ACC-1 ACC-2 BCL2L5 
BFL1 GRS HBPA1 
BCL2-related protein A1  2.82   
RP5-837I24.1     2.80 1.20 
CTD-2027G2.1     2.80   
CXCL3 CINC-2b GRO3 GROg 
MIP-2b MIP2B SCYB3 
chemokine (C-X-C motif) ligand 3  2.78 2.29 
C3orf52 TTMP chromosome 3 open reading 
frame 52  
2.75 1.43 
ARL5B ARL8 ADP-ribosylation factor-like 5B  2.74   
FOSL1P1   FOS-like antigen 1 pseudogene 1  2.74   
PRSS22 BSSP-4 hBSSP-4 protease, serine, 22  2.73 1.20 
BBC3 JFY-1 JFY1 PUMA BCL2 binding component 3  2.71   
CREBRF C5orf41 LRF CREB3 regulatory factor  2.70   
NRARP   NOTCH-regulated ankyrin repeat 
protein  
2.67   
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LCE1F LEP6 late cornified envelope 1F  2.62 1.05 
SERPINB2 HsT1201 PAI PAI-2 PAI2 
PLANH2 
serpin peptidase inhibitor, clade 
B (ovalbumin), member 2  
2.58 2.45 
ZNF750 ZFP750 zinc finger protein 750  2.58 1.90 
PLAUR CD87 U-PAR UPAR URKR plasminogen activator, urokinase 
receptor  
2.57 1.77 
ABL2 ABLL ARG v-abl Abelson murine leukemia 
viral oncogene homolog 2  
2.55 1.32 
SERPINB10 PI-10 PI10 serpin peptidase inhibitor, clade 
B (ovalbumin), member 10  
2.54 2.42 
SLC25A25 MCSC PCSCL RP11-
395P17.4 SCAMC-2 
solute carrier family 25 
(mitochondrial carrier; 
phosphate carrier), member 25  
2.54 1.13 
DLC1 ARHGAP7 HP STARD12 
p122-RhoGAP 
deleted in liver cancer 1  2.53   
FAIM3 FCMR TOSO Fas apoptotic inhibitory molecule 
3  
2.52   
RP11-
123M6.2 
    2.52   
ZFP36 G0S24 GOS24 NUP475 
RNF162A TIS11 TTP zfp-
36 
zinc finger protein 36, C3H type, 
homolog (mouse)  
2.52 1.74 
IL24 C49A FISP IL10B MDA7 
MOB5 ST16 
interleukin 24  2.48 2.01 
CCNL1 ANIA6A PRO1073 ania-
6a 
cyclin L1  2.48 1.04 
RND3 ARHE Rho8 RhoE memB Rho family GTPase 3  2.48 1.30 
PARD6B PAR6B par-6 partitioning defective 6 
homolog beta (C. elegans)  
2.46   
CKS2 CKSHS2 CDC28 protein kinase regulatory 
subunit 2  
2.46   
PRDM1 BLIMP1 PRDI-BF1 PR domain containing 1, with ZNF 
domain  
2.45 1.83 
PIM1 PIM pim-1 oncogene  2.45 1.93 
MCTP1   multiple C2 domains, 
transmembrane 1  
2.44   
FDXACB1   ferredoxin-fold anticodon binding 
domain containing 1  
-2.54   
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Supplementary Table 2. Top 100 differentially expressed genes by TEpi cells following 6 h 
intracellular infection with GAS strain JRS4. 
Following a group comparison to mock TEpi cells, genes with a significant Log2 fold change (FC) 
of ≥	1 or ≤	-1 and Benjamini–Hochberg adjusted P value (pval) of < 0.05 were considered 
differentially expressed. For each differentially expressed gene, the Log2 fold change for 5448 
infected TEpi cells is also shown.  
 
Gene symbol Aliases Description log2 Fold 
change JRS4 vs 
Mock 
log2 Fold 
change 5448 
vs Mock 
C11orf96 AG2 chromosome 11 open reading 
frame 96  
3.32 6.51 
ATF3   activating transcription factor 3  3.30 4.38 
RP11-
613D13.8 
    3.21 6.15 
PTGS2 COX-2 COX2 GRIPGHS 
PGG/HS PGHS-2 PHS-2 
hCox-2 
prostaglandin-endoperoxide 
synthase 2 (prostaglandin G/H 
synthase and cyclooxygenase)  
3.21 3.47 
AC073072.5     3.14 3.94 
IL8 CXCL8 GCP-1 GCP1 
LECT LUCT LYNAP 
MDNCF MONAP NAF 
NAP-1 NAP1 
interleukin 8  3.06 4.66 
IL36G IL-1F9 IL-1H1 IL-1RP2 
IL1E IL1F9 IL1H1 IL1RP2 
interleukin 36, gamma  3.03 4.09 
OVOL1 HOVO1 ovo-like 1(Drosophila)  2.93 3.68 
CXCL2 CINC-2a GRO2 GROb 
MGSA-b MIP-2a MIP2 
MIP2A SCYB2 
chemokine (C-X-C motif) ligand 2  2.90 4.72 
RP11-770G2.5     2.87 3.25 
IL6 BSF2 HGF HSF IFNB2 IL-
6 
interleukin 6 (interferon, beta 2)  2.85 3.74 
CLDN4   claudin 4  2.74 3.42 
TNF DIF TNF-alpha TNFA 
TNFSF2 
tumor necrosis factor  2.61 5.23 
SERPINB2 HsT1201 PAI PAI-2 PAI2 
PLANH2 
serpin peptidase inhibitor, clade 
B (ovalbumin), member 2  
2.45 2.58 
SERPINB10 PI-10 PI10 serpin peptidase inhibitor, clade 
B (ovalbumin), member 10  
2.42 2.54 
GEM KIR GTP binding protein 
overexpressed in skeletal muscle  
2.42 4.37 
MMP3 CHDS6 MMP-3 SL-1 
STMY STMY1 STR1 
matrix metallopeptidase 3 
(stromelysin 1, progelatinase)  
2.34 2.42 
CLCF1 BSF-3 BSF3 CISS2 CLC 
NNT-1 NNT1 NR6 
cardiotrophin-like cytokine factor 
1  
2.32 3.15 
CXCL3 CINC-2b GRO3 GROg 
MIP-2b MIP2B SCYB3 
chemokine (C-X-C motif) ligand 3  2.29 2.78 
IL1RL1 DER4 FIT-1 IL33R ST2 
ST2L ST2V T1 
interleukin 1 receptor-like 1  2.28 3.40 
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TNFAIP3 A20 OTUD7C TNFA1P2 tumor necrosis factor, alpha-
induced protein 3  
2.27 3.97 
DUSP1 CL100 HVH1 MKP-1 
MKP1 PTPN10 
dual specificity phosphatase 1  2.14 2.28 
DLX2 TES-1 TES1 distal-less homeobox 2  2.14 3.03 
KRTAP2-3 KAP2.3 KRTAP2.3 keratin associated protein 2-3  2.05 1.91 
IL24 C49A FISP IL10B MDA7 
MOB5 ST16 
interleukin 24  2.01 2.48 
OCLN   occludin  2.00 2.34 
HS3ST1 3OST 3OST1 heparan sulfate (glucosamine) 3-
O-sulfotransferase 1  
1.96 1.81 
ZSCAN12P1 ZNF187p1 ZNF305P1 
ZNF96L1 ZNF96P1 
ZSCAN12L1 dJ313I6.7 
zinc finger and SCAN domain 
containing 12 pseudogene 1  
1.93   
PIM1 PIM pim-1 oncogene  1.93 2.45 
EGR2 AT591 CMT1D CMT4E 
KROX20 
early growth response 2  1.93 4.34 
FOSB AP-1 G0S3 GOS3 GOSB FBJ murine osteosarcoma viral 
oncogene homolog B  
1.93 5.41 
PPP1R15A GADD34 protein phosphatase 1, 
regulatory subunit 15A  
1.92 4.06 
DUSP5 DUSP HVH3 dual specificity phosphatase 5  1.91 3.14 
TMCC3   transmembrane and coiled-coil 
domain family 3  
1.91 1.53 
ZNF750 ZFP750 zinc finger protein 750  1.90 2.58 
TRPV3 OLMS VRL3 transient receptor potential 
cation channel, subfamily V, 
member 3  
1.89 4.29 
SOCS3 ATOD4 CIS3 Cish3 
SOCS-3 SSI-3 SSI3 
suppressor of cytokine signaling 3  1.83 3.28 
PRDM1 BLIMP1 PRDI-BF1 PR domain containing 1, with ZNF 
domain  
1.83 2.45 
METRNL   meteorin, glial cell differentiation 
regulator-like  
1.83 2.12 
HBEGF DTR DTS DTSF HEGFL heparin-binding EGF-like growth 
factor  
1.82 3.87 
PDE4B DPDE4 PDE4B5 PDEIVB phosphodiesterase 4B, cAMP-
specific  
1.81 2.28 
PLAUR CD87 U-PAR UPAR 
URKR 
plasminogen activator, urokinase 
receptor  
1.77 2.57 
CD274 B7-H B7H1 PD-L1 
PDCD1L1 PDCD1LG1 
PDL1 
CD274 molecule  1.77 2.15 
EMP1 CL-20 EMP-1 TMP epithelial membrane protein 1  1.76 1.86 
ZFP36 G0S24 GOS24 NUP475 
RNF162A TIS11 TTP zfp-
36 
zinc finger protein 36, C3H type, 
homolog (mouse)  
1.74 2.52 
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HCAR2 GPR109A HCA2 HM74a 
HM74b NIACR1 
PUMAG Puma-g 
hydroxycarboxylic acid receptor 2  1.73 1.80 
AGPAT9 AGPAT8 GPAT3 LPAAT-
theta MAG1 
1-acylglycerol-3-phosphate O-
acyltransferase 9  
1.71 1.95 
RP11-
525A16.4 
    1.71 3.23 
INSIG1 CL-6 CL6 insulin induced gene 1  1.70 3.22 
PMAIP1 APR NOXA phorbol-12-myristate-13-acetate-
induced protein 1  
1.70 2.87 
RND1 ARHS RHO6 RHOS Rho family GTPase 1  1.69 2.91 
SEMA7A CD108 CDw108 H-
SEMA-K1 H-Sema-L 
JMH SEMAK1 SEMAL 
semaphorin 7A, GPI membrane 
anchor (John Milton Hagen blood 
group)  
1.67 3.10 
LMO7 FBX20 FBXO20 LOMP LIM domain 7  1.66 1.63 
FOXA1 HNF3A TCF3A forkhead box A1  1.65 1.74 
RGS2 G0S8 regulator of G-protein signaling 
2, 24kDa  
1.64 1.61 
AC058791.1     1.62 4.27 
MACC1 7A5 SH3BP4L metastasis associated in colon 
cancer 1  
1.62 1.53 
CLDN1 CLD1 ILVASC SEMP1 claudin 1  1.61 1.08 
CCL20 CKb4 LARC MIP-3-alpha 
MIP-3a MIP3A SCYA20 
ST38 
chemokine (C-C motif) ligand 20  1.59 3.90 
GPRC5A GPCR5A RAI3 RAIG1 G protein-coupled receptor, 
family C, group 5, member A  
1.56 1.15 
SHC4 RaLP SHCD SHC (Src homology 2 domain 
containing) family, member 4  
1.53 1.50 
CXCL1 FSP GRO1 GROa MGSA 
MGSA-a NAP-3 SCYB1 
chemokine (C-X-C motif) ligand 1 
(melanoma growth stimulating 
activity, alpha)  
1.52 1.88 
FOSL1 FRA FRA1 fra-1 FOS-like antigen 1  1.52 2.89 
MMP10 SL-2 STMY2 matrix metallopeptidase 10 
(stromelysin 2)  
1.51   
EGR3 EGR-3 PILOT early growth response 3  1.50 3.28 
VGLL3 VGL-3 VGL3 vestigial like 3 (Drosophila)  1.49 1.58 
IL13RA2 CD213A2 CT19 IL-13R 
IL13BP 
interleukin 13 receptor, alpha 2  1.48 2.03 
GADD45B GADD45BETA MYD118 growth arrest and DNA-damage-
inducible, beta  
1.45 3.28 
SERPINB9 CAP-3 CAP3 PI-9 PI9 serpin peptidase inhibitor, clade 
B (ovalbumin), member 9  
1.45 1.72 
FOXN2 HTLF forkhead box N2  1.45 1.24 
ADAMTS1 C3-C5 METH1 ADAM metallopeptidase with 
thrombospondin type 1 motif, 1  
1.45 1.42 
JUN AP-1 AP1 c-Jun jun proto-oncogene  1.44 1.96 
IL1B IL-1 IL1-BETA IL1F2 interleukin 1, beta  1.44 1.54 
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C3orf52 TTMP chromosome 3 open reading 
frame 52  
1.43 2.75 
ARID3B BDP DRIL2 AT rich interactive domain 3B 
(BRIGHT-like)  
1.43 2.91 
CSRNP1 AXUD1 CSRNP-1 
FAM130B TAIP-3 
URAX1 
cysteine-serine-rich nuclear 
protein 1  
1.43 3.31 
RAPGEF5 GFR MR-GEF REPAC Rap guanine nucleotide exchange 
factor (GEF) 5  
1.42 1.16 
GRHL1 LBP32 MGR NH32 
TFCP2L2 
grainyhead-like 1 (Drosophila)  1.41   
MMP1 CLG CLGN matrix metallopeptidase 1 
(interstitial collagenase)  
1.41 1.18 
WTAPP1   Wilms tumor 1 associated 
protein pseudogene 1  
1.40 1.22 
MAFF U-MAF hMafF v-maf musculoaponeurotic 
fibrosarcoma oncogene homolog 
F (avian)  
1.40 3.61 
LURAP1L C9orf150 bA3L8.2 leucine rich adaptor protein 1-
like  
1.40 1.33 
RP11-665G4.1     1.39 1.95 
CPEB2 CPE-BP2 CPEB-2 hCPEB-
2 
cytoplasmic polyadenylation 
element binding protein 2  
1.38 1.73 
SPRY2 hSPRY2 sprouty homolog 2 (Drosophila)  1.38 1.63 
BMP2 BDA2 BMP2A bone morphogenetic protein 2  1.37 1.99 
DENND2C dJ1156J9.1 DENN/MADD domain containing 
2C  
1.36 1.91 
NRG1 ARIA GGF GGF2 HGL 
HRG HRG1 HRGA 
MST131 NDF SMDF 
neuregulin 1  1.35   
EDN1 ET1 HDLCQ7 PPET1 endothelin 1  1.35 2.83 
ABL2 ABLL ARG v-abl Abelson murine leukemia 
viral oncogene homolog 2  
1.32 2.55 
PELI1   pellino E3 ubiquitin protein ligase 
1  
1.31 2.36 
ADRB2 ADRB2R ADRBR B2AR 
BAR BETA2AR 
adrenoceptor beta 2, surface  1.31 2.02 
RND3 ARHE Rho8 RhoE 
memB 
Rho family GTPase 3  1.30 2.48 
HAS2   hyaluronan synthase 2  1.30   
ADAMTS6 ADAM-TS 6 ADAM-TS6 
ADAMTS-6 
ADAM metallopeptidase with 
thrombospondin type 1 motif, 6  
1.26   
RASA2 GAP1M RAS p21 protein activator 2  1.26 1.40 
NLRP10 CLR11.1 NALP10 NOD8 
PAN5 PYNOD 
NLR family, pyrin domain 
containing 10  
1.26   
GRHL3 SOM TFCP2L4 grainyhead-like 3 (Drosophila)  1.24   
PRIM1 p49 primase, DNA, polypeptide 1 
(49kDa)  
-1.60 -1.71 
VAV3   vav 3 guanine nucleotide 
exchange factor  
-2.02 -2.16 
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Supplementary Table 3. Differentially expressed proteins detected by SWATH-MS following 
JRS4 and 5448 GAS infection of TEpi cells. 
Proteins with a significant Log2 fold change (Log2 FC) of  ≥	0.5 or ≤	-0.5 and an adjusted P value of 
< 0.01 for each group comparison are listed. Protein molecular function/ biological process was 
annotated using www.uniprot.org. Proteins with an immune function are in yellow, proteins with 
functions in metabolism are in green, proteins involved in protein translation are in blue, proteins 
involved in cell structure and trafficking pathways are in red, proteins with other functions are in 
grey. 
 
Uniprot 
accession Uniprot ID 
Gene 
symbol Protein name 
Molecular 
function/ 
Biological process  
log2FC 
5448 
vs 
Mock 
log2FC 
JRS4 
vs 
Mock 
log2FC 
5448 
vs 
JRS4 
P62140 PP1B_HUMAN PPP1CB 
Serine/threonine-protein 
phosphatase PP1-beta 
catalytic subunit 
Protein 
phosphatase, 
hydrolase, 
glycogen 
metabolism, cell 
cycle and division, 
inhibits Treg 
activity 
2.42 1.5 0.92 
P28070 PSB4_HUMAN PSMB4 Proteasome subunit beta type-4 
Protease, host-
virus interaction, 
processing of class 
I MHC peptides, 
NF-kB and MAPK 
signalling 
1.29 1.03   
Q9UMD9 COHA1_HUMAN COL17A1 Collagen alpha-1(XVII) chain 
cell-matrix 
adhesion, 
regulates 
interactions 
between lymphoid 
and non-lymphoid 
cells, is the target 
of IgA 
autoantibodies 
during bullous 
dermatosis 
0.71 0.94   
Q13200 PSMD2_HUMAN PSMD2 
26S proteasome non-
ATPase regulatory subunit 
2 
involved in 
degradation of 
ubiquitinated 
proteins, various 
biological 
processes 
including NF-kB 
signalling and 
MAPK cascade 
0.66     
Q15008 PSMD6_HUMAN PSMD6 
26S proteasome non-
ATPase regulatory subunit 
6 
regulates protein 
degradation, 
various biological 
processes 
including NF-kB 
signalling and 
MAPK cascade 
0.56     
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P04083 ANXA1_HUMAN ANXA1 Annexin A1 
Phospholipase A2 
inhibitor, plays 
important roles in 
immune response 
including 
prostaglandin 
biosynthesis, IL-1 
production, 
negative 
regulation of IL-8 
secretion 
-0.55   -0.6 
P05109 S10A8_HUMAN S100A8 Protein S100-A8 
calcium and zinc 
ion binding, TLR4 
binding, regulation 
of  immune 
responses 
including 
regulation of NF-
kB activity 
-0.78   -0.86 
P01040 CYTA_HUMAN CSTA Cystatin-A 
protease inhibitor, 
cell adhesion, 
regulates IL-8 
production 
associated with 
atopic dermatitis 
-0.93   -1.08 
P00441 SODC_HUMAN SOD1 Superoxide dismutase [Cu-Zn] 
antioxidant, 
various functions 
including 
activation of 
MAPK activity 
-1.23   -0.95 
P04080 CYTB_HUMAN CSTB Cystatin-B 
protease inhibitor, 
role in innate 
immune response 
-1.31   -1.08 
Q13561 DCTN2_HUMAN DCTN2 Dynactin subunit 2 
protein kinase 
binding, MHC 
class II antigen 
presentation 
-1.56 -2.73 1.17 
P08779 K1C16_HUMAN KRT16 Keratin, type I cytoskeletal 16 
structural 
constituent of 
cytoskeleton, 
regulator of innate 
immunity in 
response to skin 
barrier breach 
  0.55 -0.54 
Q02750 MP2K1_HUMAN MAP2K1 
Dual specificity mitogen-
activated protein kinase 
kinase 1 
Kinase, immune 
functions 
including 
activation of 
MAPK 
  0.94 -0.78 
Q16401 PSMD5_HUMAN PSMD5 
26S proteasome non-
ATPase regulatory subunit 
5 
Chaperone 
protein, various 
immune functions 
  1.48 -1.56 
P06702 S10A9_HUMAN S100A9 Protein S100-A9 
antimicrobial, 
TLR4 binding,  
roles in innate 
immune response 
    -0.71 
P30086 PEBP1_HUMAN PEBP1 Phosphatidylethanolamine-binding protein 1 
Protease inhibitor, 
MAPK activation     -0.52 
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P04792 HSPB1_HUMAN HSPB1 Heat shock protein beta-1 
chaperone, stress 
response, 
regulation of NF-
kB signalling 
    -0.55 
P42126 ECI1_HUMAN ECI1 Enoyl-CoA delta isomerase 1, mitochondrial 
Isomerase, fatty 
acid metabolism 
and lipid 
metabolism 
1.39 1.15   
P05091 ALDH2_HUMAN ALDH2 Aldehyde dehydrogenase, mitochondrial 
oxidoreductase, 
carbohydrate and 
ethanol 
metabolism 
1.31 1.37   
P22102 PUR2_HUMAN GART 
Trifunctional purine 
biosynthetic protein 
adenosine-3 
multifunctional 
enzyme, purine 
biosynthesis 
0.78 1.16   
Q02978 M2OM_HUMAN SLC25A11 
Mitochondrial 2-
oxoglutarate/malate carrier 
protein 
mitochondrial 
transport, plays 
role in several 
metabolic 
processes 
  0.87 -0.69 
Q01469 FABP5_HUMAN FABP5 Fatty acid-binding protein, epidermal 
fatty acid binding, 
lipid metabolism -0.61   -0.75 
P19367 HXK1_HUMAN HK1 Hexokinase-1 
kinase involved in 
hexose 
metabolism, 
glycolysis 
-0.72   -0.77 
Q9H299 SH3L3_HUMAN SH3BGRL3 
SH3 domain-binding 
glutamic acid-rich-like 
protein 3 
electron transfer 
activity, cell redox 
homeostasis 
-0.73   -0.73 
P30837 AL1B1_HUMAN ALDH1B1 Aldehyde dehydrogenase X, mitochondrial 
oxidoreductase, 
carbohydrate and 
ethanol 
metabolism 
-0.78 -0.89   
O95573 ACSL3_HUMAN ACSL3 Long-chain-fatty-acid--CoA ligase 3 
ligase, fatty acid 
metabolism -0.97 -0.91   
P12277 KCRB_HUMAN CKB Creatine kinase B-type kinase, creatine metabolism -1.23   -1.23 
P35613 BASI_HUMAN BSG Basigin 
blood group 
antigen, pyruvate 
metabolism 
-1.27   -1.25 
Q04760 LGUL_HUMAN GLO1 Lactoylglutathione lyase lyase, pyruvate metabolism -1.4 -2.49 1.09 
O00764 PDXK_HUMAN PDXK Pyridoxal kinase 
kinase, pyridoxal 
phosphate 
biosynthesis 
-1.7   -2 
Q02218 ODO1_HUMAN OGDH 
2-oxoglutarate 
dehydrogenase, 
mitochondrial 
oxidoreductase, 
glycolysis     -0.51 
O75390 CISY_HUMAN CS Citrate synthase, mitochondrial 
transferase, 
tricarboxylic acid 
cycle 
    -0.67 
Q13347 EIF3I_HUMAN EIF3I Eukaryotic translation initiation factor 3 subunit I 
translation 
Initiation factor, 
protein 
biosynthesis 
1.33   0.91 
 149 
P47914 RL29_HUMAN RPL29 60S ribosomal protein L29 ribosomal protein, protein translation 1.29   1.86 
P04844 RPN2_HUMAN RPN2 
Dolichyl-
diphosphooligosaccharide-
-protein 
glycosyltransferase subunit 
2 
ribosome binding, 
protein 
glycosylation  
1.14 0.7   
P20042 IF2B_HUMAN EIF2S2 Eukaryotic translation initiation factor 2 subunit 2 
translation 
initiation factor, 
protein 
biosynthesis 
0.88     
O43809 CPSF5_HUMAN NUDT21 
Cleavage and 
polyadenylation specificity 
factor subunit 5 
RNA binding, 
mRNA processing 0.71   0.56 
P07814 SYEP_HUMAN EPRS 
Bifunctional 
glutamate/proline--tRNA 
ligase 
RNA binding, 
translation 
regulation 
0.58     
P42704 LPPRC_HUMAN LRPPRC 
Leucine-rich PPR motif-
containing protein, 
mitochondrial 
RNA binding, 
mRNA 
transcription 
regulation 
0.58     
Q8NC51 PAIRB_HUMAN SERBP1 
Plasminogen activator 
inhibitor 1 RNA-binding 
protein 
RNA binding, 
regulates mRNA 
stability 
0.53 0.5   
P41250 SYG_HUMAN GARS Glycine--tRNA ligase 
ATP binding, 
protein 
biosynthesis 
0.53     
P32969 RL9_HUMAN RPL9 60S ribosomal protein L9 RNA binding, translation  -0.54   -0.52 
P62829 RL23_HUMAN RPL23 60S ribosomal protein L23 
Ribosomal 
protein, translation 
initiation 
-0.57     
Q13155 AIMP2_HUMAN AIMP2 
Aminoacyl tRNA synthase 
complex-interacting 
multifunctional protein 2 
Developmental 
protein, protein 
biosynthesis, 
apoptosis and 
differentiation 
-0.6   0.75 
P62269 RS18_HUMAN RPS18 40S ribosomal protein S18 RNA binding, translation -1.18 -0.72   
O43143 DHX15_HUMAN DHX15 
Pre-mRNA-splicing factor 
ATP-dependent RNA 
helicase DHX15 
Helicase, mRNA 
processing   1 -0.78 
P12081 SYHC_HUMAN HARS Histidine--tRNA ligase, cytoplasmic 
Ligase, protein 
biosynthesis   -1.8   
O75643 U520_HUMAN SNRNP200 
U5 small nuclear 
ribonucleoprotein 200 kDa 
helicase 
hydrolase, mRNA 
processing     -1.58 
E9PAV3 NACAM_HUMAN NACA 
Nascent polypeptide-
associated complex 
subunit alpha 
DNA binding, 
transcription 
regulation 
    -0.73 
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P17655 CAN2_HUMAN CAPN2 Calpain-2 catalytic subunit 
protease, involved 
in cytoskeletal 
remodelling and 
signal transduction 
0.91 0.78   
Q6P3W7 SCYL2_HUMAN SCYL2 SCY1-like protein 2 
component of 
clathrin coated 
structures, may 
regulate 
trafficking 
between transgolgi 
network and/or 
endosomal system 
0.83 0.76   
Q6DD88 ATLA3_HUMAN ATL3 Atlastin-3 
hydrolase, 
regulates golgi and 
endoplasmic 
reticulum 
organisation 
0.76   0.67 
O00629 IMA3_HUMAN KPNA4 Importin subunit alpha-3 nuclear protein import 0.71     
P53367 ARFP1_HUMAN ARFIP1 Arfaptin-1 
cadherin binding, 
intracellular 
protein transport 
and secretion 
0.71     
P31949 S10AB_HUMAN S100A11 Protein S100-A11 
cell-cell adhesion, 
differentiation and 
cornification of 
keratinocytes 
-0.51   -0.62 
P04259 K2C6B_HUMAN KRT6B Keratin, type II cytoskeletal 6B 
structure of 
cytoskeleton, 
keratinisation 
-0.85 -0.73   
P22528 SPR1B_HUMAN SPRR1B Cornifin-B 
peptide cross-
linking, 
keratinisation 
-1.05   -1.28 
Q9Y4L1 HYOU1_HUMAN HYOU1 Hypoxia up-regulated protein 1 
chaperone, stress 
response -1.06 0.73 -1.79 
P35221 CTNA1_HUMAN CTNNA1 Catenin alpha-1 
actin filament 
binding, cell 
adhesion 
-1.26 -0.91   
Q02790 FKBP4_HUMAN FKBP4 Peptidyl-prolyl cis-trans isomerase FKBP4 
Chaperone, 
regulation of 
microtubule 
dynamics 
  -0.63 0.62 
P43487 RANG_HUMAN RANBP1 Ran-specific GTPase-activating protein 
GTPase activation, 
nucleocytoplasmic 
transport 
  0.58   
P38606 VATA_HUMAN ATP6V1A V-type proton ATPase catalytic subunit A 
hydrolase, 
transport     0.59 
O14579 COPE_HUMAN COPE Coatomer subunit epsilon 
structural 
molecule activity, 
protein transport 
    0.65 
Q15417 CNN3_HUMAN CNN3 Calponin-3 
actin binding, 
epithelial cell 
differentiation 
    0.82 
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Q9Y696 CLIC4_HUMAN CLIC4 Chloride intracellular channel protein 4 
ion channel, 
transport     -0.58 
Q9UKY7 CDV3_HUMAN CDV3 Protein CDV3 homolog cell proliferation 1.38     
Q9NQC3 RTN4_HUMAN RTN4 Reticulon-4 
axonal growth 
inhibitor, 
neurogenesis 
0.94 0.69   
Q92888 ARHG1_HUMAN ARHGEF1 Rho guanine nucleotide exchange factor 1 
GTPase activation, 
signal transduction -1.69   1.76 
Q5JPE7 NOMO2_HUMAN NOMO2 Nodal modulator 2 
carbohydrate 
binding, protein 
destabilisation 
  1.22   
Q5VT79 AXA81_HUMAN ANXA8L1 Annexin A8-like protein 1 calcium ion binding     -0.61 
Q9H211 CDT1_HUMAN CDT1 DNA replication factor Cdt1 
chromatin binding, 
cell cycle     -0.65 
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Supplementary Table 4. Metadata for transcriptome interaction network and pathway analysis 
of 5448 intracellularly infected TEpi cells in comparison to mock TEpi cells. 
Pathway over-representation analysis performed using InnateDB of all differentially expressed genes 
(adjusted P value < 0.05, Log2FC > 1 or < -1). All significantly over-represented pathways are shown 
(adjusted P value < 0.05). Protein-protein interaction data type from stringDB output described.  
    
Gene 
symbol 
Full name Log2FC 
gene 
expression 
in 
comparison 
to mock 
cells  
Adjusted 
P-value 
Protein-
protein 
interaction 
data type 
from 
Stringdb.com 
Upregulated pathways from 
Innatedb.com 
FOSB FBJ murine 
osteosarcoma viral 
oncogene homolog 
B  
5.41 7.89E-06 experimentally 
determined, 
textmining 
AP-1 transcription factor network, 
Osteoclast differentiation 
TNF tumor necrosis 
factor  
5.23 7.66E-06 coexpression, 
textmining 
Calcineurin-regulated NFAT-
dependent transcription in lymphocytes, 
Cytokine-cytokine receptor interaction, 
Osteoclast differentiation, GPCR 
signaling, IL23-mediated signaling 
events, MAPK signaling pathway, 
Signal transduction through il1r, NOD-
like receptor signaling pathway, 
TWEAK, amb2 Integrin signaling, 
Downstream signaling in naïve CD8+ T 
cells, Toll-like receptor signaling 
pathway, Hematopoietic cell lineage, 
Hepatitis C, Keratinocyte 
differentiation, Leishmaniasis, HIV-1 
Nef: Negative effector of Fas and TNF-
alpha, T cell receptor signaling 
pathway, TNFR1 signaling pathway, 
TNF receptor signaling pathway 
CXCL2 chemokine (C-X-C 
motif) ligand 2  
4.72 3.18E-05 coexpression, 
curated 
databases, 
protein 
homology, 
textmining 
Cytokine-cytokine receptor interaction, 
GPCR ligand binding, Class A/1 
(Rhodopsin-like receptors), NOD-like 
receptor signaling pathway, Chemokine 
receptors bind chemokines, Signaling 
by GPCR, Peptide ligand-binding 
receptors, GPCR downstream signaling, 
G alpha (i) signalling events   
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IL8 interleukin 8  4.66 2.17E-05 coexpression, 
curated 
databases, 
protein 
homology, 
textmining 
AP-1 transcription factor network, 
ATF-2 transcription factor network, 
Calcineurin-regulated NFAT-
dependent transcription in lymphocytes, 
Cytokine-cytokine receptor interaction, 
Validated transcriptional targets of AP1 
family members Fra1 and Fra2, GPCR 
signaling, GPCR ligand binding, Class 
A/1 (Rhodopsin-like receptors), NOD-
like receptor signaling pathway, 
Chemokine receptors bind chemokines, 
Glucocorticoid receptor regulatory 
network, Signaling by GPCR, Toll-like 
receptor signaling pathway, 
Senescence-Associated Secretory 
Phenotype (SASP), Peptide ligand-
binding receptors, Hepatitis C, GPCR 
downstream signaling, G alpha (i) 
signalling events        
ATF3 activating 
transcription factor 
3  
4.38 7.98E-05 experimentally 
determined, 
coexpression, 
protein 
homology, 
textmining 
AP-1 transcription factor network, 
ATF-2 transcription factor network, 
Direct p53 effectors  
EGR2 early growth 
response 2  
4.34 1.07E-05 experimentally 
determined, 
coexpression, 
textmining 
Calcineurin-regulated NFAT-
dependent transcription in lymphocytes 
PPP1R15A protein phosphatase 
1, regulatory 
subunit 15A  
4.06 6.32E-07 coexpression, 
textmining 
None 
EGR4 early growth 
response 4  
3.97 1.33E-04 experimentally 
determined, 
textmining 
Calcineurin-regulated NFAT-
dependent transcription in lymphocytes, 
Downstream signaling in naïve CD8+ T 
cells   
TNFAIP3 tumor necrosis 
factor, alpha-
induced protein 3  
3.97 9.07E-06 experimentally 
determined, 
coexpression, 
textmining 
CD40/CD40L signaling, NOD-like 
receptor signaling pathway, Tnfr2 
signaling pathway, RIG-I/MDA5 
mediated induction of IFN-alpha/beta 
pathways, TNF receptor signaling 
pathway 
TRAF1 TNF receptor-
associated factor 1  
3.93 6.14E-05 experimentally 
determined, 
curated 
databases, 
coexpression, 
textmining 
CD40/CD40L signaling, TWEAK, 
Tnfr2 signaling pathway, RANKL, 
Keratinocyte differentiation, HIV-1 
Nef: Negative effector of Fas and TNF-
alpha, TNF receptor signaling pathway 
CCL20 chemokine (C-C 
motif) ligand 20  
3.90 2.41E-05 coexpression, 
curated 
databases, 
textmining 
Cytokine-cytokine receptor interaction, 
GPCR ligand binding, Class A/1 
(Rhodopsin-like receptors), NOD-like 
receptor signaling pathway, Chemokine 
receptors bind chemokines, Signaling 
by GPCR, Peptide ligand-binding 
receptors, GPCR downstream signaling,  
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LIF leukemia inhibitory 
factor  
3.87 1.34E-04 curated 
databases, 
textmining 
Cytokine-cytokine receptor interaction, 
Validated transcriptional targets of AP1 
family members Fra1 and Fra2, GPCR 
signaling, Direct p53 effectors, Jak-
STAT signaling pathway 
HBEGF heparin-binding 
EGF-like growth 
factor  
3.87 4.81E-06 curated 
databases, 
textmining 
GPCR signaling, Signaling by GPCR, 
ErbB receptor signaling network 
IRF1 interferon 
regulatory factor 1  
3.81 7.98E-05 experimentally 
determined, 
coexpression, 
curated 
databases, 
textmining 
Glucocorticoid receptor regulatory 
network, Cytokine Signaling in Immune 
system, IL6-mediated signaling events, 
Interferon alpha/beta signaling, 
Hepatitis C, RIG-I/MDA5 mediated 
induction of IFN-alpha/beta pathways 
EGR1 early growth 
response 1  
3.81 1.23E-03 experimentally 
determined, 
coexpression, 
curated 
databases, 
textmining 
AP-1 transcription factor network, 
Calcineurin-regulated NFAT-
dependent transcription in lymphocytes, 
Glucocorticoid receptor regulatory 
network, Cytokine Signaling in Immune 
system, Downstream signaling in naïve 
CD8+ T cells, Interferon alpha/beta 
signaling, Oncostatin_M 
IL6 interleukin 6 
(interferon, beta 2)  
3.74 5.25E-04 coexpression, 
curated 
databases, 
textmining 
AP-1 transcription factor network, 
ATF-2 transcription factor network, 
Cytokine-cytokine receptor interaction, 
Validated transcriptional targets of AP1 
family members Fra1 and Fra2, GPCR 
signaling, IL23-mediated signaling 
events, Signal transduction through il1r, 
NOD-like receptor signaling pathway, 
Activated TLR4 signalling, Toll Like 
Receptor 4 (TLR4) Cascade, Toll-Like 
Receptors Cascades, Jak-STAT 
signaling pathway, MyD88 dependent 
cascade initiated on endosome, Toll 
Like Receptor 7/8 (TLR7/8) Cascade, 
Glucocorticoid receptor regulatory 
network, Cytokine Signaling in Immune 
system, Signaling by GPCR, amb2 
Integrin signaling, Signaling by 
Interleukins, Toll Like Receptor 9 
(TLR9) Cascade, MyD88:Mal cascade 
initiated on plasma membrane, Toll 
Like Receptor 2 (TLR2) Cascade, Toll 
Like Receptor TLR1:TLR2 Cascade, 
Toll Like Receptor TLR6:TLR2 
Cascade, IL6-mediated signaling 
events, Toll-like receptor signaling 
pathway, MyD88 cascade initiated on 
plasma membrane, TRAF6 mediated 
induction of NFkB and MAP kinases 
upon TLR7/8 or 9 activation, Toll Like 
Receptor 10 (TLR10) Cascade, Toll 
Like Receptor 5 (TLR5) Cascade, 
Hematopoietic cell lineage, MyD88-
independent cascade, TRIF-mediated 
TLR3/TLR4 signaling, Toll Like 
Receptor 3 (TLR3) Cascade, 
Senescence-Associated Secretory 
Phenotype (SASP) 
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BIRC3 baculoviral IAP 
repeat containing 3  
3.69 3.20E-05 experimentally 
determined, 
coexpression, 
curated 
databases, 
textmining 
CD40/CD40L signaling, NOD-like 
receptor signaling pathway, Activated 
TLR4 signalling, Toll Like Receptor 4 
(TLR4) Cascade, Toll-Like Receptors 
Cascades, MyD88-independent 
cascade, TRIF-mediated TLR3/TLR4 
signaling, Toll Like Receptor 3 (TLR3) 
Cascade, Keratinocyte differentiation, 
HIV-1 Nef: Negative effector of Fas and 
TNF-alpha, TNF receptor signaling 
pathway     
NR4A1 nuclear receptor 
subfamily 4, group 
A, member 1  
3.67 1.58E-04 experimentally 
determined, 
coexpression, 
textmining 
MAPK signaling pathway, 
Glucocorticoid receptor regulatory 
network 
CD83 CD83 molecule  3.66 6.14E-05 coexpression, 
textmining 
None 
MAFF v-maf 
musculoaponeurotic 
fibrosarcoma 
oncogene homolog 
F (avian)  
3.61 9.07E-06 experimentally 
determined, 
coexpression, 
textmining 
Oxidative stress induced gene 
expression via nrf2 
PTGS2 prostaglandin-
endoperoxide 
synthase 2 
(prostaglandin G/H 
synthase and 
cyclooxygenase)  
3.47 4.77E-04 coexpression, 
textmining 
Calcineurin-regulated NFAT-
dependent transcription in lymphocytes, 
Calcium signaling in the CD4+ TCR 
pathway, Leishmaniasis   
NR4A3 nuclear receptor 
subfamily 4, group 
A, member 3  
3.40 5.08E-04 experimentally 
determined, 
textmining 
None 
EGR3 early growth 
response 3  
3.28 9.07E-06 experimentally 
determined, 
coexpression, 
textmining 
Calcineurin-regulated NFAT-
dependent transcription in lymphocytes 
GADD45B growth arrest and 
DNA-damage-
inducible, beta  
3.28 1.76E-05 experimentally 
determined, 
protein 
homology, 
textmining 
MAPK signaling pathway, IL12-
mediated signaling events 
SOCS3 suppressor of 
cytokine signaling 3  
3.28 9.07E-06 coexpression, 
curated 
databases, 
textmining 
ATF-2 transcription factor network, 
Osteoclast differentiation, IL23-
mediated signaling events, Jak-STAT 
signaling pathway, Cytokine Signaling 
in Immune system, Signaling by 
Interleukins, IL6-mediated signaling 
events, Interferon alpha/beta signaling, 
Hepatitis C, Oncostatin_M     
DUSP5 dual specificity 
phosphatase 5  
3.14 1.46E-05 experimentally 
determined, 
coexpression, 
textmining 
ATF-2 transcription factor network, 
MAPK signaling pathway, Direct p53 
effectors 
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CSF2 colony stimulating 
factor 2 
(granulocyte-
macrophage)  
2.97 6.10E-04 coexpression, 
textmining 
AP-1 transcription factor network, 
Calcineurin-regulated NFAT-
dependent transcription in lymphocytes, 
Cytokine-cytokine receptor interaction, 
GPCR signaling, Calcium signaling in 
the CD4+ TCR pathway, Jak-STAT 
signaling pathway, Glucocorticoid 
receptor regulatory network, Cytokine 
Signaling in Immune system, Signaling 
by GPCR, Signaling by Interleukins, 
Hematopoietic cell lineage, GPCR 
downstream signaling, T cell receptor 
signaling pathway 
NFKBIE nuclear factor of 
kappa light 
polypeptide gene 
enhancer in B-cells 
inhibitor, epsilon  
2.95 1.07E-05 experimentally 
determined, 
coexpression, 
textmining 
T cell receptor signaling pathway, 
TNFR1 signaling pathway, B cell 
receptor signaling pathway  
FOSL1 FOS-like antigen 1  2.89 3.82E-06 experimentally 
determined, 
coexpression, 
protein 
homology, 
curated 
databases, 
textmining 
AP-1 transcription factor network, 
Calcineurin-regulated NFAT-
dependent transcription in lymphocytes, 
Osteoclast differentiation, Validated 
transcriptional targets of AP1 family 
members Fra1 and Fra2, Calcium 
signaling in the CD4+ TCR pathway, 
Downstream signaling in naïve CD8+ T 
cells 
PMAIP1 phorbol-12-
myristate-13-
acetate-induced 
protein 1  
2.87 5.28E-06 experimentally 
determined, 
curated 
databases, 
textmining 
Direct p53 effectors 
EDN1 endothelin 1  2.83 7.07E-05 textmining AP-1 transcription factor network, 
GPCR signaling, GPCR ligand binding, 
Class A/1 (Rhodopsin-like receptors), 
Signaling by GPCR, Peptide ligand-
binding receptors, GPCR downstream 
signaling 
BCL2A1 BCL2-related 
protein A1  
2.82 5.55E-05 experimentally 
determined, 
curated 
databases, 
textmining 
BCR signaling pathway 
CXCL3 chemokine (C-X-C 
motif) ligand 3  
2.78 8.39E-05 coexpression, 
curated 
databases, 
protein 
homology, 
textmining 
Cytokine-cytokine receptor interaction, 
GPCR ligand binding, Class A/1 
(Rhodopsin-like receptors), Chemokine 
receptors bind chemokines, Signaling 
by GPCR, Peptide ligand-binding 
receptors, GPCR downstream signaling, 
G alpha (i) signalling events 
BBC3 BCL2 binding 
component 3  
2.71 3.30E-04 experimentally 
determined, 
curated 
databases, 
textmining 
Direct p53 effectors 
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SERPINB2 serpin peptidase 
inhibitor, clade B 
(ovalbumin), 
member 2  
2.58 2.35E-04 curated 
databases, 
textmining 
None 
PLAUR plasminogen 
activator, urokinase 
receptor  
2.57 2.95E-06 coexpression, 
curated 
databases, 
textmining 
Validated transcriptional targets of AP1 
family members Fra1 and Fra2, amb2 
Integrin signaling 
ZFP36 zinc finger protein 
36, C3H type, 
homolog (mouse)  
2.52 2.25E-05 experimentally 
determined, 
coexpression, 
textmining 
None 
PRDM1 PR domain 
containing 1, with 
ZNF domain  
2.45 1.67E-05 experimentally 
determined, 
textmining 
Direct p53 effectors 
PIM1 pim-1 oncogene  2.45 1.50E-04 experimentally 
determined, 
curated 
databases, 
textmining 
Jak-STAT signaling pathway 
PTX3 pentraxin 3, long  3.72 6.06E-04 coexpression, 
textmining 
None 
IL1RL1 interleukin 1 
receptor-like 1  
3.40 5.31E-04 textmining None 
IL24 interleukin 24  2.48 1.51E-04 textmining Cytokine-cytokine receptor interaction, 
IL23-mediated signaling events  
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Supplementary Table 5. Metadata for transcriptome interaction network and pathway analysis 
of JRS4 intracellularly infected TEpi cells in comparison to mock TEpi cells. 
Pathway over-representation analysis performed using InnateDB of all differentially expressed genes 
(adjusted P value < 0.05, Log2FC > 1 or < -1). All significantly over-represented pathways are shown 
(adjusted P value < 0.05). Protein-protein interaction data type from stringDB output described.   
 
Gene 
symbol 
Full name Log2FC 
gene 
expression 
in 
comparison 
to mock 
cells  
Adjusted 
P-value 
Protein-
protein 
interaction 
data type 
from 
Stringdb.com 
Upregulated pathways from 
Innatedb.com 
ATF3 activating 
transcription factor 
3  
3.30 3.59E-03 experimentally 
determined, 
co-expression, 
protein 
homology, 
curated 
databases, 
textmining 
AP-1 transcription factor network, ATF-
2 transcription factor network, Direct 
p53 effectors 
PTGS2 prostaglandin-
endoperoxide 
synthase 2 
(prostaglandin G/H 
synthase and 
cyclooxygenase)  
3.21 6.56E-03 curated 
databases, 
textmining 
Calcineurin-regulated NFAT-dependent 
transcription in lymphocytes, Calcium 
signaling in the CD4+ TCR pathway, 
Leishmaniasis 
IL8 interleukin 8  3.06 2.46E-03 co-expression, 
protein 
homology, 
curated 
databases, 
textmining 
AP-1 transcription factor network, 
Cytokine-cytokine receptor interaction, 
ATF-2 transcription factor network, 
Calcineurin-regulated NFAT-dependent 
transcription in lymphocytes, GPCR 
signaling, Chemokine receptors bind 
chemokines, GPCR ligand binding, 
Signaling by GPCR, Class A/1 
(Rhodopsin-like receptors), NOD-like 
receptor signaling pathway, Validated 
transcriptional targets of AP1 family 
members Fra1 and Fra2, Peptide ligand-
binding receptors, Amoebiasis, GPCR 
downstream signaling, G alpha (i) 
signalling events, Nfkb activation by 
nontypeable hemophilus influenzae, 
Malaria 
IL36G interleukin 36, 
gamma  
3.03 8.88E-05 co-expression, 
textmining 
None 
CXCL2 chemokine (C-X-C 
motif) ligand 2  
2.90 4.46E-03 co-expression, 
protein 
homology, 
curated 
databases, 
textmining 
Cytokine-cytokine receptor interaction, 
Chemokine receptors bind chemokines, 
GPCR ligand binding, Signaling by 
GPCR, Class A/1 (Rhodopsin-like 
receptors), NOD-like receptor signaling 
pathway, Peptide ligand-binding 
receptors, GPCR downstream signaling, 
G alpha (i) signalling events 
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IL6 interleukin 6 
(interferon, beta 2)  
2.85 1.82E-02 co-
expresssion, 
curated 
databases, 
textmining 
AP-1 transcription factor network, 
Cytokine-cytokine receptor interaction, 
ATF-2 transcription factor network, 
GPCR signaling, IL23-mediated 
signaling events, Signaling by GPCR, 
NOD-like receptor signaling pathway, 
Validated transcriptional targets of AP1 
family members Fra1 and Fra2, 
Amoebiasis, Jak-STAT signaling 
pathway, Hematopoietic cell lineage, 
Signal transduction through il1r, Graft-
versus-host disease, Malaria, Il-10 anti-
inflammatory signaling pathway        
CLDN4 claudin 4  2.74 5.47E-04 curated 
databases, 
protein 
homology, co-
expression, 
textmining 
None 
TNF tumor necrosis 
factor  
2.61 3.08E-03 co-expression, 
textmining 
Cytokine-cytokine receptor interaction, 
Calcineurin-regulated NFAT-dependent 
transcription in lymphocytes, GPCR 
signaling, IL23-mediated signaling 
events, NOD-like receptor signaling 
pathway, Amoebiasis, Hematopoietic 
cell lineage, Signal transduction through 
il1r, Graft-versus-host disease, 
Osteoclast differentiation, Nfkb 
activation by nontypeable hemophilus 
influenzae, Malaria, Il-10 anti-
inflammatory signaling pathway, 
Leishmaniasis 
SERPINB2 serpin peptidase 
inhibitor, clade B 
(ovalbumin), 
member 2  
2.45 2.86E-03 curated 
databases, 
textmining 
Amoebiasis 
MMP3 matrix 
metallopeptidase 3 
(stromelysin 1, 
progelatinase)  
2.34 2.41E-02 textmining Signaling by GPCR 
CXCL3 chemokine (C-X-C 
motif) ligand 3  
2.29 2.63E-03 co-expression, 
protein 
homology, 
curated 
databases, 
textmining 
Cytokine-cytokine receptor interaction, 
Chemokine receptors bind chemokines, 
GPCR ligand binding, Signaling by 
GPCR, Class A/1 (Rhodopsin-like 
receptors), Peptide ligand-binding 
receptors, GPCR downstream signaling, 
G alpha (i) signalling events 
IL1RL1 interleukin 1 
receptor-like 1  
2.28 3.35E-02 experimentally 
determined, 
textmining 
None 
TNFAIP3 tumor necrosis 
factor, alpha-
induced protein 3  
2.27 2.00E-03 experimentally 
determined, 
co-expression, 
textmining 
NOD-like receptor signaling pathway 
DUSP1 dual specificity 
phosphatase 1  
2.14 1.48E-03 experimentally 
determined, 
co-expression, 
curated 
databases, 
textmining 
AP-1 transcription factor network, ATF-
2 transcription factor network, Direct 
p53 effectors, Nfkb activation by 
nontypeable Hemophilus influenzae 
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DLX2 distal-less 
homeobox 2  
2.14 2.63E-02 textmining None 
IL24 interleukin 24  2.01 4.50E-03 co-expression, 
textmining 
Cytokine-cytokine receptor interaction, 
IL23-mediated signaling events, Jak-
STAT signaling pathway 
OCLN occludin  2.00 2.86E-03 experimentally 
determined, 
textmining 
None 
PIM1 pim-1 oncogene  1.93 5.21E-03 experimentally 
determined, 
curated 
databases, 
textmining 
Jak-STAT signaling pathway 
EGR2 early growth 
response 2  
1.93 1.08E-02 experimentally 
determined, 
textmining 
Calcineurin-regulated NFAT-dependent 
transcription in lymphocytes 
FOSB FBJ murine 
osteosarcoma viral 
oncogene homolog 
B  
1.93 2.03E-02 experimentally 
determined, 
curated 
databases, 
textmining 
AP-1 transcription factor network, 
Osteoclast differentiation   
PPP1R15A protein phosphatase 
1, regulatory 
subunit 15A  
1.92 3.46E-04 co-
expresssion, 
curated 
databases, 
textmining 
None 
DUSP5 dual specificity 
phosphatase 5  
1.91 2.62E-03 experimentally 
determined, 
co-expression, 
textmining 
ATF-2 transcription factor network, 
Direct p53 effectors 
SOCS3 suppressor of 
cytokine signaling 3  
1.83 2.62E-03 co-
expresssion, 
curated 
databases, 
textmining 
ATF-2 transcription factor network, 
IL23-mediated signaling events, Jak-
STAT signaling pathway, Osteoclast 
differentiation  
PRDM1 PR domain 
containing 1, with 
ZNF domain  
1.83 1.48E-03 textmining Direct p53 effectors 
HBEGF heparin-binding 
EGF-like growth 
factor  
1.82 2.94E-03 curated 
databases, 
textmining 
GPCR signaling, Signaling by GPCR, 
ErbB receptor signaling network, ErbB 
signaling pathway 
PDE4B phosphodiesterase 
4B, cAMP-specific  
1.81 7.73E-03 experimentally 
determined, 
textmining 
Signaling by GPCR, GPCR downstream 
signaling 
PLAUR plasminogen 
activator, urokinase 
receptor  
1.77 2.63E-04 co-
expresssion, 
curated 
databases, 
textmining 
Validated transcriptional targets of AP1 
family members Fra1 and Fra2 
CD274 CD274 molecule  1.77 4.26E-04 co-expression, 
textmining 
None 
ZFP36 zinc finger protein 
36, C3H type, 
homolog (mouse)  
1.74 2.00E-03 co-
expresssion, 
curated 
databases, 
textmining 
None 
HCAR2 hydroxycarboxylic 
acid receptor 2  
1.73 1.48E-03 curated 
databases, 
textmining 
GPCR ligand binding, Signaling by 
GPCR, Class A/1 (Rhodopsin-like 
receptors), GPCR downstream 
signaling, G alpha (i) signalling events 
 161 
PMAIP1 phorbol-12-
myristate-13-
acetate-induced 
protein 1  
1.70 1.48E-03 textmining Direct p53 effectors 
CLDN1 Rho family GTPase 
1  
1.69 1.10E-02 textmining None 
RND1 Rho family GTPase 
1  
1.69 1.10E-02 experimentally 
determined, 
textmining 
None 
LMO7 LIM domain 7  1.66 3.59E-03 curated 
databases, 
textmining 
None 
FOXA1 forkhead box A1  1.65 5.75E-03 textmining Direct p53 effectors 
RGS2 regulator of G-
protein signaling 2, 
24kDa  
1.64 3.25E-02 curated 
databases, 
textmining 
GPCR signaling, Signaling by GPCR, 
GPCR downstream signaling, G alpha 
(i) signalling events 
CCL20 chemokine (C-C 
motif) ligand 20  
1.59 2.82E-02 co-
expresssion, 
curated 
databases, 
textmining 
Cytokine-cytokine receptor interaction, 
Chemokine receptors bind chemokines, 
GPCR ligand binding, Signaling by 
GPCR, Class A/1 (Rhodopsin-like 
receptors), Peptide ligand-binding 
receptors, GPCR downstream signaling, 
G alpha (i) signalling events 
CXCL1 chemokine (C-X-C 
motif) ligand 1 
(melanoma growth 
stimulating activity, 
alpha)  
1.52 1.09E-02 co-expression, 
protein 
homology, 
curated 
databases, 
textmining 
Cytokine-cytokine receptor interaction, 
IL23-mediated signaling events, 
Chemokine receptors bind chemokines, 
GPCR ligand binding, Signaling by 
GPCR, Class A/1 (Rhodopsin-like 
receptors), NOD-like receptor signaling 
pathway, Peptide ligand-binding 
receptors, Amoebiasis, GPCR 
downstream signaling, G alpha (i) 
signalling events 
FOSL1 FOS-like antigen 1  1.52 1.48E-03 experimentally 
determined, 
co-expression, 
protein 
homology, 
curated 
databases, 
textmining 
AP-1 transcription factor network, 
Calcineurin-regulated NFAT-dependent 
transcription in lymphocytes, Validated 
transcriptional targets of AP1 family 
members Fra1 and Fra2, Calcium 
signaling in the CD4+ TCR pathway, 
Osteoclast differentiation 
MMP10 matrix 
metallopeptidase 10 
(stromelysin 2)  
1.51 4.00E-02 experimentally 
determined, 
co-expression, 
protein 
homology, 
curated 
databases, 
textmining 
None 
EGR3 early growth 
response 3  
1.50 7.12E-03 experimentally 
determined, 
co-expression, 
textmining 
Calcineurin-regulated NFAT-dependent 
transcription in lymphocytes 
VGLL3 vestigial like 3 
(Drosophila)  
1.49 1.48E-03 co-expression, 
textmining 
None 
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IL13RA2 interleukin 13 
receptor, alpha 2  
1.48 1.48E-03 curated 
databases, co-
expression, 
textmining 
Jak-STAT signaling pathway 
GADD45B growth arrest and 
DNA-damage-
inducible, beta  
1.45 1.43E-02 co-expression, 
textmining 
None 
ADAMTS1 ADAM 
metallopeptidase 
with 
thrombospondin 
type 1 motif, 1  
1.45 3.43E-02 textmining None 
JUN jun proto-oncogene  1.44 3.59E-03 experimentally 
determined, 
co-expression, 
curated 
databases, 
textmining 
AP-1 transcription factor network, ATF-
2 transcription factor network, 
Calcineurin-regulated NFAT-dependent 
transcription in lymphocytes, Validated 
transcriptional targets of AP1 family 
members Fra1 and Fra2, Calcium 
signaling in the CD4+ TCR pathway, 
Signal transduction through il1r, Direct 
p53 effectors, Osteoclast differentiation, 
Leishmaniasis, ErbB signaling pathway  
IL1B interleukin 1, beta  1.44 1.17E-02 experimentally 
determined, 
co-expression, 
curated 
databases, 
textmining 
Cytokine-cytokine receptor interaction, 
GPCR signaling, IL23-mediated 
signaling events, NOD-like receptor 
signaling pathway, Amoebiasis, 
Hematopoietic cell lineage, Signal 
transduction through il1r, Graft-versus-
host disease, Osteoclast differentiation, 
Nfkb activation by nontypeable 
Hemophilus influenzae, Malaria, 
Leishmaniasis 
GRHL1 grainyhead-like 1 
(Drosophila)  
1.41 4.27E-02 experimentally 
determined, 
protein 
homology, 
textmining 
None 
MMP1 matrix 
metallopeptidase 1 
(interstitial 
collagenase)  
1.41 7.25E-03 protein 
homology, 
curated 
databases, 
textmining 
AP-1 transcription factor network, 
Validated transcriptional targets of AP1 
family members Fra1 and Fra2 
MAFF v-maf 
musculoaponeurotic 
fibrosarcoma 
oncogene homolog 
F (avian)  
1.40 1.35E-02 experimentally 
determined, 
co-expression, 
textmining 
None 
BMP2 bone 
morphogenetic 
protein 2  
1.37 2.94E-03 curated 
databases, 
textmining 
Cytokine-cytokine receptor interaction, 
GPCR signaling 
NRG1 neuregulin 1  1.35 4.50E-03 co-
expresssion, 
curated 
databases, 
textmining 
GPCR signaling, ErbB receptor 
signaling network, ErbB signaling 
pathway   
EDN1 endothelin 1  1.35 3.17E-02 co-
expresssion, 
curated 
databases, 
textmining 
AP-1 transcription factor network, 
GPCR signaling, GPCR ligand binding, 
Signaling by GPCR, Class A/1 
(Rhodopsin-like receptors), Peptide 
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ligand-binding receptors, GPCR 
downstream signaling 
PELI1 pellino E3 ubiquitin 
protein ligase 1  
1.31 5.75E-03 curated 
databases, 
textmining 
None 
ADRB2 adrenoceptor beta 2, 
surface  
1.31 5.81E-03 experimentally 
determined, 
curated 
databases, 
textmining 
GPCR ligand binding, Signaling by 
GPCR, Class A/1 (Rhodopsin-like 
receptors), GPCR downstream signaling 
RND3 Rho family GTPase 
3  
1.30 8.48E-03 experimentally 
determined, 
co-expression, 
textmining 
None 
HAS2 hyaluronan 
synthase 2  
1.30 3.09E-02 textmining None 
ADAMTS6 ADAM 
metallopeptidase 
with 
thrombospondin 
type 1 motif, 6  
1.26 9.78E-03 textmining None 
GRHL3 grainyhead-like 3 
(Drosophila)  
1.24 2.72E-03 experimentally 
determined, 
protein 
homology, 
textmining 
None 
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Supplementary Table 6. Metadata for transcriptome interaction network and pathway 
analysis of 5448 intracellularly infected TEpi cells in comparison to JRS4 infected cells. 
Pathway over-representation analysis performed using InnateDB of all differentially expressed genes 
(adjusted P value < 0.05, Log2FC > 1 or < -1). All significantly over-represented pathways are shown 
(adjusted P value < 0.05). Protein-protein interaction data type from stringDB output described. 
     
Gene 
symbol 
Full name Log2FC 
gene 
expression 
in 
comparison 
to JRS4 
cells  
Adjusted 
P-value 
Protein-
protein 
interaction 
data type from 
Stringdb.com 
Upregulated pathways from 
Innatedb.com 
FOSB FBJ murine 
osteosarcoma viral 
oncogene homolog B  
3.48 3.04E-04 experimentally 
determined, 
textmining 
Osteoclast differentiation, AP-1 
transcription factor network  
EGR4 early growth 
response 4  
3.46 1.02E-03 experimentally 
determined, 
textmining 
Calcineurin-regulated NFAT-
dependent transcription in 
lymphocytes, Downstream signaling 
in naïve CD8+ T cells 
IRF1 interferon regulatory 
factor 1  
3.39 6.49E-04 experimentally 
determined, 
coexpression, 
curated 
databases, 
textmining 
Glucocorticoid receptor regulatory 
network, Cytokine Signaling in 
Immune system, IL6-mediated 
signaling events, Innate Immune 
System 
TRAF1 TNF receptor-
associated factor 1  
3.25 6.49E-04 experimentally 
determined, 
coexpression, 
curated 
databases, 
textmining 
CD40/CD40L signaling, Tnfr2 
signaling pathway, HIV-1 Nef: 
Negative effector of Fas and TNF-
alpha, RANKL, TNF receptor 
signaling pathway, TWEAK  
BIRC3 baculoviral IAP 
repeat containing 3  
2.71 6.49E-04 experimentally 
determined, 
coexpression, 
curated 
databases, 
textmining 
CD40/CD40L signaling, NOD-like 
receptor signaling pathway, HIV-1 
Nef: Negative effector of Fas and 
TNF-alpha, Toll-Like Receptors 
Cascades, Activated TLR4 
signalling, Toll Like Receptor 4 
(TLR4) Cascade, TNF receptor 
signaling pathway, Innate Immune 
System   
TNF tumor necrosis factor  2.62 6.54E-04 coexpression, 
textmining 
Calcineurin-regulated NFAT-
dependent transcription in 
lymphocytes, Osteoclast 
differentiation, Cytokine-cytokine 
receptor interaction, MAPK 
signaling pathway, NOD-like 
receptor signaling pathway, JAK 
STAT pathway and regulation, HIV-
1 Nef: Negative effector of Fas and 
TNF-alpha, Downstream signaling 
in naïve CD8+ T cells, T cell 
receptor signaling pathway, 
Hematopoietic cell lineage, Nfat and 
hypertrophy of the heart, Toll-like 
receptor signaling pathway, IL23-
mediated signaling events, TNF 
receptor signaling pathway, 
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TWEAK, Adipocytokine signaling 
pathway, GPCR signaling 
PTX3 pentraxin 3, long  2.58 3.73E-03 textmining None 
NFKBIE nuclear factor of 
kappa light 
polypeptide gene 
enhancer in B-cells 
inhibitor, epsilon  
2.47 2.12E-04 experimentally 
determined, 
coexpression, 
textmining 
T cell receptor signaling pathway, 
Adipocytokine signaling pathway 
CD83 CD83 molecule  2.43 1.09E-03 coexpression, 
textmining 
None 
EGR2 early growth 
response 2  
2.41 8.64E-04 experimentally 
determined, 
coexpression, 
textmining 
Calcineurin-regulated NFAT-
dependent transcription in 
lymphocytes, IL4-mediated 
signaling events 
GDF15 growth 
differentiation factor 
15  
2.35 2.50E-03 textmining Direct p53 effectors 
CCL20 chemokine (C-C 
motif) ligand 20  
2.31 1.01E-03 curated 
databases, 
coexpression, 
textmining 
Cytokine-cytokine receptor 
interaction, Class A/1 (Rhodopsin-
like receptors), GPCR ligand 
binding, Peptide ligand-binding 
receptors, Chemokine receptors bind 
chemokines, Signaling by GPCR, 
GPCR downstream signaling 
LIF leukemia inhibitory 
factor  
2.26 2.55E-03 curated 
databases, 
textmining 
Cytokine-cytokine receptor 
interaction, JAK STAT pathway and 
regulation, Direct p53 effectors, Nfat 
and hypertrophy of the heart, GPCR 
signaling 
MAFF v-maf 
musculoaponeurotic 
fibrosarcoma 
oncogene homolog F 
(avian)  
2.20 6.49E-04 experimentally 
determined, 
textmining 
None 
NR4A3 nuclear receptor 
subfamily 4, group A, 
member 3  
2.20 4.58E-03 experimentally 
determined, 
textmining 
None 
BCL2A1 BCL2-related protein 
A1  
2.14 8.09E-04 experimentally 
determined, 
curated 
databases, 
textmining 
None 
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PPP1R15A protein phosphatase 
1, regulatory subunit 
15A  
2.14 1.26E-04 textmining None 
TNFAIP2 tumor necrosis factor, 
alpha-induced 
protein 2  
2.11 6.85E-04 textmining None 
NR4A1 nuclear receptor 
subfamily 4, group A, 
member 1  
2.11 2.78E-03 experimentally 
determined, 
coexpression, 
textmining 
MAPK signaling pathway, 
Glucocorticoid receptor regulatory 
network, TCR, Innate Immune 
System  
HBEGF heparin-binding 
EGF-like growth 
factor  
2.04 6.71E-04 curated 
databases, 
textmining 
Signaling by GPCR, Nfat and 
hypertrophy of the heart, GPCR 
signaling, Innate Immune System 
CX3CL1 chemokine (C-X3-C 
motif) ligand 1  
2.01 6.49E-04 textmining Cytokine-cytokine receptor 
interaction, Class A/1 (Rhodopsin-
like receptors), GPCR ligand 
binding, Peptide ligand-binding 
receptors, Chemokine receptors bind 
chemokines, Direct p53 effectors, 
Signaling by GPCR   
GEM GTP binding protein 
overexpressed in 
skeletal muscle  
1.95 8.52E-03 experimentally 
determined, 
textmining 
None 
EGR1 early growth 
response 1  
1.89 3.28E-02 experimentally 
determined, 
curated 
databases, 
protein 
homology, 
textmining  
Calcineurin-regulated NFAT-
dependent transcription in 
lymphocytes, AP-1 transcription 
factor network, Glucocorticoid 
receptor regulatory network, 
Downstream signaling in naïve 
CD8+ T cells, Oncostatin_M, TCR, 
Cytokine Signaling in Immune 
system 
PTGER4 prostaglandin E 
receptor 4 (subtype 
EP4)  
1.89 7.20E-04 textmining Class A/1 (Rhodopsin-like 
receptors), GPCR ligand binding, 
Signaling by GPCR, GPCR 
downstream signaling 
ICAM1 intercellular adhesion 
molecule 1  
1.87 1.22E-03 curated 
databases, 
coexpression, 
textmining 
Glucocorticoid receptor regulatory 
network, Toll-Like Receptors 
Cascades, Activated TLR4 
signalling, Toll Like Receptor 4 
(TLR4) Cascade, Cytokine 
Signaling in Immune system, Toll-
like receptor signaling pathway, 
Innate Immune System     
BDKRB1 bradykinin receptor 
B1  
1.87 6.73E-03 curated 
databases   
Class A/1 (Rhodopsin-like 
receptors), GPCR ligand binding, 
Peptide ligand-binding receptors, 
Signaling by GPCR, GPCR 
downstream signaling 
GADD45B growth arrest and 
DNA-damage-
inducible, beta  
1.83 1.03E-03 textmining MAPK signaling pathway, IL12-
mediated signaling events 
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CXCL2 chemokine (C-X-C 
motif) ligand 2  
1.82 3.96E-03 coexpression, 
curated 
databases 
Cytokine-cytokine receptor 
interaction, NOD-like receptor 
signaling pathway, Class A/1 
(Rhodopsin-like receptors), GPCR 
ligand binding, Peptide ligand-
binding receptors, Chemokine 
receptors bind chemokines, 
Signaling by GPCR, GPCR 
downstream signaling  
EGR3 early growth 
response 3  
1.78 6.68E-04 experimentally 
determined, 
textmining 
Calcineurin-regulated NFAT-
dependent transcription in 
lymphocytes 
TNFAIP3 tumor necrosis factor, 
alpha-induced 
protein 3  
1.70 1.70E-03 experimentally 
determined, 
coexpression, 
textmining 
CD40/CD40L signaling, NOD-like 
receptor signaling pathway, Tnfr2 
signaling pathway, TNF receptor 
signaling pathway, Innate Immune 
System 
NFKBIZ nuclear factor of 
kappa light 
polypeptide gene 
enhancer in B-cells 
inhibitor, zeta  
1.65 2.48E-03 experimentally 
determined, 
textmining 
None 
CORO6 coronin 6  1.62 1.22E-03 experimentally 
determined, 
coexpression, 
textmining 
None 
LRIG3 leucine-rich repeats 
and immunoglobulin-
like domains 3  
-1.61 1.02E-03 experimentally 
determined, 
textmining 
None 
ACTL10 actin-like 10  -1.77 2.91E-03 experimentally 
determined, 
coexpression, 
textmining 
None 
HIST1H2BF histone cluster 1, 
H2bf  
-1.96 4.94E-02 experimentally 
determined, 
coexpression, 
textmining 
None 
  
 168 
10.0 References 
 
1. Steer AC, Law I, Matatolu L, Beall BW, Carapetis JR. 2009. Global emm type distribution of 
group A streptococci: systematic review and implications for vaccine development. Lancet 
Infect Dis 9:611-6. 
2. Walker MJ, Barnett TC, McArthur JD, Cole JN, Gillen CM, Henningham A, Sriprakash KS, 
Sanderson-Smith ML, Nizet V. 2014. Disease manifestations and pathogenic mechanisms of 
Group A Streptococcus. Clin Microbiol Rev 27:264-301. 
3. Stevens DL, Bryant AE. 2016. Impetigo, Erysipelas and Cellulitis. In Ferretti JJ, Stevens DL, 
Fischetti VA (ed), Streptococcus pyogenes : Basic Biology to Clinical Manifestations, 
Oklahoma City (OK). 
4. Soderholm AT, Barnett TC, Sweet MJ, Walker MJ. 2017. Group A streptococcal pharyngitis: 
immune responses involved in bacterial clearance and GAS-associated immunopathologies. 
J Leukoc Biol doi:10.1189/jlb.4MR0617-227RR. 
5. Stevens DL. 1992. Invasive group A streptococcus infections. Clin Infect Dis 14:2-11. 
6. Martin WJ, Steer AC, Smeesters PR, Keeble J, Inouye M, Carapetis J, Wicks IP. 2015. Post-
infectious group A streptococcal autoimmune syndromes and the heart. Autoimmun Rev 
14:710-25. 
7. Carapetis JR, Steer AC, Mulholland EK, Weber M. 2005. The global burden of group A 
streptococcal diseases. Lancet Infect Dis 5:685-94. 
8. Bessen DE. 2009. Population biology of the human restricted pathogen, Streptococcus 
pyogenes. Infect Genet Evol 9:581-93. 
9. Rohde M, Cleary PP. 2016. Adhesion and invasion of Streptococcus pyogenes into host cells 
and clinical relevance of intracellular streptococci. In Ferretti JJ, Stevens DL, Fischetti VA 
(ed), Streptococcus pyogenes : Basic Biology to Clinical Manifestations, Oklahoma City 
(OK). 
10. Ryan PA, Juncosa B. 2016. Group A Streptococcal Adherence. In Ferretti JJ, Stevens DL, 
Fischetti VA (ed), Streptococcus pyogenes : Basic Biology to Clinical Manifestations, 
Oklahoma City (OK). 
11. Courtney HS, Hasty DL, Dale JB. 2002. Molecular mechanisms of adhesion, colonization, 
and invasion of group A streptococci. Ann Med 34:77-87. 
12. Hardie JM, Whiley RA. 1997. Classification and overview of the genera Streptococcus and 
Enterococcus. Soc Appl Bacteriol Symp Ser 26:1S-11S. 
13. Patterson MJ. 1996. Streptococcus. In th, Baron S (ed), Medical Microbiology, Galveston 
(TX). 
 169 
14. Lancefield RC. 1933. A Serological Differentiation of Human and Other Groups of Hemolytic 
Streptococci. J Exp Med 57:571-95. 
15. Spellerberg B, Brandt C. 2016. Laboratory Diagnosis of Streptococcus pyogenes (group A 
streptococci). In Ferretti JJ, Stevens DL, Fischetti VA (ed), Streptococcus pyogenes : Basic 
Biology to Clinical Manifestations, Oklahoma City (OK). 
16. Fischetti VA. 1989. Streptococcal M protein: molecular design and biological behavior. Clin 
Microbiol Rev 2:285-314. 
17. Lancefield RC. 1962. Current knowledge of type-specific M antigens of group A streptococci. 
J Immunol 89:307-13. 
18. Lancefield RC, Dole VP. 1946. The Properties of T Antigens Extracted from Group a 
Hemolytic Streptococci. J Exp Med 84:449-71. 
19. Facklam R, Beall B, Efstratiou A, Fischetti V, Johnson D, Kaplan E, Kriz P, Lovgren M, 
Martin D, Schwartz B, Totolian A, Bessen D, Hollingshead S, Rubin F, Scott J, Tyrrell G. 
1999. emm typing and validation of provisional M types for group A streptococci. Emerg 
Infect Dis 5:247-53. 
20. McMillan DJ, Dreze PA, Vu T, Bessen DE, Guglielmini J, Steer AC, Carapetis JR, Van 
Melderen L, Sriprakash KS, Smeesters PR. 2013. Updated model of group A Streptococcus 
M proteins based on a comprehensive worldwide study. Clin Microbiol Infect 19:E222-9. 
21. Kotb M, Norrby-Teglund A, McGeer A, El-Sherbini H, Dorak MT, Khurshid A, Green K, 
Peeples J, Wade J, Thomson G, Schwartz B, Low DE. 2002. An immunogenetic and 
molecular basis for differences in outcomes of invasive group A streptococcal infections. Nat 
Med 8:1398-404. 
22. Basma H, Norrby-Teglund A, Guedez Y, McGeer A, Low DE, El-Ahmedy O, Schwartz B, 
Kotb M. 1999. Risk factors in the pathogenesis of invasive group A streptococcal infections: 
role of protective humoral immunity. Infect Immun 67:1871-7. 
23. Vlaminckx BJ, Mascini EM, Schellekens J, Schouls LM, Paauw A, Fluit AC, Novak R, 
Verhoef J, Schmitz FJ. 2003. Site-specific manifestations of invasive group a streptococcal 
disease: type distribution and corresponding patterns of virulence determinants. J Clin 
Microbiol 41:4941-9. 
24. Bisno AL, Brito MO, Collins CM. 2003. Molecular basis of group A streptococcal virulence. 
Lancet Infect Dis 3:191-200. 
25. Cunningham MW. 2000. Pathogenesis of group A streptococcal infections. Clin Microbiol 
Rev 13:470-511. 
 170 
26. Carapetis JR, Walker AM, Hibble M, Sriprakash KS, Currie BJ. 1999. Clinical and 
epidemiological features of group A streptococcal bacteraemia in a region with hyperendemic 
superficial streptococcal infection. Epidemiol Infect 122:59-65. 
27. Carapetis JR. 2007. Rheumatic heart disease in developing countries. N Engl J Med 357:439-
41. 
28. WHO. 2004. The World Health Report 2004.  WHO, Geneva. 
29. WHO. 2005. The Current Evidence for the Burden of Group A Streptococcal Diseases.  World 
Health Organisation, Department of Child and Adolescent Health and Development. 
30. Carapetis JR, McDonald M, Wilson NJ. 2005. Acute rheumatic fever. Lancet 366:155-68. 
31. Martin JM, Green M. 2006. Group A streptococcus. Semin Pediatr Infect Dis 17:140-8. 
32. Young MH, Aronoff DM, Engleberg NC. 2005. Necrotizing fasciitis: pathogenesis and 
treatment. Expert Rev Anti Infect Ther 3:279-94. 
33. Shulman ST, Tanz RR. 2010. Group A streptococcal pharyngitis and immune-mediated 
complications: from diagnosis to management. Expert Rev Anti Infect Ther 8:137-50. 
34. Ekelund K, Darenberg J, Norrby-Teglund A, Hoffmann S, Bang D, Skinhoj P, Konradsen 
HB. 2005. Variations in emm type among group A streptococcal isolates causing invasive or 
noninvasive infections in a nationwide study. J Clin Microbiol 43:3101-9. 
35. McDonald MI, Towers RJ, Fagan P, Carapetis JR, Currie BJ. 2007. Molecular typing of 
Streptococcus pyogenes from remote Aboriginal communities where rheumatic fever is 
common and pyoderma is the predominant streptococcal infection. Epidemiol Infect 
135:1398-405. 
36. Wannamaker LW. 1970. Differences between streptococcal infections of the throat and of the 
skin (second of two parts). N Engl J Med 282:78-85. 
37. Bessen DE, Sotir CM, Readdy TL, Hollingshead SK. 1996. Genetic correlates of throat and 
skin isolates of group A streptococci. J Infect Dis 173:896-900. 
38. Bessen DE. 2016. Tissue tropisms in group A Streptococcus: what virulence factors 
distinguish pharyngitis from impetigo strains? Curr Opin Infect Dis 29:295-303. 
39. Nobbs AH, Lamont RJ, Jenkinson HF. 2009. Streptococcus adherence and colonization. 
Microbiol Mol Biol Rev 73:407-50, Table of Contents. 
40. Brouwer S, Barnett TC, Rivera-Hernandez T, Rohde M, Walker MJ. 2016. Streptococcus 
pyogenes adhesion and colonization. FEBS Lett 590:3739-3757. 
41. Kratovac Z, Manoharan A, Luo F, Lizano S, Bessen DE. 2007. Population genetics and 
linkage analysis of loci within the FCT region of Streptococcus pyogenes. J Bacteriol 
189:1299-310. 
42. Bisno AL. 1996. Acute pharyngitis: etiology and diagnosis. Pediatrics 97:949-54. 
 171 
43. Cue D, Dombek PE, Lam H, Cleary PP. 1998. Streptococcus pyogenes serotype M1 encodes 
multiple pathways for entry into human epithelial cells. Infect Immun 66:4593-601. 
44. Abbot EL, Smith WD, Siou GP, Chiriboga C, Smith RJ, Wilson JA, Hirst BH, Kehoe MA. 
2007. Pili mediate specific adhesion of Streptococcus pyogenes to human tonsil and skin. Cell 
Microbiol 9:1822-33. 
45. Murakami J, Terao Y, Morisaki I, Hamada S, Kawabata S. 2012. Group A streptococcus 
adheres to pharyngeal epithelial cells with salivary proline-rich proteins via GrpE chaperone 
protein. J Biol Chem 287:22266-75. 
46. Anjos LM, Marcondes MB, Lima MF, Mondelli AL, Okoshi MP. 2014. Streptococcal acute 
pharyngitis. Rev Soc Bras Med Trop 47:409-13. 
47. Casteleyn C, Breugelmans S, Simoens P, Van den Broeck W. 2011. The tonsils revisited: 
review of the anatomical localization and histological characteristics of the tonsils of domestic 
and laboratory animals. Clin Dev Immunol 2011:472460. 
48. Roberts AL, Connolly KL, Kirse DJ, Evans AK, Poehling KA, Peters TR, Reid SD. 2012. 
Detection of group A Streptococcus in tonsils from pediatric patients reveals high rate of 
asymptomatic streptococcal carriage. BMC Pediatr 12:3. 
49. Osterlund A, Engstrand L. 1997. An intracellular sanctuary for Streptococcus pyogenes in 
human tonsillar epithelium--studies of asymptomatic carriers and in vitro cultured biopsies. 
Acta Otolaryngol 117:883-8. 
50. Osterlund A, Popa R, Nikkila T, Scheynius A, Engstrand L. 1997. Intracellular reservoir of 
Streptococcus pyogenes in vivo: a possible explanation for recurrent pharyngotonsillitis. 
Laryngoscope 107:640-7. 
51. Zautner AE, Krause M, Stropahl G, Holtfreter S, Frickmann H, Maletzki C, Kreikemeyer B, 
Pau HW, Podbielski A. 2010. Intracellular persisting Staphylococcus aureus is the major 
pathogen in recurrent tonsillitis. PLoS One 5:e9452. 
52. Chauhan S, Kashyap N, Kanga A, Thakur K, Sood A, Chandel L. 2016. Genetic Diversity 
among Group A Streptococcus Isolated from Throats of Healthy and Symptomatic Children. 
J Trop Pediatr 62:152-7. 
53. Martin J. 2016. The Streptococcus pyogenes Carrier State. In Ferretti JJ, Stevens DL, Fischetti 
VA (ed), Streptococcus pyogenes : Basic Biology to Clinical Manifestations, Oklahoma City 
(OK). 
54. Cesta MF. 2006. Normal structure, function, and histology of mucosa-associated lymphoid 
tissue. Toxicol Pathol 34:599-608. 
55. Elmore SA. 2006. Enhanced histopathology of mucosa-associated lymphoid tissue. Toxicol 
Pathol 34:687-96. 
 172 
56. Scadding GK. 1990. Immunology of the tonsil: a review. J R Soc Med 83:104-7. 
57. van Kempen MJ, Rijkers GT, Van Cauwenberge PB. 2000. The immune response in adenoids 
and tonsils. Int Arch Allergy Immunol 122:8-19. 
58. Brandtzaeg P. 2003. Immunology of tonsils and adenoids: everything the ENT surgeon needs 
to know. Int J Pediatr Otorhinolaryngol 67 Suppl 1:S69-76. 
59. Nave H, Gebert A, Pabst R. 2001. Morphology and immunology of the human palatine tonsil. 
Anat Embryol (Berl) 204:367-73. 
60. Hellings P, Jorissen M, Ceuppens JL. 2000. The Waldeyer's ring. Acta Otorhinolaryngol Belg 
54:237-41. 
61. Perry M, Whyte A. 1998. Immunology of the tonsils. Immunol Today 19:414-21. 
62. Galli J, Ardito F, Calo L, Mancinelli L, Imperiali M, Parrilla C, Picciotti PM, Fadda G. 2007. 
Recurrent upper airway infections and bacterial biofilms. J Laryngol Otol 121:341-4. 
63. Segal N, Givon-Lavi N, Leibovitz E, Yagupsky P, Leiberman A, Dagan R. 2005. Acute otitis 
media caused by Streptococcus pyogenes in children. Clin Infect Dis 41:35-41. 
64. Haley PJ. 2017. The lymphoid system: a review of species differences. J Toxicol Pathol 
30:111-123. 
65. Ruddle NH, Akirav EM. 2009. Secondary lymphoid organs: responding to genetic and 
environmental cues in ontogeny and the immune response. J Immunol 183:2205-12. 
66. Brandtzaeg P. 1988. Immunobarriers of the mucosa of the upper respiratory and digestive 
pathways. Acta Otolaryngol 105:172-80. 
67. Boyaka PN, Wright PF, Marinaro M, Kiyono H, Johnson JE, Gonzales RA, Ikizler MR, 
Werkhaven JA, Jackson RJ, Fujihashi K, Di Fabio S, Staats HF, McGhee JR. 2000. Human 
nasopharyngeal-associated lymphoreticular tissues. Functional analysis of subepithelial and 
intraepithelial B and T cells from adenoids and tonsils. Am J Pathol 157:2023-35. 
68. Lange MJ, Lasiter JC, Misfeldt ML. 2009. Toll-like receptors in tonsillar epithelial cells. Int 
J Pediatr Otorhinolaryngol 73:613-21. 
69. Kuper CF, Koornstra PJ, Hameleers DM, Biewenga J, Spit BJ, Duijvestijn AM, van Breda 
Vriesman PJ, Sminia T. 1992. The role of nasopharyngeal lymphoid tissue. Immunol Today 
13:219-24. 
70. Pracy JP, White A, Mustafa Y, Smith D, Perry ME. 1998. The comparative anatomy of the 
pig middle ear cavity: a model for middle ear inflammation in the human? J Anat 192 ( Pt 
3):359-68. 
71. Bell S, Howard A, Wilson JA, Abbot EL, Smith WD, Townes CL, Hirst BH, Hall J. 2012. 
Streptococcus pyogenes infection of tonsil explants is associated with a human beta-defensin 
 173 
1 response from control but not recurrent acute tonsillitis patients. Mol Oral Microbiol 27:160-
71. 
72. Wang B, Li S, Southern PJ, Cleary PP. 2006. Streptococcal modulation of cellular invasion 
via TGF-beta1 signaling. Proc Natl Acad Sci U S A 103:2380-5. 
73. Love JF, Tran-Winkler HJ, Wessels MR. 2012. Vitamin D and the human antimicrobial 
peptide LL-37 enhance group a streptococcus resistance to killing by human cells. MBio 3. 
74. Perry ME. 1994. The specialised structure of crypt epithelium in the human palatine tonsil 
and its functional significance. J Anat 185 ( Pt 1):111-27. 
75. Kassay D, Sandor A. 1962. The crypt system of the palatine tonsils. Arch Otolaryngol 75:144-
55. 
76. Kheirandish-Gozal L, Kim J, Goldbart AD, Gozal D. 2013. Novel pharmacological 
approaches for treatment of obstructive sleep apnea in children. Expert Opin Investig Drugs 
22:71-85. 
77. Karchev T, Kabakchiev P. 1984. M-cells in the epithelium of the nasopharyngeal tonsil. 
Rhinology 22:201-10. 
78. Gebert A. 1997. The role of M cells in the protection of mucosal membranes. Histochem Cell 
Biol 108:455-70. 
79. Howie AJ. 1982. The cells in tonsillar crypts. Clin Otolaryngol Allied Sci 7:35-44. 
80. Isaacson G, Parikh T. 2008. Developmental anatomy of the tonsil and its implications for 
intracapsular tonsillectomy. Int J Pediatr Otorhinolaryngol 72:89-96. 
81. Olofsson K, Hellstrom S, Hammarstrom ML. 1998. The surface epithelium of recurrent 
infected palatine tonsils is rich in gammadelta T cells. Clin Exp Immunol 111:36-47. 
82. Ochoa MT, Legaspi AJ, Hatziris Z, Godowski PJ, Modlin RL, Sieling PA. 2003. Distribution 
of Toll-like receptor 1 and Toll-like receptor 2 in human lymphoid tissue. Immunology 
108:10-5. 
83. Xie GC, Guo NJ, Grenman R, Wang H, Wang Y, Vuorenmma M, Zhang Q, Zhang S, Li HY, 
Pang LL, Li DD, Jin M, Sun XM, Kong XY, Duan ZJ. 2016. Susceptibility of human tonsillar 
epithelial cells to enterovirus 71 with normal cytokine response. Virology 494:108-18. 
84. Moussion C, Ortega N, Girard JP. 2008. The IL-1-like cytokine IL-33 is constitutively 
expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'? 
PLoS One 3:e3331. 
85. Cooney MK, Kenny GE. 1977. Demonstration of dual rhinovirus infection in humans by 
isolation of different serotypes in human heteroploid (HeLa) and human diploid fibroblast cell 
cultures. J Clin Microbiol 5:202-7. 
 174 
86. Pegtel DM, Middeldorp J, Thorley-Lawson DA. 2004. Epstein-Barr virus infection in ex vivo 
tonsil epithelial cell cultures of asymptomatic carriers. J Virol 78:12613-24. 
87. Shannon-Lowe C, Rowe M. 2011. Epstein-Barr virus infection of polarized epithelial cells 
via the basolateral surface by memory B cell-mediated transfer infection. PLoS Pathog 
7:e1001338. 
88. Bosch AA, Biesbroek G, Trzcinski K, Sanders EA, Bogaert D. 2013. Viral and bacterial 
interactions in the upper respiratory tract. PLoS Pathog 9:e1003057. 
89. Brook I, Gober AE. 2006. Increased recovery of Moraxella catarrhalis and Haemophilus 
influenzae in association with group A beta-haemolytic streptococci in healthy children and 
those with pharyngo-tonsillitis. J Med Microbiol 55:989-92. 
90. Babaiwa UF, Onyeagwara NC, Akerele JO. 2013. Bacterial tonsillar microbiota and 
antibiogram in recurrent tonsillitis. Biomedical Research-India 24:298-302. 
91. Demeslay J, De Bonnecaze G, Vairel B, Chaput B, Pessey JJ, Serrano E, Vergez S. 2014. 
Possible role of anti-inflammatory drugs in complications of pharyngitis. A retrospective 
analysis of 163 cases. Eur Ann Otorhinolaryngol Head Neck Dis 131:299-303. 
92. Bisno AL. 2001. Acute pharyngitis. N Engl J Med 344:205-11. 
93. Ralph AP, Carapetis JR. 2013. Group a streptococcal diseases and their global burden. Curr 
Top Microbiol Immunol 368:1-27. 
94. Shulman ST, Bisno AL, Clegg HW, Gerber MA, Kaplan EL, Lee G, Martin JM, Van Beneden 
C. 2012. Clinical practice guideline for the diagnosis and management of group A 
streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. Clin 
Infect Dis 55:1279-82. 
95. Kaplan EL. 1980. The group A streptococcal upper respiratory tract carrier state: an enigma. 
J Pediatr 97:337-45. 
96. Tanz RR, Shulman ST. 1998. Streptococcal pharyngitis: the carrier state, definition, and 
management. Pediatr Ann 27:281-5. 
97. Hayes CS, Williamson H, Jr. 2001. Management of Group A beta-hemolytic streptococcal 
pharyngitis. Am Fam Physician 63:1557-64. 
98. Steer AC, Carapetis JR, Dale JB, Fraser JD, Good MF, Guilherme L, Moreland NJ, 
Mulholland EK, Schodel F, Smeesters PR. 2016. Status of research and development of 
vaccines for Streptococcus pyogenes. Vaccine 34:2953-8. 
99. Wilkening RV, Federle MJ. 2017. Evolutionary Constraints Shaping Streptococcus pyogenes-
Host Interactions. Trends Microbiol doi:10.1016/j.tim.2017.01.007. 
100. Hollingshead SK, Simecka JW, Michalek SM. 1993. Role of M protein in pharyngeal 
colonization by group A streptococci in rats. Infect Immun 61:2277-83. 
 175 
101. Park HS, Francis KP, Yu J, Cleary PP. 2003. Membranous cells in nasal-associated lymphoid 
tissue: a portal of entry for the respiratory mucosal pathogen group A streptococcus. J 
Immunol 171:2532-7. 
102. Sumby P, Tart AH, Musser JM. 2008. A non-human primate model of acute group a 
Streptococcus pharyngitis. Methods Mol Biol 431:255-67. 
103. Kasper KJ, Zeppa JJ, Wakabayashi AT, Xu SX, Mazzuca DM, Welch I, Baroja ML, Kotb M, 
Cairns E, Cleary PP, Haeryfar SM, McCormick JK. 2014. Bacterial superantigens promote 
acute nasopharyngeal infection by Streptococcus pyogenes in a human MHC Class II-
dependent manner. PLoS Pathog 10:e1004155. 
104. Dinis M, Plainvert C, Kovarik P, Longo M, Fouet A, Poyart C. 2014. The innate immune 
response elicited by Group A Streptococcus is highly variable among clinical isolates and 
correlates with the emm type. PLoS One 9:e101464. 
105. Klenk M, Nakata M, Podbielski A, Skupin B, Schroten H, Kreikemeyer B. 2007. 
Streptococcus pyogenes serotype-dependent and independent changes in infected HEp-2 
epithelial cells. ISME J 1:678-92. 
106. Persson ST, Wilk L, Morgelin M, Herwald H. 2015. Vigilant keratinocytes trigger pathogen-
associated molecular pattern signaling in response to streptococcal M1 protein. Infect Immun 
83:4673-81. 
107. Shea PR, Virtaneva K, Kupko JJ, 3rd, Porcella SF, Barry WT, Wright FA, Kobayashi SD, 
Carmody A, Ireland RM, Sturdevant DE, Ricklefs SM, Babar I, Johnson CA, Graham MR, 
Gardner DJ, Bailey JR, Parnell MJ, Deleo FR, Musser JM. 2010. Interactome analysis of 
longitudinal pharyngeal infection of cynomolgus macaques by group A Streptococcus. Proc 
Natl Acad Sci U S A 107:4693-8. 
108. Chung WO, Dale BA. 2004. Innate immune response of oral and foreskin keratinocytes: 
utilization of different signaling pathways by various bacterial species. Infect Immun 72:352-
8. 
109. Veckman V, Miettinen M, Matikainen S, Lande R, Giacomini E, Coccia EM, Julkunen I. 
2003. Lactobacilli and streptococci induce inflammatory chemokine production in human 
macrophages that stimulates Th1 cell chemotaxis. J Leukoc Biol 74:395-402. 
110. Tsai PJ, Chen YH, Hsueh CH, Hsieh HC, Liu YH, Wu JJ, Tsou CC. 2006. Streptococcus 
pyogenes induces epithelial inflammatory responses through NF-kappaB/MAPK signaling 
pathways. Microbes Infect 8:1440-9. 
111. Egesten A, Eliasson M, Johansson HM, Olin AI, Morgelin M, Mueller A, Pease JE, Frick IM, 
Bjorck L. 2007. The CXC chemokine MIG/CXCL9 is important in innate immunity against 
Streptococcus pyogenes. J Infect Dis 195:684-93. 
 176 
112. Klenk M, Koczan D, Guthke R, Nakata M, Thiesen HJ, Podbielski A, Kreikemeyer B. 2005. 
Global epithelial cell transcriptional responses reveal Streptococcus pyogenes Fas regulator 
activity association with bacterial aggressiveness. Cell Microbiol 7:1237-50. 
113. Linge HM, Sastalla I, Nitsche-Schmitz DP, Egesten A, Frick IM. 2007. Protein FOG is a 
moderate inducer of MIG/CXCL9, and group G streptococci are more tolerant than group A 
streptococci to this chemokine's antibacterial effect. Microbiology 153:3800-8. 
114. Wang B, Ruiz N, Pentland A, Caparon M. 1997. Keratinocyte proinflammatory responses to 
adherent and nonadherent group A streptococci. Infect Immun 65:2119-26. 
115. Verma V, Kumar P, Dhanda RS, Yadav M. 2016. Kinetics of cytokine profile in response to 
Mycobacterium bovis BCG and Streptococcus pyogenes activated cells. Data Brief 7:445-8. 
116. Agren K, Brauner A, Andersson J. 1998. Haemophilus influenzae and Streptococcus 
pyogenes group A challenge induce a Th1 type of cytokine response in cells obtained from 
tonsillar hypertrophy and recurrent tonsillitis. ORL J Otorhinolaryngol Relat Spec 60:35-41. 
117. Nakagawa I, Nakata M, Kawabata S, Hamada S. 2004. Transcriptome analysis and gene 
expression profiles of early apoptosis-related genes in Streptococcus pyogenes-infected 
epithelial cells. Cell Microbiol 6:939-52. 
118. Miettinen M, Veckman V, Latvala S, Sareneva T, Matikainen S, Julkunen I. 2008. Live 
Lactobacillus rhamnosus and Streptococcus pyogenes differentially regulate Toll-like 
receptor (TLR) gene expression in human primary macrophages. J Leukoc Biol 84:1092-100. 
119. Gratz N, Hartweger H, Matt U, Kratochvill F, Janos M, Sigel S, Drobits B, Li XD, Knapp S, 
Kovarik P. 2011. Type I interferon production induced by Streptococcus pyogenes-derived 
nucleic acids is required for host protection. PLoS Pathog 7:e1001345. 
120. Castiglia V, Piersigilli A, Ebner F, Janos M, Goldmann O, Dambock U, Kroger A, Weiss S, 
Knapp S, Jamieson AM, Kirschning C, Kalinke U, Strobl B, Muller M, Stoiber D, 
Lienenklaus S, Kovarik P. 2016. Type I Interferon Signaling Prevents IL-1beta-Driven Lethal 
Systemic Hyperinflammation during Invasive Bacterial Infection of Soft Tissue. Cell Host 
Microbe 19:375-87. 
121. Gratz N, Siller M, Schaljo B, Pirzada ZA, Gattermeier I, Vojtek I, Kirschning CJ, Wagner H, 
Akira S, Charpentier E, Kovarik P. 2008. Group A streptococcus activates type I interferon 
production and MyD88-dependent signaling without involvement of TLR2, TLR4, and TLR9. 
J Biol Chem 283:19879-87. 
122. Dileepan T, Smith ED, Knowland D, Hsu M, Platt M, Bittner-Eddy P, Cohen B, Southern P, 
Latimer E, Harley E, Agalliu D, Cleary PP. 2016. Group A Streptococcus intranasal infection 
promotes CNS infiltration by streptococcal-specific Th17 cells. J Clin Invest 126:303-17. 
 177 
123. Linehan JL, Dileepan T, Kashem SW, Kaplan DH, Cleary P, Jenkins MK. 2015. Generation 
of Th17 cells in response to intranasal infection requires TGF-beta1 from dendritic cells and 
IL-6 from CD301b+ dendritic cells. Proc Natl Acad Sci U S A 112:12782-7. 
124. Dileepan T, Linehan JL, Moon JJ, Pepper M, Jenkins MK, Cleary PP. 2011. Robust antigen 
specific th17 T cell response to group A Streptococcus is dependent on IL-6 and intranasal 
route of infection. PLoS Pathog 7:e1002252. 
125. Mortensen R, Nissen TN, Blauenfeldt T, Christensen JP, Andersen P, Dietrich J. 2015. 
Adaptive Immunity against Streptococcus pyogenes in Adults Involves Increased IFN-gamma 
and IgG3 Responses Compared with Children. J Immunol 195:1657-64. 
126. Kerakawauchi H, Kurono Y, Mogi G. 1997. Immune responses against Streptococcus 
pyogenes in human palatine tonsils. Laryngoscope 107:634-9. 
127. Rizzo A, Losacco A, Carratelli CR, Domenico MD, Bevilacqua N. 2013. Lactobacillus 
plantarum reduces Streptococcus pyogenes virulence by modulating the IL-17, IL-23 and 
Toll-like receptor 2/4 expressions in human epithelial cells. Int Immunopharmacol 17:453-
61. 
128. Wang B, Dileepan T, Briscoe S, Hyland KA, Kang J, Khoruts A, Cleary PP. 2010. Induction 
of TGF-beta1 and TGF-beta1-dependent predominant Th17 differentiation by group A 
streptococcal infection. Proc Natl Acad Sci U S A 107:5937-42. 
129. Courtney HS, Ofek I, Hasty DL. 1997. M protein mediated adhesion of M type 24 
Streptococcus pyogenes stimulates release of interleukin-6 by HEp-2 tissue culture cells. 
FEMS Microbiol Lett 151:65-70. 
130. Viciani E, Montagnani F, Tavarini S, Tordini G, Maccari S, Morandi M, Faenzi E, Biagini C, 
Romano A, Salerni L, Finco O, Lazzi S, Ruggiero P, De Luca A, Barocchi MA, Manetti AG. 
2016. Paediatric obstructive sleep apnoea syndrome (OSAS) is associated with tonsil 
colonisation by Streptococcus pyogenes. Sci Rep 6:20609. 
131. Goldmann O, Hertzen E, Hecht A, Schmidt H, Lehne S, Norrby-Teglund A, Medina E. 2010. 
Inducible cyclooxygenase released prostaglandin E2 modulates the severity of infection 
caused by Streptococcus pyogenes. J Immunol 185:2372-81. 
132. Ignotz RA, Massague J. 1986. Transforming growth factor-beta stimulates the expression of 
fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 
261:4337-45. 
133. Zambruno G, Marchisio PC, Marconi A, Vaschieri C, Melchiori A, Giannetti A, De Luca M. 
1995. Transforming growth factor-beta 1 modulates beta 1 and beta 5 integrin receptors and 
induces the de novo expression of the alpha v beta 6 heterodimer in normal human 
keratinocytes: implications for wound healing. J Cell Biol 129:853-65. 
 178 
134. Dohrmann S, Cole JN, Nizet V. 2016. Conquering Neutrophils. PLoS Pathog 12:e1005682. 
135. Chen X, Li N, Bi S, Wang X, Wang B. 2016. Co-Activation of Th17 and Antibody Responses 
Provides Efficient Protection against Mucosal Infection by Group A Streptococcus. PLoS One 
11:e0168861. 
136. Laan M, Prause O, Miyamoto M, Sjostrand M, Hytonen AM, Kaneko T, Lotvall J, Linden A. 
2003. A role of GM-CSF in the accumulation of neutrophils in the airways caused by IL-17 
and TNF-alpha. Eur Respir J 21:387-93. 
137. Bozinovski S, Seow HJ, Chan SP, Anthony D, McQualter J, Hansen M, Jenkins BJ, Anderson 
GP, Vlahos R. 2015. Innate cellular sources of interleukin-17A regulate macrophage 
accumulation in cigarette- smoke-induced lung inflammation in mice. Clin Sci (Lond) 
129:785-96. 
138. Fan X, Wang X, Li N, Cui H, Hou B, Gao B, Cleary PP, Wang B. 2014. Sortase A induces 
Th17-mediated and antibody-independent immunity to heterologous serotypes of group A 
streptococci. PLoS One 9:e107638. 
139. Buchanan JT, Simpson AJ, Aziz RK, Liu GY, Kristian SA, Kotb M, Feramisco J, Nizet V. 
2006. DNase expression allows the pathogen group A Streptococcus to escape killing in 
neutrophil extracellular traps. Curr Biol 16:396-400. 
140. Cole JN, Barnett TC, Nizet V, Walker MJ. 2011. Molecular insight into invasive group A 
streptococcal disease. Nat Rev Microbiol 9:724-36. 
141. Walker MJ, Hollands A, Sanderson-Smith ML, Cole JN, Kirk JK, Henningham A, McArthur 
JD, Dinkla K, Aziz RK, Kansal RG, Simpson AJ, Buchanan JT, Chhatwal GS, Kotb M, Nizet 
V. 2007. DNase Sda1 provides selection pressure for a switch to invasive group A 
streptococcal infection. Nat Med 13:981-5. 
142. Ji Y, Carlson B, Kondagunta A, Cleary PP. 1997. Intranasal immunization with C5a peptidase 
prevents nasopharyngeal colonization of mice by the group A Streptococcus. Infect Immun 
65:2080-7. 
143. Ji Y, McLandsborough L, Kondagunta A, Cleary PP. 1996. C5a peptidase alters clearance 
and trafficking of group A streptococci by infected mice. Infect Immun 64:503-10. 
144. Alam FM, Bateman C, Turner CE, Wiles S, Sriskandan S. 2013. Non-invasive monitoring of 
Streptococcus pyogenes vaccine efficacy using biophotonic imaging. PLoS One 8:e82123. 
145. Zinkernagel AS, Timmer AM, Pence MA, Locke JB, Buchanan JT, Turner CE, Mishalian I, 
Sriskandan S, Hanski E, Nizet V. 2008. The IL-8 protease SpyCEP/ScpC of group A 
Streptococcus promotes resistance to neutrophil killing. Cell Host Microbe 4:170-8. 
146. Kurupati P, Turner CE, Tziona I, Lawrenson RA, Alam FM, Nohadani M, Stamp GW, 
Zinkernagel AS, Nizet V, Edwards RJ, Sriskandan S. 2010. Chemokine-cleaving 
 179 
Streptococcus pyogenes protease SpyCEP is necessary and sufficient for bacterial 
dissemination within soft tissues and the respiratory tract. Mol Microbiol 76:1387-97. 
147. Hidalgo-Grass C, Mishalian I, Dan-Goor M, Belotserkovsky I, Eran Y, Nizet V, Peled A, 
Hanski E. 2006. A streptococcal protease that degrades CXC chemokines and impairs 
bacterial clearance from infected tissues. EMBO J 25:4628-37. 
148. Barnett TC, Cole JN, Rivera-Hernandez T, Henningham A, Paton JC, Nizet V, Walker MJ. 
2015. Streptococcal toxins: role in pathogenesis and disease. Cell Microbiol 17:1721-41. 
149. Sierig G, Cywes C, Wessels MR, Ashbaugh CD. 2003. Cytotoxic effects of streptolysin o and 
streptolysin s enhance the virulence of poorly encapsulated group a streptococci. Infect 
Immun 71:446-55. 
150. Miyoshi-Akiyama T, Takamatsu D, Koyanagi M, Zhao J, Imanishi K, Uchiyama T. 2005. 
Cytocidal effect of Streptococcus pyogenes on mouse neutrophils in vivo and the critical role 
of streptolysin S. J Infect Dis 192:107-16. 
151. Urb M, Sheppard DC. 2012. The role of mast cells in the defence against pathogens. PLoS 
Pathog 8:e1002619. 
152. Di Nardo A, Yamasaki K, Dorschner RA, Lai Y, Gallo RL. 2008. Mast cell cathelicidin 
antimicrobial peptide prevents invasive group A Streptococcus infection of the skin. J 
Immunol 180:7565-73. 
153. Matsui H, Sekiya Y, Takahashi T, Nakamura M, Imanishi K, Yoshida H, Murayama SY, 
Takahashi T, Tsuchimoto K, Uchiyama T, Ubukata K. 2011. Dermal mast cells reduce 
progressive tissue necrosis caused by subcutaneous infection with Streptococcus pyogenes in 
mice. J Med Microbiol 60:128-34. 
154. von Kockritz-Blickwede M, Goldmann O, Thulin P, Heinemann K, Norrby-Teglund A, 
Rohde M, Medina E. 2008. Phagocytosis-independent antimicrobial activity of mast cells by 
means of extracellular trap formation. Blood 111:3070-80. 
155. Stassen M, Muller C, Richter C, Neudorfl C, Hultner L, Bhakdi S, Walev I, Schmitt E. 2003. 
The streptococcal exotoxin streptolysin O activates mast cells to produce tumor necrosis 
factor alpha by p38 mitogen-activated protein kinase- and protein kinase C-dependent 
pathways. Infect Immun 71:6171-7. 
156. Watanabe Y, Todome Y, Ohkuni H, Sakurada S, Ishikawa T, Yutsudo T, Fischetti VA, 
Zabriskie JB. 2002. Cysteine protease activity and histamine release from the human mast 
cell line HMC-1 stimulated by recombinant streptococcal pyrogenic exotoxin B/streptococcal 
cysteine protease. Infect Immun 70:3944-7. 
157. Fieber C, Janos M, Koestler T, Gratz N, Li XD, Castiglia V, Aberle M, Sauert M, Wegner M, 
Alexopoulou L, Kirschning CJ, Chen ZJ, von Haeseler A, Kovarik P. 2015. Innate immune 
 180 
response to Streptococcus pyogenes depends on the combined activation of TLR13 and TLR2. 
PLoS One 10:e0119727. 
158. Mishalian I, Ordan M, Peled A, Maly A, Eichenbaum MB, Ravins M, Aychek T, Jung S, 
Hanski E. 2011. Recruited macrophages control dissemination of group A Streptococcus from 
infected soft tissues. J Immunol 187:6022-31. 
159. Latvala S, Makela SM, Miettinen M, Charpentier E, Julkunen I. 2014. Dynamin inhibition 
interferes with inflammasome activation and cytokine gene expression in Streptococcus 
pyogenes-infected human macrophages. Clin Exp Immunol 178:320-33. 
160. Dennis EA, Norris PC. 2015. Eicosanoid storm in infection and inflammation. Nat Rev 
Immunol 15:511-23. 
161. Serezani CH, Ballinger MN, Aronoff DM, Peters-Golden M. 2008. Cyclic AMP: master 
regulator of innate immune cell function. Am J Respir Cell Mol Biol 39:127-32. 
162. Soares EM, Mason KL, Rogers LM, Serezani CH, Faccioli LH, Aronoff DM. 2013. 
Leukotriene B4 enhances innate immune defense against the puerperal sepsis agent 
Streptococcus pyogenes. J Immunol 190:1614-22. 
163. Goldmann O, Sastalla I, Wos-Oxley M, Rohde M, Medina E. 2009. Streptococcus pyogenes 
induces oncosis in macrophages through the activation of an inflammatory programmed cell 
death pathway. Cell Microbiol 11:138-55. 
164. Gryllos I, Grifantini R, Colaprico A, Cary ME, Hakansson A, Carey DW, Suarez-Chavez M, 
Kalish LA, Mitchell PD, White GL, Wessels MR. 2008. PerR confers phagocytic killing 
resistance and allows pharyngeal colonization by group A Streptococcus. PLoS Pathog 
4:e1000145. 
165. Franklin L, Nobbs AH, Bricio-Moreno L, Wright CJ, Maddocks SE, Sahota JS, Ralph J, 
O'Connor M, Jenkinson HF, Kadioglu A. 2013. The AgI/II family adhesin AspA is required 
for respiratory infection by Streptococcus pyogenes. PLoS One 8:e62433. 
166. Barnett TC, Liebl D, Seymour LM, Gillen CM, Lim JY, Larock CN, Davies MR, Schulz BL, 
Nizet V, Teasdale RD, Walker MJ. 2013. The globally disseminated M1T1 clone of group A 
Streptococcus evades autophagy for intracellular replication. Cell Host Microbe 14:675-82. 
167. Thulin P, Johansson L, Low DE, Gan BS, Kotb M, McGeer A, Norrby-Teglund A. 2006. 
Viable group A streptococci in macrophages during acute soft tissue infection. PLoS Med 
3:e53. 
168. Loof TG, Rohde M, Chhatwal GS, Jung S, Medina E. 2007. The contribution of dendritic 
cells to host defenses against Streptococcus pyogenes. J Infect Dis 196:1794-803. 
169. Veckman V, Miettinen M, Pirhonen J, Siren J, Matikainen S, Julkunen I. 2004. Streptococcus 
pyogenes and Lactobacillus rhamnosus differentially induce maturation and production of 
 181 
Th1-type cytokines and chemokines in human monocyte-derived dendritic cells. J Leukoc 
Biol 75:764-71. 
170. Ye J, Ortaldo JR, Conlon K, Winkler-Pickett R, Young HA. 1995. Cellular and molecular 
mechanisms of IFN-gamma production induced by IL-2 and IL-12 in a human NK cell line. 
J Leukoc Biol 58:225-33. 
171. Schroder K, Sweet MJ, Hume DA. 2006. Signal integration between IFNgamma and TLR 
signalling pathways in macrophages. Immunobiology 211:511-24. 
172. Goldmann O, Chhatwal GS, Medina E. 2005. Contribution of natural killer cells to the 
pathogenesis of septic shock induced by Streptococcus pyogenes in mice. J Infect Dis 
191:1280-6. 
173. Loof TG, Goldmann O, Gessner A, Herwald H, Medina E. 2010. Aberrant inflammatory 
response to Streptococcus pyogenes in mice lacking myeloid differentiation factor 88. Am J 
Pathol 176:754-63. 
174. Fieber C, Kovarik P. 2014. Responses of innate immune cells to group A Streptococcus. Front 
Cell Infect Microbiol 4:140. 
175. Tsatsaronis JA, Walker MJ, Sanderson-Smith ML. 2014. Host responses to group a 
streptococcus: cell death and inflammation. PLoS Pathog 10:e1004266. 
176. Loof TG, Goldmann O, Medina E. 2008. Immune recognition of Streptococcus pyogenes by 
dendritic cells. Infect Immun 76:2785-92. 
177. Oldenburg M, Kruger A, Ferstl R, Kaufmann A, Nees G, Sigmund A, Bathke B, Lauterbach 
H, Suter M, Dreher S, Koedel U, Akira S, Kawai T, Buer J, Wagner H, Bauer S, Hochrein H, 
Kirschning CJ. 2012. TLR13 recognizes bacterial 23S rRNA devoid of erythromycin 
resistance-forming modification. Science 337:1111-5. 
178. Eigenbrod T, Pelka K, Latz E, Kreikemeyer B, Dalpke AH. 2015. TLR8 Senses Bacterial 
RNA in Human Monocytes and Plays a Nonredundant Role for Recognition of Streptococcus 
pyogenes. J Immunol 195:1092-9. 
179. Kruger A, Oldenburg M, Chebrolu C, Beisser D, Kolter J, Sigmund AM, Steinmann J, Schafer 
S, Hochrein H, Rahmann S, Wagner H, Henneke P, Hornung V, Buer J, Kirschning CJ. 2015. 
Human TLR8 senses UR/URR motifs in bacterial and mitochondrial RNA. EMBO Rep 
16:1656-63. 
180. Campbell GR, Spector SA. 2012. Toll-like receptor 8 ligands activate a vitamin D mediated 
autophagic response that inhibits human immunodeficiency virus type 1. PLoS Pathog 
8:e1003017. 
 182 
181. Nakagawa I, Amano A, Mizushima N, Yamamoto A, Yamaguchi H, Kamimoto T, Nara A, 
Funao J, Nakata M, Tsuda K, Hamada S, Yoshimori T. 2004. Autophagy defends cells against 
invading group A Streptococcus. Science 306:1037-40. 
182. Latz E, Xiao TS, Stutz A. 2013. Activation and regulation of the inflammasomes. Nat Rev 
Immunol 13:397-411. 
183. Harder J, Franchi L, Munoz-Planillo R, Park JH, Reimer T, Nunez G. 2009. Activation of the 
Nlrp3 inflammasome by Streptococcus pyogenes requires streptolysin O and NF-kappa B 
activation but proceeds independently of TLR signaling and P2X7 receptor. J Immunol 
183:5823-9. 
184. Hancz D, Westerlund E, Bastiat-Sempe B, Sharma O, Valfridsson C, Meyer L, Love JF, 
O'Seaghdha M, Wessels MR, Persson JJ. 2017. Inhibition of Inflammasome-Dependent 
Interleukin 1beta Production by Streptococcal NAD+-Glycohydrolase: Evidence for 
Extracellular Activity. MBio 8. 
185. Lin AE, Beasley FC, Keller N, Hollands A, Urbano R, Troemel ER, Hoffman HM, Nizet V. 
2015. A group A Streptococcus ADP-ribosyltransferase toxin stimulates a protective 
interleukin 1beta-dependent macrophage immune response. MBio 6:e00133. 
186. LaRock CN, Todd J, LaRock DL, Olson J, O'Donoghue AJ, Robertson AA, Cooper MA, 
Hoffman HM, Nizet V. 2016. IL-1beta is an innate immune sensor of microbial proteolysis. 
Sci Immunol 1. 
187. Medina E, Anders D, Chhatwal GS. 2002. Induction of NF-kappaB nuclear translocation in 
human respiratory epithelial cells by group A streptococci. Microb Pathog 33:307-13. 
188. Chandrasekaran S, Caparon MG. 2016. The NADase-Negative Variant of the Streptococcus 
pyogenes Toxin NAD(+) Glycohydrolase Induces JNK1-Mediated Programmed Cellular 
Necrosis. MBio 7:e02215-15. 
189. Okahashi N, Sakurai A, Nakagawa I, Fujiwara T, Kawabata S, Amano A, Hamada S. 2003. 
Infection by Streptococcus pyogenes induces the receptor activator of NF-kappaB ligand 
expression in mouse osteoblastic cells. Infect Immun 71:948-55. 
190. Hai T, Curran T. 1991. Cross-family dimerization of transcription factors Fos/Jun and 
ATF/CREB alters DNA binding specificity. Proc Natl Acad Sci U S A 88:3720-4. 
191. Kalinski P. 2012. Regulation of immune responses by prostaglandin E2. J Immunol 188:21-
8. 
192. Agard M, Asakrah S, Morici LA. 2013. PGE(2) suppression of innate immunity during 
mucosal bacterial infection. Front Cell Infect Microbiol 3:45. 
 183 
193. Vega LA, Malke H, McIver KS. 2016. Virulence-Related Transcriptional Regulators of 
Streptococcus pyogenes. In Ferretti JJ, Stevens DL, Fischetti VA (ed), Streptococcus 
pyogenes : Basic Biology to Clinical Manifestations, Oklahoma City (OK). 
194. Sumby P, Zhang S, Whitney AR, Falugi F, Grandi G, Graviss EA, Deleo FR, Musser JM. 
2008. A chemokine-degrading extracellular protease made by group A Streptococcus alters 
pathogenesis by enhancing evasion of the innate immune response. Infect Immun 76:978-85. 
195. Egesten A, Olin AI, Linge HM, Yadav M, Morgelin M, Karlsson A, Collin M. 2009. SpeB of 
Streptococcus pyogenes differentially modulates antibacterial and receptor activating 
properties of human chemokines. PLoS One 4:e4769. 
196. Shelburne SA, 3rd, Granville C, Tokuyama M, Sitkiewicz I, Patel P, Musser JM. 2005. 
Growth characteristics of and virulence factor production by group A Streptococcus during 
cultivation in human saliva. Infect Immun 73:4723-31. 
197. Svensson MD, Scaramuzzino DA, Sjobring U, Olsen A, Frank C, Bessen DE. 2000. Role for 
a secreted cysteine proteinase in the establishment of host tissue tropism by group A 
streptococci. Mol Microbiol 38:242-53. 
198. Leao SC, Leal IO, Rocha HM, Rodrigues TM. 2015. Evaluation of cytokines produced by 
beta-hemolytic streptococcus in acute pharyngotonsillitis. Braz J Otorhinolaryngol 81:402-7. 
199. Kapur V, Majesky MW, Li LL, Black RA, Musser JM. 1993. Cleavage of interleukin 1 beta 
(IL-1 beta) precursor to produce active IL-1 beta by a conserved extracellular cysteine 
protease from Streptococcus pyogenes. Proc Natl Acad Sci U S A 90:7676-80. 
200. Sakurai A, Okahashi N, Nakagawa I, Kawabata S, Amano A, Ooshima T, Hamada S. 2003. 
Streptococcus pyogenes infection induces septic arthritis with increased production of the 
receptor activator of the NF-kappaB ligand. Infect Immun 71:6019-26. 
201. Lappalainen U, Whitsett JA, Wert SE, Tichelaar JW, Bry K. 2005. Interleukin-1beta causes 
pulmonary inflammation, emphysema, and airway remodeling in the adult murine lung. Am 
J Respir Cell Mol Biol 32:311-8. 
202. Kazmi SU, Kansal R, Aziz RK, Hooshdaran M, Norrby-Teglund A, Low DE, Halim AB, 
Kotb M. 2001. Reciprocal, temporal expression of SpeA and SpeB by invasive M1T1 group 
a streptococcal isolates in vivo. Infect Immun 69:4988-95. 
203. Olsen RJ, Raghuram A, Cantu C, Hartman MH, Jimenez FE, Lee S, Ngo A, Rice KA, 
Saddington D, Spillman H, Valson C, Flores AR, Beres SB, Long SW, Nasser W, Musser JM. 
2015. The majority of 9,729 group A streptococcus strains causing disease secrete SpeB 
cysteine protease: pathogenesis implications. Infect Immun 83:4750-8. 
 184 
204. Yang D, Chertov O, Oppenheim JJ. 2001. The role of mammalian antimicrobial peptides and 
proteins in awakening of innate host defenses and adaptive immunity. Cell Mol Life Sci 
58:978-89. 
205. Frick IM, Nordin SL, Baumgarten M, Morgelin M, Sorensen OE, Olin AI, Egesten A. 2011. 
Constitutive and inflammation-dependent antimicrobial peptides produced by epithelium are 
differentially processed and inactivated by the commensal Finegoldia magna and the pathogen 
Streptococcus pyogenes. J Immunol 187:4300-9. 
206. Dorschner RA, Pestonjamasp VK, Tamakuwala S, Ohtake T, Rudisill J, Nizet V, Agerberth 
B, Gudmundsson GH, Gallo RL. 2001. Cutaneous injury induces the release of cathelicidin 
anti-microbial peptides active against group A Streptococcus. J Invest Dermatol 117:91-7. 
207. Yu J, Mookherjee N, Wee K, Bowdish DM, Pistolic J, Li Y, Rehaume L, Hancock RE. 2007. 
Host defense peptide LL-37, in synergy with inflammatory mediator IL-1beta, augments 
immune responses by multiple pathways. J Immunol 179:7684-91. 
208. Quinn GA, Cole AM. 2007. Suppression of innate immunity by a nasal carriage strain of 
Staphylococcus aureus increases its colonization on nasal epithelium. Immunology 122:80-9. 
209. Fernie-King BA, Seilly DJ, Lachmann PJ. 2004. The interaction of streptococcal inhibitor of 
complement (SIC) and its proteolytic fragments with the human beta defensins. Immunology 
111:444-52. 
210. Peschel A, Sahl HG. 2006. The co-evolution of host cationic antimicrobial peptides and 
microbial resistance. Nat Rev Microbiol 4:529-36. 
211. Frick IM, Akesson P, Rasmussen M, Schmidtchen A, Bjorck L. 2003. SIC, a secreted protein 
of Streptococcus pyogenes that inactivates antibacterial peptides. J Biol Chem 278:16561-6. 
212. Fernie-King BA, Seilly DJ, Davies A, Lachmann PJ. 2002. Streptococcal inhibitor of 
complement inhibits two additional components of the mucosal innate immune system: 
secretory leukocyte proteinase inhibitor and lysozyme. Infect Immun 70:4908-16. 
213. Lukomski S, Hoe NP, Abdi I, Rurangirwa J, Kordari P, Liu M, Dou SJ, Adams GG, Musser 
JM. 2000. Nonpolar inactivation of the hypervariable streptococcal inhibitor of complement 
gene (sic) in serotype M1 Streptococcus pyogenes significantly decreases mouse mucosal 
colonization. Infect Immun 68:535-42. 
214. Hollands A, Gonzalez D, Leire E, Donald C, Gallo RL, Sanderson-Smith M, Dorrestein PC, 
Nizet V. 2012. A bacterial pathogen co-opts host plasmin to resist killing by cathelicidin 
antimicrobial peptides. J Biol Chem 287:40891-7. 
215. Lauth X, von Kockritz-Blickwede M, McNamara CW, Myskowski S, Zinkernagel AS, Beall 
B, Ghosh P, Gallo RL, Nizet V. 2009. M1 protein allows Group A streptococcal survival in 
phagocyte extracellular traps through cathelicidin inhibition. J Innate Immun 1:202-14. 
 185 
216. LaRock CN, Dohrmann S, Todd J, Corriden R, Olson J, Johannssen T, Lepenies B, Gallo RL, 
Ghosh P, Nizet V. 2015. Group A Streptococcal M1 Protein Sequesters Cathelicidin to Evade 
Innate Immune Killing. Cell Host Microbe 18:471-7. 
217. Fernie-King BA, Seilly DJ, Willers C, Wurzner R, Davies A, Lachmann PJ. 2001. 
Streptococcal inhibitor of complement (SIC) inhibits the membrane attack complex by 
preventing uptake of C567 onto cell membranes. Immunology 103:390-8. 
218. Serruto D, Rappuoli R, Scarselli M, Gros P, van Strijp JA. 2010. Molecular mechanisms of 
complement evasion: learning from staphylococci and meningococci. Nat Rev Microbiol 
8:393-9. 
219. Thern A, Stenberg L, Dahlback B, Lindahl G. 1995. Ig-binding surface proteins of 
Streptococcus pyogenes also bind human C4b-binding protein (C4BP), a regulatory 
component of the complement system. J Immunol 154:375-86. 
220. Horstmann RD, Sievertsen HJ, Knobloch J, Fischetti VA. 1988. Antiphagocytic activity of 
streptococcal M protein: selective binding of complement control protein factor H. Proc Natl 
Acad Sci U S A 85:1657-61. 
221. Johnsson E, Berggard K, Kotarsky H, Hellwage J, Zipfel PF, Sjobring U, Lindahl G. 1998. 
Role of the hypervariable region in streptococcal M proteins: binding of a human complement 
inhibitor. J Immunol 161:4894-901. 
222. Carlsson F, Sandin C, Lindahl G. 2005. Human fibrinogen bound to Streptococcus pyogenes 
M protein inhibits complement deposition via the classical pathway. Mol Microbiol 56:28-
39. 
223. Ly D, Taylor JM, Tsatsaronis JA, Monteleone MM, Skora AS, Donald CA, Maddocks T, 
Nizet V, West NP, Ranson M, Walker MJ, McArthur JD, Sanderson-Smith ML. 2014. 
Plasmin(ogen) acquisition by group A Streptococcus protects against C3b-mediated 
neutrophil killing. J Innate Immun 6:240-50. 
224. von Bernuth H, Picard C, Puel A, Casanova JL. 2012. Experimental and natural infections in 
MyD88- and IRAK-4-deficient mice and humans. Eur J Immunol 42:3126-35. 
225. Picard C, Casanova JL, Puel A. 2011. Infectious diseases in patients with IRAK-4, MyD88, 
NEMO, or IkappaBalpha deficiency. Clin Microbiol Rev 24:490-7. 
226. Hyland KA, Brennan R, Olmsted SB, Rojas E, Murphy E, Wang B, Cleary PP. 2009. The 
early interferon response of nasal-associated lymphoid tissue to Streptococcus pyogenes 
infection. FEMS Immunol Med Microbiol 55:422-31. 
227. Raeder RH, Barker-Merrill L, Lester T, Boyle MD, Metzger DW. 2000. A pivotal role for 
interferon-gamma in protection against group A streptococcal skin infection. J Infect Dis 
181:639-45. 
 186 
228. Dong C. 2008. IL-23/IL-17 biology and therapeutic considerations. J Immunotoxicol 5:43-6. 
229. Korn T, Bettelli E, Oukka M, Kuchroo VK. 2009. IL-17 and Th17 Cells. Annu Rev Immunol 
27:485-517. 
230. Carey AJ, Weinberg JB, Dawid SR, Venturini C, Lam AK, Nizet V, Caparon MG, Walker 
MJ, Watson ME, Ulett GC. 2016. Interleukin-17A Contributes to the Control of Streptococcus 
pyogenes Colonization and Inflammation of the Female Genital Tract. Sci Rep 6:26836. 
231. Chong DL, Ingram RJ, Lowther DE, Muir R, Sriskandan S, Altmann DM. 2012. The nature 
of innate and adaptive interleukin-17A responses in sham or bacterial inoculation. 
Immunology 136:325-33. 
232. Joosten LA, Abdollahi-Roodsaz S, Heuvelmans-Jacobs M, Helsen MM, van den Bersselaar 
LA, Oppers-Walgreen B, Koenders MI, van den Berg WB. 2008. T cell dependence of chronic 
destructive murine arthritis induced by repeated local activation of Toll-like receptor-driven 
pathways: crucial role of both interleukin-1beta and interleukin-17. Arthritis Rheum 58:98-
108. 
233. Martin B, Hirota K, Cua DJ, Stockinger B, Veldhoen M. 2009. Interleukin-17-producing 
gammadelta T cells selectively expand in response to pathogen products and environmental 
signals. Immunity 31:321-30. 
234. Costalonga M, Cleary PP, Fischer LA, Zhao Z. 2009. Intranasal bacteria induce Th1 but not 
Treg or Th2. Mucosal Immunol 2:85-95. 
235. Taylor AL, Cross EL, Llewelyn MJ. 2012. Induction of contact-dependent CD8(+) regulatory 
T cells through stimulation with staphylococcal and streptococcal superantigens. Immunology 
135:158-67. 
236. Price JD, Schaumburg J, Sandin C, Atkinson JP, Lindahl G, Kemper C. 2005. Induction of a 
regulatory phenotype in human CD4+ T cells by streptococcal M protein. J Immunol 175:677-
84. 
237. Shaler CR, Choi J, Rudak PT, Memarnejadian A, Szabo PA, Tun-Abraham ME, Rossjohn J, 
Corbett AJ, McCluskey J, McCormick JK, Lantz O, Hernandez-Alejandro R, Haeryfar SMM. 
2017. MAIT cells launch a rapid, robust and distinct hyperinflammatory response to bacterial 
superantigens and quickly acquire an anergic phenotype that impedes their cognate 
antimicrobial function: Defining a novel mechanism of superantigen-induced 
immunopathology and immunosuppression. PLoS Biol 15:e2001930. 
238. Crowe CC, Sanders WE, Jr., Longley S. 1973. Bacterial interference. II. Role of the normal 
throat flora in prevention of colonization by group A Streptococcus. J Infect Dis 128:527-32. 
 187 
239. Sanders E. 1969. Bacterial interference. I. Its occurrence among the respiratory tract flora and 
characterization of inhibition of group A streptococci by viridans streptococci. J Infect Dis 
120:698-707. 
240. Belkaid Y, Hand TW. 2014. Role of the microbiota in immunity and inflammation. Cell 
157:121-41. 
241. Niers LE, Timmerman HM, Rijkers GT, van Bleek GM, van Uden NO, Knol EF, Kapsenberg 
ML, Kimpen JL, Hoekstra MO. 2005. Identification of strong interleukin-10 inducing lactic 
acid bacteria which down-regulate T helper type 2 cytokines. Clin Exp Allergy 35:1481-9. 
242. Christensen HR, Frokiaer H, Pestka JJ. 2002. Lactobacilli differentially modulate expression 
of cytokines and maturation surface markers in murine dendritic cells. J Immunol 168:171-8. 
243. Saroj SD, Maudsdotter L, Tavares R, Jonsson AB. 2016. Lactobacilli Interfere with 
Streptococcus pyogenes Hemolytic Activity and Adherence to Host Epithelial Cells. Front 
Microbiol 7:1176. 
244. Capaldo CT, Nusrat A. 2009. Cytokine regulation of tight junctions. Biochim Biophys Acta 
1788:864-71. 
245. Burton JP, Wescombe PA, Moore CJ, Chilcott CN, Tagg JR. 2006. Safety assessment of the 
oral cavity probiotic Streptococcus salivarius K12. Appl Environ Microbiol 72:3050-3. 
246. Di Pierro F, Donato G, Fomia F, Adami T, Careddu D, Cassandro C, Albera R. 2012. 
Preliminary pediatric clinical evaluation of the oral probiotic Streptococcus salivarius K12 in 
preventing recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes and 
recurrent acute otitis media. Int J Gen Med 5:991-7. 
247. Di Pierro F, Colombo M, Zanvit A, Rottoli AS. 2016. Positive clinical outcomes derived from 
using Streptococcus salivarius K12 to prevent streptococcal pharyngotonsillitis in children: a 
pilot investigation. Drug Healthc Patient Saf 8:77-81. 
248. Di Pierro F, Colombo M, Giuliani MG, Danza ML, Basile I, Bollani T, Conti AM, Zanvit A, 
Rottoli AS. 2016. Effect of administration of Streptococcus salivarius K12 on the occurrence 
of streptococcal pharyngo-tonsillitis, scarlet fever and acute otitis media in 3 years old 
children. Eur Rev Med Pharmacol Sci 20:4601-4606. 
249. Di Pierro F, Adami T, Rapacioli G, Giardini N, Streitberger C. 2013. Clinical evaluation of 
the oral probiotic Streptococcus salivarius K12 in the prevention of recurrent pharyngitis 
and/or tonsillitis caused by Streptococcus pyogenes in adults. Expert Opin Biol Ther 13:339-
43. 
250. Wessels MR. 2016. Pharyngitis and Scarlet Fever. In Ferretti JJ, Stevens DL, Fischetti VA 
(ed), Streptococcus pyogenes : Basic Biology to Clinical Manifestations, Oklahoma City 
(OK). 
 188 
251. Marijon E, Mirabel M, Celermajer DS, Jouven X. 2012. Rheumatic heart disease. Lancet 
379:953-64. 
252. Seckeler MD, Hoke TR. 2011. The worldwide epidemiology of acute rheumatic fever and 
rheumatic heart disease. Clin Epidemiol 3:67-84. 
253. Birdi N, Hosking M, Clulow MK, Duffy CM, Allen U, Petty RE. 2001. Acute rheumatic fever 
and poststreptococcal reactive arthritis: diagnostic and treatment practices of pediatric 
subspecialists in Canada. J Rheumatol 28:1681-8. 
254. Gerber MA, Baltimore RS, Eaton CB, Gewitz M, Rowley AH, Shulman ST, Taubert KA. 
2009. Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal 
pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, 
Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in 
the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, 
and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by 
the American Academy of Pediatrics. Circulation 119:1541-51. 
255. Chalker V, Jironkin A, Coelho J, Al-Shahib A, Platt S, Kapatai G, Daniel R, Dhami C, 
Laranjeira M, Chambers T, Guy R, Lamagni T, Harrison T, Chand M, Johnson AP, 
Underwood A, Scarlet Fever Incident Management T. 2017. Genome analysis following a 
national increase in Scarlet Fever in England 2014. BMC Genomics 18:224. 
256. Davies MR, Holden MT, Coupland P, Chen JH, Venturini C, Barnett TC, Zakour NL, Tse H, 
Dougan G, Yuen KY, Walker MJ. 2015. Emergence of scarlet fever Streptococcus pyogenes 
emm12 clones in Hong Kong is associated with toxin acquisition and multidrug resistance. 
Nat Genet 47:84-7. 
257. Tse H, Bao JY, Davies MR, Maamary P, Tsoi HW, Tong AH, Ho TC, Lin CH, Gillen CM, 
Barnett TC, Chen JH, Lee M, Yam WC, Wong CK, Ong CL, Chan YW, Wu CW, Ng T, Lim 
WW, Tsang TH, Tse CW, Dougan G, Walker MJ, Lok S, Yuen KY. 2012. Molecular 
characterization of the 2011 Hong Kong scarlet fever outbreak. J Infect Dis 206:341-51. 
258. Ben Zakour NL, Davies MR, You Y, Chen JH, Forde BM, Stanton-Cook M, Yang R, Cui Y, 
Barnett TC, Venturini C, Ong CL, Tse H, Dougan G, Zhang J, Yuen KY, Beatson SA, Walker 
MJ. 2015. Transfer of scarlet fever-associated elements into the group A Streptococcus M1T1 
clone. Sci Rep 5:15877. 
259. Johnson LP, L'Italien JJ, Schlievert PM. 1986. Streptococcal pyrogenic exotoxin type A 
(scarlet fever toxin) is related to Staphylococcus aureus enterotoxin B. Mol Gen Genet 
203:354-6. 
260. Viciani E, Montagnani F, Tordini G, Romano A, Salerni L, De Luca A, Ruggiero P, Manetti 
AG. 2017. Prevalence of M75 Streptococcus pyogenes Strains Harboring slaA Gene in 
 189 
Patients Affected by Pediatric Obstructive Sleep Apnea Syndrome in Central Italy. Front 
Microbiol 8:294. 
261. Nagiec MJ, Lei B, Parker SK, Vasil ML, Matsumoto M, Ireland RM, Beres SB, Hoe NP, 
Musser JM. 2004. Analysis of a novel prophage-encoded group A Streptococcus extracellular 
phospholipase A(2). J Biol Chem 279:45909-18. 
262. Nickoloff BJ. 1991. The cytokine network in psoriasis. Arch Dermatol 127:871-84. 
263. Prinz JC. 2001. Psoriasis vulgaris--a sterile antibacterial skin reaction mediated by cross-
reactive T cells? An immunological view of the pathophysiology of psoriasis. Clin Exp 
Dermatol 26:326-32. 
264. Roberson ED, Bowcock AM. 2010. Psoriasis genetics: breaking the barrier. Trends Genet 
26:415-23. 
265. Sigmundsdottir H, Gudjonsson JE, Jonsdottir I, Ludviksson BR, Valdimarsson H. 2001. The 
frequency of CLA+ CD8+ T cells in the blood of psoriasis patients correlates closely with the 
severity of their disease. Clin Exp Immunol 126:365-9. 
266. Ruiz-Romeu E, Ferran M, Sagrista M, Gomez J, Gimenez-Arnau A, Herszenyi K, Hollo P, 
Celada A, Pujol R, Santamaria-Babi LF. 2016. Streptococcus pyogenes-induced cutaneous 
lymphocyte antigen-positive T cell-dependent epidermal cell activation triggers TH17 
responses in patients with guttate psoriasis. J Allergy Clin Immunol 138:491-499 e6. 
267. Sigurdardottir SL, Thorleifsdottir RH, Valdimarsson H, Johnston A. 2013. The role of the 
palatine tonsils in the pathogenesis and treatment of psoriasis. Br J Dermatol 168:237-42. 
268. Thorleifsdottir RH, Sigurdardottir SL, Sigurgeirsson B, Olafsson JH, Sigurdsson MI, Petersen 
H, Arnadottir S, Gudjonsson JE, Johnston A, Valdimarsson H. 2012. Improvement of 
psoriasis after tonsillectomy is associated with a decrease in the frequency of circulating T 
cells that recognize streptococcal determinants and homologous skin determinants. J Immunol 
188:5160-5. 
269. Weisenseel P, Prinz JC. 2005. Incidental detection of S. pyogenes-DNA in psoriatic skin by 
PCR. Arch Dermatol Res 296:573-6. 
270. Chatellier S, Ihendyane N, Kansal RG, Khambaty F, Basma H, Norrby-Teglund A, Low DE, 
McGeer A, Kotb M. 2000. Genetic relatedness and superantigen expression in group A 
streptococcus serotype M1 isolates from patients with severe and nonsevere invasive diseases. 
Infect Immun 68:3523-34. 
271. Norgren M, Caparon MG, Scott JR. 1989. A method for allelic replacement that uses the 
conjugative transposon Tn916: deletion of the emm6.1 allele in Streptococcus pyogenes 
JRS4. Infect Immun 57:3846-50. 
 190 
272. Schagger H, von Jagow G. 1987. Tricine-sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem 
166:368-79. 
273. Liao Y, Smyth GK, Shi W. 2013. The Subread aligner: fast, accurate and scalable read 
mapping by seed-and-vote. Nucleic Acids Res 41:e108. 
274. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. 2015. limma powers 
differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids 
Res 43:e47. 
275. Wells CA, Mosbergen R, Korn O, Choi J, Seidenman N, Matigian NA, Vitale AM, Shepherd 
J. 2013. Stemformatics: visualisation and sharing of stem cell gene expression. Stem Cell Res 
10:387-95. 
276. Edgar R, Domrachev M, Lash AE. 2002. Gene Expression Omnibus: NCBI gene expression 
and hybridization array data repository. Nucleic Acids Res 30:207-10. 
277. Oshlack A, Robinson MD, Young MD. 2010. From RNA-seq reads to differential expression 
results. Genome Biol 11:220. 
278. Robinson MD, Oshlack A. 2010. A scaling normalization method for differential expression 
analysis of RNA-seq data. Genome Biol 11:R25. 
279. Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, Cheng JX, Murre C, Singh H, 
Glass CK. 2010. Simple combinations of lineage-determining transcription factors prime cis-
regulatory elements required for macrophage and B cell identities. Mol Cell 38:576-89. 
280. Gilmore TD. 2006. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 
25:6680-4. 
281. Siebenlist U, Franzoso G, Brown K. 1994. Structure, regulation and function of NF-kappa B. 
Annu Rev Cell Biol 10:405-55. 
282. Hop HT, Reyes AWB, Huy TXN, Arayan LT, Min W, Lee HJ, Rhee MH, Chang HH, Kim 
S. 2017. Activation of NF-kB-Mediated TNF-Induced Antimicrobial Immunity Is Required 
for the Efficient Brucella abortus Clearance in RAW 264.7 Cells. Front Cell Infect Microbiol 
7:437. 
283. Lavon I, Goldberg I, Amit S, Landsman L, Jung S, Tsuberi BZ, Barshack I, Kopolovic J, 
Galun E, Bujard H, Ben-Neriah Y. 2000. High susceptibility to bacterial infection, but no liver 
dysfunction, in mice compromised for hepatocyte NF-kappaB activation. Nat Med 6:573-7. 
284. Beinke S, Ley SC. 2004. Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology. 
Biochem J 382:393-409. 
 191 
285. Clark MA, Wilson C, Sama A, Wilson JA, Hirst BH. 2000. Differential cytokeratin and 
glycoconjugate expression by the surface and crypt epithelia of human palatine tonsils. 
Histochem Cell Biol 114:311-21. 
286. Kopitar-Jerala N. 2006. The role of cystatins in cells of the immune system. FEBS Lett 
580:6295-301. 
287. Magister S, Kos J. 2013. Cystatins in immune system. J Cancer 4:45-56. 
288. Kato T, Takai T, Mitsuishi K, Okumura K, Ogawa H. 2005. Cystatin A inhibits IL-8 
production by keratinocytes stimulated with Der p 1 and Der f 1: biochemical skin barrier 
against mite cysteine proteases. J Allergy Clin Immunol 116:169-76. 
289. Ehrchen JM, Sunderkotter C, Foell D, Vogl T, Roth J. 2009. The endogenous Toll-like 
receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, 
autoimmunity, and cancer. J Leukoc Biol 86:557-66. 
290. Gao H, Zhang X, Zheng Y, Peng L, Hou J, Meng H. 2015. S100A9-induced release of 
interleukin (IL)-6 and IL-8 through toll-like receptor 4 (TLR4) in human periodontal ligament 
cells. Mol Immunol 67:223-32. 
291. Wu S, Ma C, Gao X, Zhang L, Miao Q, Li M, Li W, Song X, Wang X, Liu J, Wei L. 2016. 
Group A Streptococcus induces less p65 nuclear translocation and non-classical nuclear factor 
kappa B activation in macrophages, which possibly leads to a weaker inflammatory response. 
Int J Infect Dis 44:50-60. 
292. Goldmann O, von Kockritz-Blickwede M, Holtje C, Chhatwal GS, Geffers R, Medina E. 
2007. Transcriptome analysis of murine macrophages in response to infection with 
Streptococcus pyogenes reveals an unusual activation program. Infect Immun 75:4148-57. 
293. Lin WJ, Zheng X, Lin CC, Tsao J, Zhu X, Cody JJ, Coleman JM, Gherzi R, Luo M, Townes 
TM, Parker JN, Chen CY. 2011. Posttranscriptional control of type I interferon genes by 
KSRP in the innate immune response against viral infection. Mol Cell Biol 31:3196-207. 
294. Andreoni F, Ogawa T, Ogawa M, Madon J, Uchiyama S, Schuepbach RA, Zinkernagel AS. 
2014. The IL-8 protease SpyCEP is detrimental for Group A Streptococcus host-cells 
interaction and biofilm formation. Front Microbiol 5:339. 
295. Kovach MA, Singer B, Martinez-Colon G, Newstead MW, Zeng X, Mancuso P, Moore TA, 
Kunkel SL, Peters-Golden M, Moore BB, Standiford TJ. 2017. IL-36gamma is a crucial 
proximal component of protective type-1-mediated lung mucosal immunity in Gram-positive 
and -negative bacterial pneumonia. Mucosal Immunol 10:1320-1334. 
296. Gabay C, Towne JE. 2015. Regulation and function of interleukin-36 cytokines in 
homeostasis and pathological conditions. J Leukoc Biol 97:645-52. 
 192 
297. Nelson DC, Garbe J, Collin M. 2011. Cysteine proteinase SpeB from Streptococcus pyogenes 
- a potent modifier of immunologically important host and bacterial proteins. Biol Chem 
392:1077-88. 
298. Lyon WR, Madden JC, Levin JC, Stein JL, Caparon MG. 2001. Mutation of luxS affects 
growth and virulence factor expression in Streptococcus pyogenes. Mol Microbiol 42:145-57. 
299. Vogl T, Gharibyan AL, Morozova-Roche LA. 2012. Pro-inflammatory S100A8 and S100A9 
proteins: self-assembly into multifunctional native and amyloid complexes. Int J Mol Sci 
13:2893-917. 
300. Rodriguez-Iturbe B, Musser JM. 2008. The current state of poststreptococcal 
glomerulonephritis. J Am Soc Nephrol 19:1855-64. 
301. Gudjonsson JE, Thorarinsson AM, Sigurgeirsson B, Kristinsson KG, Valdimarsson H. 2003. 
Streptococcal throat infections and exacerbation of chronic plaque psoriasis: a prospective 
study. Br J Dermatol 149:530-4. 
302. Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, Santos A, Doncheva 
NT, Roth A, Bork P, Jensen LJ, von Mering C. 2017. The STRING database in 2017: quality-
controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res 
45:D362-D368. 
303. NHMRC. 2013. Australian code for the care and use of animals for scientific purposes.  
National Health and Medical Research Council, Canberra, Australia. 
304. Eliopoulos AG, Gallagher NJ, Blake SM, Dawson CW, Young LS. 1999. Activation of the 
p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent 
membrane protein 1 coregulates interleukin-6 and interleukin-8 production. J Biol Chem 
274:16085-96. 
305. Kaunisto A, Henry WS, Montaser-Kouhsari L, Jaminet SC, Oh EY, Zhao L, Luo HR, Beck 
AH, Toker A. 2015. NFAT1 promotes intratumoral neutrophil infiltration by regulating IL8 
expression in breast cancer. Mol Oncol 9:1140-54. 
306. Jundi K, Greene CM. 2015. Transcription of Interleukin-8: How Altered Regulation Can 
Affect Cystic Fibrosis Lung Disease. Biomolecules 5:1386-98. 
307. Oeckinghaus A, Ghosh S. 2009. The NF-kappaB family of transcription factors and its 
regulation. Cold Spring Harb Perspect Biol 1:a000034. 
308. Spencer JA, Misra RP. 1996. Expression of the serum response factor gene is regulated by 
serum response factor binding sites. J Biol Chem 271:16535-43. 
309. Ellenberger TE, Brandl CJ, Struhl K, Harrison SC. 1992. The GCN4 basic region leucine 
zipper binds DNA as a dimer of uninterrupted alpha helices: crystal structure of the protein-
DNA complex. Cell 71:1223-37. 
 193 
310. Turner CE, Kurupati P, Jones MD, Edwards RJ, Sriskandan S. 2009. Emerging role of the 
interleukin-8 cleaving enzyme SpyCEP in clinical Streptococcus pyogenes infection. J Infect 
Dis 200:555-63. 
311. Edwards RJ, Taylor GW, Ferguson M, Murray S, Rendell N, Wrigley A, Bai Z, Boyle J, 
Finney SJ, Jones A, Russell HH, Turner C, Cohen J, Faulkner L, Sriskandan S. 2005. Specific 
C-terminal cleavage and inactivation of interleukin-8 by invasive disease isolates of 
Streptococcus pyogenes. J Infect Dis 192:783-90. 
312. Port GC, Paluscio E, Caparon MG. 2015. Complete Genome Sequences of emm6 
Streptococcus pyogenes JRS4 and Parental Strain D471. Genome Announc 3. 
313. Fiebig A, Loof TG, Babbar A, Itzek A, Koehorst JJ, Schaap PJ, Nitsche-Schmitz DP. 2015. 
Comparative genomics of Streptococcus pyogenes M1 isolates differing in virulence and 
propensity to cause systemic infection in mice. Int J Med Microbiol 305:532-43. 
314. Zingaretti C, Falugi F, Nardi-Dei V, Pietrocola G, Mariani M, Liberatori S, Gallotta M, 
Tontini M, Tani C, Speziale P, Grandi G, Margarit I. 2010. Streptococcus pyogenes SpyCEP: 
a chemokine-inactivating protease with unique structural and biochemical features. FASEB J 
24:2839-48. 
315. Stanley AC, Lacy P. 2010. Pathways for cytokine secretion. Physiology (Bethesda) 25:218-
29. 
316. Murphy C, McGurk M, Pettigrew J, Santinelli A, Mazzucchelli R, Johnston PG, Montironi 
R, Waugh DJ. 2005. Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and 
CXCR2 correlates with cell proliferation and microvessel density in prostate cancer. Clin 
Cancer Res 11:4117-27. 
317. Ulukus M, Ulukus EC, Tavmergen Goker EN, Tavmergen E, Zheng W, Arici A. 2009. 
Expression of interleukin-8 and monocyte chemotactic protein 1 in women with 
endometriosis. Fertil Steril 91:687-93. 
318. Buchholz KR, Stephens RS. 2006. Activation of the host cell proinflammatory interleukin-8 
response by Chlamydia trachomatis. Cell Microbiol 8:1768-79. 
319. Rao A, Luo C, Hogan PG. 1997. Transcription factors of the NFAT family: regulation and 
function. Annu Rev Immunol 15:707-47. 
320. Bestebroer J, De Haas CJ, Van Strijp JA. 2010. How microorganisms avoid phagocyte 
attraction. FEMS Microbiol Rev 34:395-414. 
321. Reichle A. 2010. From molecular to modular tumor therapy : tumors are reconstructible 
communicatively evolving systems. Springer, Dordrecht ; New York. 
322. Sun L, Ye RD. 2012. Role of G protein-coupled receptors in inflammation. Acta Pharmacol 
Sin 33:342-50. 
 194 
323. Ye RD. 2001. Regulation of nuclear factor kappaB activation by G-protein-coupled receptors. 
J Leukoc Biol 70:839-48. 
324. Lodowski DT, Palczewski K. 2009. Chemokine receptors and other G protein-coupled 
receptors. Curr Opin HIV AIDS 4:88-95. 
325. Ruiz N, Wang B, Pentland A, Caparon M. 1998. Streptolysin O and adherence synergistically 
modulate proinflammatory responses of keratinocytes to group A streptococci. Mol Microbiol 
27:337-46. 
326. Tweten RK, Hotze EM, Wade KR. 2015. The Unique Molecular Choreography of Giant Pore 
Formation by the Cholesterol-Dependent Cytolysins of Gram-Positive Bacteria. Annu Rev 
Microbiol 69:323-40. 
327. Shewell LK, Harvey RM, Higgins MA, Day CJ, Hartley-Tassell LE, Chen AY, Gillen CM, 
James DB, Alonzo F, 3rd, Torres VJ, Walker MJ, Paton AW, Paton JC, Jennings MP. 2014. 
The cholesterol-dependent cytolysins pneumolysin and streptolysin O require binding to red 
blood cell glycans for hemolytic activity. Proc Natl Acad Sci U S A 111:E5312-20. 
328. Sekiya K, Satoh R, Danbara H, Futaesaku Y. 1993. A ring-shaped structure with a crown 
formed by streptolysin O on the erythrocyte membrane. J Bacteriol 175:5953-61. 
329. Shatursky O, Heuck AP, Shepard LA, Rossjohn J, Parker MW, Johnson AE, Tweten RK. 
1999. The mechanism of membrane insertion for a cholesterol-dependent cytolysin: a novel 
paradigm for pore-forming toxins. Cell 99:293-9. 
330. Madden JC, Ruiz N, Caparon M. 2001. Cytolysin-mediated translocation (CMT): a functional 
equivalent of type III secretion in gram-positive bacteria. Cell 104:143-52. 
331. Chandrasekaran S, Caparon MG. 2015. The Streptococcus pyogenes NAD(+) glycohydrolase 
modulates epithelial cell PARylation and HMGB1 release. Cell Microbiol 17:1376-90. 
332. Bricker AL, Cywes C, Ashbaugh CD, Wessels MR. 2002. NAD+-glycohydrolase acts as an 
intracellular toxin to enhance the extracellular survival of group A streptococci. Mol 
Microbiol 44:257-69. 
333. Bhattacharjee P, Keyel PA. 2018. Cholesterol-dependent cytolysins impair pro-inflammatory 
macrophage responses. Sci Rep 8:6458. 
334. Keyel PA, Loultcheva L, Roth R, Salter RD, Watkins SC, Yokoyama WM, Heuser JE. 2011. 
Streptolysin O clearance through sequestration into blebs that bud passively from the plasma 
membrane. J Cell Sci 124:2414-23. 
335. Xie M, Low MG. 1995. Streptolysin-O induces release of glycosylphosphatidylinositol-
anchored alkaline phosphatase from ROS cells by vesiculation independently of 
phospholipase action. Biochem J 305 ( Pt 2):529-37. 
 195 
336. Walev I, Vollmer P, Palmer M, Bhakdi S, Rose-John S. 1996. Pore-forming toxins trigger 
shedding of receptors for interleukin 6 and lipopolysaccharide. Proc Natl Acad Sci U S A 
93:7882-7. 
337. Rose-John S. 2012. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-
inflammatory activities of IL-6. Int J Biol Sci 8:1237-47. 
338. Chu J, Thomas LM, Watkins SC, Franchi L, Nunez G, Salter RD. 2009. Cholesterol-
dependent cytolysins induce rapid release of mature IL-1beta from murine macrophages in a 
NLRP3 inflammasome and cathepsin B-dependent manner. J Leukoc Biol 86:1227-38. 
339. Cywes Bentley C, Hakansson A, Christianson J, Wessels MR. 2005. Extracellular group A 
Streptococcus induces keratinocyte apoptosis by dysregulating calcium signalling. Cell 
Microbiol 7:945-55. 
340. Uchiyama S, Dohrmann S, Timmer AM, Dixit N, Ghochani M, Bhandari T, Timmer JC, 
Sprague K, Bubeck-Wardenburg J, Simon SI, Nizet V. 2015. Streptolysin O Rapidly Impairs 
Neutrophil Oxidative Burst and Antibacterial Responses to Group A Streptococcus. Front 
Immunol 6:581. 
341. Timmer AM, Timmer JC, Pence MA, Hsu LC, Ghochani M, Frey TG, Karin M, Salvesen GS, 
Nizet V. 2009. Streptolysin O promotes group A Streptococcus immune evasion by 
accelerated macrophage apoptosis. J Biol Chem 284:862-71. 
342. Kristian SA, Datta V, Weidenmaier C, Kansal R, Fedtke I, Peschel A, Gallo RL, Nizet V. 
2005. D-alanylation of teichoic acids promotes group a streptococcus antimicrobial peptide 
resistance, neutrophil survival, and epithelial cell invasion. J Bacteriol 187:6719-25. 
343. Ashbaugh CD, Alberti S, Wessels MR. 1998. Molecular analysis of the capsule gene region 
of group A Streptococcus: the hasAB genes are sufficient for capsule expression. J Bacteriol 
180:4955-9. 
344. Wessels MR, Moses AE, Goldberg JB, DiCesare TJ. 1991. Hyaluronic acid capsule is a 
virulence factor for mucoid group A streptococci. Proc Natl Acad Sci U S A 88:8317-21. 
345. Dale JB, Washburn RG, Marques MB, Wessels MR. 1996. Hyaluronate capsule and surface 
M protein in resistance to opsonization of group A streptococci. Infect Immun 64:1495-501. 
346. Svensson MD, Sjobring U, Luo F, Bessen DE. 2002. Roles of the plasminogen activator 
streptokinase and the plasminogen-associated M protein in an experimental model for 
streptococcal impetigo. Microbiology 148:3933-45. 
347. Chiang-Ni C, Wu JJ. 2008. Effects of streptococcal pyrogenic exotoxin B on pathogenesis of 
Streptococcus pyogenes. J Formos Med Assoc 107:677-85. 
348. Horstmann RD, Sievertsen HJ, Leippe M, Fischetti VA. 1992. Role of fibrinogen in 
complement inhibition by streptococcal M protein. Infect Immun 60:5036-41. 
 196 
349. Metzgar D, Zampolli A. 2011. The M protein of group A Streptococcus is a key virulence 
factor and a clinically relevant strain identification marker. Virulence 2:402-12. 
350. Uchiyama S, Andreoni F, Schuepbach RA, Nizet V, Zinkernagel AS. 2012. DNase Sda1 
allows invasive M1T1 Group A Streptococcus to prevent TLR9-dependent recognition. PLoS 
Pathog 8:e1002736. 
351. O'Seaghdha M, Wessels MR. 2013. Streptolysin O and its co-toxin NAD-glycohydrolase 
protect group A Streptococcus from Xenophagic killing. PLoS Pathog 9:e1003394. 
352. Agniswamy J, Lei B, Musser JM, Sun PD. 2004. Insight of host immune evasion mediated by 
two variants of group a Streptococcus Mac protein. J Biol Chem 279:52789-96. 
353. Lin A, Loughman JA, Zinselmeyer BH, Miller MJ, Caparon MG. 2009. Streptolysin S inhibits 
neutrophil recruitment during the early stages of Streptococcus pyogenes infection. Infect 
Immun 77:5190-201. 
354. Flaherty RA, Puricelli JM, Higashi DL, Park CJ, Lee SW. 2015. Streptolysin S Promotes 
Programmed Cell Death and Enhances Inflammatory Signaling in Epithelial Keratinocytes 
during Group A Streptococcus Infection. Infect Immun 83:4118-33. 
355. Evans BC, Nelson CE, Yu SS, Beavers KR, Kim AJ, Li H, Nelson HM, Giorgio TD, Duvall 
CL. 2013. Ex vivo red blood cell hemolysis assay for the evaluation of pH-responsive 
endosomolytic agents for cytosolic delivery of biomacromolecular drugs. J Vis Exp 
doi:10.3791/50166:e50166. 
356. Hershko DD, Robb BW, Luo G, Hasselgren PO. 2002. Multiple transcription factors 
regulating the IL-6 gene are activated by cAMP in cultured Caco-2 cells. Am J Physiol Regul 
Integr Comp Physiol 283:R1140-8. 
357. Faggioli L, Costanzo C, Donadelli M, Palmieri M. 2004. Activation of the Interleukin-6 
promoter by a dominant negative mutant of c-Jun. Biochim Biophys Acta 1692:17-24. 
358. Koo JB, Han JS. 2016. Cigarette smoke extract-induced interleukin-6 expression is regulated 
by phospholipase D1 in human bronchial epithelial cells. J Toxicol Sci 41:77-89. 
359. Franchimont N, Durant D, Rydziel S, Canalis E. 1999. Platelet-derived growth factor induces 
interleukin-6 transcription in osteoblasts through the activator protein-1 complex and 
activating transcription factor-2. J Biol Chem 274:6783-9. 
360. Reimold AM, Kim J, Finberg R, Glimcher LH. 2001. Decreased immediate inflammatory 
gene induction in activating transcription factor-2 mutant mice. Int Immunol 13:241-8. 
361. Jairaman A, Maguire CH, Schleimer RP, Prakriya M. 2016. Allergens stimulate store-
operated calcium entry and cytokine production in airway epithelial cells. Sci Rep 6:32311. 
362. Fric J, Zelante T, Wong AY, Mertes A, Yu HB, Ricciardi-Castagnoli P. 2012. NFAT control 
of innate immunity. Blood 120:1380-9. 
 197 
363. Abbott KL, Loss JR, 2nd, Robida AM, Murphy TJ. 2000. Evidence that Galpha(q)-coupled 
receptor-induced interleukin-6 mRNA in vascular smooth muscle cells involves the nuclear 
factor of activated T cells. Mol Pharmacol 58:946-53. 
364. Libermann TA, Baltimore D. 1990. Activation of interleukin-6 gene expression through the 
NF-kappa B transcription factor. Mol Cell Biol 10:2327-34. 
365. Quay JL, Reed W, Samet J, Devlin RB. 1998. Air pollution particles induce IL-6 gene 
expression in human airway epithelial cells via NF-kappaB activation. Am J Respir Cell Mol 
Biol 19:98-106. 
366. Beetz A, Peter RU, Oppel T, Kaffenberger W, Rupec RA, Meyer M, van Beuningen D, Kind 
P, Messer G. 2000. NF-kappaB and AP-1 are responsible for inducibility of the IL-6 promoter 
by ionizing radiation in HeLa cells. Int J Radiat Biol 76:1443-53. 
367. Viedt C, Hansch GM, Brandes RP, Kubler W, Kreuzer J. 2000. The terminal complement 
complex C5b-9 stimulates interleukin-6 production in human smooth muscle cells through 
activation of transcription factors NF-kappa B and AP-1. FASEB J 14:2370-2. 
368. Guerci A, Lahoute C, Hebrard S, Collard L, Graindorge D, Favier M, Cagnard N, Batonnet-
Pichon S, Precigout G, Garcia L, Tuil D, Daegelen D, Sotiropoulos A. 2012. Srf-dependent 
paracrine signals produced by myofibers control satellite cell-mediated skeletal muscle 
hypertrophy. Cell Metab 15:25-37. 
369. Mauer J, Denson JL, Bruning JC. 2015. Versatile functions for IL-6 in metabolism and cancer. 
Trends Immunol 36:92-101. 
370. Bastiat-Sempe B, Love JF, Lomayesva N, Wessels MR. 2014. Streptolysin O and NAD-
glycohydrolase prevent phagolysosome acidification and promote group A Streptococcus 
survival in macrophages. MBio 5:e01690-14. 
371. McKay S, Hirst SJ, Haas MB, de Jongste JC, Hoogsteden HC, Saxena PR, Sharma HS. 2000. 
Tumor necrosis factor-alpha enhances mRNA expression and secretion of interleukin-6 in 
cultured human airway smooth muscle cells. Am J Respir Cell Mol Biol 23:103-11. 
372. Brosnahan AJ, Mantz MJ, Squier CA, Peterson ML, Schlievert PM. 2009. Cytolysins 
augment superantigen penetration of stratified mucosa. J Immunol 182:2364-73. 
373. Walev I, Hombach M, Bobkiewicz W, Fenske D, Bhakdi S, Husmann M. 2002. Resealing of 
large transmembrane pores produced by streptolysin O in nucleated cells is accompanied by 
NF-kappaB activation and downstream events. FASEB J 16:237-9. 
374. Feil SC, Ascher DB, Kuiper MJ, Tweten RK, Parker MW. 2014. Structural studies of 
Streptococcus pyogenes streptolysin O provide insights into the early steps of membrane 
penetration. J Mol Biol 426:785-92. 
 198 
375. Limbago B, Penumalli V, Weinrick B, Scott JR. 2000. Role of streptolysin O in a mouse 
model of invasive group A streptococcal disease. Infect Immun 68:6384-90. 
376. Miyoshi-Akiyama T, Zhao J, Kikuchi K, Kato H, Suzuki R, Endoh M, Uchiyama T. 2003. 
Quantitative and qualitative comparison of virulence traits, including murine lethality, among 
different M types of group A streptococci. J Infect Dis 187:1876-87. 
377. Lu H, Wu JY, Kudo T, Ohno T, Graham DY, Yamaoka Y. 2005. Regulation of interleukin-6 
promoter activation in gastric epithelial cells infected with Helicobacter pylori. Mol Biol Cell 
16:4954-66. 
378. Zhang Y, Broser M, Rom WN. 1994. Activation of the interleukin 6 gene by Mycobacterium 
tuberculosis or lipopolysaccharide is mediated by nuclear factors NF-IL6 and NF-kappa B. 
Proc Natl Acad Sci U S A 91:2225-9. 
379. Abos B, Wang T, Castro R, Granja AG, Leal E, Havixbeck J, Luque A, Barreda DR, 
Secombes CJ, Tafalla C. 2016. Distinct Differentiation Programs Triggered by IL-6 and LPS 
in Teleost IgM(+) B Cells in The Absence of Germinal Centers. Sci Rep 6:30004. 
380. Hernandez-Quintero M, Kuri-Harcuch W, Gonzalez Robles A, Castro-Munozledo F. 2006. 
Interleukin-6 promotes human epidermal keratinocyte proliferation and keratin cytoskeleton 
reorganization in culture. Cell Tissue Res 325:77-90. 
381. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. 2006. 
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and 
regulatory T cells. Nature 441:235-8. 
382. Ting L, Rad R, Gygi SP, Haas W. 2011. MS3 eliminates ratio distortion in isobaric 
multiplexed quantitative proteomics. Nat Methods 8:937-40. 
383. Gursoy UK, Gursoy M, Kononen E, Sintim HO, Uitto VJ, Syrjanen S. 2016. Construction 
and characterization of a multilayered gingival keratinocyte culture model: the TURK-U 
model. Cytotechnology 68:2345-2354. 
384. Belair C, Baud J, Chabas S, Sharma CM, Vogel J, Staedel C, Darfeuille F. 2011. Helicobacter 
pylori interferes with an embryonic stem cell micro RNA cluster to block cell cycle 
progression. Silence 2:7. 
385. Sumby P, Porcella SF, Madrigal AG, Barbian KD, Virtaneva K, Ricklefs SM, Sturdevant DE, 
Graham MR, Vuopio-Varkila J, Hoe NP, Musser JM. 2005. Evolutionary origin and 
emergence of a highly successful clone of serotype M1 group a Streptococcus involved 
multiple horizontal gene transfer events. J Infect Dis 192:771-82. 
386. McGee DW, Bamberg T, Vitkus SJ, McGhee JR. 1995. A synergistic relationship between 
TNF-alpha, IL-1 beta, and TGF-beta 1 on IL-6 secretion by the IEC-6 intestinal epithelial cell 
line. Immunology 86:6-11. 
 199 
 
